

International Society for Heart and Lung Transplantation  
A Society That Includes Basic Science, the Failing Heart, and Advanced Lung Disease  
27th Annual Meeting and Scientific Sessions  
April 25-28, 2007  
Convening at the Hilton San Francisco, San Francisco, CA, USA  
FINAL PROGRAM

## **International Society for Heart and Lung Transplantation**

### **BOARD OF DIRECTORS**

#### **President**

Robert C. Robbins, MD, Stanford, CA

#### **Past President**

Mark L. Barr, MD, Los Angeles, CA

#### **President-Elect**

Paul A. Corris, MB, FRCP, Newcastle, UK

#### **Secretary-Treasurer**

Mandeep R. Mehra, MD, Baltimore, MD

### **DIRECTORS**

Nicholas R. Banner, FRCP, Harefield, UK

Fabienne Dobbels, PhD, Leuven, Belgium

Mariell Jessup, MD, Philadelphia, PA

Ronald H. Kerman, PhD, Houston TX

Shaf Keshavjee, MD, FRCSC, FACS, Toronto, Canada

Walter Klepetko, MD, Vienna, Austria

Stephen R. Large, FRCS, Cambridge, UK

Joren C. Madsen, MD, Dphil, Boston, MA

Bruno M. Meiser, MD, Munich, Germany

Randall C. Starling, MD, MPH, Cleveland, OH

Steven A. Webber, MB ChB, Pittsburgh PA

### **EX OFFICIO BOARD MEMBERS**

#### **JHLT Editor**

James K. Kirklin, MD, Birmingham AL

#### **Transplant Registry Medical Director**

Marshall I. Hertz, MD, Minneapolis, MN

#### **Scientific Program Chair**

Duane Davis, MD, Durham, NC

#### **Development Committee Co-Chair**

Leslie W. Miller, MD, Washington, DC

#### **Staff**

Amanda W. Rowe

Executive Director

Phyllis Glenn

Assistant Executive Director

Director of Membership Services

Lisa A. Edwards

Director of Meetings

Lee Ann Mills

Director of Operations

14673 Midway Road, Suite 200

Addison, TX 75001

Phone: 972-490-9495

Fax: 972-490-9499

[www.ishlt.org](http://www.ishlt.org)

[ishlt@ishlt.org](mailto:ishlt@ishlt.org)

## **International Society for Heart and Lung Transplantation 27th Annual Meeting and Scientific Sessions**

Note: A name preceded by an asterisk indicates that the individual has indicated a relationship which, in the context of this CME activity, could be perceived as a potential conflict of interest. Please refer to the disclosure information provided in this booklet for additional information about specific individuals' disclosure information.

### **SCIENTIFIC PROGRAM COMMITTEE**

\*Duane Davis, MD, Durham, NC, Program Chair  
Robert C. Robbins, MD, Stanford, CA, President  
\*Barbara D. Alexander, MD, Durham, NC  
Carla C. Baan, PhD, Rotterdam, The Netherlands  
Nancy P. Blumenthal, MSN, CRNP, Ardmore, PA  
\*Paul A. Corris, MB, FRCP, Newcastle Upon Tyne, United Kingdom  
John Dark, MB, FRCS, Newcastle Upon Tyne, United Kingdom  
Thomas J. Dengler, MD, Heidelberg, Germany  
\*Fabienne Dobbels, MSc. PhD, Leuven, Belgium  
\*Thomas M. Egan, MD, Chapel Hill, NC  
Michael C. Fishbein, MD, Los Angeles, CA  
Joshua M. Hare, MD, Miami, FL  
Axel Haverich, MD, Hannover, Germany  
Michael J. Jurmann, MD, Berlin, Germany  
\*Shaf Keshavjee, MD, Toronto, ON, Canada  
James K. Kirklin, MD, Birmingham, AL  
Joren C. Madsen, MD, D.Phil., Boston, MA  
Cynthia M. Magro, MD, New York, NY  
\*Mandeep R. Mehra, MD, Baltimore, MD  
\*Bryan F. Meyers, MD, St. Louis, MO  
\*Carmelo A. Milano, MD, Durham, NC  
Michael S. Mulligan, MD, Seattle, WA  
\*Scott M. Palmer, MD, Durham, NC  
Jean B. Rea, RN, MS, CCTC, Durham, NC  
\*Joseph G. Rogers, MD, Durham, NC  
\*Bruce R. Rosengard, MD, FRCS, FACS, Boston, MA  
\*Stuart D. Russell, MD, Baltimore, MD  
\*Gregory I. Snell, FRACP, MBBS, Prahran, VIC, Australia  
\*Stuart C. Sweet, MD, PhD, St. Louis, MO  
Jeffrey A. Towbin, MD, Houston, TX  
Thomas K. Waddell, MD, PhD, Toronto, ON, Canada  
\*Lori J. West, MD, D.Phil, Edmonton, AB, Canada  
\*Martin R. Zamora, MD, Denver, CO  
\*Andreas O. Zuckermann, MD, Vienna, Austria

### **ABSTRACT REVIEWERS**

Vivek N. Ahya, MD, Philadelphia, PA  
James S. Allan, MD, Marblehead, MA  
Abbas Ardehali, MD, Los Angeles, CA  
\*Nicholas R. Banner, FRCP, Harefield, Middlesex, United Kingdom  
\*Maher A. Baz, MD, Gainesville, FL  
Christian Benden, MD, Zurich, Switzerland  
\*Gerald J. Berry, MD, Stanford, CA,  
\*Sangeeta M. Bhorade, MD, Chicago, IL  
\*Emily A. Blumberg, MD, Philadelphia, PA  
\*Annette Boehler, MD, Zurich, Switzerland  
\*Steven F. Bolling, MD, Ann Arbor, MI  
\*Susan C. Brozena, MD, North Wales, PA  
\*Michael Burch, MD, London, United Kingdom  
Margaret Burke, FRCPATH, Harefield, Middlesex, United Kingdom  
\*Marcelo Cantarovich, MD, Montreal, PQ, Canada  
\*Charles E. Canter, MD, St. Louis, MO  
\*Leway Chen, MD, MPH, Rochester, NY  
Susan M. Chernenko, MN, Toronto, ON, Canada  
Cliff K. C. Choong, FRACS, Cambridge, United Kingdom  
John V. Conte, MD, Baltimore, MD  
Andrea M. D'Armini, MD, Pavia, Italy  
Hiroshi Date, MD, Okayama, Japan  
\*Nicolaas De Jonge, MD, Utrecht, The Netherlands

Roel A. de Weger, PhD, Utrecht, The Netherlands  
\*Sabrina M. DeGeest, RN, PhD, NFESC, Basel, Switzerland  
\*Mario C. Deng, MD, New York, NY  
William J. Dreyer, MD, Houston, TX  
\*J. Stephen Dummer, MD, Brentwood, TN  
\*Howard J. Eisen, MD, Philadelphia, PA  
Okan Elidemir, MD, Houston, TX  
Stefan M. Ensminger, MD, PhD, Erlangen, Germany  
Leif Eriksson, MD, Lund, Sweden  
\*Donald S. Esmore, MBBS, FRACS, Melbourne, Australia  
Marc Estenne, MD, Brussels, Belgium  
\*Gregory A. Ewald, MD, St. Louis, MO  
\*David S. Feldman, MD, PhD, Columbus, OH  
\*G. Michael Felker, MD, Durham, NC  
\*Andrew J. Fisher, MRCP, PhD, Newcastle Upon Tyne, United Kingdom  
Seth D. Force, MD, Atlanta, GA  
Mary H. Freeman, MSW, LCSW, Gainesville, FL  
\*Eli Gabbay, FRACP, Perth, Australia  
Edward R. Garrity, Jr., MD, Chicago, IL  
\*Allan R. Glanville, MD, FRACP, Sydney, Australia  
Martin J. Goddard, FRCS, MRCPATH, Cambridge, United Kingdom  
\*Kate Gould, FRCPATH, Newcastle Upon Tyne, United Kingdom  
Edoardo G. Gronda, MD, Milan, Italy  
\*Paolo Grossi, MD, PhD, Varese, Italy  
Denis Hadjiladis, MD, Philadelphia, PA  
Ari L. J. Harjula, MD, Helsinki, Finland  
Ray E. Hershberger, MD, Portland, OR  
\*Roland Hetzer, MD, PhD, Berlin, Germany  
Gregory M. Hirsch, MD, Halifax, Nova Scotia, Canada  
\*William L. Holman, MD, Birmingham, AL  
\*Sally H. Houston, MD, Tampa, FL  
Daphne T. Hsu, MD, New York, NY  
Val Jeevanandam, MD, Chicago, IL  
Gundars J. Katlaps, MD, Richmond, VA  
\*Anne Keogh, MBBS, MD, Sydney, Australia  
\*Shaf Keshavjee, MD, FRCSC, Toronto, ON, Canada  
\*Walter Klepetko, MD, Vienna, Austria  
Christiane Kugler, MScN, PhD (c), Hannover, Germany  
Chi K. Lai, MD, Los Angeles, CA  
Dorothy M. Lanuza, PhD, Madison, WI  
\*Stephen R. Large, MS, MRFP, FRCS, Cambridge, United Kingdom  
Christine L. Lau, MD, University City, MO  
\*Hans B. Lehmkuhl, MD, Berlin, Germany  
Shu S. Lin, MD, Durham, NC  
\*James W. Long, MD, PhD, Salt Lake City, UT  
\*Peter MacDonald, MBBS, Sydney, Australia  
\*Charles C. Marboe, MD, New York, NY  
H. Todd Massey, MD, Rochester, NY  
\*Paul J. Mather, MD, Philadelphia, PA  
Paul J. Mohacsi, MD, Bern, Switzerland  
\*Yoshifumi Naka, MD, PhD, New York, NY  
Linda Ohler, RN, MSN, FAAN, Arlington, VA  
\*Jonathan B. Orens, MD, Baltimore, MD  
Elfriede Pahl Schuette, MD, Chicago, IL  
Octavio Pajaro, MD, PhD, Birmingham, AL  
Wayne D. Paris, PhD, Carbondale, IL  
Michael G. Petty, MS, RN, CCNS, Minneapolis, MN  
Richard N. Pierson, III, MD, Baltimore, MD  
Bill A. Pietra, MD, Littleton, CO  
\*Gregorio Rabago, MD, Pamplona, Spain  
\*Barry K. Rayburn, MD, Birmingham, AL  
\*Marlene Rose, PhD, Harefield, United Kingdom  
Alan G. Rose, MD, FRCPATH, Minneapolis, MN  
\*Heather J. Ross, MD, FRCPC, MHSC, Toronto, ON, Canada  
Christopher T. Salerno, MD, Indianapolis, IN  
Ralph A. Schmid, MD, Berne, Switzerland  
Andre R. Simon, MD, Hannover, Germany  
\*Lianne G. Singer, MD, FRACP, Toronto, ON, Canada  
Mark S. Slaughter, MD, Oak Lawn, IL

\*Nicholas G. Smedira, MD, Cleveland, OH  
\*Randall C. Starling, MD, Cleveland, OH  
Susan Stewart, FRCPath, Cambridge, United Kingdom  
Doris A. Taylor, PhD, Minneapolis, MD  
\*Henry D. Tazelaar, MD, Scottsdale, AZ  
George Tellides, MD, New Haven, CT  
Gero Tenderich, MD, PhD, Bad Oeynhausen, Germany  
Katsuhito Teranishi, MD, Aichi, Japan  
Patricia A. Thistlethwaite, MD, PhD, San Diego, CA  
\*Elbert P. Trulock, MD, St. Louis, MO  
\*Steven S.L. Tsui, MD, FRCS, Cambridge, United Kingdom  
\*Patricia A. Uber, Pharm.D., Baltimore, MD  
\*Adrian B. Van Bakel, MD, Charleston, SC  
Dirk Van Raemdonck, MD, Leuven, Belgium  
Geert M. Verleden, MD, PhD, Leuven, Belgium  
\*Lynne E. Wagoner, MD, Cincinnati, OH  
David A. Waltz, MD, Boston, MA  
\*Steven A. Webber, MD, Pittsburgh, PA  
David Weill, MD, Stanford, CA  
Richard D. Weisel, MD, Toronto, ON, Canada  
\*Glen P. Westall, FRACP, Melbourne, Australia  
\*Willem Wiemar, MD, Rotterdam, The Netherlands  
\*George M. Wieselthaler, MD, Vienna, Austria  
Samuel A. Yousem, MD, Pittsburgh, PA  
John G. Zaroff, MD, San Francisco, CA  
\*Mark J. Zucker, MD, Newark, NJ

## **DEVELOPMENT COMMITTEE**

Mandeep R. Mehra, MD, *Co-Chair*  
Leslie W. Miller, MD, *Co-Chair*  
Mark L. Barr, MD  
Paul A. Corris, MB, FRCP  
Robert C. Robbins, MD

## **EDUCATION COMMITTEE**

Mandeep R. Mehra, MD, *Chair*  
Mark L. Barr, MD  
John Dark, MD, FRCS  
Duane Davis, MD  
Robert C. Robbins, MD  
Lori J. West, MD, D.Phil

## **FINANCE COMMITTEE**

Mandeep R. Mehra, MD, *Treasurer and Chair*  
Mark L. Barr, MD  
Robert Robbins, MD  
James K. Kirklin, MD  
Leslie W. Miller, MD

## **GRANTS AND AWARDS COMMITTEE**

Mark L. Barr, MD, *Chair*  
John Dark, MB, FRCS, *Co-Chair*  
Susan Stewart, FRCPath, *Co-Chair*

## **HISTORY AND ARCHIVES COMMITTEE**

Hector Ventura, MD, *Co-Chair*  
Stephan Schueler, MD, *Co-Chair*  
Mandeep Mehra, MD, *Board Liaison*

## **NOMINATING COMMITTEE**

Mark L. Barr, MD, *Chair*  
Jon Kobashigawa, MD  
Alec Patterson, MD  
Robert C. Robbins, MD  
Stephan Schueler, MD

## **REGISTRY EXECUTIVE COMMITTEE**

Marshall I. Hertz, MD, *Medical Director*  
Mark M. Boucek, MD, *Associate Director for Pediatric Heart Transplantation*  
Paul Aurora, MD, *Associate Director for Pediatric Lung Transplantation*  
Leah B. Edwards, PhD, *Associate Director for Data Analysis*  
Berkeley M. Keck, RN, MPH, *Associate Director for Database Management*  
David O. Taylor, MD, *Associate Director for Heart Transplantation*  
Elbert P. Trulock, MD, *Associate Director for Lung Transplantation*  
Jason Christie, MD, *Associate Co-Director for Lung Transplantation*  
Fabienne Dobbels, PhD, *Associate Director for Outcomes Analysis*

## **SCIENTIFIC COUNCIL CHAIRS**

### **Cell Transplantation/Tissue Engineering**

Joshua M. Hare, *Chair*  
Robert C. Robbins, MD, *Board Liaison*

**Heart Failure, Transplant Medicine and Mechanical Support**

Maria Rosa Costanzo, MD, *Co-Chair*

Edoardo Gronda, MD, *Co-Chair*

Mariell Jessup, MD, *Board Liaison*

**Infectious Diseases**

F. Kate Gould, MBBS, *Chair*

Mariell Jessup, MD, *Board Liaison*

**Nursing and Social Sciences**

Jane MacIver, RN, MSN, *Co-Chair*

Catherine M. Murks, RN, MS, CS, ANP, *Co-Chair*

Fabienne Dobbels, MSc, PhD, *Board Liaison*

**Pathology and Basic Science**

Susan Stewart, FRCPath, *Co-Chair*

James George, PhD, *Co-Chair*

Ronald H. Kerman, PhD, *Board Liaison*

**Pediatric Transplantation**

Michael Burch, MD, *Co-Chair*

Maryanne Chrisant, MD, *Co-Chair*

Francesco Parisi, MD, *Co-Chair*

Stuart Sweet, MD, PhD, *Co-Chair*

Lori West, MD, DPhil, *Co-Chair*

Steven Webber, MB, ChB, *Board Liaison*

**Pulmonary Arterial Hypertension**

Raymond Benza, MD, *Co-Chair*

Reda Girgis, MB BCh, *Co-Chair*

John Scott, MD, *Co-Chair*

Paul Corris, MB, FRCP, *Board Liaison*

**Pulmonary Transplantation**

Allan Glanville, MD, FRACP, *Co-Chair*

Marc Estenne, MD, *Co-Chair*

Paul Corris, MB, FRCP, *Board Liaison*

## **ISHLT PAST PRESIDENTS**

1981-1982	Michael Hess, MD
1982-1984	Jack Copeland, MD
1984-1986	Terence English, FRCS
1986-1988	Stuart Jamieson, MD
1988-1990	Bruno Reichart, MD
1990-1991	Margaret Billingham, MD
1991-1992	Christian Cabrol, MD
1992-1993	John O'Connell, MD
1993-1994	Eric Rose, MD
1994-1995	John Wallwork, FRCS
1995-1996	Sharon Hunt, MD
1996-1997	William Baumgartner, MD
1997-1998	Leslie Miller, MD
1998-1999	Alan Menkis, MD, FRCS(C)
1999-2000	Robert L. Kormos, MD
2000-2001	Anne Keogh, MBBS, MD
2001-2002	James B. Young, MD
2002-2003	Stephan Schuler, MD
2003-2004	Jon Kobashigawa, MD
2004-2005	Alec Patterson, MD
2005-2006	Mark L. Barr, MD

## **PAST PROGRAM CHAIRS**

### **1988 Los Angeles, CA**

John C. Baldwin, MD

### **1989 Munich, Germany**

Bruno Reichart, MD

D. Glenn Pennington, MD

### **1990 San Diego, CA**

D. Glenn Pennington, MD

### **1991 Paris, France**

John B. O'Connell, MD

### **1992 San Diego, CA**

Eric A. Rose, MD

### **1993 Boca Raton, FL**

Maria Rosa Costanzo, MD

### **1994 Venice, Italy**

John Wallwork, MBChB, FRCS

### **1995 San Francisco, CA**

Leslie W. Miller, MD

### **1996 New York, NY**

William A. Baumgartner, MD

### **1997 London, England**

Stephan Schueler, MD

### **1998 Chicago, IL**

James B. Young, MD

### **1999 San Francisco, CA**

Mark L. Barr, MD

### **2000 Osaka, Japan**

Jon Kobashigawa, MD

### **2001 Vancouver, Canada**

David O. Taylor, MD

### **2002 Washington, DC**

Robert C. Robbins, MD

### **2003 Vienna, Austria**

Bruce R. Rosengard, MD

### **2004 San Francisco, CA**

Mandeep Mehra, MD

### **2005 Philadelphia, PA**

Shaf Keshavjee, MD

### **2006 Madrid, Spain**

John Dark, MB, FRCS

## **ISHLT AWARD RECIPIENTS**

### **Lifetime Achievement Award**

2004 Sir Magdi Yacoub, MD  
1999 Keith Reemtsma, MD  
1996 Norman Shumway, MD

### **Lifetime Service Award**

1997 Jacques Losman  
1996 Michael Kaye

### **ISHLT/Astellas Transplant Career Development Award**

2006 Dennis A. Wigle, MD, PhD

### **ISHLT/Roche Transplant Career Development Award**

2000 Gordon D. Wu, MD

### **ISHLT Transplant Career Development Award**

2002 Anthony Azakie, MD

### **ISHLT/Novartis Transplant Career Development Award**

2004 Allan M. Ramirez, MD

### **ISHLT/Roche Transplant Research Fellowship Grant**

2006 Rachel L. Anderson, MBBS  
2005 Ahmad Saad, MD  
2004 Kendra N. Taylor, PhD  
2003 Felix Fernandez, MD  
2002 Ruediger Hoebelt, MD  
2001 Matteo Vatta, PhD  
2001 Arnar Geirsson, MD  
2000 Christopher H. Wigfield, FRCS  
1999 Donald Wong, PhD  
Sivasai Krovvidi, PhD  
1998 Kelly S.A. Blair, MD  
A.M. El Gamel, MD  
1997 Jonathen Chen, MD  
Anne K. Raisanen-Sokolowski, MD  
1996 Tuija S. Ikonen, MD

### **ISHLT/Novartis Transplant Research Fellowship Grant**

2006 Matthew J. Weiss, MD  
2000 Richard S. Lee, MD  
1999 George Juang, MD  
1999 Satoshi Saito, MD  
1998 Margaret L. Schwarze, MD

### **ISHLT/Astellas (Fujisawa) Transplant Research Fellowship Grant**

2005 Arne Neyrinck, MD  
2004 Christian A. Gleissner, MD  
2003 Ewout J. van den Bos, MD  
1997 Alyssa M. Krasinskas, MD

### **ISHLT/Actelion Transplant Research Fellowship Grant**

2004 Tsuyoshi Shoji, MD, PhD

### **ISHLT/XDx Transplant Research Fellowship Grant**

2006 Edward N. Seung, PhD  
2004 Monica Zwierzchonieuska, MD

### **ISHLT/Encysive Transplant Research Fellowship Grant**

2006 Heather E. Merry, MD

### **ISHLT/Transmedics Transplant Research Fellowship Grant**

2006 Zhaohui Li, PhD

### **ISHLT/Chiron Transplant Research Fellowship Grant**

2005 Ryan C. Fields, MD

### **ISHLT/Wyeth-Ayerst Transplant Research Fellowship Grant**

1998 Christine L. Lau, MD

### **ISHLT/Ortho Biotech Transplant Research Fellowship Grant**

1997 Owen T. Lawrence, MD  
1996 Andrew F. Pierre, MD  
1995 Frances L. Johnson, MD

### **ISHLT Transplant Research Fellowship Grant**

1998 Scott D. Ross, MD

### **ISHLT Nursing Research Grant**

2006 Thierry Troosters, PhD  
2005 Annemarie F. Kaan, MCN  
2004 Deidre E. Logan, PhD  
2003 Diane H. Leloudis, RN, MSN  
2003 Janet E. Madill, PhD  
2002 Annette J. De Vito Dabbs, RN, MN, PhD  
2001 Lynn Doering, RN, DNSc  
2000 Nancy M. Albert, MSN, RN  
1999 Jeanne Salyer, PhD  
1998 Katherine St. Clair, RN, MSN  
1997 Eileen Collins, RN, PhD

### **Caves Award**

2006 Gregor Warnecke, MD  
2005 Sigrid Sandner, MD  
2005 Frank D'Ovidio, MD  
2004 M.D. Peterson, MD  
2003 Sigrid Sandner, MD  
2002 Peter Blaha, MD  
2001 Alexander S. Krupnick, MD  
2000 Michael P. Fischbein, MD  
1999 Joerg Koglin, MD  
1998 Carla C. Baan, MD  
1997 Simon D. Eiref, MD  
1996 Moninder S. Bhabra, MD  
1995 Elizabeth A. Davis, MD  
1994 Jobst Winter, MD  
1994 Alain Chapelier, MD

1993 David Marshman, MD  
1992 David P. Kapelanski, MD  
1991 A. Jiminez, MD  
1990 Andres J. Duncan, MD  
1989 A.M. Wood, MD  
1988 Charles D. Fraser, Jr., MD  
1987 Wim Van Der Bij, MD  
1986 Stuart J. Knechtle, MD  
1985 Michael A. Breda, MD  
1984 Hermann Reichensperner, MD  
1983 Robbin G. Cohen, MD

**Nursing Excellence Research Award**

2006 Kathleen L. Grady, PhD, RN  
2005 Mary Amanda Dew, PhD

## **International Society for Heart and Lung Transplantation 27th Annual Meeting and Scientific Sessions**

### **ABOUT ISHLT**

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit organization dedicated to the advancement of the science and treatment of end-stage heart and lung diseases. ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 2300 members from over 45 countries, representing over 10 different disciplines involved in the management and treatment of end-stage heart and lung disease.

This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, and transplant coordinators. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

The mission of the Society is:

1. To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease, and related sciences.
2. To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.
3. To hold scientific meetings featuring presentations and discussions relevant to these disciplines.
4. To sponsor a scientific journal for the publication of manuscripts related to these disciplines.
5. To establish and maintain an international registry for heart and lung transplantation.
6. To award research grants and establish endowments for the study of these disciplines.

### **ABOUT SAN FRANCISCO**

ISHLT is returning to San Francisco for our 4<sup>th</sup> time in 12 years. Why? Because San Francisco is a great city that our members love to visit – our meeting attendance is consistently the highest when we meet in San Francisco. San Francisco in April has so much to offer: some of the best weather of the year, miles of shorefront that bustles with activity, cable cars, world-famous international cuisine, unparalleled shopping, world-class museums, acres of parkland and recreation areas, to name just a few. San Francisco is so familiar to so many, but here are a few tidbits you may not have already known:

- You can walk the entire 7 mile shoreline from the Golden Gate Bridge to the San Francisco-Oakland Bay Bridge, along beautiful promenades and pathways.
- Historic trolleys from all over the world travel along the tracks from the Ferry Building to Fisherman's Wharf.
- San Francisco's famous Piers are numbered, beginning at the Ferry Building. The even numbers are to the East, the odd numbers are to the West, and some piers no longer exist.
- In the winter months, as many as 900 wild sea lions live at Pier 39.
- The following were invented in San Francisco: the martini, chop suey, the fortune cookie, the mai tai, cioppino, Crab Louis, and Irish coffee.
- The water temperature of San Francisco Bay is around 48 degrees Fahrenheit.
- At the Hyde Street Pier, you can see vessels that sailed the bay 600 years ago.
- The giant coastal redwoods in the Muir Woods National Monument can reach a height of 250 feet.
- Sonoma and Napa counties are home to over 300 wineries that produce nearly 2 billion bottles of wine each year.
- The steepest street in San Francisco is Filbert, at 31.5 degrees in parts.
- San Francisco's cable cars travel at a speed of 9 miles per hour.
- The Palace of the Legion of Honor holds one of the world's most significant collections of Rodin sculpture.
- There are 14,000 Victorian homes in San Francisco.
- Alcatraz means Pelican in Spanish.
- San Francisco is approximately 7 miles long and 7 miles wide.
- Denim jeans were invented in San Francisco for the Gold Rush miners who needed tough, comfortable clothing.
- The statue in the middle of Washington Square Park is of Ben Franklin, not George Washington.
- Some of the internationally-known companies headquartered in or near San Francisco: Google, Yahoo, EBay, Gap, Hewlett Packard, Apple Computer, VISA, Wells Fargo, Levi Strauss, and Adobe Systems.

### **NEW FOR 2007**

This year, the meeting schedule has been revised to better conform with the attendance practices of our delegates. We hope that you will find the schedule changes to be advantageous and we are interested in your feedback.

The most important schedule changes apply to the first and last days of the meeting, Wednesday and Saturday. On Wednesday, we have moved the meeting up to begin at 8 am. We will conduct 11 satellite symposia from 8 am – Noon, followed by a luncheon symposium from 12:30-2:00 pm. The Opening Plenary Session will begin at 2:30 pm, followed by concurrent sessions.

On Saturday, we will end the meeting at Noon to enable you to enjoy the many advantages of free time in San Francisco. Saturday morning will open with concurrent sessions at 8:00 am and will close with a thought-provoking and entertaining Plenary Session at 9:45 am.

Also new this year is the expansion of the meeting from 4 concurrent sessions to 6 concurrent sessions. We are fortunate to be using a facility with the flexibility to expand our meeting, and the number of excellent abstract submissions prompted the Program Committee to take advantage of this. With six concurrent sessions, we have been able to accept all of the abstracts that were considered worthy of oral presentation, and we were also able to incorporate several invited lectures into the abstract sessions. We hope that you find this expanded format to be valuable, and we would appreciate your feedback.

Back on the program again this year are the Sunrise Symposia. These early morning sessions are designed to provide a more in-depth review of a focused topic. There are eight symposia total, scheduled four each day on Thursday and Friday from 7 am – 8 am.

Topics include:

- Immunobiology for Clinicians: Basic Biology
- State of the Art Management Options for Bronchiolitis Obliterans
- Fungal Disease: Shifting Trends/New Treatments
- Management Issues with Continuous Flow Devices
- Immunobiology for Clinicians: Principles of Therapy
- Novel Insights in Mechanisms of Bronchiolitis Obliterans
- From Observation to Research in Nursing and Social Sciences: Acting on Your Ideas
- When Palliation Fails: Transplantation for the Adult with Congenital Heart Disease

## **HIGHLIGHTS OF THE SCIENTIFIC PROGRAM**

While this year's program offers a greater breadth and depth of information related to thoracic transplantation than previously possible, it also spotlights the role that the newest technological advances will have in medicine and transplantation.

Wednesday morning's satellite symposia cover a broad range of topics. These include sessions exploring the latest advances and the future directions in circulatory support, advances in our understanding and treatment of pulmonary hypertension, the role of cellular immune therapy in transplantation, the interactions between innate immunity and the adaptive immune response, and strategies to minimize nephrotoxicity in transplant recipients.

Additional areas of major focus in this meeting are the changes in organ allocation, particularly the rationale, the implications and the future directions of heart and lung allocation, and the role of antibody mediated organ injury. Advances in our understanding of immunobiology, diagnostic testing, and current and future treatment strategies will be highlighted.

This year we have re-introduced the sunrise symposia highlighted by sessions covering basic immunobiology and immune therapies for the clinician, enabling clinical research, advances in the understanding and treatment of BOS, new and improved diagnosis and treatment of fungal infections, and the state of the art using continuous flow devices.

We will have the opportunity to revisit the origins of our society and profession through the insights of Donald McRae, author of *Every Second Counts: The Race to Perform the First Human Heart Transplant*, and to explore the future of our society in Robert Robbins's presidential address.

One of the most exciting components of this year's meeting will be a series of lectures covering the hottest areas of scientific advances and their application in medicine and transplantation. These include the roles that nanotechnology, genomics and proteomics, RNA interference and cell therapy will play in the future management of our patients. We look forward to your attendance and active participation in this year's meeting.

## **PHILLIP K. CAVES AWARD SESSION**

The 8 finalists for the Philip K. Caves Award will present their original research work in a dedicated session. This prestigious Award is named for the pioneer of the technique of transvenous endomyocardial biopsy. The \$1000 prize is awarded to the best presentation by a resident/fellow/student who is first author of the abstract. Come and support the best and brightest residents, fellows and graduate students – the future of our society - as they present their research findings and are judged for the winner of this prestigious award.

## **PRESIDENT'S GALA RECEPTION**

The President's Gala Reception will be held Wednesday, April 25, from 8:00 pm – 10:00 pm at San Francisco's beautiful and ornate City Hall, which is just a few blocks from the Hilton. The talented Marginal Donors, starring our own Heather Ross, MD, will be performing for the crowd. Please be sure to join us for this wonderful event on the opening day of the meeting.

One ticket to the Gala Reception is included with each paid registration. Additional tickets may be purchased for \$75 each.

# **International Society for Heart and Lung Transplantation**

## **27th Annual Meeting and Scientific Sessions**

### **CONTINUING MEDICAL EDUCATION INFORMATION**

#### **Accreditation**

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart and Lung Transplantation is accredited by the ACCME to provide continuing medical education for physicians. ISHLT designates this activity for a maximum of 32.25 hours in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Continuing Education Point/Contact Hours have been applied for with the American Board of Transplant Coordinators (ABTC) and Critical Care Nurses (AACN).

#### **Disclosure**

Current guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect a speaker's presentation. Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair. These disclosures will be printed in the Final Program and made available at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

#### **Educational Objectives**

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their needs.

#### **Goals**

To enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease; and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

#### **Target Audience**

The audience for this program includes physicians, surgeons, scientists, nurses, and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end stage heart or lung disease.

#### **Learning Objectives**

At the conclusion of this meeting, participants should be able to:

1. evaluate different approaches to and ethical issues surrounding organ allocation
2. identify, prevent, and treat post-transplant complications of immunosuppression including infection, renal dysfunction, and post-transplant malignancy
3. compare and evaluate the relative advantages and disadvantages of various pharmacologic, non-pharmacologic, and biologic immunosuppression techniques
4. understand current and developing organ preservation/reperfusion techniques and the impact of these on the transplanted organ, and use that knowledge to optimize donor selection and extend the donor pool
5. compare and evaluate the advantages and disadvantages of various mechanical circulatory support systems and their associated patient selection criteria
6. describe the state of the art in clinical heart and lung failure treatment and the criteria for the selection of patients for transplant therapy
7. understand current animal models of basic science immunology and their application to the transplant setting
8. evaluate issues of controversy, such as age, prior transplantation, and systemic diseases, in the selection of candidates for heart and lung transplantation
9. understand the pathology of acute and chronic rejection and its application in the formulation of a definitive diagnosis of rejection
10. identify the issues unique to pediatric transplantation, and apply to pediatric transplantation the relevant practices and therapies of adult transplantation
11. evaluate the current and developing alternatives to orthotopic transplantation, including mechanical circulatory support, xenotransplantation, and a variety of surgical alternatives; assess the future of these therapies; and compare the value of these therapies as alternatives and/or bridges to transplantation
12. evaluate and implement the use of alternative methods of monitoring and treating rejection
13. identify, prevent, and treat donor-transmitted diseases
14. understand how psychosocial and behavioral issues impact clinical post-transplant outcomes

## Disclosure

Current ACCME guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect a speaker's presentation or a chair or program planner's involvement in the activity.

Every speaker, chair, and program committee member has been required to complete a disclosure statement. The names of the individuals that have indicated a relationship which, in the context of their presentation(s) or involvement in the program, could be perceived as a potential conflict of interest (e.g. ownership of stock, significant honoraria/consulting fees, or direct research support from a commercial organization, etc.) are indicated in the program with an asterisk and are listed below. The program committee has taken steps to ensure that any potential conflicts of interest have been resolved to their satisfaction. Individuals whose names are not marked with an asterisk and who are not listed below have indicated to ISHLT that they have no relationships to disclose. Additionally, all speakers and chairs have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

<b>Name</b>	<b>Presentations/Sessions</b>	<b>Company Affiliation(s)</b>	<b>Nature of Affiliation(s)</b>
Barbara Alexander	Roche Symposium, Concurrent 11, Prog Comm	Roche Astellas Enzon Pfizer Schering Plough	Consultant (modest) Research Grant/Speakers Bureau Consultant/Advisory Board Speakers Bureau/Advisory Board Advisory Board/Consultant
Selim Arcasoy	Sunrise 2	Astellas	Research Grant (significant)
Nicholas Banner	XDx Lunch, #37, Abstract Reviewer	Roche	Speaker/Investigator (modest)
David Baran	Sunrise 5	Astellas	Honorarium (modest)
Maher Baz	Abstract Reviewer	Astellas	Investigator
Raymond Benza	Satellite 8	Actelion Pfizer United Therapeutics Lung Rx Myogen	Speaker/Grants (modest) Speaker/Grants (modest) Speaker/Grants (modest) Speaker/Grants (modest) Speaker/Grants (modest)
Gerald Berry	Concurrent 22, Abs Review	XDx	Consultant (modest)
Sangeeta Bhorade	Abstract Reviewer	Astellas	Grant Research Support
Emily Blumberg	Abstract Reviewer	Roche	Consultant/Speakers Bureau
Annette Boehler	Sunrise 6, Abstract Review, Mini Oral 1	Roche Novartis	Research Support (modest) Research Support (modest)
Stephen Bolling	Abstract Reviewer	Edwards Orqis	
Robert Boucek	# 509	Astellas	Advisory Board (modest)
Susan Brozena	Abstract Reviewer	GSK Medtronic Wyeth	Advisory Board/Speaker Research Support Research Support
Michael Burch	#176, Concurrent 18, Satellite 3, Abstract Review	Roche Astellas	Travel Grant (modest) Research Support (modest)
Martin Cadeiras	# 215	XDx	Research Support (significant)
Marcelo Cantarovich	Abstract Reviewer	Novartis Roche Astellas	Travel Grant (modest) Advisory Board/Honorarium (modest) Honorarium (modest)
Charles Canter	Satellite 3, Abstract Review	Blue Cross Blue Shield	Consultant (modest)
Hunter Champion	Satellite 2	Pfizer Encysive Coherix	Speaker (significant) Speaker (modest) Speaker (modest)
Leway Chen	Concurrent 36, Abstract Reviewer	Johnson&Johnson Ariomed Inc Thoratec	Grant/Research Support (significant) Speakers Bureau (modest) Consultant (modest)
Kenneth Chien	Opening Plenary	Cytori Progenitor	Consultant/Advisor (significant) Founder (modest)

Paul Corris	Concurrent 13, #524, 530, Program Committee, Closing Plenary, Satellite 8	Encysive Actelion GSK Pfizer	Speaker/ Scientific Advisor (modest) Speaker/Advisory Board Research Support Speaker/Advisory Board
Duane Davis	Program Committee, Opening Plenary, Satellite 5	XDX St Jude INO DOMPE Roche	Grant Support (significant) Grant Support/ Speaker (modest) Consultant (modest) Grant Support (significant) Grant Support (significant)
Sabine DeGeest	Abstract Reviewer	BMS Novartis Sanofi-Aventis	Consultant Consultant Conslutant
Nicholas De Jonge	Concurrent 36, # 478, Abstract Reviewer	Novartis	Advisory Board (modest)
Mario Deng	# 58, Abstract Reviewer	XDx	Research Support (significant)
Mary Amanda Dew	# 368, Sunrise 7	Astellas	Research Support (modest)
Anne Dipchand	Satellite 3, #512, 567	Novartis Astellas Roche	Research Support (modest) Research Support (modest) Research Support (modest)
Fabienne Dobbels	Satellite 6, Program Committee	BMS Novartis	Research Support/Speaker (modest) Speaker (modest)
Robert Dowling	Satellite 1	Abiomed	Honorarium (modest)
Stephen Dummer	Abstract Reviewer	Pfizer	Honorarium (modest)
Tom Egan	Program Committee	Medtronic Ethicon Terumo Cryolife Vitrolife	Research Support Research Support Research Support Research Support Research Support
Howard Eisen	Satellite 12, # 46, Abstract Reviewer	Novartis Wyeth XDx	Grants/Research/Consultant/Advisor (significant) Grants/Research/Consultant/Advisor (modest) Consultant/Advisor (modest)
Donald Esmore	# 121, Abstract Reviewer	Ventracor	Consultant (significant)
Gregory Ewald	Abstract Reviewer	Boston Scientific GSK Scios	Consultant/Advisory Board Speakers Bureau Speakers Bureau
David Farrar	# 94	Thoratec	Employee (significant)
Roberto Falaloro	Concurrent 41	Novartis	Clinical Trial PI
David Feldman	Concurrent 38, Abstract Reviewer	GSK Medtronic Scios Thoratec Abbot	Consultant/Advisor (significant) Consultant/Advisor (significant) Consultant/Speaker (modest) Consultant (modest) Consultant (modest)
Michael Felker	Abstract Reviewer	Amgen Guidant Abott Roche Diagnostics	Grant/Consulting/Honoraria Consulting Advisory Board Grant Support
Matthew Fenton	# 176	Astellas Roche	Research Funding (modest) Research Funding (modest)
Andrew Fisher	Abstract Reviewer	Actelion	Travel Grant (modest)
Maureen Flattery	Sunrise 7	XDx	Speakers Bureau (modest)
F. Jay Fricker	Sunrise 8	Encysive	Consultant (modest)
Eli Gabbay	Abstract Reviewer	Actelion Schering Encysive Myogen	Advisory Board/Grants/Research Support Grant/Research Support Advisory Board Research Support

Howard Gebel	Thursday Plenary	One Lambda	Research Support/Consultant (significant)
H. Ardeschir Ghofrani	Satellite 8	Encysive Novartis Pfizer	Advisory Board/Speaker (modest) Advisory Board (modest) Advisory Board/Speaker (modest)
Reda Girgis	Satellite 2, #159, Concurrent 28	Encysive Actelion Cotherix Pfizer United Therapeutics	Speaker/Research Support/Consultant (modest) Speaker/Research Support/Consultant (modest) Consultant (modest) Research Support (modest) Consultant/Research Support (modest)
Allan Glanville	Abstract Reviewer	Novartis Roche Janssen-Cilag	Advisory Board Advisory Board Advisory Board
Jeffrey Golden	# 154	XDx Roche Cotherix	Grant/Research Support (significant) Grant/Research Support (significant) Grant/Research Support (significant)
Julian Gooi	# 8	Transmedics	sponsored workshop (modest)
Kate Gould	Concurrent 39, Abstract Reviewer	Novartis	Speaker/Clinical Advisor (modest)
Bartley Griffith	Satellite 1, Concurrent 40 #91	Circulite	Surgical Advisory Board (none)
Jan Groetzner	# 469, Concurrent 14	Roche	Travel Grant (modest)
Paolo Grossi	Abstract Reviewer	MSD Pfizer Schering Plough Roche Bayer	Advisory Board Advisory Board Advisory Board Advisory Board Advisory Board
Ramsey Hachem	# 14, 138	Astellas	Speaker (modest)
Ari Halldorsson	# 303	Organ Transport Systems	Grant (matching funds)
John Herre	# 339	Medtonic St Jude Guidant	Grant/Research Support (significant) Grant/Research Support (significant) Grant/Research Support (significant)
Marshall Hertz	Opening Plenary	Astellas	Study Monitor (modest)
Roland Hetzer	Abstract Reviewer	Berlin Heart	Consultant
Nicola Hiemann	# 220, 234, 261	Roche	Grant Support (modest)
William Holman	Satellite 7	Thoratec Heartware Myoetech Evaheart	Advisory Board (modest) Advisory Board (modest) Advisory Board (modest) Consultant (modest)
Sally Houston	Abstract Reviewer	Merck Pfizer	Stock Stock
Atul Humar	Concurrent 11	Roche Astellas	Grant/Research Support/Speaker (significant) Grant/Research Support (significant)
Judson Hunt	Novartis Symposium, #398	Roche	PI/Grants/Research Support (modest)
Shahid Husain	Sunrise 3, Concurrent 11	Astellas Biorad Pfizer Enzon Schering-Plough	Grants (significant) Grants (modest) Speaker (modest) Grants (significant) Consultant (modest)
Martin Iversen	# 449	Novartis Roche	Research Grant (significant) Research Grant (significant)
Maryl Johnson	Satellite 9	Astellas CareMark	Consultant (modest) Consultant (modest)
Anne Keogh	Satellite 2, Novartis Satellite,	Roche Novartis	Investigator/Speaker/Advisory Board (modest) Investigator/Speaker/Advisory Board (modest)

	#396, 352, 475, Abstract Reviewer	Encysive Myogen Pfizer Ventracor Wyeth	Investigator/Speaker/Advisory Board (modest) Investigator (modest) Investigator (modest) Investigator (modest) Investigator/Consultant (modest)
Shaf Keshavjee	Abstract 351, 421, Program Committee	XDx Astellas	Scientific Advisor/Study PI (modest) Research Support
Michelle Kittleson	# 461, 542	Novartis	Research Grants (significant)
Walter Klepetko	Friday Plenary, Novartis Symposium, Abstract Reviewer	Astellas Roche Novartis Genzyme	Research Support Research Support Research Support Research Support
Jon Kobashigawa	Satellite 5, #466	Novartis Astellas Roche XDx	Speaker/Advisory Board/Grant/Honoraria (modest) Speaker/Advisory Board/Grant/Honoraria (modest) Speaker/Advisory Board/Grant/Honoraria (modest) Grants/Advisory Board/ Honorarium (modest)
Daniel Kreisel	Concurrent 21	Roche	Grant (significant)
Bernard Kubak	Sunrise 3	Pfizer Merck Enzon	Speakers Bureau (modest) Speakers Bureau (modest) Speakers Bureau (modest)
Stephen Large	Satellite 1, Abstract Reviewer	Levitronix Thoratec St. Jude	Travel Grant (modest) Travel Grant (modest) Travel Grant (modest)
Angeline Leet	# 465, Concurrent 41	Roche Novartis	Grant/Research Support/Speaker (modest) Grant Support (modest)
Antonio Legorreta	# 468	Novartis	Grant/Research Support (significant)
Hans Lehmkuhl	#397, 341, 397, Concurrent 17, Abstract Reviewer Concurrent 12	Astellas Roche Novartis Genzyme	Consultant (modest) Consultant (modest) Consultant (modest) Consultant (modest)
Bronwyn Levey	# 416	Novartis	Grant/Research Support (modest)
Matthias Loebe	# 103	Micromed	Consultant (significant)
James Long	Satellite 7, Abstract Reviewer	WorldHeart Thoratec	Consultant/Stockholder/Scientific Advisor (significant) Speaker (modest)
Peter MacDonald	Abstract Reviewer	Roche Actelion	Advisory Board (modest) Advisory Board (modest)
Balukrisynan Mahesh	# 378	Imperial College	Intellectual Property Rights (modest)
Charles Marboe	Abstract Reviewer	XDx Novartis	Consultant Consultant
David Markham	# 125	Novartis	Speaker (modest)
Paul Mather	Abstract Reviewer	Orqis Astra-Zeneca	Advisory Board Speakers Bureau
Frauke Mattner	# 450	Pfizer	Research Support (modest)
Simon Maybaum	# 414	Columbia University	Patent/Inventor (modest)
Kenneth McCurry	Concurrent 27, Mini Oral 3	XDx	Consultant/Speaker (modest)
Mandeep Mehra	#131, 171, Satellite 12, Opening Plenary, Program Committee, XDx Symposium	XDx Astellas Novartis Roche Scios Medtronic	Consultant/Research Grants (modest) Consultant (modest) Consultant (modest) Consultant./Research Grants (modest) Consultant (modest) Consultant/Research grants (modest)
Bruno Meiser	# 29	Roche Astellas	Research Grant/Consultant (significant) Research Grant/Consultant (significant)

Bryan Meyers	Program Committee	DOMPE	Consultant
Carmelo Milano	Program Committee	Thoratec Abiomed	Consultant/Speaker Speaker
Nick Morrell	Satellite 2	Actelion Novartis	Speaker (modest) Consultant (modest)
Johannes Mueller	# 338	Berlin Heart	Employee/Officer (significant)
Yoshifumi Naka	Sunrise 4, Concurrent 25, Abstract Reviewer	Terumo Heart Inc Ventracor Thoratec	Consultant (modest) Consultant (modest) Steering Committee/Speaker Bureau (modest)
Devin Nelson	# 335, 389	WorldHeart	Stockholder (modest)
Duc Nguyen	# 82, 388	Thoratec	Fellowship Support (significant)
Jonathan Orens	Sunrise 2, Abstract Review	Astellas	Advisory Board (modest)
Scott Palmer	Program Committee	Roche	Investigator
Francesco Parisi	Satellite 3	Novartis	Medical Advisor (modest)
Myung Park	Satellite 2	Actelion United Therapeutics Encysive	Consultant/Speaker/Research Support (significant) Speaker/Sci Adv Board (modest) Consultant (modest)
Gareth Parry	Mini Oral 2	Roche	Travel Grant (modest)
Jignesh Patel	# 27, 490	Astellas Novartis Medtonic	Research Grant/ Advisory BoD/Honoraria (significant) Research Grant/ Advisory BoD/Honoraria (significant) Research Grants (modest)
David Pauly	# 477	National Institute of Health Florida Dept of Health Novartis Astellas Expression Diagnostics	Grant/Research Support (modest) Grant/Research Support (modest) Grant/Research Support (modest) Grant/Research Support (modest) Grant/Research Support (modest)
Si Pham	# 59	Astellas XDx	Research Support (significant) Consultant (modest)
Luciana Potena	# 238, 501	Novartis	Speaker Bureau (modest)
Gregorio Rabago	Abstract Reviewer	Roche Wyeth	Grant/Research/Advisory Board Advisory Board
Barry Rayburn	Concurrent 31, Prog Comm	Encysive	Speaker Bureau (modest)
Hermann Reichenspurner	Roche Symposium, #420	Astellas Roche	Study Sponsor Study Sponsor
Andrew Rivard	# 304	Hibernicor	Board Member (modest)
Joe Rogers	Program Committee	GSK Medtronic	Speakers Bureau Speakers Bureau
Marlene Rose	Abstract Reviewer	Imperial Innovations	Patent Inventor
David Rosenbaum	# 12	Organ Transport Systems	Research Grant (significant)
Bruce Rosengard	Sunrise 5, Program Comm	Transmedics	PI (none)
Heather Ross	Novartis Symposium, #42, 474, Abstract Reviewer	Novartis Wyeth Astellas	Consultant/ Grants/ Research (modest) Consultant/Advisory Board (modest) Consultant/ Grants/ Research (modest)
Joseph Rossano	# 429, 507	Scios	Grant/Research Support (significant)
Theresa Rowe	# 128	XDx	Speakers Bureau (modest)
Stuart Russell	Sunrise 4, Concurrent 17, Program Committee	Thoratec	Consultant (modest)
Hani Sabbah	# 385	Orqis Medical Inc	Research Grant/Speakers Bureau (significant)
Daniel Salomon	Friday Plenary	Appimetrix	Grant Research Support (significant)

		Rocite	Grant Research Support (significant)
Michael Schmoeckel	# 498	Medtronic	Travel Grant (modest)
Mark Schnitzler	# 7, 9	Roche Novartis Astellas Transmedics	Grants/Research Support (significant) Grants/Research Support/Advisory Board (significant) Grants/Research Support (significant) Grants/Research Support (significant)
Sebastian Schulte-Eistrup	# 300	Transmedics	Travel Grant (modest)
Lianne Singer	Concurrent 13, # 280, Abstract Reviewer	Roche Astellas	Grants/Research Support (modest) Honorarium (modest)
Marvin Slepian	# 85	Syncardia	Scientific Advisor (modest)
Nick Smedira	Abstract Reviewer	Syncardia Vital Sensors	Proctor (modest) Consultant
Greg Snell	# 147, 481, 285, Mini Oral 1, Program Committee	Actelion Roche Novartis	Research Support/Grant (significant) Medical Advisor (modest) Grants Research Support (modest)
Randall Starling	XDx Symposium, Session 8, Abstract Reviewer	XDx Novartis Astellas Thoratec WorldHeart Roche	Investigator/Contractor/Advisory Board (significant) Advisor, Research Support (significant) Research Support/Honorarium (modest) Research Support Advisory Board Research Support
Duncan Stewart	Satellite 8	Northern Therapeutics	CSO/Founding Scientist (significant)
Samuel Strober	Satellite 4	Genzyme	Consultant (modest)
Martin Strueber	Concurrent 2, Satellite 1, # 470, 331	Novartis Thoratec Roche	Grants/Research Support (significant) Grants/Research Support (significant) Grants/Research Support (significant)
Sean Studer	#153, 331	Novartis Encysive	Grants/Research Support (significant) Consultant (modest)
Benjamin Sun	# 540	Thoratec	Research Support (modest)
Stuart Sweet	Mini Oral 2, Program Comm	XDx Chiron	Research Support (significant) Speakers Bureau (modest)
Jacqueline Szmuszkovicz	Concurrent 45	Encysive	Consultant (modest)
Henry Tazelaar	Abstract Reviewer	XDx	Conmsultant
Thomas Tedder	Satellite 5	MedImmune Angelica Therapeutics	Consultant/Advisory Board (significant) Consultant/Stockholder (significant)
Bert Trulock	Abstract Reviewer	XDx Nabi Pharma Astellas Chiron	Research Support Research Support Research Support Research Support
Steven Tsui	Concurrent 40, Abstract Reviewer	Ventracor ALung Ltd	Research Grant/Consultant/Advisor (significant) Grant/Research Support
Patricia Uber	Concurrent 17, Abs. Review	Astellas	Speakers Bureau (modest)
Jean-Luc Vachieri	Concurrent 28	Encysive GSK	Consultant (modest) Consultant/Medical Advisor (modest)
Miriam Van Albada	# 354	Astellas Actelion	Support printing thesis (modest) Support printing thesis (modest)
Adrian Van Bakel	Abstract Reviewer	Scios Orqis Medical Novartis Medtronic	Research Support Research Support Research Support Research Support
Johan Van Haecke	Concurrent 5	Roche Novartis Astellas XDx	Speaker/Research Support (modest) Advisory Board (modest) Advisory Board (modest) Research Support (modest)

Erik Verschuuren	#136, Concurrent 42	Astellas	Travel Grant (modest)
Lynne Wagoner	Abstract Reviewer	Astellas	Consultant
Steven Webber	Satellite 12, Abs Review	Genetech	Research Grant (significant)
Willem Weimar	Abstract Reviewer	Novartis Astellas Roche Wyeth	Consultant Consultant Research Grant Reseach Grant
Lori West	Satellite 5, #36, Opening Plenary, Closing Plenary, Program Committee	Astellas Novartis	Grant/Research Support (modest) Research Support
Glen Westall	# 239, 441, Abstract Reviewer	Cellestis Roche	Research Grant (significant) Speakers Bureau (modest)
George Wieselthaler	Program Committee, Satellite 1, Concurrent 7	HeartWare	Advisory Board (modest)
James Young	Concurrent 1	Acorn Guidant Medtronic WorldHeart	Consultant (modest) Consultant/Grants/Research Support (modest) Consultant/Grants/Research Support (modest) Consultant/Grants/Research Support (significant)
Aimee Zaas	Sunrise 3	Pfizer Pfizer	Speaker (modest) Speaker (Spouse) (modest)
Marty Zamora	Program Committee	Roche Biogenesis DOMPE	Grant/Research Support Speakers Bureau Research Support
Michael Zakliczynski	# 23, 267	Astellas	Consultant (modest)
Mark Zucker	Concurrent 19, Abstract Reviewer	Encysive Nitromed Paracor CVT	Speakers Bureau (modest) Speaker (modest) Clinical Committee (modest) Speaker (modest)
Rachelle Zomack	Sunrise 7	XDx	Advisory Board (modest)
Andreas Zuckermann	Program Committee	Genzyme Astellas Novartis Roche Wyeth	Speaker Speaker Speaker/Study Committee Speaker/Study Member Speaker/investigator

The International Society for Heart and Lung Transplantation is most grateful for the educational grants and the support of

Gold Partners

**Astellas Pharma US**

**Novartis**

**Roche**

Silver Partners

**Actelion**

**Encysive**

**TransMedics**

**XDx**

toward this

Twenty Seventh Annual Meeting and Scientific Sessions

ADD TEMPLATE HERE – becky, since we have 6 concurrent sessions this year, you may want to do the template as a fold-out page

## SCIENTIFIC PROGRAM

All meetings and activities will take place at the Hilton San Francisco unless otherwise specified. All papers will be presented in English. Abstract presenter names are underlined. A presentation title or name preceded by an asterisk indicates that the presenter/chair has indicated a relationship which, in the context of this CME activity, could be perceived as a potential conflict of interest. Please refer to the disclosure information provided in this booklet for additional information about specific presenter and chair disclosure information.

### MONDAY, APRIL 23, 2007

#### **3:00 PM – 10:00 PM**

Exhibit Hall Build (Continental Ballroom)

### TUESDAY, APRIL 24, 2007

#### **8:00 AM – NOON**

Registration Build (West Lounge Foyer)

#### **8:00 AM – 8:00 PM**

Exhibit Hall Build (Continental Ballroom)

Internet Café Set-up (Continental Ballroom Foyer)

Poster Board Set-up (Continental Ballroom and Yosemite Ballroom)

#### **6:00 PM – 10:00 PM**

ISHLT Board of Directors Meeting (Union Square 19-20)

#### **6:00 PM – 9:00 PM**

Registration Desk Open (West Lounge Foyer)

#### **6:00 PM – 9:00 PM**

Slide Ready Room Open (Green Room)

### WEDNESDAY, APRIL 25, 2007

#### **6:00 AM – 6:00 PM**

Registration Desk Open (West Lounge Foyer)

#### **6:00 AM – 6:00 PM**

Slide Ready Room Open (Green Room)

#### **7:00 AM – NOON**

Exhibitor Move-In (Continental Ballroom)

General Poster Session 1 Mounting (Continental Ballroom)

#### **7:00 AM – 6:00 PM**

Press Office Open (Executive Boardroom)

#### **7:00 AM – 24 Hours**

Internet Café Open (Continental Ballroom Foyer)

#### **8:00 AM – 10:00 AM**

##### **SATELLITE SYMPOSIUM 1**

##### **New Mechanical Circulatory Support (MCS) Technology (Grand Ballroom B)**

\*Chairs: O. Howard Frazier, MD and \*Stephen R. Large, MD

##### **Continuous Flow Devices**

\*8:00 AM *MicroMed*, George M. Wieselthaler, MD, University of Vienna, Vienna, Austria

8:10 AM *INCOR*, Michael J. Jurmann, MD, Deutsches Herzzentrum Berlin, Berlin, Germany

\*8:20 AM *HeartMate II*, Martin Strueber, MD, Hannover Medical School, Hannover, Germany

##### **Total Artificial Heart**

\*8:30 AM *AbiCor*, Robert D. Dowling, MD, University of Louisville / Jewish Hospital, Louisville, KY

8:45 AM *Cardiowest*, Jack G. Copeland, MD, University of Arizona Health Science Center, Tucson, AZ

##### **Percutaneous Devices**

9:00 AM *Tandem Heart*, Reynolds M. Delgado, MD, Texas Heart Institute, Houston, TX

\*9:15 AM *Impella*, Bartley P. Griffith, MD, University of Maryland, Baltimore, MD

9:30 AM *Bioengineering Perspective*, Greg Burgreen, PhD, Mississippi State University, Mississippi State, MS

9:50 AM Discussion

#### **8:00 AM – 10:00 AM**

##### **SATELLITE SYMPOSIUM 2**

**Pulmonary Hypertension: A Tale of the Lungs and Two Ventricles (Grand Ballroom A)**

*Supported by an Unrestricted Educational Grant from Actelion*

**\*Chairs:** \*Reda Girgis, MB, BCh and \*Anne Keogh, MBBS, MD

**\*8:00 AM** *Pathobiology of Pulmonary Hypertension*, Nick W. Morrell, MD, FRCP, *University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom*

**8:20 AM** Discussion

**\*8:30 AM** *The Role of Rho Kinase Pathway in Right Heart Failure*, Hunter C. Champion, MD, PhD, FAHA, Johns Hopkins Hospital, Baltimore, MD

**8:50 AM** Discussion

**9:00 AM** *Pulmonary Hypertension in the Cardiac Transplant Setting*, Leslie W. Miller, MD, Georgetown University Hospital, Washington, DC

**9:20 AM** Discussion

**\*9:30 AM** *Pulmonary Hypertension in the Perioperative Setting*, Myung H. Park, MD, University of Maryland School of Medicine, Baltimore, MD

**9:50 AM** Discussion

**8:00 AM – 10:00 AM**

**SATELLITE SYMPOSIUM 3**

**Protecting the Kidney in Pediatric Thoracic Transplant (Imperial Ballroom A)**

**\*Chairs:** \*Charles E. Canter, MD and Glen P. Westall, FRACP

**8:00 AM** *Renal Complications Following Solid Organ Transplant - Risk Factors and Management Strategies*, Kathleen M. Campbell, MD, Cincinnati Children's Hospital, Cincinnati, OH

**8:20 AM** Discussion

**\*8:25 AM** *Minimizing Immunosuppression in Pediatric Recipients*, Anne I. Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada

**8:45 AM** Discussion

**8:50 AM** *Debate: TOR Inhibitors – Time to Switch?*

**\*8:50 AM** *Pro:* Francesco Parisi, MD, Ospedale Pediatrico "Bambino Gesù", Rome, Italy

**\*9:05 AM** *Con:* Michael Burch, MD, Great Ormond Street Hospital, London, United Kingdom

**9:20 AM** *Pro Rebuttal*

**9:25 AM** *Con Rebuttal*

**Update on the NHLBI's Pediatric Circulatory Support Program**

**9:30 AM** *Program Officer's Perspective*, Timothy Baldwin, PhD, National Institutes of Health, Bethesda, MD

**9:45 AM** *Investigator's Perspective*, Brian W. Duncan, MD, Cleveland Clinic Foundation, Cleveland, OH

**8:00 AM – 10:00 AM**

**SATELLITE SYMPOSIUM 4**

**Cellular Immune Therapy (Imperial Ballroom B)**

**Chairs:** Carla C. Baan, PhD and Thomas K. Waddell, MD, PhD

**8:00 AM** *Mesenchymal Stem Cell Regulation of Alloresponses*, TBA

**\*8:30 AM** *The Role of Hematopoietic Stem Cells in Tolerance*, Samuel Strober, MD, Stanford University, Palo Alto, CA

**9:00 AM** *Regulatory Cells: Ready for the Clinic?* TBA

**9:30 AM** *Dendritic Cell Therapy*, Angus Thomson, PhD, DSc, FRCPath, University of Pittsburgh School of Medicine, Pittsburgh, PA

**8:00 AM – 10:00 AM**

**SATELLITE SYMPOSIUM 5**

**The Evolving Problem of Antibodies in Thoracic Transplantation (Plaza Ballroom A)**

**\*Chairs:** \*Lori West and \*Duane Davis, MD

**8:00 AM** *Who are the Players: B Cells and Plasma Cells*, Michael P. Cancro, MD, University of Pennsylvania School of Medicine, Philadelphia, PA

**8:20 AM** Discussion

**8:25 AM** *Antibodies and Their Targets*, Ronald H. Kerman, PhD, University of Texas Medical School, Houston TX

**8:45 AM** Discussion

**\*8:50 AM** *Clinical Therapies Currently in Use: Do Any of Them Work?* Jon Kobashigawa, MD, University of California at Los Angeles, Los Angeles, CA

**9:10 AM** Discussion

**9:15 AM** *When is Antibody not Destructive?* Jeffrey L. Platt, MD, Mayo Foundation, Rochester, MN

**9:30 AM** Discussion

**\*9:35 AM** *Future Directions in Therapy*, Thomas F. Tedder, PhD, Duke University Medical Center, Durham, NC

**9:55 AM** Discussion

**8:00 AM – NOON**

**SATELLITE SYMPOSIUM 6**

**Joint ISHLT/ITNS/NATCO Clinical Update (Plaza Ballroom B)**

**Chairs:** Nancy P. Blumenthal, CRNP and Bronwyn J. Levvey, RN

**8:00 AM** *International Perspectives on Thoracic Transplantation*, Susan M. Chernenko, MN, Toronto General Hospital, Toronto, ON, Canada

**8:20 AM** Discussion

**8:25 AM** *Current Issues in Lung and Heart Transplantation: Impact of the New Allocation System*, Jean B. Rea, RN, MS, CCTC, Duke University Medical Center, Durham, NC

**8:45 AM** *Discussion*

**8:50 AM** *High Risk Behavior in the Recipient Pre-Transplant: Is it a Predictor of Poor Outcomes?* Ashley Finlen Copeland, MSW, LCSW, Duke University Medical Center, Durham, NC

**9:10 AM** *Discussion*

**9:15 AM** *Retransplantation: Indications, Outcomes, Allocation, and Equity*, Katherine Hoercher, RN, Cleveland Clinic Foundation, Cleveland, OH

**9:35 AM** *Discussion*

**9:40 AM** BREAK

**10:00 AM** *Bugs and Drugs: New Fungal Infections and Therapies*, Kathy Schwab, RN BSN CCTC, Mayo Clinic, Rochester, MN

**10:20 AM** *Discussion*

**\*10:25 AM** *Patient Reported Outcomes in Transplantation*, Fabienne Dobbels, MSc, PhD, University Hospital Leuven, Leuven, Belgium

**10:45 AM** *Discussion*

**10:50 AM** *Optimizing and Increasing Thoracic Organ Donors: Utilizing Virtual Cross-match, ECD, and Living Lobar Donors*, Kevin C. Carney, RN, CCTC, University of Pennsylvania Medical Center, Philadelphia, PA

**10:10 AM** *Discussion*

**11:15 AM** *Trading One Disease for Another? Can We Reduce the Co-Morbidities Post Transplant?* Nancy K. Harrington, RN, BS, MS, CCTC, University Medical Center, Tucson, AZ

**11:35 AM** *Discussion*

**11:40 AM** *Panel Discussion*

**10:00 AM – 10:15 AM**

**Coffee Break (Continental Foyer/West Foyer)**

**10:15 AM – 12:15 PM**

**SATELLITE SYMPOSIUM 7**

**Strategies and Results from MCS Therapy: Myocardial Recovery and Permanent Support (Grand Ballroom B)**

**\*Chairs:** Robert L. Kormos, MD and \*Joseph G. Rogers, MD

***Myocardial Recovery***

**\*10:15 AM** *Berlin Heart Center Experience*, Roland Hetzer, MD, PhD, German Heart Institute, Berlin, Germany

**10:30 AM** *Harefield Hospital Experience*, Emma Birks, MRCP, Harefield Hospital, Harefield, United Kingdom

**10:45 AM** *Myocardial Recovery on Mechanical Circulatory Support: Fundamental Mechanisms*, Guillermo Torre-Amione, MD, PhD, Baylor College of Medicine, Houston, TX

**11:00 AM** *Discussion*

***Issues in Permanent Mechanical Circulatory Support***

**11:15 AM** *Criteria and Patient Selection*, Leslie W. Miller, MD, Georgetown University Hospital, Washington, DC

**\*11:30 AM** *Anticoagulation*, William L. Holman, MD, University of Alabama, Birmingham, AL

**11:45 AM** *Building a DT Practice*, Mark S. Slaughter, MD, Advocate Christ Medical Center, Oak Lawn, IL

**\*NOON** *Device Reliability and Durability Issues*, James W. Long, MD, PhD, LDS Hospital, Salt Lake City, UT

**10:15 AM – 12:15 PM**

**SATELLITE SYMPOSIUM 8**

**Hot Topics in Pulmonary Arterial Hypertension**

***Supported by an Unrestricted Educational Grant from Encysive Pharmaceuticals (Grand Ballroom A)***

**\*Chairs:** \*Raymond L. Benza, MD and \*Paul A. Corris, MB, FRCP

**\*10:15 AM** *Angiogenesis in PAH: Pathogenic or Compensatory?* Duncan J. Stewart, MD, FRCPC, St. Michael's Hospital, Toronto, ON, Canada

**10:35 AM** *Discussion*

**10:45 AM** *PH in Left Heart Disease – Role of Specific Therapies*, José A. Tallaj, MD, University of Alabama at Birmingham, Birmingham, AL

**11:05 AM** *Discussion*

**11:15 AM** *Treatment of PAH in Congenital Heart Disease*, Michael J. Landzberg, MD, Children's Hospital Boston, Boston, MA

**11:35 AM** *Discussion*

**\*11:45 AM** *Exploiting Novel Therapeutic Pathways in PAH*, H. Ardeschir Ghofrani, MD, Justus-Liebig-University, Giessen, Germany

**12:05 PM** *Discussion*

**10:15 AM – 12:15 PM**

**SATELLITE SYMPOSIUM 9**

**Continued Evaluation of Heart and Lung Allocation Using Evidence Based Research (Imperial Ballroom A)**

**\*Chairs:** J. David Vega, MD and \*Bryan F. Meyers, MD

**10:15 AM** *How is the Lung Allocation Score Working in the US?* Leah Edwards, PhD, United Network for Organ Sharing, Richmond, VA

**10:30 AM** *How to Get New Data Into an Existing Allocation Algorithm*, Susan Murray, ScD, Scientific Registry of Transplant Recipients, Ann Arbor, MI

**\*10:45 AM** *Building a New Heart Allocation System That Goes Beyond Status*, Maryl R. Johnson, MD, University of Wisconsin, Madison, WI

**11:00 AM** *Issues in Heart and Lung Allocation in East and West Europe*, Dirk van Raemdonck, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

**11:15 AM** *Ethical Issues in Organ Allocation/Solicitation*, James DuBois, PhD, DSc, St. Louis University, St. Louis, MO

**11:45 AM** *Discussion*

**10:15 AM – 12:15 PM**  
**SATELLITE SYMPOSIUM 10**

**Interplay of Innate and Adaptive Immunity (Imperial Ballroom B)**

**\*Chairs:** \*Scott M. Palmer, MD and Michael S. Mulligan, MD

**10:15 AM** *The Role of Innate Immune Signaling in Allograft Rejection*, Dianne McKay, MD, The Scripps Research Institute, La Jolla, CA

**10:45 AM** *The Role of Macrophages in Adaptive Immunity*, Allan D. Kirk, MD, PhD, National Institutes of Health, Bethesda, MD

**11:15 AM** *The Role of NK Cells in Adaptive Immunity*, Joren C. Madsen, MD, D.Phil., Massachusetts General Hospital, Boston, MA

**11:45 AM** *The Role of Mast Cells in Adaptive Immunity*, Soman N. Abraham, MD, PhD, Duke University Medical School, Durham, NC

**10:15 AM – 12:15 PM**  
**SATELLITE SYMPOSIUM 11**

**Antibody-Mediated Rejection of the Lung: What are the Morphologic and Clinical Findings? (Plaza Ballroom A)**

**Chairs:** Michael C. Fishbein, MD and Susan Stewart, FRCPath

**10:15 AM** *Antibody Mediated Rejection in Extrapulmonary Organ Sites*, Michael C. Fishbein, MD, University of California School of Medicine, Los Angeles, CA

**10:30 AM** *Discussion*

**10:35 AM** *Antibody Mediated Rejection of the Lung: Are There Reliable Morphologic Criteria?* Cynthia M. Magro, MD, Weill College of Medicine/Cornell University, New York, NY

**10:50 AM** *Discussion*

**10:55 AM** *Antibody Mediated Rejection of the Lung: Are There Reliable Morphologic Criteria?* Samuel A. Yousem, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

**11:10 AM** *Discussion*

**11:15 AM** *The Clinical Prognostic Significance of the C3d and C4d Deposition in Lung Biopsy Specimens*, Glen P. Westall, FRACP, Alfred Hospital, Melbourne, Australia

**11:30 AM** *Discussion*

**\*11:35 AM** *The Clinical Recognition of Antibody Mediated Rejection*, Martin R. Zamora, MD, University of Colorado Health Science Center, Denver, CO

**11:50 AM** *Discussion*

**NOON – 7:15 PM**

Exhibit Hall Open (Continental Ballroom)

General Poster Session 1 Viewing (Continental Ballroom)

**12:15 PM – 12:30 PM**

Box Lunch Pick-up (ticket required) (Yosemite Ballroom)

**12:30 PM – 2:00 PM**  
**LUNCHEON SYMPOSIUM**

**Practical Implications of Using PSI's In Thoracic Transplantation (Grand Ballroom B)**

*Supported by an Unrestricted Educational Grant from Novartis*

**\*Chairs:** John Dark, MB, FRCS and \*Heather Ross, MD

**\*12:30 PM** *The Challenge of Renal Dysfunction in Thoracic Transplantation: A Multi Disciplinary Approach*, Judson M. Hunt, MD, Dallas Nephrology Associates, Dallas, TX

**\*12:50 PM** *Unique Surgical Issues With PSIs: Tissue Regeneration and Beyond?* Walter Klepetko, MD, University of Vienna, Vienna, Austria

**1:10 PM** *Denovo CNI and PSI-based Immunosuppression: Achieving Optimal Balance*

**\*1:10 PM (396)** *Everolimus in De Novo Heart Transplant Recipients: Six Month Data on Cyclosporine Reduction and Impact on Renal Function*; A. Keogh,<sup>1</sup> S.S. Wang,<sup>2</sup> A. Zuckermann,<sup>3</sup> H. Ross,<sup>4</sup> M. Frigerio,<sup>5</sup> H. Eisen,<sup>6</sup> C. Bara,<sup>7</sup> G. Laufer,<sup>8</sup> M. Cotrufo,<sup>9</sup> S. Lena,<sup>10</sup> C. Sips,<sup>10</sup> <sup>1</sup>St. Vincent's Hospital, Sydney, Australia; <sup>2</sup>National Taiwan University Hospital, Taipei, Taiwan; <sup>3</sup>University of Vienna, Vienna, Austria; <sup>4</sup>Toronto General Hospital, Toronto, Canada; <sup>5</sup>Az Ops. Niguarda Ca'Granda, Milano, Italy; <sup>6</sup>Hahnemann Hospital, Philadelphia; <sup>7</sup>Kliniken der Medizinischen Hochschule, Hannover, Germany; <sup>8</sup>Universitätsklinik, Innsbruck, Austria; <sup>9</sup>Azienda Ospedaliera Monaldi, Napoli, Italy; <sup>10</sup>Novartis Pharma AG, Basel, Switzerland

**\*1:20 PM (397)** *Everolimus with Reduced Cyclosporine Exposure vs. MMF and Conventional Cyclosporine: Results from a Study in De Novo Heart Transplant Recipients*; H. Lehmkuhl,<sup>1</sup> U. Livi,<sup>2</sup> P. Boissonnat,<sup>3</sup> J. Arizon,<sup>4</sup> M. Vigano,<sup>5</sup> C. Magelli,<sup>6</sup> L. Almenar,<sup>7</sup> K.H. Abeywickrama,<sup>8</sup> Y. Gezahegn,<sup>8</sup> <sup>1</sup>Department of Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>2</sup>Department Cardiovascular Sciences, Az. Osp. S. Maria della Misericordia, Udine, Italy; <sup>3</sup>Cardiac Transplantation, Hospital Cardiologique de Lyon, Lyon, France; <sup>4</sup>Cardiology, Hospital Universitario Reina Sofia, Cordoba, Spain; <sup>5</sup>Cattedra di Cardiochirurgia, Policlinico S. Matteo-IRCCS Università degli Studi di Pavia, Pavia, Italy; <sup>6</sup>Cardiology, Az. Osp. di Bologna Policl. S. Orsola - Malpighi, Bologna, Italy; <sup>7</sup>Cardiology, Hospital Universitario La Fe, Valencia, Spain; <sup>8</sup>Infectious Diseases, Transplantation and Immunology, Novartis Pharma AG, Basel, Switzerland

**1:30 PM** *Panel Discussion*

**2:15 PM – 4:15 PM**

**OPENING PLENARY SESSION (Grand Ballroom B)**

**\*Chairs:** Robert C. Robbins, MD and \*Duane Davis, MD

**\*2:15 PM** *Welcome and Program Committee Report*, Robert C. Robbins, MD, ISHLT President, Stanford University School of Medicine, Palo Alto, CA and \*Duane Davis, MD, Scientific Program Chair, Duke University Medical Center, Durham, NC

**\*2:20 PM** *ISHLT International Thoracic Transplant Registry Report*, Marshall I. Hertz, University of Minnesota, Minneapolis, MN

**2:45 PM (1)** *Progress in Heart Transplantation: Riskier Patients yet Better Outcomes: A 15-Year Multi-Institutional Study*; D.O. Taylor,<sup>1</sup> R.N. Brown,<sup>2</sup> M.L. Jessup,<sup>3</sup> R.C. Starling,<sup>1</sup> K.D. Aaronson,<sup>4</sup> B.K. Rayburn,<sup>2</sup> J. Czerr,<sup>1</sup> D.C. Naftel,<sup>2</sup> J.K. Kirklin,<sup>2</sup> the Cardiac Transplant Research Database,<sup>2</sup> <sup>1</sup>Cleveland Clinic, Cleveland, OH; <sup>2</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>University of Pennsylvania, Philadelphia, PA; <sup>4</sup>University of Michigan, Ann Arbor, MI

**\*3:00 PM** *The New ISHLT International Heart Failure Guidelines*, Mandeep R. Mehra, MD, University of Maryland, Baltimore, MD

**\*3:15 PM** *Promises and Limitations of Cell Therapy*, Kenneth Chien, MD, PhD, Massachusetts General Hospital, Harvard Medical School and Harvard Stem Cell Institute, Boston, MA

**3:45 PM** *The Application of Nanotechnology in Medicine and Transplantation*, Nan Marie Jokerst, Duke University, Durham, NC

**4:15 PM – 4:45 PM**

**Coffee Break/View Posters (Continental Ballroom)**

**4:45 PM – 6:15 PM**

**CONCURRENT SESSION 1**

**Myocardial Recovery During Mechanical Circulatory Support (Grand Ballroom B)**

**\*Chairs:** Guillermo Torre-Amione, MD, PhD and \*Michael Dandel, MD

**\*4:45 PM** *Invited Lecture: The Role of INTERMACS in Facilitating Device Development*, James B. Young, MD, Cleveland Clinic Foundation, Cleveland, OH

**5:00 PM (2)** *Complete Discontinuation of Mechanical Support and Assessment of Inotropic Reserve in Patients with Left Ventricular Assist Devices*; R.S. George,<sup>1,2</sup> G. Tasca,<sup>1</sup> C.T. Bowles,<sup>1</sup> C. Webb,<sup>1</sup> G. Dreyfus,<sup>1</sup> A. Khaghani,<sup>1</sup> M.H. Yacoub,<sup>2</sup> E.J. Birks,<sup>1,2</sup> <sup>1</sup>Transplant and Mechanical Circulatory Support, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom; <sup>2</sup>Heart Science Centre, Magdi Yacoub Institute, Imperial College, Harefield, Middlesex, United Kingdom

**5:15 PM (3)** *Biplanar 2D-Echo Strain Imaging Documents Improvement in LV Function in Patients with VAD*; S. Zieroth,<sup>1,2</sup> M. Thangaroopan,<sup>3</sup> S. Carasso,<sup>2</sup> V. Rao,<sup>2</sup> D. Delgado,<sup>2</sup> H. Rakowski,<sup>2</sup> H. Ross,<sup>2</sup> <sup>1</sup>Department of Cardiology, St. Boniface General Hospital, Winnipeg, MB, Canada; <sup>2</sup>Department of Cardiac Transplant, University Health Network, Toronto, ON, Canada; <sup>3</sup>Massachusetts General Hospital, Boston, MA

**5:30 PM (4)** *Which Factors Predict the Recovery of Natural Heart Function after Left Ventricular Assist System Insertion*; A. Mano,<sup>1</sup> T. Nakatani,<sup>1</sup> N. Oda,<sup>1</sup> T.S. Kato,<sup>1</sup> K. Niwaya,<sup>1</sup> O. Tagusari,<sup>2</sup> H. Nakajima,<sup>2</sup> T. Funatsu,<sup>2</sup> K. Komamura,<sup>3</sup> A. Hanatani,<sup>1</sup> M. Kitakaze,<sup>3</sup> J. Kobayashi,<sup>2</sup> T. Yagihara,<sup>2</sup> S. Kitamura,<sup>2</sup> <sup>1</sup>Organ Transplantation, National Cardiovascular Center, Suita, Osaka, Japan; <sup>2</sup>Cardiovascular Surgery, National Cardiovascular Center, Suita, Osaka, Japan; <sup>3</sup>Cardiology, National Cardiovascular Center, Suita, Osaka, Japan

**5:45 PM (5)** *Differential Hypertrophic Response of Unloaded Terminal Failing Myocardium in Response to Pulsatile and Non-Pulsatile Ventricular Assist Device Support*; H. Milting,<sup>1</sup> A. Kassner,<sup>1</sup> L. Arusoglu,<sup>1</sup> M. Morshuis,<sup>1</sup> D. Roefe,<sup>1</sup> R. Cebulla,<sup>1</sup> R. Koerfer,<sup>1</sup> A. El Banayosy,<sup>1</sup> <sup>1</sup>Erich und Hanna Klessmann-Institut fuer Kardiovaskulaere Forschung und Entwicklung, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany

**6:00 PM (6)** *Cathepsin G Is Co-Localized in Trypsin/Chymase Positive Human Cardiac Mast Cells (MC<sub>TC</sub>) during Heart Failure and Mechanical Circulatory Support*; J. Jahanyar,<sup>1</sup> K.A. Youker,<sup>2</sup> G.P. Noon,<sup>1</sup> G. Torre-Amione,<sup>2</sup> M. Loebe,<sup>1</sup> <sup>1</sup>Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX; <sup>2</sup>Methodist DeBakey Heart Center, The Methodist Hospital, Houston, TX

**4:45 PM – 6:15 PM**

**CONCURRENT SESSION 2**

**Cardiac Ischemic Time: Warm, Cold, or Pump? (Grand Ballroom A)**

**\*Chairs:** John D. Vega, MD and \*Martin Strueber, MD

**\*4:45 PM (7)** *The Cost-Effectiveness of Increasing the Supply of Hearts for Transplant*; M.A. Schnitzler,<sup>1</sup> P.M. Buchanan,<sup>1</sup> J. Swindle,<sup>1</sup> R. Lee,<sup>1</sup> P.J. Hauptman,<sup>1</sup> <sup>1</sup>Internal Medicine, Saint Louis University, St. Louis, MO

**\*5:00 PM (8)** *The Potential Impact of Reducing Cold Ischaemic Time on Cardiac Transplant Survival*; J.H. Gooi,<sup>1</sup> A. Fracs,<sup>2</sup> L. Sharples,<sup>1</sup> K. Goldsmith,<sup>1</sup> D. Jenkins,<sup>1</sup> K. Dhital,<sup>1</sup> S. Large,<sup>1</sup> S. Tsui,<sup>1</sup> <sup>1</sup>Transplant Surgery Department, Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom; Australia and New Zealand Cardiothoracic Organ Transplant Registry, funded by the Department of Health and Aged Care, Australia

**\*5:15 PM (9)** *Impact of Ischemia Time on the Outcomes of Heart Transplant*; M.A. Schnitzler,<sup>1</sup> P.M. Buchanan,<sup>1</sup> T.E. Burroughs,<sup>1</sup> R. Lee,<sup>1</sup> P.J. Hauptman,<sup>1</sup> <sup>1</sup>Saint Louis University, St. Louis, MO

**5:30 PM (10)** *Prospective Multi-Center European Trial To Evaluate the Safety and Performance of the Organ Care System for Heart Transplants (PROTECT)*; G. Tenderich,<sup>1</sup> A. El-Banayosy,<sup>1</sup> B. Rosengard,<sup>2</sup> S. Tsui,<sup>2</sup> J. Wallwork,<sup>2</sup> R. Hetzer,<sup>3</sup> R. Koerfer,<sup>1</sup> W. Hassanein,<sup>4</sup> <sup>1</sup>Thoracic and Cardiovascular Surgery, Heart Center North Rhine-Westphalia, Bad Oeynhausen, Germany; <sup>2</sup>Cardiothoracic Surgery, Papworth Hospital, Papworth, United Kingdom; <sup>3</sup>Cardiothoracic and Vascular Surgery, German Heart Institute, Berlin, Germany; <sup>4</sup>TransMedics, Inc., Andover, MA

**5:45 PM (11)** *Use of Continuous Ex Vivo Perfusion to Resuscitate Hearts after Warm Ischemia: Animal Studies with Clinical Validation*; M.J. Collins,<sup>1</sup> T. Ozeki,<sup>1</sup> J. Gu,<sup>1</sup> N.S. Burris,<sup>1</sup> R.N. Pierson,<sup>2</sup> B.P. Griffith,<sup>1</sup> R.S. Poston,<sup>1</sup> <sup>1</sup>Division of Cardiac Surgery, Department of Surgery, University of Maryland Medical Center, Baltimore, MD; <sup>2</sup>Department of Surgery, Veterans Administration Hospital, Baltimore, MD

**\*6:00 PM (12)** *Cardiac Storage with a Perfusion Device Prevents Tissue Lactate Accumulation*; D.H. Rosenbaum,<sup>1</sup> M. Peltz,<sup>1</sup> M.E. Merritt,<sup>2</sup> H. Sasaki,<sup>1</sup> M.E. Jessen,<sup>1</sup> <sup>1</sup>Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center at Dallas, Dallas, TX; <sup>2</sup>Radiology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX

**4:45 PM – 6:15 PM**

**CONCURRENT SESSION 3**

**Lung Allocation and Recipient Complications (Imperial Ballroom A)**

**Chairs:** Vivek N. Ahya, MD and Dirk van Raemdonck, MD, PhD

**4:45 PM (13) *Extracorporeal Life Support Is a Viable Bridge to Lung Transplantation in Patients with Acute Cor Pulmonale and End Stage Pulmonary Fibrosis: A Case Series***; J.K. Wall,<sup>1</sup> J. Parekh,<sup>1</sup> S. Hays,<sup>2</sup> J.A. Golden,<sup>2</sup> C. Hoopes,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, University of California San Francisco, San Francisco, CA; <sup>2</sup>Transplant Pulmonology, University of California San Francisco, San Francisco, CA

**\*5:00 PM (14) *Impact of the New Lung Allocation System in the United States***; R.R. Hachem,<sup>1</sup> B.F. Meyers,<sup>1</sup> R.D. Yusen,<sup>1</sup> G.A. Patterson,<sup>1</sup> E.P. Trulock,<sup>1</sup> <sup>1</sup>Lung Transplant Program, Washington University School of Medicine, St. Louis, MO

**5:15 PM (15) *The ISHLT Primary Graft Dysfunction (PGD) Grading System: Time for Refinement?***; T. Oto,<sup>1</sup> B.J. Levvey,<sup>1</sup> G.I. Snell,<sup>1</sup> <sup>1</sup>Lung Transplant Unit, The Alfred Hospital, Melbourne, Victoria, Australia

**5:30 PM (16) *Primary Graft Dysfunction (PGD) and Development of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant Recipients***; D. Hadjiliadis,<sup>1</sup> R. Lingaraju,<sup>1</sup> J. Mendez,<sup>1</sup> N.P. Blumenthal,<sup>1</sup> V.N. Ahya,<sup>1</sup> J.S. Sager,<sup>1</sup> R.M. Kotloff,<sup>1</sup> A. Pochettino,<sup>1</sup> J.D. Christie,<sup>1</sup> <sup>1</sup>Lung Transplant Program, University of Pennsylvania, Philadelphia, PA

**5:45 PM (17) *A Prospective Study of a Management Algorithm to Minimise Lung Transplant (LTx) Primary Graft Dysfunction (PGD)***; J.A. Currey,<sup>1</sup> D.V. Pilcher,<sup>2</sup> A. Davies,<sup>2</sup> C. Schienkestel,<sup>2</sup> M. Botti,<sup>1</sup> T. Oto,<sup>3</sup> G. Snell,<sup>3</sup> <sup>1</sup>Alfred/Deakin Nursing Research Centre, Faculty of Health, Medicine, Nursing and Behavioural Sciences, Deakin University and The Alfred, Melbourne, Victoria, Australia; <sup>2</sup>Intensive Care Unit, Alfred Hospital, Melbourne, Victoria, Australia; <sup>3</sup>Lung Transplant Service, Alfred Hospital, Melbourne, Victoria, Australia

**6:00 PM (18) *Long Term Outcome of Severe Reperfusion Injury Post Lung Transplantation Following the Administration of Endobronchial Surfactant***; P.M. Hopkins,<sup>1</sup> F. Kermeen,<sup>1</sup> J. Dunning,<sup>1</sup> K.D. McNeil,<sup>1</sup> <sup>1</sup>Queensland Heart-Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Queensland, Australia

**4:45 PM – 6:15 PM**

**CONCURRENT SESSION 4**

**Good Heart, Bad Vessels (Imperial Ballroom B)**

**Chairs:** Stephen R. Large, FRCP, FRCS and Patricia P. Chang, MD

**4:45 PM (19) *C-Reactive Protein, Cardiac Allograft Vasculopathy and Coronary Interventions in Heart Transplant Patients***; C.A. Labarrere,<sup>1</sup> G. Campana,<sup>1</sup> G. Boguslawski,<sup>1</sup> M.A. Ortiz,<sup>1</sup> M.J. Sosa,<sup>1</sup> C. Terry,<sup>1</sup> D.E. Pitts,<sup>2</sup> J.A. O'Donnell,<sup>3</sup> D.A. Hormuth,<sup>2</sup> <sup>1</sup>Methodist Research Institute, Clarian Health Partners, Indianapolis, IN; <sup>2</sup>Clarian Health Transplant Center, Clarian Health Partners, Indianapolis, IN; <sup>3</sup>Krannert Institute of Cardiology, Indianapolis, IN

**5:00 PM (20) *QT Dispersion for Detection of Cardiac Allograft Vasculopathy in Heart Transplant Patients***; A. Kashem,<sup>1</sup> S. Panse,<sup>2</sup> R.C. Cross,<sup>1</sup> W.P. Santamore,<sup>1</sup> A.A. Bove,<sup>1</sup> <sup>1</sup>Section of Cardiology, Temple University, Philadelphia, PA; <sup>2</sup>Internal Medicine, Abington Memorial Hospital, Philadelphia, PA

**5:15 PM (21) *In Vivo Intravascular Ultrasound Derived Cardiac Allograft Vasculopathy Characterization Using Ultrasound Radiofrequency Analysis***; J.M. De la Torre Hernandez,<sup>1</sup> F. Sainz Laso,<sup>1</sup> V. Burgos,<sup>2</sup> F. Gonzalez Vilchez,<sup>2</sup> M. Ruiz Lera,<sup>2</sup> L. Fernandez Frieria,<sup>2</sup> R. Martin Duran,<sup>2</sup> M. Fernandez Valls,<sup>2</sup> J. Ruano,<sup>2</sup> J.A. Vazquez de Prada,<sup>2</sup> <sup>1</sup>U. de Hemodinamica, H.U. Marques de Valdecilla, Santander, Cantabria, Spain; <sup>2</sup>Unidad de Trasplante Cardiaco, H.U. Marques de Valdecilla, Santander, Cantabria, Spain

**5:30 PM (22) *Asymptomatic Cardiac Allograft Dysfunction in Heart Transplant Recipients with Normal Coronary Angiograms: Risk Factors Analysis and Predictive Role on Cardiac Allograft Vasculopathy Onset***; F. Tona,<sup>1</sup> A.L.P. Caforio,<sup>1</sup> A. Gambino,<sup>2</sup> A. Angelini,<sup>3</sup> A. Ramondo,<sup>1</sup> G. Feltrin,<sup>2</sup> G. Toscano,<sup>2</sup> G. Thiene,<sup>3</sup> G. Gerosa,<sup>2</sup> S. Iliceto,<sup>1</sup> <sup>1</sup>Cardiology, University of Padova, Padova, Italy; <sup>2</sup>Cardiovascular Surgery, University of Padova, Padova, Italy; <sup>3</sup>Cardiovascular Pathology, University of Padova, Padova, Italy

**\*5:45 PM (23) *Quilty Effect (QE) Correlates with Biopsy Proven Acute Cellular Rejection but Does Not Predict Transplanted Heart Coronary Artery Vasculopathy (CAV)***; M. Zakliczynski,<sup>1</sup> J. Nozynski,<sup>1</sup> D. Konecka-Mrowka,<sup>1</sup> M. Zembala,<sup>1</sup> <sup>1</sup>Department of Cardiac Surgery & Transplantation, Silesian Center for Heart Disease, Zabrze, Poland

**6:00 PM (24) *Functional Evaluation Using Intracoronary Pressure-Flow Derived Analysis to Detect Transplant Coronary Vasculopathy***; T.J.R. De Potter,<sup>1</sup> J. Bartunek,<sup>1</sup> S. Vercauteren,<sup>1</sup> S. Verstreken,<sup>1</sup> M. Goethals,<sup>1</sup> B. De Bruyne,<sup>1</sup> M. Vanderheyden,<sup>1</sup> F. Wellens,<sup>1</sup> <sup>1</sup>Cardiovascular Center, OLV Hospital, Aalst, BE, Belgium

**4:45 PM – 6:15 PM**

**CONCURRENT SESSION 5**

**Immunosuppression After Cardiac Transplantation: New Cocktails at the Bar – Finding the Right Mix (Plaza Ballroom A)**

**\*Chairs:** \*Joseph G. Rogers, MD and \*Johan Vanhaecke, MD

**4:45 PM (25) *Sirolimus as Primary Immunosuppression Prevents Progression of Cardiac Allograft Vasculopathy: A 3-D IVUS Study***; E. Raichlin,<sup>1</sup> B.S. Edwards,<sup>1</sup> A.L. Clavell,<sup>1</sup> R.J. Rodeheffer,<sup>1</sup> R.P. Frantz,<sup>1</sup> J.A. Wagner,<sup>1</sup> R.C. Daly,<sup>2</sup> A. Lerman,<sup>1</sup> S.S. Kushwaha,<sup>1</sup> <sup>1</sup>Cardiovascular Diseases, Mayo Clinic, Rochester, MN; <sup>2</sup>Cardiothoracic Surgery, Mayo Clinic, Rochester, MN

**5:00 PM (26) *Three Year Outcome of a Randomized Trial Comparing C<sub>0</sub> Against C<sub>2</sub> Monitoring in Stable Heart Transplant Patients***; P.K.W. Lam,<sup>1</sup> C. Payne,<sup>1</sup> J. Lockhart,<sup>1</sup> M. Kerr,<sup>1</sup> A. Kirk,<sup>2</sup> A.J. Murday,<sup>1</sup> <sup>1</sup>Scottish National Advanced Heart Failure Service, Glasgow Royal Infirmary, Glasgow, United Kingdom; <sup>2</sup>Cardiothoracic Surgery, Western General Infirmary, Glasgow, United Kingdom

**\*5:15 PM (27) Practically Speaking: The Initiation of Lower Dose Mycophenolate Mofetil (MMF) 1000 mg BID Appears to Have Similar Outcome to 1500 mg BID after Heart Transplantation;** J.K. Patel,<sup>1</sup> M.A. Kawano,<sup>1</sup> G.W. Wu,<sup>1</sup> J.C. Kawano,<sup>1</sup> M. Yajnik,<sup>1</sup> M.M. Kittleson,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA

**5:30 PM (28) Dose Reduction of MMF Due to Gastrointestinal Intolerance Is Associated with Increased Rejection in Heart Transplant Recipients;** P.J. Galiwango,<sup>1</sup> D. Delgado,<sup>1</sup> H.J. Ross,<sup>1</sup> <sup>1</sup>Division of Cardiology, Toronto General Hospital, Toronto, ON, Canada

**\*5:45 PM (29) Trough Level Adapted MMF in Combination with Either Tacrolimus or Cyclosporine – The Pan-EU-HTx Trial;** B. Meiser,<sup>1</sup> J. Van Cleemput,<sup>2</sup> F. Perez Villa,<sup>3</sup> A. Zuckermann,<sup>9</sup> M. Crespo,<sup>4</sup> M. Goenen,<sup>5</sup> K. Karason,<sup>6</sup> J.F. Delgado,<sup>7</sup> R. Voss,<sup>8</sup> B. Reichart,<sup>1</sup> <sup>1</sup>Cardiac Surgery, University of Munich, Munich, Germany; <sup>2</sup>Cardiology, University Hospital Gasthuisberg, Leuven, Belgium; <sup>3</sup>Heart Transplantation Program, University of Barcelona, Barcelona, Spain; <sup>4</sup>Cardiac Surgery, Juan Canalejo Hospital, La Coruña, Spain; <sup>5</sup>Cardiovascular Surgery, University of Louvain, Brussels, Belgium; <sup>6</sup>Cardiology, Sahlgrenska University Hospital, Goteborg, Sweden; <sup>7</sup>Cardiology, Hospital Doce de Octubre, Madrid, Spain; <sup>8</sup>Cardiology, University of Giessen, Giessen, Germany; <sup>9</sup>Cardio-Thoracic Surgery, University of Vienna, Vienna, Austria

**6:00 PM (30) Tacrolimus with Sirolimus or Mycophenolate Mofetil (MMF) Compared with Calcineurin Inhibitor-Free Immunosuppression (Sirolimus/MMF) after Heart Transplantation: 1-Year Results;** I. Kaczmarek,<sup>1</sup> O. Delgado,<sup>1</sup> S. Michel,<sup>1</sup> S. Sadoni,<sup>1</sup> M. Schmoedel,<sup>1</sup> B. Reichart,<sup>1</sup> B. Meiser,<sup>1</sup> <sup>1</sup>Cardiac Surgery, University Hospital Grosshadern, LMU Munich, Munich, Germany

**4:45 PM – 6:15 PM**

#### **CONCURRENT SESSION 6**

#### **Immune Regulation and Tolerance (Plaza Ballroom B)**

**\*Chairs:** \*William Weimar, MD and David S. Wilkes, MD

**4:45 PM (31) Mixed Hematopoietic Chimerism Prevents Lung Allograft Rejection in Miniature Swine;** H. Sahara,<sup>1</sup> M.J. Weiss,<sup>1</sup> K.J. Wikel,<sup>1</sup> J.K. Sayre,<sup>1</sup> A.C. Pujara,<sup>1</sup> C.Y. Ng,<sup>1</sup> P.L. Cho,<sup>1</sup> B.M. Horner,<sup>1</sup> S.L. Houser,<sup>1</sup> J.C. Wain,<sup>1</sup> D.H. Sachs,<sup>1</sup> J.C. Madsen,<sup>1</sup> C.A. Huang,<sup>1</sup> J.S. Allan,<sup>1</sup> <sup>1</sup>Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA

**5:00 PM (32) High Suppressive Potency of Isolated CD25+ T Cells in Porcine Allogeneic Lung Transplantation In Vitro;** S. Thissen,<sup>1</sup> B. Kruse,<sup>1</sup> G. Warnecke,<sup>1</sup> M. Avsar,<sup>1</sup> R. Reinhard,<sup>1</sup> C. Peters,<sup>1</sup> A.R. Simon,<sup>1</sup> A. Haverich,<sup>1</sup> M. Strueber,<sup>1</sup> <sup>1</sup>Division of Thoracic and CV Surgery, Hannover Medical School, Hannover, Germany

**5:15 PM (33) Acute Rejection Is Associated with High FOXP3 mRNA Expression Levels in the Graft, but Not in the Peripheral Blood, of Heart Transplant Recipients;** I.E. Dijke,<sup>1</sup> K. Caliskan,<sup>2</sup> S.S. Korevaar,<sup>1</sup> A.H. Balk,<sup>2</sup> P.E. Zondervan,<sup>3</sup> A.P. Maat,<sup>2</sup> W. Weimar,<sup>1</sup> C.C. Baan,<sup>1</sup> <sup>1</sup>Internal Medicine, Erasmus MC, Rotterdam, Netherlands; <sup>2</sup>Thorax Center, Erasmus MC, Rotterdam, Netherlands; <sup>3</sup>Pathology, Erasmus MC, Rotterdam, Netherlands

**5:30 PM (34) FoxP3+ T Cells Can Be Expanded from Rejecting Human Cardiac Allografts;** I.E. Dijke,<sup>1</sup> J.H. Velthuis,<sup>1</sup> A.H. Balk,<sup>2</sup> P. de Kuiper,<sup>1</sup> M. Klepper,<sup>1</sup> K. Caliskan,<sup>2</sup> W. Weimar,<sup>1</sup> C.C. Baan,<sup>1</sup> <sup>1</sup>Internal Medicine, Erasmus MC, Rotterdam, Netherlands; <sup>2</sup>Cardiology, Erasmus MC, Rotterdam, Netherlands

**5:45 PM (35) Frequency of FoxP3+ Regulatory CD4 Cells Recovered in Bronchoalveolar Lavage Does Not Predict Acute Rejection Score;** D.C. Neujahr,<sup>1</sup> E.C. Lawrence,<sup>1</sup> A. Pelaez,<sup>1</sup> A. Ramirez,<sup>1</sup> S. Force,<sup>2</sup> A. Gal,<sup>3</sup> C.P. Larsen,<sup>2</sup> <sup>1</sup>Medicine, Emory University, Atlanta, GA; <sup>2</sup>Surgery, Emory University, Atlanta, GA; <sup>3</sup>Pathology, Emory University, Atlanta, GA

**\*6:00 PM (36) Deletional vs Suppressive Neonatal Tolerance to Cardiac Allografts Depends on Inoculum Source;** K. Tao,<sup>1</sup> L. Mai,<sup>2</sup> L.J. West,<sup>1</sup> <sup>1</sup>Pediatrics, Surgery and Immunology, University of Alberta, Edmonton, AB, Canada; <sup>2</sup>Infection, Immunity, Injury and Repair, Hospital for Sick Children, Toronto, ON, Canada

**6:15 PM – 7:15 PM**

#### **GENERAL POSTER SESSION 1/Wine and Cheese Reception (Continental Ballroom)**

**(37) Should Ambulatory Heart Failure Patients Be Transplanted?;** N.R. Banner,<sup>1</sup> C.A. Rogers,<sup>2</sup> K. Ranganathan,<sup>1</sup> S. Jayakumar,<sup>3</sup> R.S. Bonser,<sup>3</sup> <sup>1</sup>Cardiology and Transplant Medicine, Harefield Hospital, Harefield, Middlesex, United Kingdom; <sup>2</sup>Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom; <sup>3</sup>Cardiothoracic Surgery, Queen Elizabeth Hospital, Birmingham, United Kingdom

**(38) The Selective If Channel Antagonist Ivabradine in Stable Patients after Heart Transplantation (HTX);** A.O. Doesch,<sup>1</sup> S. Celik,<sup>1</sup> P.h Ehlermann,<sup>1</sup> L. Frankenstein,<sup>1</sup> A. Koch,<sup>2</sup> T.J. Dengler,<sup>1</sup> <sup>1</sup>Department of Cardiology, University of Heidelberg, Heidelberg, Germany; <sup>2</sup>Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany

**(39) Cardiac Reserve in the Transplanted Heart Depends on a Graft Polymorphism in the beta-1-Adrenergic Receptor;** M. Scharin Täng, E. Lindberg, Y. Magnusson, B. Andersson Department of Metabolism and Cardiovascular Research and Wallenberg Laboratory, Institute of Medicine, Sahlgrenska Academy, Göteborg University, Sweden

**(40) The Prognostic Value of Pre- and within One Year Postoperative Right Heart Hemodynamics in Heart Transplant Recipients;** E. Gude,<sup>1</sup> S. Arora,<sup>1</sup> S. Simonsen,<sup>1</sup> L. Gullestad,<sup>1</sup> O. Geiran,<sup>1</sup> A. Andreassen,<sup>1</sup> <sup>1</sup>Department of Cardiology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway

**(41) Current Status of Heart Transplantation as Therapy for Advanced Heart Failure in African Americans;** R.S.D. Higgins,<sup>1</sup> L.L. Edwards,<sup>2</sup> E.J. Okum,<sup>1</sup> G.M. Mullen,<sup>1</sup> S.H. Dunlap,<sup>1</sup> P.J. Hauptman,<sup>3</sup> F.D. Pagani,<sup>4</sup> K.D. Aaronson,<sup>4</sup> <sup>1</sup>Cardiovascular-Thoracic Surgery, Rush University Medical Center, Chicago, IL; <sup>2</sup>United Network for Organ Sharing, Richmond, VA; <sup>3</sup>Heart Failure and Transplantation, Saint Louis University School of Medicine, St. Louis, MO; <sup>4</sup>Heart Failure and Transplantation, University of Michigan, Ann Arbor, MI

- \* (42) *Detection of Renal Tubular Injury in Cardiac Transplant Recipients by Urine Proteomic Analysis*; S. Zieroth,<sup>1</sup> \*H. Ross,<sup>2</sup> S. Famure,<sup>2</sup> S. Schaub,<sup>1</sup> K. Sangster,<sup>1</sup> J. Wilkins,<sup>1</sup> D. Rush,<sup>1</sup> P. Nickerson,<sup>1</sup> <sup>1</sup>Medicine, University of Manitoba, Winnipeg, MB, Canada; <sup>2</sup>Medicine, University of Toronto, Toronto, ON, Canada
- (43) *Renal Function after Thoracic Organ Transplantation*; A.A. Mennander,<sup>1</sup> P.P. Frohnert,<sup>1</sup> B.S. Edwards,<sup>1</sup> R.C. Daly,<sup>1</sup> S.G. Peters,<sup>1</sup> S.D. Cassivi,<sup>1</sup> C.G.A. McGregor,<sup>1</sup> <sup>1</sup>Mayo Clinic-Roch William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN
- (44) *New Insights in the Management of Cardiogenic Shock Complicating Myocardial Infarction Role of Urgent Heart Transplantation*; D. Arzamendi,<sup>1</sup> F. Perez Villa,<sup>1</sup> E. Roig,<sup>1</sup> A. Garcia-Alvarez,<sup>1</sup> R. Kiamco,<sup>1</sup> M. Masotti,<sup>1</sup> A. Batriu,<sup>1</sup> <sup>1</sup>Cardiology - Thorax Institute, Hospital Clinic, Barcelona, Spain
- (45) *Decreased Incidence of Clinically Significant Allograft Rejection Following Simultaneous Heart-Kidney Versus Isolated Heart Transplantation*; S.M. Brunelli,<sup>1,3</sup> S.V. Chambers,<sup>2</sup> P. Curry-Stutman,<sup>2</sup> E. Kotloff,<sup>1</sup> A.M. Doyle,<sup>1</sup> <sup>1</sup>Division of Renal-Electrolyte and Hypertension, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; <sup>2</sup>Division of Cardiology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; <sup>3</sup>Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA
- \* (46) *Identification of Cardiac Allograft Rejection Using Raman Spectrophotometry*; S. Rassadi,<sup>1</sup> C. Chang,<sup>2</sup> D. Cao,<sup>1</sup> \*H.J. Eisen,<sup>3</sup> <sup>1</sup>Department of Medicine, Drexel University College of Medicine, Philadelphia, PA; <sup>2</sup>Department of Biomedical Engineering, Drexel University, Philadelphia, PA; <sup>3</sup>Division of Cardiology/Department of Medicine, Drexel University College of Medicine, Philadelphia, PA
- \* (47) *Rate of Kidney Function Decline after Heart Transplantation*; M. Chandavimol,<sup>1</sup> O. Johnston,<sup>1</sup> C. Rose,<sup>1</sup> A. Cheung,<sup>1</sup> A. Ignaszewski,<sup>1</sup> J. Gill,<sup>1</sup> <sup>1</sup>Cardiology, Nephrology, Cardiac Surgery, University of British Columbia, Vancouver, BC, Canada
- (48) *Association of CMV Activation with Th1 Chemokines in Human Heart Transplant Recipients*; N. Khan,<sup>1</sup> J.E. Fildes,<sup>1</sup> M. Al-Aloul,<sup>1</sup> S. Patel,<sup>1</sup> C.T. Leonard,<sup>1</sup> N. Yonan,<sup>1</sup> <sup>1</sup>The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom
- (49) *A1, A2, or A3 Adenosine Receptor Activation Ameliorates Lung Ischemia Reperfusion Injury*; L.M. Gazoni,<sup>1</sup> C.G. Tribble,<sup>1</sup> P.I. Ellman,<sup>1</sup> V.E. Laubach,<sup>1</sup> J. Linden,<sup>1</sup> I.L. Kron,<sup>1</sup> <sup>1</sup>Surgery, University of Virginia, Charlottesville, VA
- (50) *Cell Free Soluble Interleukin-2 Receptor Is Associated with Clinical Stability Following Heart Transplantation*; J.E. Fildes,<sup>1</sup> N.U. Khan,<sup>1</sup> M. Al-Aloul,<sup>1</sup> S.G. Williams,<sup>1</sup> C.T. Leonard,<sup>1</sup> N. Yonan,<sup>1</sup> <sup>1</sup>The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom
- (51) *Rapamycin and Its Influence on Arterial Vascular Function after Short-Term Incubation*; M.T. Grapow,<sup>1</sup> D.C. Reineke,<sup>1</sup> H.R. Zerkowski,<sup>1</sup> E. Müller-Schweinitzer,<sup>1</sup> T. Carrel,<sup>1,2</sup> <sup>1</sup>University of Basel, Cardio-Thoracic Surgery, Basel, Switzerland; <sup>2</sup>University of Berne, Cardiovascular Surgery, Berne, Switzerland
- (52) *Non-Hypoxic Ischemia: An Accurate Cell Culture Model of Ischemia Reperfusion Injury in Lung Transplantation*; M. Casiraghi,<sup>1</sup> A. Mendoza,<sup>2</sup> J. Blackwell,<sup>2</sup> L. Watson,<sup>2</sup> J.R. Tatreau,<sup>3</sup> M. Sevala,<sup>2</sup> S.H. Randell,<sup>3</sup> T.M. Egan,<sup>2</sup> <sup>1</sup>Division of General Thoracic Surgery, University "Vita-Salute" San Raffaele, Milan, Italy; <sup>2</sup>Division Cardiothoracic Surgery, University of North Carolina, Chapel Hill, NC; <sup>3</sup>Division of Pulmonary and Critical Care Medicine, University of North Carolina, Chapel Hill, NC
- (53) *Selective Blockade of Canonical IκB Kinase Activity Attenuates Inflammatory Responses to Lung Ischemia Reperfusion Signals*; H.J. Huang,<sup>1</sup> N.A. Das,<sup>2</sup> M. Okazaki,<sup>2</sup> J.M. Lai,<sup>2</sup> G.A. Patterson,<sup>2</sup> A.S. Krupnick,<sup>2</sup> D. Kreisel,<sup>2</sup> A.E. Gelman,<sup>2</sup> <sup>1</sup>Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine; <sup>2</sup>Cardiothoracic Surgery, Washington University School of Medicine, Saint Louis, MO
- (54) *Differential Gene Expression in Human Endothelial Cells after Stimulation with sCD40L*; D. Schuster,<sup>1</sup> B. Molitor,<sup>1</sup> B. Parviz,<sup>1</sup> A. Weber,<sup>1</sup> A. Barth,<sup>1</sup> P. Harwaldt,<sup>1</sup> H. Holschermann,<sup>1</sup> H. Tillmanns,<sup>1</sup> T.H.W. Stadlbauer,<sup>1</sup> <sup>1</sup>Medicine, University of Giessen, Giessen, Germany
- (55) *FR167653 Ameliorates Expression of Proinflammatory Mediators in HUVEC and Human Monocytes*; M. Schaub,<sup>1</sup> P. Harwaldt,<sup>1</sup> B. Parviz,<sup>1</sup> A. Weber,<sup>1</sup> A. Barth,<sup>1</sup> H. Tillmanns,<sup>1</sup> T.H.W. Stadlbauer,<sup>1</sup> <sup>1</sup>Medicine, University of Giessen, Giessen, Germany
- (56) *Reduced Levels of Transplant Arteriosclerosis after Treatment with Clopidogrel (Plavix®) Are Associated with Reduced Graft-Infiltration with Dendritic Cells*; S. Abele,<sup>1</sup> M. Wollin,<sup>2</sup> B. Spriewald,<sup>2</sup> N.E. Hiemann,<sup>3</sup> M. Ramsperger-Gleichner,<sup>1</sup> M. Weyand,<sup>1</sup> S.M. Ensminger,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, University of Erlangen-Nuernberg, Erlangen, Bavaria, Germany; <sup>2</sup>Medicine III, University of Erlangen-Nuernberg, Erlangen, Bavaria, Germany; <sup>3</sup>Cardiothoracic Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany
- (57) *Modulation of Leukocyte Subpopulations, Activation Marker Expression and Impaired T Cell Function in Patients with Chronic Heart Failure*; M.H. Konstandin,<sup>1</sup> C. Lorenz,<sup>1</sup> N. Sommer,<sup>2</sup> C. Zugck,<sup>1</sup> A. Remppis,<sup>1</sup> G.H. Wabnitz,<sup>2</sup> H.A. Katus,<sup>1</sup> T.J. Dengler,<sup>1</sup> <sup>1</sup>Cardiology, Universitätsklinik Heidelberg, Heidelberg, Germany; <sup>2</sup>Institute for Immunology, Universitätsklinik Heidelberg, Heidelberg, Germany
- \* (58) *Unmasking Networks to Identify Key Regulatory Modules during Rejection and Quiescence. A Systems Biology Approach to Heart Transplantation*; M.C. Deng,<sup>1</sup> A. Sinha,<sup>2</sup> M. Cadeiras,<sup>3</sup> M.P. Bayern,<sup>4</sup> W. Lim,<sup>5</sup> R. Dedrick,<sup>6</sup> T. Klingler,<sup>7</sup> C.C. Marboe,<sup>8</sup> A. Califano,<sup>9</sup> <sup>1</sup>College of Physicians and Surgeons, Columbia University, New York, NY; <sup>2</sup>R&D, XDx, Inc., South San Francisco, CA

- (59) *Proteasome Dysfunction during Cold Ischemia and Reperfusion in a Murine Heart Transplantation Model*; M. Majetschak,<sup>1</sup> M.B. Patel,<sup>1</sup> C. Liotta,<sup>1</sup> S. Li,<sup>1</sup> L.T. Busby,<sup>1</sup> S.M. Pham,<sup>1</sup> DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL
- (60) *Apoptotic Cell Death Occurs during Accelerated Rejection in Sensitized Recipients of Cardiac Allografts*; T.H.W. Stadlbauer,<sup>1</sup> N. Dongowski,<sup>1</sup> N. Pfuhl,<sup>1</sup> P. Kranich,<sup>1</sup> H. Tillmanns,<sup>1</sup> M. Schaub,<sup>1</sup> Medicine, University of Giessen, Giessen, Germany
- (61) *Recombinant Adenoviral Gene Transfer by Ex Vivo Perfusion Does Not Affect Cardiac Allograft Vasculopathy*; V.P. Rao,<sup>1</sup> S.E. Branzoli,<sup>1</sup> D. Ricci,<sup>1</sup> N. Miyagi,<sup>1</sup> T. O'Brien,<sup>2</sup> H.D. Tazelaar,<sup>1</sup> S.J. Russell,<sup>2</sup> C.G. McGregor,<sup>1</sup> William J. von Leibig Transplant Center, Mayo Clinic, Rochester, MN;<sup>2</sup>Department of Molecular Medicine, Mayo Clinic, Rochester, MN
- (62) *Tetrahydrobiopterin Improves Myocardial Protection during Cardioplegic Arrest*; U.M. Fischer,<sup>1</sup> B. De Santis,<sup>1</sup> Y. Heppelmann,<sup>2</sup> J.H. Fischer,<sup>2</sup> U. Mehlhorn,<sup>1</sup> W. Bloch,<sup>3</sup> Department of Cardiac Surgery, University of Cologne, Cologne, Germany;<sup>2</sup>Institute for Experimental Medicine, University of Cologne, Cologne, Germany;<sup>3</sup>Institute for Molecular and Cellular Sports Medicine, German Sports Medicine, Cologne, Germany
- (63) *Autoreponse to Collagen V Is Associated with the Development of OB Following Lung Transplantation*; R.E. Fawson,<sup>1</sup> J.D. Smith,<sup>1</sup> M.R. Carby,<sup>2</sup> M.L. Rose,<sup>1</sup> Transplant Immunology, Imperial College, Harefield Hospital, London, Middlesex, United Kingdom;<sup>2</sup>Cardiothoracic Department, Harefield Hospital, Harefield, Middlesex, United Kingdom
- (64) *Balanced Matrix Metalloproteinase Inhibition: Refining a Therapeutic Strategy for Developing/Established Fibrosis of Airway Obliteration*; M. Sato,<sup>1</sup> T. Ogura,<sup>1</sup> G. D'Cruz,<sup>1</sup> M. Anraku,<sup>1</sup> M. Cypel,<sup>1</sup> T.K. Waddell,<sup>1</sup> M. Liu,<sup>1</sup> S. Keshavjee,<sup>1</sup> Thoracic Surgery Research Laboratory, Toronto General Research Institute, University Health Network, Toronto, ON, Canada
- (65) *The Role of Interleukin-15 in Cytomegalovirus Activation Following Heart Transplantation*; K. Rogacev,<sup>1</sup> J.E. Fildes,<sup>1</sup> N.U. Khan,<sup>1</sup> M. Al-Aloul,<sup>1</sup> S.G. Williams,<sup>1</sup> C.T. Leonard,<sup>1</sup> N. Yonan,<sup>1</sup> The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom
- (66) *Significance of Endothelial CD26 in Acute Rejection after Orthotopic Single Lung Transplantation in the Rat*; C. Riemer,<sup>1</sup> S.V. Hoersten,<sup>2</sup> Y. Li,<sup>1</sup> C. Moerike,<sup>1</sup> A. Haverich,<sup>1</sup> A.R. Simon,<sup>1</sup> Hannover Thoracic Transplant Program (Division of Thoracic- and Cardiovascular Surgery), Hannover Medical School, Hannover, Germany;<sup>2</sup>Division of Functional and Applied Anatomy, Hannover Medical School, Hannover, Germany
- (67) *Comparison of Twenty Eight Key Circulating Immunologic Messengers in Heart Transplant Recipients Treated with Azathioprine vs Mycophenolate Mofetil*; N.U. Khan,<sup>1</sup> J.E. Fildes,<sup>1</sup> M. Al-Aloul,<sup>1</sup> S.G. Williams,<sup>1</sup> C.T. Leonard,<sup>1</sup> N. Yonan,<sup>1</sup> The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom
- \* (68) *Stress-Induced Premature Senescence in Airway Epithelium and Accelerated Lung Allograft Aging*; S.M. Parker,<sup>1</sup> C. Ward,<sup>1</sup> G. Johnson,<sup>1</sup> F. Black,<sup>1</sup> J.L. Lordan,<sup>1</sup> P.A. Corris,<sup>1</sup> G.C. Saretzki,<sup>2</sup> A.J. Fisher,<sup>1</sup> Applied Immunobiology and Transplantation Research Group, University of Newcastle upon Tyne, Newcastle, United Kingdom;<sup>2</sup>Institute for Aging and Health, University of Newcastle upon Tyne, Newcastle, United Kingdom
- (69) *Expression of Ghrelin, a Novel Cardiovascular Hormone, and Its Peptide in the Myocardium of Patients Undergoing Heart Transplantation*; A. Beiras-Fernandez,<sup>1</sup> I. Kaczmarek,<sup>1</sup> M. Schmoedel,<sup>1</sup> A. Beiras,<sup>2</sup> C. Vicol,<sup>1</sup> B. Reichart,<sup>1</sup> Department of Cardiac Surgery, University Hospital Grosshadern, LM-University, Munich, Germany;<sup>2</sup>Department of Morphological Sciences, University of Santiago de Compostela, Santiago, Spain
- (70) *Kinetics of Bronchial Epithelial Chimerism after Transplantation – A Sex Mis-Match Independent Method*; B. Banerjee,<sup>1</sup> A. Saxena,<sup>2</sup> D. Ravine,<sup>2</sup> E. Gabbay,<sup>1</sup> S. Temple,<sup>3</sup> D. Chambers,<sup>1</sup> Lung Transplant Unit, Royal Perth Hospital, Perth, Western Australia, Australia;<sup>2</sup>Western Australian Institute for Medical Research, University of Western Australia, Perth, Western Australia, Australia;<sup>3</sup>School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia
- (71) *Nonischemic Dilated Cardiomyopathy Upregulates Myocardial Vascular Endothelial Growth Factor*; B.H. Muneer,<sup>1</sup> M. Montpetit,<sup>1</sup> A.M. Samarel,<sup>1</sup> S. Danzi,<sup>2</sup> A.L. Heroux,<sup>1</sup> Department of Cardiology, Loyola University Medical Center, Maywood, IL;<sup>2</sup>Department of Medicine, North Shore University Hospital, Manhasset, NY
- (72) *Mannose-Binding Lectin – Influence on Acute Graft Rejection Following Heart Transplantation*; J.E. Fildes,<sup>1</sup> M. McAlindon,<sup>1</sup> A.H. Walker,<sup>1</sup> C.T. Leonard,<sup>1</sup> B. Keevil,<sup>2</sup> N. Yonan,<sup>1</sup> The Transplant Centre, South Manchester University Hospitals NHS Trust, Manchester, United Kingdom;<sup>2</sup>Department of Biochemistry, South Manchester University Hospitals NHS Trust, Manchester, United Kingdom
- (73) *Serum Interleukin-12 Concentration Is Associated with Circulating Basophils Following Heart Transplantation*; J.E. Fildes,<sup>1</sup> N.U. Khan,<sup>1</sup> M. Al-Aloul,<sup>1</sup> S.G. Williams,<sup>1</sup> C.T. Leonard,<sup>1</sup> N. Yonan,<sup>1</sup> The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom
- (74) *Permanent Circulatory Assist Device Implantation Using Counterpulsation*; V. Jeevanandam,<sup>1</sup> M. Chen,<sup>1</sup> M. Myren,<sup>1</sup> A. Anderson,<sup>1</sup> A. Kantrowitz,<sup>2</sup> J. Raman,<sup>1</sup> Cardiothoracic Surgery, University of Chicago, Chicago, IL;<sup>2</sup>LVAD Technologies, Detroit, MI
- (75) *Clinical Utility of the Levitronix® CentriMag™ in Extracorporeal Membrane Oxygenation for Severe Cardiogenic Shock*; D.A. Chung,<sup>1,2</sup> L. Kizner,<sup>2</sup> M. Al-Deiri,<sup>2</sup> L. Arusoglu,<sup>2</sup> M. Morshuis,<sup>2</sup> D. Roefe,<sup>2</sup> R. Koerfer,<sup>2</sup> A. El-Banayosy,<sup>2</sup> Heart and Lung Division, Wythenshawe Hospital, Manchester, Greater Manchester, United Kingdom;<sup>2</sup>Herzzentrum, Herz-und Diabeteszentrum, Bad Oeynhausen, Nordrhein-Westfalen, Germany

**(76) Pulsatile ECMO as Bridge to Recovery and Cardiac Transplantation in Pediatric Population: A Comparative Study;** S. Agati,<sup>1</sup> G. Ciccarello,<sup>2</sup> D. Salvo,<sup>1</sup> A. Undar,<sup>3</sup> C. Mignosa,<sup>1</sup> <sup>1</sup>Pediatric Cardiac Surgery, San Vincenzo Hospital, Taormina, Messina, Italy; <sup>2</sup>Perfusion Service, EPS, Taormina, Messina, Italy; <sup>3</sup>Pediatrics, Surgery, and Bioengineering, Penn State College of Medicine, Hershey, PA

**(77) Out of Hospital Treatment in Patients with a Total Artificial Heart;** A. El-Banayosy,<sup>1</sup> M. Morshuis,<sup>1</sup> L. Arusoglu,<sup>1</sup> L. Kizner,<sup>1</sup> H. Kastning,<sup>1</sup> D. Cobaugh,<sup>1</sup> R. Koerfer,<sup>1</sup> <sup>1</sup>Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany

**(78) Safety and Feasibility of Noncardiac Surgery in Patients with Ventricular Assist Device Support;** J.D. McCue,<sup>1</sup> S.J. Prabhu,<sup>2</sup> A.G. Kolb,<sup>3</sup> M. Colvin-Adams,<sup>4</sup> A. Boyle,<sup>4</sup> K. Liao,<sup>5</sup> L.W. Miller,<sup>6</sup> L. Joyce,<sup>5</sup> R. John,<sup>5</sup> <sup>1</sup>Department of Surgery, University of Minnesota, Minneapolis, MN; <sup>2</sup>University of Minnesota Medical School, University of Minnesota, Minneapolis, MN; <sup>3</sup>Center for Cardiovascular Repair, University of Minnesota, Minneapolis, MN; <sup>4</sup>Department of Cardiology, University of Minnesota, Minneapolis, MN; <sup>5</sup>Department of Thoracic and Cardiovascular Surgery, University of Minnesota, Minneapolis, MN; <sup>6</sup>Department of Cardiology, Georgetown University, Washington, DC

**(79) Left Ventricular Pressure Unloading with Continuous and Pulsatile Left Ventricular Assist Devices in Advanced Heart Failure Patients;** M.S. Slaughter,<sup>1</sup> M.A. Sobieski,<sup>1</sup> G.M. Pantalos,<sup>2</sup> G.A. Giridharan,<sup>2</sup> R.D. Dowling,<sup>2</sup> S. Prabhu,<sup>3</sup> D.J. Farrar,<sup>4</sup> S.C. Koenig,<sup>2</sup> <sup>1</sup>Cardiovascular Surgery, Advocate Christ Medical Center, Oak Lawn, IL; <sup>2</sup>Bioengineering & Surgery, University of Louisville, Louisville, KY; <sup>3</sup>Medicine, University of Louisville, Louisville, KY; <sup>4</sup>Thoratec Corporation, Pleasanton, CA

**(80) Real-Time Hepatic Venous Saturation: Is It a Sensitive Indicator of Hemodynamic Compromise?;** Y. Wadia,<sup>1</sup> R.M. Delgado, III,<sup>2</sup> B. Kar,<sup>2</sup> I. Gregoric,<sup>3</sup> O.H. Frazier,<sup>3</sup> <sup>1</sup>Cardiovascular Surgery and Transplant Research, Texas Heart Institute, Houston, TX; <sup>2</sup>Mechanical Support Devices for Heart Failure, Texas Heart Institute, Houston, TX; <sup>3</sup>Cardiopulmonary Transplantation, Texas Heart Institute, Houston, TX

**(81) Bridge to Decision with Levitronix® Centrimag® Short-Term Ventricular Assist Device;** F. De Robertis,<sup>1</sup> E.J. Birks,<sup>2</sup> P. Rogers,<sup>2</sup> M. Petrou,<sup>1</sup> M. Amrani,<sup>2</sup> J.R. Pepper,<sup>1</sup> A. Khaghani,<sup>1</sup> G. Dreyfus,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, Royal Brompton & Harefield NHS Trust, Harefield, Middlesex, United Kingdom; <sup>2</sup>Cardiology, Royal Brompton & Harefield NHS Trust, Harefield, Middlesex, United Kingdom

**\* (82) Evolving Use of Left Ventricular (LVAD) vs Biventricular (BiVAD) Assist Devices;** D. Nguyen,<sup>1</sup> J. Bhamra,<sup>1</sup> C. Bermudez,<sup>1</sup> Y. Toyoda,<sup>1</sup> J. Teuteberg,<sup>2</sup> M. Simon,<sup>2</sup> K. McCurry,<sup>1</sup> R. Kormos,<sup>1</sup> <sup>1</sup>Heart Lung and Esophageal Institute, University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>Cardiovascular Institute, University of Pittsburgh, Pittsburgh, PA

**(83) Outcomes of Female Heart Transplant Recipients Bridged to Transplantation with a Ventricular Assist Device;** D. Magyar,<sup>1</sup> N.G. Smedira,<sup>2</sup> K.J. Hoercher,<sup>2</sup> J.L. Navia,<sup>2</sup> T. Mihaljevic,<sup>2</sup> D.O. Taylor,<sup>2</sup> R.C. Starling,<sup>2</sup> G.V. Gonzalez-Stawinski,<sup>2</sup> <sup>1</sup>School of Medicine, Case Western University, Cleveland, OH; <sup>2</sup>Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, OH

**(84) Preoperative Variables That Predict Postoperative Course and May Aide Timing of LVAD Implantation;** S. Haj-Yahia,<sup>1,2</sup> G. Tasca,<sup>1</sup> M. Amrani,<sup>1</sup> M. Petrou,<sup>1</sup> N. Banner,<sup>1</sup> J. Pepper,<sup>1</sup> G. Dreyfus,<sup>1</sup> A. Khaghani,<sup>1</sup> E.J. Birks,<sup>1</sup> <sup>1</sup>Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom; <sup>2</sup>NHLI, Imperial College for Thecnology, science and Medicine, London, United Kingdom

**\* (85) Use of the Total Artificial Heart for Salvage of Patients with Refractory Cardiogenic Shock Complicating Acute Myocardial Infarction;** M.J. Slepian,<sup>1</sup> R.G. Smith,<sup>1</sup> P.E. Nolan,<sup>1</sup> D. McClellan,<sup>1</sup> P. Tsau,<sup>1</sup> R. Bose,<sup>1</sup> G. Sethi,<sup>1</sup> J.G. Copeland,<sup>1</sup> <sup>1</sup>Sarver Heart Center, University of Arizona, Tucson, AZ

**(86) New Generation Axial-Flow Left-Ventricular Assist Device Supports Patients with Various Degrees of Right Ventricular Dysfunction;** G.V. Moukarbel,<sup>1</sup> S. Ennis,<sup>2</sup> S.A. Moore,<sup>1</sup> T.E. MacGillivray,<sup>2</sup> <sup>1</sup>Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; <sup>2</sup>Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA

**(87) Ischemic Cardiomyopathy Independently Predicts Higher Mortality after Ventricular Assist Device Implantation;** M.A. Simon,<sup>1</sup> A. Shah,<sup>1</sup> D. Nguyen,<sup>2</sup> J. Bhamra,<sup>2</sup> C. Bermudez,<sup>2</sup> Y. Toyoda,<sup>2</sup> J. Teuteberg,<sup>2</sup> K. McCurry,<sup>2</sup> R. Kormos,<sup>2</sup> <sup>1</sup>Cardiovascular Institute, University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>Heart Lung and Esophageal Institute, University of Pittsburgh, Pittsburgh, PA

**(88) Significance of Anemia in Patients Undergoing Long-Term LVAD Support;** B. Vrtovec, R. Radovancevic, R.M. Delgado, B. Radovancevic, A.W. Bracey, I.D. Gregoric, O.H. Frazier, <sup>1</sup>Ljubljana University Medical Center, Ljubljana, Slovenia; <sup>2</sup>Center for Cardiac Support, Texas Heart Institute/St. Luke's Episcopal Hospital, Houston, TX

**(89) Systemic Vascular Input Impedance in Humans, Calves, and Pigs: Clinical Implications with Medical Devices and Xenotransplantation;** S.C. Koenig,<sup>1</sup> G.A. Giridharan,<sup>1</sup> C. Ionan,<sup>1</sup> G.M. Pantalos,<sup>1</sup> R.D. Dowling,<sup>1</sup> S. Prabhu,<sup>2</sup> M.A. Sobieski,<sup>3</sup> M.S. Slaughter,<sup>3</sup> <sup>1</sup>Bioengineering & Surgery, University of Louisville, Louisville, KY; <sup>2</sup>Medicine, University of Louisville, Louisville, KY; <sup>3</sup>Cardiovascular Surgery, Advocate Christ Medical Center, Oak Lawn, IL

**(90) The Impact of Different LVADs on Rejections Pattern Post Cardiac Transplant;** S. Klotz,<sup>1</sup> H. Welp,<sup>1</sup> J. Stypmann,<sup>2</sup> C. Schmid,<sup>1</sup> A. Rukosujew,<sup>1</sup> H.H. Scheld,<sup>1</sup> <sup>1</sup>Department of Thoracic- and Cardiovascular Surgery, University Hospital Muenster, Muenster, Germany; <sup>2</sup>Department of Cardiology and Angiology, University Hospital Muenster, Muenster, Germany

**\* (91) Progress and Initial In-Vivo Experience of the Pediatric Jarvik 2000 Hearts;** Z.J. Wu,<sup>1</sup> A. Kilic,<sup>1</sup> J. Zhang,<sup>1</sup> G.W. Burgreen,<sup>2</sup> G. Cheng,<sup>1</sup> G.K. Yankey,<sup>1</sup> T. Li,<sup>1</sup> R. Jarvik,<sup>3</sup> B.P. Griffith,<sup>1</sup> <sup>1</sup>Surgery, University of Maryland, Baltimore, MD; <sup>2</sup>Computational Simulation and Design Center, Mississippi State University, Starkville, MS; <sup>3</sup>Jarvik Heart, Inc., New York, NY

**(92) To Explant or Not to Explant: Use of Invasive and Non-Invasive Monitoring in a Brief Protocol to Determine Need for Continued Ventricular Assist Device Support;** S. Osaki,<sup>1</sup> N.K. Sweitzer,<sup>2</sup> P.S. Rahko,<sup>2</sup> M.A. Murray,<sup>1</sup> J.A. Hoffmann,<sup>2</sup> M.R. Johnson,<sup>2</sup> N.M. Edwards,<sup>1</sup> T. Kohmoto,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI; <sup>2</sup>Heart Failure and Transplant Cardiology, University of Wisconsin School of Medicine and Public Health, Madison, WI

**(93) Increased Number of Circulating Progenitor Cells Following Implantation of Ventricular Assist Devices;** A. Manginas, G. Giamouzis, A. Tsiavou, P. Sfirakis, L. Tsourelis, E. Leontiadis, D. Degiannis, P.A. Alivizatos, D.V. Kokkinos, <sup>1</sup>Cardiology, Onassis Cardiac Surgery Center, Athens, Greece; <sup>1</sup>Cardiology, Onassis Cardiac Surgery Center, Athens, Greece; External Partner, Onassis Cardiac Surgery Center, Athens, Greece; <sup>1</sup>Cardiothoracic and Transplantation Services, Onassis Cardiac Surgery Center, Athens, Greece; <sup>1</sup>Cardiothoracic and Transplantation Services, Onassis Cardiac Surgery Center, Athens, Greece; <sup>1</sup>Cardiology, Onassis Cardiac Surgery Center, Athens, Greece; Immunopathology & Histocompatibility Lab., Onassis Cardiac Surgery Center, Athens, Greece; <sup>1</sup>Cardiothoracic and Transplantation Services, Onassis Cardiac Surgery Center, Athens, Greece; <sup>1</sup>Cardiology, Onassis Cardiac Surgery Center, Athens, Greece

\* **(94) Diminished Left Ventricular Contractility Overtime during LVAD Support in Ischemic Heart Failure;** P.I. McConnell,<sup>1</sup> C.L. Del Rio,<sup>1</sup> P. Kwiatkowski,<sup>1</sup> \*D.J. Farrar,<sup>2</sup> B.C. Sun,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, The Ohio State University, Columbus, OH; <sup>2</sup>Thoratec Corp, Pleasanton, CA

**(95) Effectiveness of Miniaturised Axial Flow Pumps (AFP) Compared to Large Pulsatile VADs in Rescuing the Endstage Heart Failure Patient;** S. Haj-Yahia,<sup>1,2</sup> G. Tasca,<sup>1</sup> H. Taghipour,<sup>1</sup> M. Petrou,<sup>1</sup> M. Amrani,<sup>1</sup> J. Pepper,<sup>1</sup> G. Dreyfus,<sup>1</sup> E.J. Birks,<sup>1</sup> A. Khaghani,<sup>1</sup> <sup>1</sup>Cardiothoracic Transplantation & Mechanical Circulatory Support, Royal Brompton & Harefield Hospital, London, United Kingdom; <sup>2</sup>National Heart & Lung Institute, Imperial College for Science, Technology & Medicine, London, United Kingdom

**(96) Bridge-to-Transplant Experiences in Patients with Cardiogenic Shock after Acute Myocardial Infarction;** S. Schenk,<sup>1</sup> M. Morshuis,<sup>1</sup> L. Arusoglu,<sup>1</sup> G. Tenderich,<sup>1</sup> R. Koerfer,<sup>1</sup> A. El-Banayosy,<sup>1</sup> <sup>1</sup>Thoracic and Cardiovascular Surgery, Heart Center NRW, Bad Oeynhausen, Germany

**(97) The Impact of New Mechanical Circulatory Support Technology on Post-Operative Recovery and Length of Hospital Stay;** S. Ennis,<sup>1</sup> G.V. Moukarbel,<sup>2</sup> S.A. Moore,<sup>2</sup> C. Ennis,<sup>1</sup> T.E. MacGillivray,<sup>1</sup> <sup>1</sup>Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA; <sup>2</sup>Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

**(98) Long Term Support with Continuous Flow LVAD: Effect of Reduced Pulsatility on Renal Function;** M.S. Slaughter,<sup>1</sup> M.A. Sobieski,<sup>1</sup> L. Gallagher,<sup>2</sup> M. Dia,<sup>3</sup> M.A. Silver,<sup>3</sup> <sup>1</sup>Cardiovascular Surgery, Advocate Christ Medical Center, Oak Lawn, IL; <sup>2</sup>Cardiovascular Research, Cardiac Surgery Clinical Research Center, Inc, Oak Lawn, IL; <sup>3</sup>Cardiology, Advocate Christ Medical Center, Oak Lawn, IL

**(99) Is Native Cardiac Recovery Sustainable Following Successful Ventricular Assist Device Support in Cardiogenic Shock Post Acute Myocardial Infarction?;** M. Anderson,<sup>1</sup> M. Madani,<sup>2</sup> Y. Naka,<sup>3</sup> D. Raess,<sup>4</sup> L. Samuels,<sup>5</sup> B. Sun,<sup>6</sup> <sup>1</sup>Department of Cardiac Surgery, Robert Wood Johnson, New Brunswick, NJ; <sup>2</sup>Division of Cardiothoracic Surgery, University of California San Diego, San Diego, CA; <sup>3</sup>Department of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; <sup>4</sup>Department of Cardiothoracic Surgery, St. Francis Hospital, Indianapolis, IN; <sup>5</sup>Department of Cardiothoracic Surgery, Lankenau Medical Science Hospital, Philadelphia, PA; <sup>6</sup>Department of Cardiothoracic Surgery, Ohio State University Medical Center, Columbus, OH

**(100) Clinical Experience with the AB5000 as a Bridge-to-Transplant VAD: Successful Cross-Over for Extended Bridge-to-Recovery Patients;** J. Elefteriades,<sup>1</sup> M. Madani,<sup>2</sup> A.J. Crumbley,<sup>3</sup> D. Adams,<sup>4</sup> M. Anderson,<sup>5</sup> <sup>1</sup>Department of Cardiothoracic Surgery, Yale University Medical Center, New Haven, CT; <sup>2</sup>Division of Cardiothoracic Surgery, University of California San Diego, San Diego, CA; <sup>3</sup>Cardiovascular Surgery, Medical University of South Carolina, Charleston, SC; <sup>4</sup>Department of Thoracic Surgery, Mount Sinai Medical Center, New York, NY

**(101) Are Bridge to Recovery Patients Sick Enough to Require Ventricular Assist Device in Refractory Acute Myocardial Infarction Cardiogenic Shock?: Benchmark Against the SHOCK Trial;** M. Anderson,<sup>1</sup> M. Madani,<sup>2</sup> Y. Naka,<sup>3</sup> D. Raess,<sup>4</sup> L. Samuels,<sup>5</sup> B. Sun,<sup>6</sup> L. Sleeper,<sup>7</sup> <sup>1</sup>Department of Cardiac Surgery, Robert Wood Johnson, New Brunswick, NJ; <sup>2</sup>Division of Cardiothoracic Surgery, University of California San Diego, San Diego, CA; <sup>3</sup>Department of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; <sup>4</sup>Department of Cardiothoracic Surgery, St. Francis Hospital, Indianapolis, IN; <sup>5</sup>Department of Cardiothoracic Surgery, Lankenau Medical Science Hospital, Philadelphia, PA; <sup>6</sup>Department of Cardiothoracic Surgery, Ohio State University Medical Center, Columbus, OH; <sup>7</sup>New England Research Institute, Watertown, MA

**(102) Omega-3 Fatty Acids Cause Blood Cells to Become Insensitive to Mechanical Stress in Patients with Cardiac Assist Devices;** J. Mueller,<sup>2</sup> M. Brodde,<sup>1</sup> K. Brandes,<sup>2</sup> P. Goettel,<sup>2</sup> B. Kehrel,<sup>1</sup> <sup>1</sup>Hematology, University of Muenster, Muenster, Germany; <sup>2</sup>Research and Development, Berlin Heart, Berlin, Germany

\* **(103) Improved Clinical Results with the Redesigned MicroMed DeBakey VAD;** M. Loebe,<sup>1</sup> G.P. Noon,<sup>1</sup> R. Benkowski,<sup>2</sup> P. Gruber,<sup>2</sup> T. Richards,<sup>2</sup> <sup>1</sup>ME DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX; <sup>2</sup>MicroMed Inc., Houston, TX

**(104) CCR4, CCR5, CCR6 and CCR7 Expression on BAL Lymphocytes and Macrophages of Patients with Bronchiolitis Obliterans Syndrome (BOS);** F. Meloni,<sup>1</sup> M. Morosini,<sup>1</sup> S. Miserere,<sup>1</sup> C. Pellegrini,<sup>2</sup> A.M. Fietta,<sup>1</sup> <sup>1</sup>Department Haematol Pneumol Cardiovasc Sc - Sect Pneumology, University of Pavia & Pol San Matteo, Pavia, Italy; <sup>2</sup>Department Cardiac Surgery, Pol San Matteo, Pavia, Italy

**(105) Elevation of Serum KL-6 Can Predict Development of Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients;** O. Elidemir,<sup>1</sup> M.L. Doan,<sup>1</sup> M.G. Schechter,<sup>1</sup> E.D. McKenzie,<sup>2</sup> J.S. Heinle,<sup>2</sup> H. Seethamraju,<sup>3</sup> G.B. Mallory,<sup>3</sup> <sup>1</sup>Pediatric Pulmonology, Baylor College of Medicine, Houston, TX; <sup>2</sup>Congenital Heart Surgery, Baylor College of Medicine, Houston, TX; <sup>3</sup>Medicine, Baylor College of Medicine, Houston, TX

**(106) Serum KL-6 during Acute Rejection Episodes after Lung Transplantation;** O. Elidemir,<sup>1</sup> M.L. Doan,<sup>1</sup> M.G. Schechter,<sup>1</sup> E.D. McKenzie,<sup>2</sup> J.S. Heinle,<sup>2</sup> H. Seethamraju,<sup>3</sup> G.B. Mallory,<sup>3</sup> <sup>1</sup>Pediatric Pulmonology, Baylor College of Medicine, Houston, TX; <sup>2</sup>Congenital Heart Surgery, Baylor College of Medicine, Houston, TX; <sup>3</sup>Medicine, Baylor College of Medicine, Houston, TX

**(107) Risk Factors for Primary Graft Dysfunction after Lung Transplantation;** C. Van De Wauwer,<sup>1</sup> D.E.M. Van Raemdonck,<sup>1</sup> W. Coosemans,<sup>1</sup> G. Decker,<sup>1</sup> P. De Leyn,<sup>1</sup> L. Dupont,<sup>2</sup> P.h Nafteux,<sup>1</sup> G.M. Verleden,<sup>2</sup> T. Lerut,<sup>1</sup> <sup>1</sup>Department of Thoracic Surgery, UZ Leuven, Leuven, Belgium; <sup>2</sup>Department of Pulmonary Medicine, UZ Leuven, Leuven, Belgium

**(108) Assessment of Toll-Like Receptors and Cytokines Within Lung Transplant Patients for Predictors of Infection and Graft Rejection;** K.N. Taylor, E. Cohick, Y.L. Colson Department of Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, MA; Department of Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, MA; Department of Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, MA

**(109) Postoperative Swallowing Disorders Are Associated with Increased Mortality after Lung Transplantation;** B.Z. Atkins,<sup>1</sup> M. Trachtenberg,<sup>2</sup> K.R. Balsara,<sup>1</sup> G. Vess,<sup>2</sup> R.D. Davis,<sup>1</sup> <sup>1</sup>Cardiovascular and Thoracic Surgery, Duke University School of Medicine, Durham, NC; <sup>2</sup>Speech Pathology and Audiology, Duke University School of Medicine, Durham, NC

**(110) Early Re-Admission Is a Predictor of Survival Following Isolated Lung Transplantation;** F. Lamounier,<sup>4</sup> S. Bhorade,<sup>2</sup> E. Garrity,<sup>2</sup> C. Alex,<sup>3</sup> M. Hellenowski,<sup>1</sup> K. Pelletire,<sup>3</sup> W.T. Vigneswaran,<sup>1</sup> <sup>1</sup>Surgery, University of Chicago, Chicago, IL; <sup>2</sup>Medicine, University of Chicago, Chicago, IL; <sup>3</sup>Medicine, Loyola University Medical Center, Maywood, IL; <sup>4</sup>Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL

**(111) Predictors of Independent Lung Ventilation – An Analysis of 170 Single Lung Transplants;** D.V. Pilcher,<sup>1</sup> G.M. Auzinger,<sup>1</sup> B. Mitra,<sup>1</sup> D.V. Tuxen,<sup>1</sup> R.F. Salamonsen,<sup>1</sup> A.R. Davies,<sup>1</sup> T.J. Williams,<sup>2</sup> G.I. Snell,<sup>2</sup> <sup>1</sup>Department of Intensive Care Medicine, The Alfred Hospital, Melbourne, Victoria, Australia; <sup>2</sup>Department of Respiratory Medicine, The Alfred Hospital, Melbourne, Victoria, Australia

**(112) Symptom Experience Associated with Side Effects of Immunosuppressive Therapy in Lung Transplant Recipients;** D.S. Bosscher,<sup>1</sup> O.H. Bosma,<sup>1</sup> P. Moons,<sup>2</sup> E.A.M. Verschuuren,<sup>1</sup> W. van der Bij,<sup>1</sup> <sup>1</sup>Pulmonary Diseases, University Medical Centre Groningen, Groningen, Netherlands; <sup>2</sup>Centre for Health Services and Nursing Research, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium

**(113) Refractory Severe Complications of Lung Transplantation: Safety and Efficacy of Hyperbaric Oxygen Therapy;** T. Higuchi,<sup>1</sup> T. Oto,<sup>1</sup> B.J. Levvey,<sup>1</sup> T.J. Williams,<sup>1</sup> I.L. Millar,<sup>2</sup> G.I. Snell,<sup>1</sup> <sup>1</sup>Lung Transplant Service, Alfred Hospital & Monash University, Melbourne, Victoria, Australia; <sup>2</sup>Department of Intensive Care & Hyperbaric Medicine, Alfred Hospital, Melbourne, Victoria, Australia

**(114) Prolonged Postoperative Mechanical Ventilation of More Than Twenty-Four Hours (PPMV) Following Lung Transplantation: Incidence, Indications and Outcomes;** C.K. Choong,<sup>1,2</sup> L.D. Sharples,<sup>1</sup> J.S. Parmar,<sup>1</sup> P.R. Sivasothy,<sup>1</sup> H. Castle,<sup>1</sup> J. Wallwork,<sup>1,2</sup> <sup>1</sup>Transplant Unit, Papworth Hospital NHS Trust, Cambridge, England, United Kingdom; <sup>2</sup>Department of Surgery, University of Cambridge, Cambridge, England, United Kingdom

**(115) Aprotinin Use and Primary Allograft Dysfunction Following Off-Pump Bilateral Orthotopic Lung Transplantation;** K.R. Balsara,<sup>1</sup> S.T. Morozowich,<sup>2</sup> E.L. Bush,<sup>1</sup> B. Phillips-Bute,<sup>2</sup> M. Hill,<sup>2</sup> R.D. Davis,<sup>1</sup> S.S. Lin,<sup>1,3</sup> I.J. Welsby,<sup>2</sup> <sup>1</sup>Department of Surgery, Duke University Medical Center, Durham, NC; <sup>2</sup>Division of Cardiothoracic Anesthesia and Critical Care, Duke University Medical Center, Durham, NC; <sup>3</sup>Department of Immunology, Duke University Medical Center, Durham, NC

**(116) Lung Malignancy Incidence Following Lung Transplantation;** S. Evman,<sup>2</sup> A. Machaal,<sup>1</sup> N. Khasati,<sup>1</sup> C. Leonard,<sup>1</sup> N. Yonan,<sup>1</sup> <sup>1</sup>Transplant Unit/Cardiothoracic Surgery Department, Wythenshawe Hospital, Manchester, United Kingdom; <sup>2</sup>Thoracic Surgery, Marmara University Hospital, Istanbul, Turkey

**(117) Antiviral Prophylaxis May Decrease Incidence of Post-Transplant Lymphoproliferative Disorder (PTLD) after Lung Transplantation;** L.E. Leard,<sup>1</sup> J.D. Obata,<sup>2</sup> S.R. Hays,<sup>1</sup> C. Hoopes,<sup>2</sup> J.A. Golden,<sup>1</sup> <sup>1</sup>Division of Pulmonary Medicine, University of California San Francisco, San Francisco, CA; <sup>2</sup>Division of Cardiothoracic Surgery, Department of Surgery, University of California San Francisco, San Francisco, CA

**(118) Specific Pattern of Serum HGF and Broncho-Alveolar Lavage MMP-9 in Acute and Chronic Lung Transplant Rejection;** K. Krenn,<sup>1,2</sup> S. Taghavi,<sup>2</sup> P. Jaksch,<sup>2</sup> W. Klepetko,<sup>2</sup> S. Aharinejad,<sup>2,1</sup> <sup>1</sup>Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria; <sup>2</sup>Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria

**(119) Painful Sensory Neuropathy Induced by Voriconazole in Transplanted Patients;** V. Boussaud,<sup>1</sup> N. Daudet,<sup>2</sup> R. Guillemain,<sup>1</sup> E. Billaud,<sup>3</sup> C. Le Beller,<sup>2</sup> P. Chevalier,<sup>1</sup> C. Amrein,<sup>1</sup> M. Berger,<sup>3</sup> R. Souilamas,<sup>4</sup> A. Lillo-Le Louet,<sup>2</sup> <sup>1</sup>Cardiovascular Surgery, Hopital Européen Georges Pompidou, APHP, Paris, France; <sup>2</sup>Pharmacovigilance, Hopital Européen Georges Pompidou, APHP, Paris, France; <sup>3</sup>Pharmacology, Hopital Européen Georges Pompidou, APHP, Paris, France; <sup>4</sup>Thoracic Surgery, Hopital Européen Georges Pompidou, APHP, Paris, France

**(120) Elevated Levels of Pepsin in BALF of Lung Transplant Recipients with and without Allograft Dysfunction: Is Gastric Aspiration Important in the Development of BOS?;** K. Blondeau,<sup>1</sup> V. Mertens,<sup>1</sup> B.M. Vanaudenaerde,<sup>2</sup> D.E. Van Raemdonck,<sup>2</sup> G.M. Verleden,<sup>2</sup> D. Sifrim,<sup>1</sup> L.J. Dupont,<sup>2</sup> <sup>1</sup>Center for Gastroenterological Research, Katholieke Universiteit Leuven, Leuven, Belgium; <sup>2</sup>Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium

#### **7:15 PM – 8:15 PM**

General Poster Session 1 Removal (Continental Ballroom)

Mini Oral Sessions 1 - 4 Poster Mounting (Yosemite Ballroom)

#### **7:30 PM – 8:00 PM**

Bus Departure for Gala Reception (?????)

**8:00 PM – 10:00 PM**  
**GALA RECEPTION (City Hall)**

**THURSDAY, APRIL 26, 2007**

**24 Hours**

Internet Café Open (Continental Ballroom Foyer)

**6:00 AM – 6:00 PM**

Registration Desk Open (West Foyer)

**6:00 AM – 7:45 PM**

Slide Ready Room Open (Green Room)

**7:00 AM – 8:00 AM**

Mini Oral Sessions 1-4 Poster Mounting (Yosemite Ballroom)

**7:00 AM – 9:00 AM**

General Poster Session 2 Mounting (Continental Ballroom)

**7:00 AM – 6:00 PM**

Press Office Open (Executive Boardroom)

**7:00 AM – 8:00 AM**

**SUNRISE SYMPOSIUM 1**

**Immunobiology for Clinicians: Basic Biology (Imperial Ballroom A)**

**Chairs:** Dianne McKay, MD and James S. Allan, MD

**\*7:00 AM** *Overview of Innate Immunity*, Scott M. Palmer, MD, Duke University, Durham, NC

**7:30 AM** *Overview of Adaptive Immunity*, Thomas K. Waddell, MD, Toronto General Hospital, Toronto, ON, Canada

**7:00 AM – 8:00 AM**

**SUNRISE SYMPOSIUM 2**

**State of the Art Management Options for Bronchiolitis Obiterans (Imperial Ballroom B)**

**\*Chairs:** \*Selim M. Arcasoy, MD and \*Jonathan B. Orens, MD

**\*7:00 AM** *Novel Immune Therapies*, Selim M. Arcasoy, MD, Columbia University, New York, NY

**7:30 AM** *Non-Immune Therapies*, Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

**7:00 AM – 8:00 AM**

**SUNRISE SYMPOSIUM 3**

**Fungal Disease: New Diagnostics, New Treatments (Plaza Ballroom A)**

**\*Chairs:** \*Bernard M. Kubak, MD, PhD and Robin Avery, MD

**\*7:00 AM** *Tests for Diagnosis and Disease Management*, Shahid Husain, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

**7:20 AM** *The Azoles – Important Options, Especially for Oral Therapy*, Jose G. Montoya, MD, Stanford University, Stanford, CA

**\*7:40 AM** *The Echinocandins – A Wealth of Choice*, Aimee K. Zaas, MD, Duke University Medical Center, Durham, NC

**7:00 AM – 8:00 AM**

**SUNRISE SYMPOSIUM 4**

**Management Issues with Continuous Flow Devices (Plaza Ballroom B)**

**\*Chairs:** Nader Moazami, MD and \*Yoshifumi Naka, MD, PhD

**\*7:00 AM** *Operative Issues*, Carmelo Milano, MD, Duke University Medical Center, Durham, NC

**\*7:20 AM** *Setting Flow Rate*, Stuart D. Russell, MD, John's Hopkins Hospital, Baltimore, MD

**7:40 AM** *Anticoagulation*, Mark S. Slaughter, MD, Advocate Christ Medical Center, Oak Lawn, IL

**8:00 AM – 6:45 PM**

Mini Oral Sessions 1-4 Poster Viewing (Yosemite Ballroom)

**8:15 AM – 10:15 AM**

**PLENARY SESSION (Grand Ballroom B)**

**Chairs:** Stephan Schueler, MD, PhD, FRCS and Mark L. Barr, MD

**8:15 AM** *INTERMACS Report*, James K. Kirklin, MD, University of Alabama, Birmingham, AL

**8:30 AM** *Report on the Summit on Mechanical Support for Advanced Heart Failure*, Robert C. Robbins, MD, Stanford University Medical Center, Palo Alto, CA

**\*8:45 AM (121) Featured Abstract:** *Cumulative Support Outcomes of 3 Clinical Trials for the Ventriassist LVAD*; D.S. Esmore,<sup>1</sup> D. Kaye,<sup>1</sup> J.C. Negri,<sup>1</sup> M.R. Buckland,<sup>1</sup> R.F. Salamonson,<sup>1</sup> J. Begg,<sup>2</sup> F.L. Rosenfeldt,<sup>1</sup> J.C. Woodard,<sup>2</sup> <sup>1</sup>Cardiothoracic Surgery, Alfred Hospital, Melbourne, Victoria, Australia; <sup>2</sup>Ventracor Ltd, Sydney, NSW, Australia

**9:00 AM HeartMate II Trial**, Frances D. Pagani, MD, PhD, University of Michigan Hospital, Ann Arbor, MI

**9:15 AM Update on the Revised Working Formulation for the Diagnosis of Lung Transplant Rejection**, Susan Stewart, FRCPath, Papworth Hospital, Cambridge, United Kingdom

**\*9:35 AM Immunobiology of the B Cell**, Lori West, MD, D.Phil, University of Alberta, Edmonton, AB, Canada

**\*9:55 AM ABCs of HLA and non-HLA Antibodies in Transplantation**, Howard M. Gebel, PhD, Emory University Hospital, Atlanta, GA

**9:30 AM – 6:45 PM**

Exhibit Hall Open (Continental Ballroom)

General Poster Session 2 Poster Viewing (Continental Ballroom)

**10:15 AM – 10:45 AM**

**Coffee Break/Poster Viewing (Continental Ballroom)**

**10:45 AM – 12:15 PM**

**CONCURRENT SESSION 7**

**Management Issues During Mechanical Circulatory Support (Grand Ballroom B)**

**\*Chairs:** H. Todd Massey, MD and \*George M. Wieselthaler, MD

**10:45 AM (122) Is VAD Therapy Coming of Age? Perspectives from a 10 Year History of 200 Patients and 100 Patient-Years of Support**; Y. Suzuki,<sup>1</sup> J. Haft,<sup>1</sup> D.B. Dyke,<sup>2</sup> K.D. Aaronson,<sup>2</sup> S. Wright,<sup>1</sup> F.D. Pagani,<sup>1</sup> <sup>1</sup>Section of Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI; <sup>2</sup>Division of Cardiovascular Medicine, University of Michigan Health System, Ann Arbor, MI

**11:00 AM Invited Lecture:** The Role of INTERMACS in Capturing Adverse Events After Mechanical Circulatory Support Therapy, *Robert L. Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA*

**11:15 AM (123) Survival and Weight Loss in the Obese Patient after the Implantation of Ventricular Assist Devices**; J.J. Teuteberg,<sup>1</sup> S. Weaver,<sup>2</sup> E. Stanford,<sup>2</sup> M. Simon,<sup>1</sup> D. McNamara,<sup>1</sup> Y. Toyoda,<sup>2</sup> C. Bermudez,<sup>2</sup> K. McCurry,<sup>2</sup> R. Kormos,<sup>2</sup> <sup>1</sup>Cardiovascular Institute, University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>Cardiovascular Surgery, University of Pittsburgh, Pittsburgh, PA

**11:30 AM (124) Preoperative Risk Assessment for Right Ventricular Failure Following Implantation of a Left Ventricular Assist Device**; J.C. Matthews,<sup>1</sup> F.D. Pagani,<sup>2</sup> K.D. Aaronson,<sup>1</sup> <sup>1</sup>Division of Cardiovascular Medicine, University of Michigan Health System, Ann Arbor, MI; <sup>2</sup>Section of Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI

**\*11:45 AM (125) Treatment of HLA Sensitized Pre-Transplant Patients with Mechanical Support Is Effective for PRA Reduction**; P.C. Patel,<sup>1</sup> C.L. Fitzsimmons,<sup>1</sup> P.A. Kaiser,<sup>1</sup> P. Stastny,<sup>3</sup> J.M. DiMaio,<sup>2</sup> W.S. Ring,<sup>2</sup> C.W. Yancy,<sup>1</sup> M.H. Drazner,<sup>1</sup> D.M. Meyer,<sup>2</sup> \*D.W. Markham,<sup>1</sup> <sup>1</sup>Division of Cardiology, UT Southwestern Medical Center, Dallas, TX; <sup>2</sup>Division of Cardiothoracic Surgery, UT Southwestern Medical Center, Dallas, TX; <sup>3</sup>Department of Transplantation Immunology, UT Southwestern Medical Center, Dallas, TX

**Noon (126) Left Ventricular Assist Device Exchange – Indications and Outcomes**; R. John,<sup>1</sup> K. Liao,<sup>1</sup> K. Lietz,<sup>2</sup> M. Colvin-Adams,<sup>2</sup> A. Boyle,<sup>2</sup> L. Miller,<sup>2</sup> L. Joyce,<sup>1</sup> <sup>1</sup>Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN; <sup>2</sup>Division of Cardiology, University of Minnesota, Minneapolis, MN

**10:45 AM – 12:15 PM**

**CONCURRENT SESSION 8**

**Find and Fight Rejection (Grand Ballroom A)**

**\*Chairs:** \*Randall C. Starling, MD and Andre R. Simon, MD

**10:45 AM (127) Monitoring of Cell-Mediated Immunity during Immunosuppression Reduction in Heart Transplant Patients with Systemic Infections: An Objective Measurement**; M.W. Weston,<sup>1</sup> D. Rinde-Hoffman,<sup>1</sup> M. Lopez-Cepero,<sup>2</sup> L. DiChiara,<sup>3</sup> <sup>1</sup>Cardiology, LifeLink HealthCare Institute, Tampa, FL; <sup>2</sup>Immunology, LifeLink Immunology Laboratory, Tampa, FL; <sup>3</sup>Cardiology, Tampa General Hospital, Tampa, FL

**\*11:00 AM (128) Novel Immunosuppressive Strategies: Using a Molecular Diagnostic Assay for Weaning of Immunosuppressive Agents**; K. Albright,<sup>1</sup> T. Rowe,<sup>1</sup> S.R. Hankins,<sup>2</sup> H.J. Eisen,<sup>2</sup> <sup>1</sup>Center for Advanced Heart Failure Care, Hahnemann University Hospital, Philadelphia, PA; <sup>2</sup>Division of Cardiology/Department of Medicine, Drexel University College of Medicine, Philadelphia, PA

**11:15 AM (129) Early Screening for Antibody-Mediated Rejection in Heart Transplant Recipients**; A.G. Kfoury, M.E.H. Hammond, J. Stehlik, G.L. Snow, B.B. Reid, J.W. Long, E.M. Gilbert, F.M. Bader, D.G. Renlund, U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT

**11:30 AM (130) HLA and MICA: Targets of Antibody Mediated Rejection in Heart Transplantation**; Q. Zhang,<sup>1,3</sup> K. Si,<sup>1,3</sup> P. Ge,<sup>1,3</sup> G. Wu,<sup>2</sup> J.K. Patel,<sup>2</sup> J. Kobashigawa,<sup>2</sup> M.C. Fishbein,<sup>3</sup> E.F. Reed,<sup>1,3</sup> <sup>1</sup>Immunogenetics Center, David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>3</sup>Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA

**\*11:45 AM (131) Gene Expression and Prediction of Early Cardiac Allograft Rejection: Discovery of a Gene-Based Corticosteroid Efficacy Measure**; M.R. Mehra,<sup>1</sup> R.C. Starling,<sup>2</sup> P.G. Lal,<sup>3</sup> R.G. Woodward,<sup>3</sup> R.L. Dedrick,<sup>3</sup> S. Rosenberg,<sup>3</sup> <sup>1</sup>Medicine, University of Maryland Medical Center, Baltimore, MD; <sup>2</sup>Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH; <sup>3</sup>Research and Development, XDx, South San Francisco, CA

**NOON (132) *TGF- $\beta$  Polymorphisms, Gender and Age and Their Effect on Acute Cardiac Rejection***; D.M. Pekarek,<sup>1</sup> J.A. Barchue,<sup>2</sup> H.E. Grenett,<sup>2</sup> J.A. Tallaj,<sup>2</sup> R.C. Bourge,<sup>2</sup> J.A. Kirklin,<sup>4</sup> B.K. Rayburn,<sup>2</sup> C.S. Coffey,<sup>3</sup> R.L. Benza,<sup>2</sup> <sup>1</sup>Genetics, University of Alabama at Birmingham, Birmingham, AL; <sup>2</sup>Medicine/Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>Biostatistics, University of Alabama at Birmingham, Birmingham, AL; <sup>4</sup>Surgery, University of Alabama at Birmingham, Birmingham, AL

**10:45 AM – 12:15 PM**

**CONCURRENT SESSION 9**

**Clinical and Immunological Predictors of BOS (Imperial Ballroom A)**

**\*Chairs:** \*Bryan F. Meyers, MD and \*Andrew J. Fisher, MRCP, PhD

**\*10:45 AM (133) *Severity of Lymphocytic Bronchiolitis Predicts Long Term Outcome after Lung Transplantation***; A.R. Glanville,<sup>1</sup> C.L. Aboyou,<sup>1</sup> A. Havryk,<sup>1</sup> M. Pliit,<sup>1</sup> S. Rainer,<sup>1</sup> M.A. Malouf,<sup>1</sup> <sup>1</sup>Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia

**11:00 AM (134) *Impact of Airway Colonization with Gram-Negative Bacteria on Development of Bronchiolitis-Obliterans-Syndrome in Lung Transplant Recipients with Cystic Fibrosis***; J. Gottlieb,<sup>1</sup> F. Mattner,<sup>2</sup> H. Weissbrodt,<sup>2</sup> M. Dierich,<sup>1</sup> A. Simon,<sup>3</sup> M. Strueber,<sup>3</sup> T. Welte,<sup>1</sup> <sup>1</sup>Pulmonary Medicine, Hannover Thoracic Transplant Program, Hannover, Germany; <sup>2</sup>Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany; <sup>3</sup>Thoracic and Cardiovascular Surgery, Hannover Thoracic Transplant Program, Hannover, Germany

**11:15 AM (135) *Donor Glutathione-S-Transferase (GST) mu Null Genotype in Lung Transplant Recipients Is Associated with Increased Rates of Bronchiolitis Obliterans Syndrome (BOS) Independent of Acute Rejection***; D. Hadjiliadis,<sup>1</sup> R. Lingaraju,<sup>1</sup> J. Mendez,<sup>1</sup> A. Pochettino,<sup>1</sup> V.N. Ahya,<sup>1</sup> J.S. Sager,<sup>1</sup> R.M. Kotloff,<sup>1</sup> J.D. Christie,<sup>1</sup> <sup>1</sup>Lung Transplant Program, University of Pennsylvania, Philadelphia, PA

**\*11:30 AM (136) *Low Rate of Bronchiolitis Obliterans Syndrome Following Pre-Emptive Treatment of Post-Transplant Lymphoproliferative Disease after Lung Transplantation***; E.A.M. Verschuuren,<sup>1</sup> M.E. Erasmus,<sup>2</sup> B.G. Hepkema,<sup>3</sup> N. Veeger,<sup>4</sup> C.G.M. Kallenberg,<sup>5</sup> W. van der Bij,<sup>1</sup> <sup>1</sup>Pulmonary Diseases, University Medical Center, Groningen, Netherlands; <sup>2</sup>Cardio-Thoracic Surgery, University Medical Center, Groningen, Netherlands; <sup>3</sup>University Medical Center, Groningen, Netherlands; <sup>4</sup>Clinical Epidemiology, University Medical Center, Groningen, Netherlands; <sup>5</sup>Clinical Immunology, University Medical Center, Groningen, Netherlands

**11:45 AM (137) *Pre-Transplant MICA, HLA Class I or II Antibodies Are Associated with Earlier Onset of Bronchiolitis Obliterans Syndrome in Lung Transplant Recipient***; D.M. Lyu,<sup>1</sup> M. Nicolls,<sup>1</sup> B. Freed,<sup>1</sup> L. Cagle,<sup>1</sup> M.R. Zamora,<sup>1</sup> <sup>1</sup>Medicine, University of Colorado Health Sciences Center, Denver, CO

**\*NOON (138) *Impact of Primary Graft Dysfunction on Bronchiolitis Obliterans Syndrome after Lung Transplantation***; R.R. Hachem,<sup>1</sup> R.D. Yusen,<sup>1</sup> G.A. Patterson,<sup>1</sup> E.P. Trulock,<sup>1</sup> <sup>1</sup>Lung Transplant Program, Washington University School of Medicine, St. Louis, MO

**10:45 AM – 12:15 PM**

**CONCURRENT SESSION 10**

**Improving the Donor Lung (Imperial Ballroom B)**

**Chairs:** Michael S. Mulligan, MD and Michiel Erasmus, MD, PhD

**10:45 AM (139) *Fibrinolytic Treatment Improves the Quality of Lungs Retrieved from Non-Heart-Beating Donors***; I. Inci,<sup>1</sup> W. Zhai,<sup>1</sup> S. Arni,<sup>1</sup> D. Inci,<sup>2</sup> S. Hillinger,<sup>1</sup> D. Lardinois,<sup>1</sup> W. Weder,<sup>1</sup> <sup>1</sup>Department of Thoracic Surgery, University Hospital, Zurich, Switzerland; <sup>2</sup>Department of Pediatrics, University Children Hospital, Zurich, Switzerland

**11:00 AM (140) *Lung Transplantation from Deceased Donors without Pretreatment***; T.A. Butt, J.D. Aitchison, P.A. Corris, J. Wardle, S. Clark, J.H. Dark, Cardiothoracic Transplant, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; Cardiothoracic Transplant, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; Cardiothoracic Transplant, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; Cardiothoracic Transplant, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; Cardiothoracic Transplant, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; Cardiothoracic Transplant, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

**11:15 AM (141) *Inhibition of Poly (ADP-Ribose) Polymerase Improves Endothelial and Myocardial Function after Brain Death***; G. Szabó,<sup>1</sup> U. Heger,<sup>1</sup> C. Michel-Gröschel,<sup>1</sup> C. Szabó,<sup>2</sup> S. Hagl,<sup>1</sup> S. Bährle,<sup>1</sup> <sup>1</sup>Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; <sup>2</sup>Cellscreen Applied Research Center, Semmelweis University, Budapest, Hungary

**11:30 AM (142) *Resuscitation of the Brain Dead Organ Donor with Arginine Vasopressin (AVP) – An Alternative Vasoconstrictor***; A.J. Rostron,<sup>1</sup> V.S. Avlonitis,<sup>1</sup> D.M.W. Cork,<sup>1</sup> D.S. Grenade,<sup>1</sup> J.A. Kirby,<sup>1</sup> J.H. Dark,<sup>1</sup> <sup>1</sup>School of Surgical and Reproductive Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom

**11:45 AM (143) *Azithromycin Reduces Inflammation in a Murine Lung Ischemia-Reperfusion Injury Model***; N. Geudens,<sup>1</sup> L. Timmermans,<sup>1</sup> B.M. Vanaudenaerde,<sup>2</sup> C. Van De Wauwer,<sup>1</sup> T. Lerut,<sup>3</sup> E. Verbeke,<sup>4</sup> G.M. Verleden,<sup>2</sup> D.E.M. Van Raemdonck,<sup>1,3</sup> <sup>1</sup>Experimental Thoracic Surgery, Katholieke Universiteit, Leuven, Belgium; <sup>2</sup>Laboratory of Pneumology, Katholieke Universiteit, Leuven, Belgium; <sup>3</sup>Department of Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium; <sup>4</sup>Department of Pathology, University Hospital Gasthuisberg, Leuven, Belgium

**NOON (144) *A New Concept of Reconditioning Predamaged Donor Lungs in an Ex-Vivo Reperfusion Pig Model***; S.H. Wipper,<sup>1</sup> J. Schirmer,<sup>1</sup> B. Martens,<sup>1</sup> A. Lebatschi,<sup>1</sup> H.C. Reichenspurner,<sup>1</sup> F.M. Wagner,<sup>1</sup> <sup>1</sup>Cardiovascular Surgery, University Heart Center, Hamburg, Germany

**10:45 AM – 12:15 PM**

**CONCURRENT SESSION 11**

**Transplant Transmitted Infections: Risk and Outcomes (Plaza Ballroom A)**

**\*Chairs:** \*Barbara D. Alexander, MD and \*Shahid Husain, MD

**\*10:45 AM *Respiratory and Vector Borne Viruses***, Atul Humar, MD, MSC, FRCP, University of Toronto, Toronto, ON, Canada

**11:10 AM *Chagas Disease: An Increasing Threat***, Edimar A. Bocchi, MD, University of Sao Paulo, Sao Paulo, Brazil

11:35 AM *Hepatitis C*, Robin Avery, MD, The Cleveland Clinic, Cleveland, OH  
NOON Discussion

10:45 AM – 12:15 PM  
CONCURRENT SESSION 12

**Mechanisms of Allograft Vasculopathy (Plaza Ballroom B)**

**Chairs:** Roel A. de Weger, PhD and Vivek Rao, MD, PhD

**10:45 AM (145)** *A Synthetic Retinoid, Am80, Suppresses IL-6 Expression, and Inhibits Both Acute Rejection and Cardiac Allograft Vasculopathy in Cardiac Transplantation*; Y. Ogawa,<sup>1</sup> T. Shindo,<sup>2</sup> I. Manabe,<sup>1</sup> J. Suzuki,<sup>3</sup> M. Isobe,<sup>3</sup> R. Nagai,<sup>1</sup> <sup>1</sup>Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; <sup>2</sup>Department of Organ Regeneration, Graduate School of Medicine, Shinshu University, Matsumoto-shi, Nagano, Japan; <sup>3</sup>Department of Cardiovascular Medicine, Graduate School of Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan

**11:00 AM (146)** *IFN- $\gamma$  Production by Graft Antigen Specific CD4+ T Cells Is Not Required for the Development of Intimal Hyperplasia*; S.J. Huddleston,<sup>1</sup> W.S. Hays,<sup>1</sup> E. Ingulli,<sup>2</sup> M.K. Jenkins,<sup>3</sup> <sup>1</sup>Department of Surgery, University of Minnesota, Minneapolis, MN; <sup>2</sup>Department of Pediatrics, University of Minnesota, Minneapolis, MN; <sup>3</sup>Department of Microbiology, Center for Immunology, University of Minnesota, Minneapolis, MN

**\*11:15 AM (147)** *Airway Wall Endothelin-1 (ET-1) Expression Is Increased Prior to the Development of BOS in Lung Transplant Recipients*; L. Zheng,<sup>1</sup> G.I. Snell,<sup>2</sup> K. Kotsimbos,<sup>2</sup> B. Levvey,<sup>2</sup> G. Westall,<sup>2</sup> H.M. Whitford,<sup>2</sup> T.J. Williams,<sup>2</sup> <sup>1</sup>Department of Medicine, Monash Medical School, Monash University, Prahran, Vic, Australia; <sup>2</sup>Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Monash University, Melbourne, Vic, Australia

**11:30 AM (148)** *The IL-23/IL-17 Axis in Human Cardiac Allograft Vasculopathy*; J. van Kuik,<sup>1</sup> E. de Koning,<sup>1</sup> D.F. van Wichen,<sup>1</sup> M.F.M. van Oosterhout,<sup>1</sup> F.H.J. Gmelig-Meyling,<sup>2</sup> N. de Jonge,<sup>3</sup> R.A. de Weger,<sup>1</sup> <sup>1</sup>Pathology, University Medical Center, Utrecht, Netherlands; <sup>2</sup>Immunology, University Medical Center, Utrecht, Netherlands; <sup>3</sup>Heart Lung Center, University Medical Center, Utrecht, Netherlands

**11:45 AM (149)** *Cytochrome p450 (CYP) 2C Contributes to Cardiac Allograft Vasculopathy*; A.L. Hunter,<sup>1</sup> A. Kerjner,<sup>1</sup> K.J. Mueller,<sup>1</sup> B.M. McManus,<sup>1</sup> D.J. Granville,<sup>1</sup> <sup>1</sup>James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, University of British Columbia, Vancouver, BC, Canada

**NOON (150)** *Increased Levels of Transplant Arteriosclerosis in the Absence of CCR7 Are Associated with Reduced Expression of Foxp3*; S.M. Ensminger,<sup>1</sup> S. Helm,<sup>1</sup> L. Ohl,<sup>2</sup> B. Spriewald,<sup>3</sup> M. Weyand,<sup>1</sup> R. Foerster,<sup>2</sup> <sup>1</sup>Cardiothoracic Surgery, University of Erlangen-Nuernberg, Erlangen, Bavaria, Germany; <sup>2</sup>Institute for Immunology, Medizinische Hochschule Hannover, Hannover, Lower Saxony, Germany; <sup>3</sup>Medicine III, University of Erlangen-Nuernberg, Erlangen, Bavaria, Germany

12:15 PM – 12:30 PM  
Box Lunch Pick-up (ticket required) (Yosemite Ballroom)

12:30 PM – 2:00 PM  
LUNCHEON SYMPOSIUM

**Emerging Issues In Immunosuppression and Antiviral Therapy In Heart and Lung Transplantation (Grand Ballroom B)**

*Supported by an Unrestricted Educational Grant from Roche*

**\*Chairs:** Axel Haverich, MD and \*Barbara D. Alexander, MD

**\*12:30 PM A)** *Has Modern Immunosuppression Altered Long Term Outcomes After Heart and Lung Transplantation?* Hermann Reichenspurner, MD, PhD, University of Hamburg, Hamburg, Germany

1:00 PM Discussion

**\*1:10 PM B)** *Striking an Optimal Balance Between CMV Prophylaxis and Emergence of Resistance*

**\*1:10 PM** *Optimal Prophylaxis: Balancing Prevention with Resistance*, Scott M. Palmer, MD, Duke University Medical Center, Durham, NC

**1:25 PM** *Ganciclovir Resistance: Management Strategies*, Sunwen Chou, MD, Oregon Health and Science University, Portland, OR

**1:40 PM** *Viral Related Causes of Rejection and Graft Failure*, Jeffrey A. Towbin, MD, Texas Children's Hospital, Houston, TX

1:55 PM Discussion

12:30 PM – 2:00 PM  
FELLOWS LUNCHEON (ticket required) (Union Square 15/16)  
**Chairs:** Robert C. Robbins, MD and Paul A. Corris, MB, FRCP

12:30 PM – 2:00 PM  
JHLT Editorial Board Meeting (Union Square 19/20)

12:30 PM – 2:00 PM  
International Thoracic Transplant Registry Meeting (Union Square 23/24)

12:30 PM – 2:00 PM  
MINI ORAL SESSION 1 (Imperial Ballroom A)  
**\*Chairs:** \*Gregory I. Snell, FRACP, MBBS and \*Annette Boehler, MD

**12:30 PM (151) Long-Term Improvement in Graft Function after Bilateral Living-Donor Lobar Lung Transplantation in Adults and Pediatrics;** M. Yamane,<sup>1</sup> H. Date,<sup>1</sup> M. Okazaki,<sup>1</sup> S. Toyooka,<sup>1</sup> M. Aoe,<sup>1</sup> Y. Sano,<sup>1</sup> <sup>1</sup>Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Okayama City, Japan

**12:35 PM (152) Twenty Six Years Experience of Lymphoproliferative Disease Following Lung Transplantation (PTLD);** S.M. Bianchi,<sup>1</sup> F.M. Black,<sup>1</sup> G. Parry,<sup>1</sup> F.K. Gould,<sup>1</sup> A.J. Fisher,<sup>1</sup> J. Lordan,<sup>1</sup> J.H. Dark,<sup>1</sup> P.A. Corris,<sup>1</sup> <sup>1</sup>Department of Cardiopulmonary Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

**\*12:40 PM (153) Association of Alveolar Duct Fibrosis with Chronic Rejection Following Lung Transplantation;** S.M. Studer,<sup>1</sup> S. Husain,<sup>2</sup> M. Crespo,<sup>1</sup> K.R. McCurry,<sup>3</sup> B.A. Johnson,<sup>1</sup> S.A. Yousem,<sup>4</sup> <sup>1</sup>Division of Pulmonary, Allergy & Critical Care, University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>Division of Infectious Disease, University of Pittsburgh, Pittsburgh, PA; <sup>3</sup>Division of Thoracic & Foregut Surgery, University of Pittsburgh, Pittsburgh, PA; <sup>4</sup>Department of Pathology, University of Pittsburgh, Pittsburgh, PA

**12:45 PM (154) Pre-Lung Transplant Immunosuppression Assessment of Candidates with Risk of Possible Hepatitis C (HCV) Post-Transplantation;** J.A. Golden,<sup>1</sup> N. Bass,<sup>1</sup> S. Hays,<sup>1</sup> L. Leard,<sup>1</sup> M. Kleinhenz,<sup>1</sup> C. Hoopes,<sup>1</sup> <sup>1</sup>University of California San Francisco, San Francisco, CA

**12:50 PM (155) Clinical Benefit of Chronic Low Dose Azithromycin Treatment in Patients with Bronchiolitis Obliterans;** F. Meloni,<sup>1</sup> A.M. Fietta,<sup>1</sup> C. Lastoria,<sup>1</sup> N. Solari,<sup>1</sup> F. Bini,<sup>1</sup> A. Cascina,<sup>1</sup> T. Oggionni,<sup>1</sup> <sup>1</sup>Dept Haematol Pneumol Cardiovasc Sc - Sect Pneumol, University of Pavia & Pol San Matteo, Pavia, Italy

**12:55 PM (156) Bilateral Pulmonary Lobe Transplantation for Cystic Fibrosis: Techniques, Results and Outcomes;** P. Puyot, P. Bonnette, M. Stern, A. Bisson, D. Grenet, F. Gonin, A. Colchen, P. Loirat, M. Fischler, A. Chapelier, Department of Thoracic Surgery and Lung Transplantation, Hopital FOCH, Suresnes, France; Department of Thoracic Surgery and Lung Transplantation, Hopital FOCH, Suresnes, France; Lung Transplant Group, Hopital FOCH, Suresnes, France; Lung Transplant Group, Hopital FOCH, Suresnes, France; Lung Transplant Group, Hopital FOCH, Suresnes, France; Department of Thoracic Surgery and Lung Transplantation, Hopital FOCH, Suresnes, France; Department of Thoracic Surgery and Lung Transplantation, Hopital FOCH, Suresnes, France; Lung Transplant Group, Hopital FOCH, Suresnes, France; Lung Transplant Group, Hopital FOCH, Suresnes, France; Department of Thoracic Surgery and Lung Transplantation, Hopital FOCH, Suresnes, France

**1:00 PM (157) Perioperative Predictors of Renal Failure Following Off-Pump Primary Double Lung Transplantation;** E.L. Bush,<sup>1</sup> K.R. Balsara,<sup>1</sup> M. Hartwig,<sup>1</sup> B.G. Phillips-Bute,<sup>3</sup> A. Shaw,<sup>3</sup> E. Cantu, III,<sup>1</sup> J.Z. Appel,<sup>1</sup> R.D. Davis,<sup>2</sup> I.J. Welsby,<sup>3</sup> S.S. Lin,<sup>2,4</sup> <sup>1</sup>Department of Surgery, Duke University Medical Center, Durham, NC; <sup>2</sup>Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC; <sup>3</sup>Division of Cardiothoracic Anesthesia and Critical Care Medicine, Department of Surgery, Duke University Medical Center, Durham, NC; <sup>4</sup>Department of Immunology, Duke University Medical Center, Durham, NC

**1:05 PM (158) Osteoporosis before and after in Lung Transplantation; Effect of a Steroid Minimization Strategy;** D.B. Zaldonis,<sup>1</sup> M.M. Crespo,<sup>3</sup> C.A. Bermudez,<sup>1</sup> Y. Toyoda,<sup>1</sup> J.W. Wilson,<sup>2</sup> J.M. Pilewski,<sup>3</sup> K.R. McCurry,<sup>1</sup> <sup>1</sup>Surgery, University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>Department of Biostatistics, Graduate School of Public Health, Pittsburgh, PA; <sup>3</sup>Department of Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA

**\*1:10 PM (159) Clinical Characteristics of Pulmonary Hypertension Associated with Sarcoidosis and Response to Therapy;** R.E. Girgis,<sup>1</sup> K. Osei,<sup>1</sup> S.C. Mathai,<sup>1</sup> D. Moeller,<sup>1</sup> E. Chen,<sup>1</sup> P.M. Hassoun,<sup>1</sup> <sup>1</sup>Medicine, Johns Hopkins University, Baltimore, MD

**1:15 PM (160) Long-Term Survival with End-Stage Idiopathic Pulmonary Arterial Hypertension (IPAH): Impact of Prostanoid and Endothelin-Receptor Antagonist Treatment after Patients' Listing for Transplantation;** M. Dandel,<sup>1</sup> H.B. Lehmkühl,<sup>1</sup> S. Mulahasanovic,<sup>1</sup> Y. Weng,<sup>1</sup> O. Grauhan, C. Knosalla, R. Hetzer <sup>1</sup>Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

**1:20 PM (161) Comparison of Infection Profiles from Cystic Fibrosis (CF) and Non-CF Patients after Lung Transplantation;** R.W. Bonvillain,<sup>1</sup> V.G. Valentine,<sup>2</sup> S.G. LaPlace,<sup>2</sup> G.A. Lombard,<sup>2</sup> D.E. Taylor,<sup>2</sup> G. Wang,<sup>1</sup> <sup>1</sup>Medicine and Genetics, LSU Health Sciences Center, New Orleans, LA; <sup>2</sup>Lung Transplantation, Ochsner Medical Center, New Orleans, LA

**1:25 PM (162) Lung Transplantation for End Stage Emphysema in the Veterans Administration (VA) Population. Are There Alternatives?;** J.D. Maloney,<sup>1</sup> N.C. De Oliveira,<sup>1</sup> R.D. Cornwell,<sup>2</sup> K.C. Meyers,<sup>2</sup> J.G. McCartney,<sup>2</sup> T.A. Hall,<sup>1</sup> T. Kohmoto,<sup>1</sup> N.M. Edwards,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, University of Wisconsin Hospitals and Clinics, Madison, WI; <sup>2</sup>Medicine, University of Wisconsin Hospitals and Clinics, Madison, WI

**1:30 PM (163) The Feasibility of Diaphragmatic Transplantation in a Canine Model: Novel Potential Therapy for Treatment of Duchenne Muscular Dystrophy-Associated Respiratory Failure;** A.S. Krupnick,<sup>1</sup> M. Okazaki,<sup>1</sup> N. Das,<sup>1</sup> J. Lai,<sup>1</sup> T. Tung,<sup>1</sup> S. Richardson,<sup>1</sup> A.E. Gelman,<sup>1</sup> G.A. Patterson,<sup>1</sup> D. Kreisel,<sup>1</sup> <sup>1</sup>Surgery, Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, MO

**1:35 PM (164) Successful Treatment of Adenovirus Pneumonia in Pediatric Lung Transplant Recipients with Cidofovir;** O. Elidemir,<sup>1</sup> M.L. Doan,<sup>1</sup> M.G. Schecter,<sup>1</sup> E.D. McKenzie,<sup>2</sup> J.S. Heinle,<sup>2</sup> G.B. Mallory,<sup>1</sup> <sup>1</sup>Pediatric Pulmonology, Baylor College of Medicine, Houston, TX; <sup>2</sup>Congenital Heart Surgery, Baylor College of Medicine, Houston, TX

**1:40 PM (165) Variability in Immunization Guidelines in Children before and after Lung Transplantation;** C. Bendon,<sup>1</sup> L.A. Danziger-Isakov,<sup>2</sup> T. Astor,<sup>3</sup> P. Aurora,<sup>4</sup> K. Bluemchen,<sup>5</sup> D. Boyer,<sup>6</sup> C. Conrad,<sup>7</sup> I. Eichler,<sup>8</sup> O. Elidemir,<sup>9</sup> S. Goldfarb,<sup>10</sup> M. Michaels,<sup>11</sup> P.J. Mogayzel,<sup>12</sup> C. Mueller,<sup>13</sup> D. Parakininkas,<sup>14</sup> D. Oberkfell,<sup>15</sup> M. Solomon,<sup>16</sup> A. Boehler,<sup>1</sup> <sup>1</sup>Division of Pulmonary Medicine and Lung Transplantation, University Hospital, Zurich, Switzerland; <sup>2</sup>The Children's Hospital at Cleveland Clinic, Cleveland, OH; <sup>3</sup>Columbus Children's Hospital, Columbus, OH; <sup>4</sup>Great Ormond Street Hospital for Children, London, United Kingdom; <sup>5</sup>University Childrens Hospital Charité, Berlin, Germany; <sup>6</sup>Boston Children's Hospital, Boston, MA; <sup>7</sup>Lucile Packard Children's Hospital at Stanford University, Palo Alto, CA; <sup>8</sup>University Children's Hospital, Vienna, Austria; <sup>9</sup>Texas Children's Hospital, Houston, TX; <sup>10</sup>Children's Hospital of Philadelphia, Philadelphia, PA; <sup>11</sup>Children's Hospital of Pittsburgh, Pittsburgh, PA; <sup>12</sup>Department of Pediatrics, John Hopkins University Hospital, Baltimore, MD; <sup>13</sup>Children's Hospital, Medical School Hanover, Germany; <sup>14</sup>Children's Hospital Wisconsin, Milwaukee, WI; <sup>15</sup>St Louis Children's Hospital, St. Louis, MO; <sup>16</sup>Hospital for Sick Children, Toronto, ON, Canada

**12:30 PM – 2:00 PM**

**MINI ORAL SESSION 2 (Imperial Ballroom B)**

\*Chairs: \*Gareth Parry, MB, FRCP and \*Stuart C. Sweet, MD, PhD

**12:30 PM (166) Predictors of Survival beyond Twenty Years after Orthotopic Heart Transplant;** S. Haj-Yahia,<sup>1,2</sup> G. Tasca,<sup>1</sup> H. Taghipour,<sup>1</sup> M. Petrou,<sup>1</sup> M. Amrani,<sup>1</sup> A. Pomerance,<sup>1</sup> J. Smith,<sup>1</sup> M. Rose,<sup>1</sup> E.J. Birks,<sup>1</sup> G. Dreyfus,<sup>1</sup> N.R. Banner,<sup>1</sup> A. Khaghani,<sup>1</sup> <sup>1</sup>Cardiothoracic Transplantation & Mechanical Circulatory Support, Royal Brompton & Harefield Hospital, London, United Kingdom; <sup>2</sup>National Heart & Lung Institute, Imperial College of Science, Technology & Medicine, London, United Kingdom

**12:35 PM (167) Immunity after Hepatitis B Vaccination and Its Effect on Outcomes in Heart Transplant Patients;** M. Montpetit,<sup>1</sup> A. Singh,<sup>1</sup> E. Muller,<sup>1</sup> C. Sech,<sup>1</sup> B. Pavlovic-Surjancev,<sup>1</sup> J. Sinacore,<sup>1</sup> A. Heroux,<sup>1</sup> <sup>1</sup>Heart Failure/Heart Transplant Program, Loyola University Medical Center, Maywood, IL

**12:40 PM (168) Combined Analysis of NT-proBNP and C-Reactive Protein Improves Their Predictive Value for Development of Cardiac Allograft Vasculopathy and All-Cause Mortality but Not Acute Cellular Rejection in Heart Transplant Recipients;** S. Arora,<sup>1</sup> L. Gullestad,<sup>1</sup> R. Wergeland,<sup>2</sup> T. Holm,<sup>1</sup> A. Hognestad,<sup>1</sup> O. Geiran,<sup>3,4</sup> A.K. Andreassen,<sup>1</sup> <sup>1</sup>Department of Cardiology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway; <sup>2</sup>Department of Medical Chemistry, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway; <sup>3</sup>Department of Cardiothoracic Surgery, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway; <sup>4</sup>Faculty Division Rikshospitalet, University of Oslo, Oslo, Norway

**12:45 PM (169) The Validity of BNP Blood Levels to Detect Heart Failure in Heart Transplant Patients;** Y.S. Vaidya,<sup>1</sup> M. Yajnik,<sup>1</sup> J.K. Patel,<sup>1</sup> D. Cruz,<sup>1</sup> G.W. Wu,<sup>1</sup> M.M. Kittleston,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA

**12:50 PM (170) Gene Expression Profiling Distinguishes Moderate to Severe from Mild Acute Cellular Rejection in Cardiac Allograft Recipients;** D. Bernstein,<sup>1</sup> G. Berry,<sup>1</sup> M. Billingham,<sup>1</sup> C.C. Marboe,<sup>2</sup> M.C. Deng,<sup>2</sup> S. Mital,<sup>2</sup> H. Eisen,<sup>3</sup> G.E. Williams,<sup>4</sup> H. Baron,<sup>4</sup> T.M. Klingler,<sup>4</sup> J.G. Wohlgemuth,<sup>4</sup> J. Kobashigawa,<sup>5</sup> <sup>1</sup>Stanford University, Stanford, CA; <sup>2</sup>Columbia University, New York, NY; <sup>3</sup>Hahnemann University Hospital, Philadelphia, PA; <sup>4</sup>XDx, South San Francisco, CA; <sup>5</sup>University of California, Los Angeles, Los Angeles, CA

**\*12:55 PM (171) Does Induction Therapy Influence the Utility of Gene Expression Testing for Cardiac Allograft Rejection?;** M. Mehra,<sup>1</sup> M.C. Deng,<sup>2</sup> R. Starling,<sup>3</sup> S. Murali,<sup>4</sup> D. Pauly,<sup>5</sup> P. Lal,<sup>6</sup> M. Cadeiras,<sup>2</sup> H. Baron,<sup>6</sup> S. Rosenberg,<sup>6</sup> H. Eisen,<sup>7</sup> <sup>1</sup>University of Maryland, Baltimore, MD; <sup>2</sup>Columbia University Medical Center, New York, NY; <sup>3</sup>Cleveland Clinical, Cleveland, OH; <sup>4</sup>Allegheny General Hospital, Pittsburgh, PA; <sup>5</sup>University of Florida, Gainesville, FL; <sup>6</sup>XDx, South San Francisco, CA; <sup>7</sup>Drexel University College of Medicine, Philadelphia, PA

**1:00 PM (172) Time Lapse Analysis of Changes in Doppler-Derived Index of Coronary Flow Reserve over Time Could Reduce Frequency of Endomyocardial Biopsy;** N. Oda,<sup>1</sup> T.S. Kato,<sup>1</sup> S. Hashimoto,<sup>1</sup> C. Kamiya,<sup>1</sup> K. Hashimura,<sup>1</sup> A. Mano,<sup>1</sup> H.I. Ueda,<sup>2</sup> M. Kitakaze,<sup>1</sup> T. Nakatani,<sup>3</sup> <sup>1</sup>Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan; <sup>2</sup>Department of Pathology, National Cardiovascular Center, Suita, Osaka, Japan; <sup>3</sup>Department of Transplantation, National Cardiovascular Center, Suita, Osaka, Japan

**1:05 PM (173) Clinical Utility of Coronary Perfusion Reserve and Strain Rate Imaging Obtained by Echocardiography as a Noninvasive Evaluation for Sub-Clinical Acute Rejection in Heart Transplant Recipients;** T.S. Kato,<sup>1</sup> S. Hashimoto,<sup>1</sup> N. Oda,<sup>1</sup> A. Mano,<sup>2</sup> T. Nakatai,<sup>2</sup> K. Hashimura,<sup>1</sup> H.I. Ueda,<sup>3</sup> M. Kitakaze,<sup>1</sup> S. Kitamura,<sup>4</sup> <sup>1</sup>Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan; <sup>2</sup>Department of Transplantation, National Cardiovascular Center, Suita, Osaka, Japan; <sup>3</sup>Department of Pathology, National Cardiovascular Center, Suita, Osaka, Japan; <sup>4</sup>Department of Cardiovascular Surgery, National Cardiovascular Center, Suita, Osaka, Japan

**1:10 PM (174) Longitudinal Changes in Chronotropic Response to Exercise and Heart Rate Recovery in Pediatric Heart Transplant Recipients;** T.P. Singh,<sup>1</sup> J. Rhodes,<sup>1</sup> K. Gauvreau,<sup>1</sup> E.D. Blume,<sup>1</sup> <sup>1</sup>Cardiology, Children's Hospital, Boston, MA

**1:15 PM (175) Too Fat or Too Thin? Body Habitus Assessment in Children Listed for Heart Transplant and Impact on Outcome;** B.D. Kaufman,<sup>1</sup> M.L. Nagle,<sup>1</sup> N. Vijaynathan,<sup>1</sup> B.D. Hanna,<sup>1</sup> S. Paridon,<sup>1</sup> C. Ravishankar,<sup>1</sup> M.K. Chrisant,<sup>1</sup> <sup>1</sup>Department of Pediatrics, Thoracic Organ Transplant Program, University of Pennsylvania, Philadelphia, PA

**\*\*1:20 PM (176) Tacrolimus Morbidity after Pediatric Heart Transplant Using Statins and Steroid Withdrawal;** \*M. Fenton,<sup>1</sup> C. Dewar,<sup>1</sup> \*M. Burch,<sup>1</sup> <sup>1</sup>Transplant, Great Ormond Street, London, United Kingdom

**1:25 PM (177) Impact of Failed Fontan Physiology on Outcome from Heart Transplant (Tx);** J.S. Killinger,<sup>1</sup> A.J. Smerling,<sup>1</sup> D.T. Hsu,<sup>1</sup> J.M. Lamour,<sup>1</sup> L.J. Addonizio,<sup>1</sup> <sup>1</sup>Columbia University, New York, NY

**1:30 PM (178) Outcomes of Pneumocystis jiroveci Pneumonia Infections in Pediatric Heart Transplant Recipients;** R.E. Edens,<sup>1</sup> D. Naftel,<sup>2</sup> A.I. Dipchand,<sup>3</sup> P. Rusconi,<sup>4</sup> G.J. Boyle,<sup>5</sup> T.E. Zaoutis,<sup>6</sup> the Pediatric Heart Transplant Study <sup>1</sup>Pediatrics, University of Arkansas & Arkansas Children's Hospital, Little Rock, AR; <sup>2</sup>Surgery, University of Alabama, Birmingham, AL; <sup>3</sup>Pediatrics, University of Toronto & Toronto Hospital for Sick Children, Toronto, ON, Canada; <sup>4</sup>Pediatrics, University of Miami, Miami, FL; <sup>5</sup>Pediatrics, Cleveland Clinic Foundation, Cleveland, OH; <sup>6</sup>Pediatrics, University of Pennsylvania & Children's Hospital of Philadelphia, Philadelphia, PA

**1:35 PM (179) The Influence of Induction Therapy, Immunosuppressive Regimen and Antiviral Prophylaxis on the Development of Lymphomas after Heart Transplantation: Data from the Spanish Heart Transplant Tumour Registry;** M.G. Crespo-Leiro,<sup>1</sup> L. Alonso-Pulpón,<sup>1</sup> J.M. Arizón,<sup>1</sup> L. Almenar,<sup>1</sup> J. Delgado,<sup>1</sup> J. Palomo,<sup>1</sup> M. Camprecios,<sup>1</sup> N. Manito,<sup>1</sup> G. Rabago,<sup>1</sup> E. Lage,<sup>1</sup> B. Diaz-Molina,<sup>1</sup> E. Roig,<sup>1</sup> D. Pascual,<sup>1</sup> T. Blasco,<sup>1</sup> L. De la Fuente,<sup>1</sup> M. Valls,<sup>1</sup> J. Muñiz,<sup>2</sup> <sup>1</sup>Spanish Heart Transplant Tumor Registry, Sociedad Española de Cardiología, Madrid, Spain; <sup>2</sup>Instituto Ciencias de la Salud, Universidad de la Coruña, La Coruña, Spain

**1:40 PM (180) Recurrent Viral Myocarditis after Cardiac Transplantation in Pediatric Population;** F. Calabrese, A. Angelini, A. Gambino, G. Gerosa, S. Rizzo, E. Carturan, G. Thiene, Department of Diagnostic and Medical Sciences and Special Therapies, University of Padua, Padua, Italy; Department of Diagnostic and Medical Sciences and Special Therapies, University of Padua, Padua, Italy; Department of Cardiothoracic Sciences, University of Padua, Padua, Italy; Department of Cardiothoracic Sciences, University of Padua, Padua, Italy; Department of Diagnostic and Medical Sciences and Special Therapies, University of Padua, Padua, Italy; Department of Diagnostic and Medical Sciences and Special Therapies, University of Padua, Padua, Italy; Department of Diagnostic and Medical Sciences and Special Therapies, University of Padua, Padua, Italy

**1:45 PM (181) Pre-Existing Neoplasms and Risk for Malignancy after Heart Transplantation. Data from the Spanish Post-Heart Transplant Tumors Registry;** J.F. Delgado,<sup>1</sup> M.G. Crespo,<sup>2</sup> L.A. Pulpon,<sup>3</sup> J.M. Arizon,<sup>4</sup> L. Almenar,<sup>5</sup> J. Palomo,<sup>6</sup> N. Manito,<sup>7</sup> G. Rabago,<sup>8</sup> E. Lage,<sup>9</sup> B. Diaz,<sup>10</sup> E. Roig,<sup>11</sup> D. Pascual,<sup>12</sup> T. Blasco,<sup>13</sup> L. Fuente,<sup>14</sup> M. Vals,<sup>15</sup> M. Camprecios,<sup>16</sup> J. Muniz,<sup>1</sup> <sup>1</sup>Hospital Doce de Octubre, Madrid, Spain; <sup>2</sup>Hospital Juan Canalejo, A Coruna, Spain; <sup>3</sup>Hospital Puerta de Hierro, Madrid, Spain; <sup>4</sup>Hospital Reina Sofia, Cordoba, Spain; <sup>5</sup>Hospital La Fe, Valencia, Spain; <sup>6</sup>Hospital Gregorio Marañon, Madrid, Spain; <sup>7</sup>Hospital de Bellvitge, Barcelona, Spain; <sup>8</sup>Clinica Universitaria de Navarra, Pamplona, Spain; <sup>9</sup>Hospital Virgen del Rocío, Sevilla, Spain; <sup>10</sup>Hospital Central de Asturias, Oviedo, Spain; <sup>11</sup>Hospital Clinic, Barcelona, Spain; <sup>12</sup>Hospital Virgen de la Arrixaca, Murcia, Spain; <sup>13</sup>Hospital Miguel Servet, Zaragoza, Spain; <sup>14</sup>Hospital Clinico, Valladolid, Spain; <sup>15</sup>Hospital Marques de Valdecilla, Santander, Spain; <sup>16</sup>Hospital S. Cruz y S. Pablo, Barcelona, Spain

**2:15 PM – 3:45 PM**

### **CONCURRENT SESSION 13**

#### **Outcomes Following Lung Transplantation (Grand Ballroom B)**

**\*Chairs:** \*Paul A. Corris, MB, FRCP and \*Lianne G. Singer, MD, FRCPC

**2:15 PM (182) Time Course of Physical Reconditioning during 3 Years after Lung Transplantation – Effects of Exercise Rehabilitation;** U. Tegtbur,<sup>2</sup> J. Gottlieb,<sup>3</sup> C. Kugler,<sup>1</sup> E. Guetzlaff,<sup>2</sup> L. Stein,<sup>2</sup> A. Simon,<sup>1</sup> T. Welte,<sup>3</sup> A. Haverich,<sup>1</sup> M. Strueber,<sup>1</sup> <sup>1</sup>Hannover Thoracic Transplant Program, Thoracic and Cardiovascular Surgery, Medical School, Hannover, Germany; <sup>2</sup>Sportsmedicine, Medical School, Hannover, Germany; <sup>3</sup>Pulmonology, Medical School, Hannover, Germany

**2:30 PM (183) Comparative Study of Lung Transplantation Long Term Results with Non Heart Beating Donors (NHBD): A Sustainable Break Through?;** P. Ussetti,<sup>1</sup> C. Lopez Garcia-Gallo,<sup>1</sup> D. Gomez de Antonio,<sup>2</sup> R. Laporta,<sup>1</sup> C. Carreño,<sup>3</sup> P. Gamez,<sup>2</sup> M. Córdoba,<sup>2</sup> M. Ramos,<sup>1</sup> M.J. Ferreiro,<sup>1</sup> A. Varela,<sup>2</sup> <sup>1</sup>Pneumology, Clinica Puerta de Hierro, Madrid, Spain; <sup>2</sup>Thoracic Surgery, Clínica Puerta de Hierro, Madrid, Spain; <sup>3</sup>Internal Medicine, Clinica Puerta de Hierro, Madrid, Spain

**2:45 PM (184) 90 Day Lung Transplant Mortality Following New Organ Allocation Guidelines;** J.D. McCue,<sup>1</sup> C.S. Herrington,<sup>1</sup> I.I. Hertz,<sup>1</sup> P.S. Dahlberg,<sup>1</sup> <sup>1</sup>Thoracic Transplantation, University of Minnesota, Minneapolis, MN

**3:00 PM (185) Survival Outcomes Following Lung Transplantation for Cystic Fibrosis Patients Infected with Burkholderia Cenocepacia – A UK Experience;** G.J. Meachery,<sup>1</sup> L. Archer,<sup>2</sup> A. De Soya,<sup>1</sup> G. Parry,<sup>1</sup> S. Clark,<sup>1</sup> K. Tocewicz,<sup>1</sup> A. Fisher,<sup>1</sup> J. Lordan,<sup>1</sup> S. Schueler,<sup>1</sup> F.K. Gould,<sup>2</sup> J.H. Dark,<sup>1</sup> P.A. Corris,<sup>1</sup> <sup>1</sup>Applied Immunobiology and Transplantation Group, The Freeman Hospital, Newcastle Upon Tyne, United Kingdom; <sup>2</sup>Department of Medical Microbiology, The Freeman Hospital, Newcastle Upon Tyne, United Kingdom

**3:15 PM (186) Combined Lung and Liver Transplantation in Patients with Cystic Fibrosis;** R. Souilamas,<sup>1</sup> R. Guillemain,<sup>2</sup> V. Boussaud,<sup>3</sup> C. Amrein,<sup>2</sup> P. chevalier,<sup>4</sup> J.-N. Fabiani,<sup>4</sup> <sup>1</sup>Thoracic Surgery, European Georges Pompidou Hospital, Paris, France; <sup>2</sup>Anesthesiology-Intensive Care Unit, European Georges Pompidou Hospital, Paris, France; <sup>3</sup>Intensive Care Unit, European Georges Pompidou Hospital, Paris, France; <sup>4</sup>Cardiovascular Surgery, European Georges Pompidou Hospital, Paris, France

**3:30 PM (187) Lung Transplantation in Patients with Connective Tissue Disorders and Esophageal Dysmotility;** W.J. Gasper,<sup>1</sup> M.P. Sweet,<sup>1</sup> M.G. Patti,<sup>1</sup> C. Hoopes,<sup>1</sup> L.E. Leard,<sup>2</sup> S.R. Hays,<sup>2</sup> J.A. Golden,<sup>2</sup> <sup>1</sup>Department of Surgery, University of California, San Francisco, San Francisco, CA; <sup>2</sup>Department of Medicine, University of California, San Francisco, San Francisco, CA

**2:15 PM – 3:45 PM**

### **CONCURRENT SESSION 14**

#### **Fat, Flow, and Function: New Insights into Allograft Vasculopathy (Grand Ballroom A)**

**\*Chairs:** \*Gregory A. Ewald, MD and \*Jan Groetzner, MD

**2:15 PM (188) Donor Specific HLA-Antibodies Predict the Risk for Vasculopathy and Decreased Survival after Heart Transplantation;** L. Kaczmarek,<sup>1</sup> A. Beiras-Fernandez,<sup>1</sup> O. Delgado,<sup>1</sup> S. Michel,<sup>1</sup> T. Kauke,<sup>2</sup> M. Schmoeckel,<sup>1</sup> B. Meiser,<sup>1</sup> B. Reichart,<sup>1</sup> <sup>1</sup>Cardiac Surgery, University Hospital Grosshadern, LMU Munich, Munich, Germany; <sup>2</sup>Laboratories for Immunogenetics, University Hospital Grosshadern, LMU Munich, Munich, Germany

**2:30 PM (189) Relationship between Insulin Resistance Features and Progression of Cardiac Allograft Vasculopathy;** S.A. Virani,<sup>1</sup> A.M. Wilson,<sup>1</sup> M.X. Pham,<sup>1</sup> H.A. Valentine,<sup>1</sup> J.P. Cooke,<sup>1</sup> W.F. Fearon,<sup>1</sup> <sup>1</sup>Cardiovascular Medicine, Stanford University, Stanford, CA

**2:45 PM (190) Predictors of Microvascular Damage in Heart Transplant Recipients without Cardiac Allograft Vasculopathy: A Contrast-Enhanced Echocardiographic Study;** E. Tona,<sup>1</sup> A.L.P. Caforio,<sup>1</sup> R. Montisci,<sup>2</sup> A. Gambino,<sup>3</sup> A. Ramondo,<sup>1</sup> G. Toscano,<sup>3</sup> M. Ruscazio,<sup>2</sup> A. Angelini,<sup>4</sup> G. Gerosa,<sup>3</sup> S. Iliceto,<sup>1</sup> <sup>1</sup>Cardiology, University of Padova, Padova, Italy; <sup>2</sup>Cardiology, University of Cagliari, Cagliari, Italy; <sup>3</sup>Cardiovascular Surgery, University of Padova, Padova, Italy; <sup>4</sup>Cardiovascular Pathology, University of Padova, Padova, Italy

**3:00 PM (191) Rapamycin Inhibits Endothelial Cell Recovery after Hypoxic Injury;** J.L. Jackman,<sup>1</sup> L. Tumiati,<sup>1</sup> N. Xu,<sup>1</sup> D. Ramzay,<sup>1</sup> R. Sheshgiri,<sup>1</sup> M. Badiwala,<sup>1</sup> V. Rao,<sup>1</sup> <sup>1</sup>Cardiovascular Surgery, University of Toronto, Toronto, ON, Canada

**3:15 PM (192) Systemic Inflammation and Metabolic Syndrome in Cardiac Allograft Vasculopathy;** E.R. Raichlin,<sup>1</sup> J.P. McConnell,<sup>2</sup> W.K. Kremers,<sup>3</sup> B.S. Edwards,<sup>1</sup> S.S. Kushwaha,<sup>1</sup> A.L. Clavell,<sup>1</sup> R.J. Rodeheffer,<sup>1</sup> R.P. Frantz,<sup>1</sup> <sup>1</sup>Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN; <sup>2</sup>Laboratory Medicine, Mayo Clinic College of Medicine, Rochester, MN; <sup>3</sup>Biostatistics, Mayo Clinic College of Medicine, Rochester, MN

**3:30 PM (193) Allomap Test Does Not Correlate with Late Survival or Coronary Artery Vasculopathy in Heart Transplantation;** D. Torres,<sup>1</sup> M. Macha,<sup>1</sup> E.J. Molina,<sup>1</sup> J. deFranco,<sup>1</sup> J.P. Gaughan,<sup>1</sup> D. Beltramo,<sup>1</sup> J.B. McClurken,<sup>1</sup> S. Furukawa,<sup>1</sup> <sup>1</sup>Surgery, Temple University, Philadelphia, PA

**2:15 PM – 3:45 PM**

### **CONCURRENT SESSION 15**

#### **“Humoral” Factors in Rejection (Imperial Ballroom A)**

**Chairs:** Elizabeth Hammond, MD and Cynthia M. Magro, MD

**2:15 PM (194)** *'Normal' Myocardial Complement Deposition after Heart Transplantation*; I.M. Hamour,<sup>1</sup> M.L. Rose,<sup>2</sup> D. Simpson,<sup>3</sup> B. Mitchelson,<sup>3</sup> N.R. Banner,<sup>1</sup> M.M. Burke,<sup>3</sup> <sup>1</sup>Cardiology and Transplantation, Harefield Hospital, Harefield, Middlesex, United Kingdom; <sup>2</sup>Transplant Immunology, Heart & Science Center, Imperial College, Harefield Hospital, Harefield, Middlesex, United Kingdom; <sup>3</sup>Transplant Pathology, Harefield Hospital, Harefield, Middlesex, United Kingdom

**2:30 PM (195)** *Cardiac C4d Staining Is Not Associated with Abnormal Hemodynamics*; S.E. Fedson,<sup>1</sup> S.S. Daniel,<sup>2</sup> A.S. Anderson,<sup>1</sup> A.Y. Kim,<sup>1</sup> A.N. Husain,<sup>3</sup> <sup>1</sup>Medicine, University of Chicago, Chicago, IL; <sup>2</sup>Pritzker School of Medicine, Chicago, IL; <sup>3</sup>Pathology, University of Chicago, Chicago, IL

**2:45 PM (196)** *Pattern of C4d Staining Is Important in Cardiac Transplantation*; S.E. Fedson,<sup>1</sup> S.S. Daniel,<sup>2</sup> A.N. Husain,<sup>3</sup> <sup>1</sup>Medicine, University of Chicago, Chicago, IL; <sup>2</sup>Pritzker School of Medicine, Chicago, IL; <sup>3</sup>Pathology, University of Chicago, Chicago, IL

**3:00 PM (197)** *Deposition of C4d in Heart Transplants: A Factor in the Development of CAV?*; E. Moseley,<sup>1</sup> C. Atkinson,<sup>2</sup> J. Cornelissen,<sup>1</sup> J. Wallwork,<sup>1</sup> M. Goddard,<sup>1</sup> <sup>1</sup>Pathology Department, Papworth NHS Trust Hospital, Cambridge, Cambridgeshire, United Kingdom; <sup>2</sup>Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC

**3:15 PM (198)** *Fibrin Deposition in Cardiac Allograft Rejection: An Incidental Finding or a Prognostic Marker?*; J. Stehlik, A.G. Kfoury, G.L. Snow, E.M. Gilbert, F.M. Bader, D.G. Renlund, J.W. Long, D.A. Bull, M.E.H. Hammond, U.T.A.H Cardiac Transplant Program, Salt Lake City, UT

**3:30 PM Invited Lecture:** *Pathologic Assessment of AMR in the Lung*, Cynthia M. Magro, MD, Weill College of Med/Cornell University, New York, NY

**2:15 PM – 3:45 PM**

**CONCURRENT SESSION 16**

**Better Living Through Drugs (Imperial Ballroom B)**

**Chairs:** Stephan M. Ensminger, MD, PhD and James S. Allan, MD

**2:15 PM (199)** *Endothelin-1 Antagonism Prevents CyA Induced Vasomotor Impairment: Implication for Transplant Related Vascular Injury*; D. Ramzy,<sup>1</sup> L.C. Tumiati,<sup>1</sup> N. Xu,<sup>1</sup> E. Tepperman, D.H. Delgado,<sup>1</sup> J. Jackman,<sup>1</sup> R. Sheshgiri,<sup>1</sup> M. Badiwala,<sup>1</sup> V. Rao,<sup>1</sup> <sup>1</sup>Cardiac Surgery, University of Toronto, Toronto, ON, Canada

**2:30 PM (200)** *ATGs Reduce the Expression of Inflammation and Adhesion Molecules In Vivo in a Model of Ischemia/Reperfusion*; A. Beiras-Fernandez,<sup>1,2</sup> D. Chappell,<sup>1</sup> E. Thein,<sup>1</sup> B. Reichart,<sup>2</sup> C. Hammer,<sup>1</sup> <sup>1</sup>Institute for Surgical Research, LM-University, Munich, Germany; <sup>2</sup>Department of Cardiac Surgery, LM-University, Munich, Germany

**2:45 PM (201)** *Pharmacokinetics of Aerosolized Tacrolimus in Rats*; S. Schrepfer,<sup>1</sup> T. Deuse,<sup>2</sup> J. Hoffmann,<sup>1</sup> M. Haddad,<sup>3</sup> M.P. Fischbein,<sup>1</sup> H. Reichenspurner,<sup>2</sup> R.C. Robbins,<sup>1</sup> M.P. Pelletier,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, Stanford University School of Medicine, Palo Alto, CA; <sup>2</sup>Cardiovascular Surgery, University Heart Center Hamburg gGmbH, Hamburg, Germany; <sup>3</sup>Clinical Chemistry, University Hospital Hamburg, Hamburg, Germany

**3:00 PM (202)** *The Effect of Calcineurin Inhibitors (CNI) on the Release of Secretory Leucoprotease Inhibitor (SLPI) by Lung Epithelial Cells in the Presence of Transforming Growth Factor-beta (TGF-beta)*; R.L. Anderson,<sup>1</sup> P.S. Hiemstra,<sup>2</sup> L. Borthwick,<sup>1</sup> J. Lordan,<sup>1</sup> P.A. Corris,<sup>1</sup> A.J. Fisher,<sup>1</sup> <sup>1</sup>Applied Immunobiology and Transplant Research Group, Newcastle University, Newcastle, United Kingdom; <sup>2</sup>Pulmonology Department, Leiden University Medical Centre, Leiden, Netherlands

**3:15 PM (203)** *Dasatinib, a Novel Immunosuppressant Specifically Targeting T Cell Antigen Receptor Activation*; A.E. Schade,<sup>1,2</sup> H. Szpurka,<sup>1</sup> A. Jankowska,<sup>1</sup> G. Gonzalez-Stawinski,<sup>3</sup> B.W. Lytle,<sup>3</sup> J.P. Maciejewski,<sup>1</sup> <sup>1</sup>Section of Experimental Hematology and Hematopoiesis, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH; <sup>2</sup>Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH; <sup>3</sup>Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH

**3:30 PM (204)** *mTOR Knockdown Inhibits Anti-HLA Antibody Induced MHC Class I Signaling*; P.T. Jindra,<sup>1</sup> E.F. Reed,<sup>1</sup> <sup>1</sup>UCLA Immunogenetics Center, David Geffen School of Medicine, UCLA, Los Angeles, CA

**2:15 PM – 3:45 PM**

**CONCURRENT SESSION 17**

**Evaluation for Transplant: Where Are We in 2007? (Plaza Ballroom A)**

**\*Chairs:** \*Hans B. Lehmkuhl, MD and \*Patricia A. Uber, Pharm.D

**2:15 PM Invited Lecture:** *Cardiopulmonary Stress Testing: What do the ISHLT Guidelines Tell Us?* Stuart D. Russell, MD, John's Hopkins Hospital, Baltimore, MD

**2:30 PM (205)** *Improved Survival on Heart Transplant (HT) Waiting Lists – Analysis of UNOS/OPTN 1988-2006*; K. Lietz,<sup>1</sup> L.W. Miller,<sup>1</sup> <sup>1</sup>Cardiovascular Division, Georgetown University - Washington Hospital Center, Washington, DC

**2:45 PM (206)** *Intravenous Sildenafil Citrate for Selective Pulmonary Vasodilatation in Heart Failure*; P. Botha,<sup>1</sup> G. Parry,<sup>1</sup> J.H. Dark,<sup>1</sup> G.A. MacGowan,<sup>1</sup> <sup>1</sup>Cardiopulmonary Transplantation, Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, United Kingdom

**3:00 PM (207)** *Panel Reactive Antibody Screening and Treatment Practices Following Bridge to Transplant Ventricular Assist Device Placement*; I. Tawfik,<sup>1</sup> M. Shinnar,<sup>1</sup> M.B. Anderson,<sup>2</sup> T. Prendergast,<sup>2</sup> R.S. Freudenberger,<sup>1</sup> <sup>1</sup>Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ; <sup>2</sup>Surgery, Robert Wood Johnson Medical School, New Brunswick, NJ

**3:15 PM (208)** *Value of the Natriuretic Peptide NT-proBNP for Selecting Patients with High Priority for Heart Transplantation*; T. Komoda,<sup>1</sup> H.B. Lehmkuhl,<sup>1</sup> C. Knosalla,<sup>1</sup> E. Potapov,<sup>1</sup> M. Dandel,<sup>1</sup> O. Grauhan,<sup>1</sup> R. Hetzer,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

**3:30 PM Invited Lecture:** *Novel Biomarkers for Risk Prediction in Heart Failure*, Thomas J. Dengler, MD, PhD, University of Heidelberg, Heidelberg, Germany

**2:15 PM – 3:45 PM**

**CONCURRENT SESSION 18**

**Monitoring for Heart Transplant Rejection (Plaza Ballroom B)**

**\*Chairs:** \*Michael Burch, MD and Jacqueline M. Lamour, MD

**2:15 PM (209)** *Elevated Doppler Tissue Imaging-Derived Indices Reflect Cellular and Humoral Rejection in Pediatric Heart Transplant Recipients*; S.K. Behera,<sup>1</sup> J. Trang,<sup>1</sup> S. Drant,<sup>2</sup> J.C. Alejos,<sup>1</sup> <sup>1</sup>Pediatric Cardiology, University of California, Los Angeles, Los Angeles, CA; <sup>2</sup>Pediatric Cardiology, University of Pittsburgh, Pittsburgh, PA

**2:30 PM (210)** *Screening for Rejection in Symptomatic Pediatric Heart Transplant Patients: The Sensitivity of BNP*; D.E. Harake,<sup>1</sup> M.K. Geiger,<sup>1</sup> D.S. Levi,<sup>1</sup> N.J. Halnon,<sup>1</sup> J.C. Alejos,<sup>1</sup> <sup>1</sup>Pediatric Cardiology, University of California, Los Angeles, Los Angeles, CA

**2:45 PM (211)** *Coronary Flow Reserve Detects Endothelial Dysfunction and Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Patients*; S. Schubert,<sup>1</sup> H. Abdul-Khaliq,<sup>1</sup> P. Ewert,<sup>1</sup> H.B. Lehmkuhl,<sup>3</sup> B. Peters,<sup>1</sup> E. Wellnhofer,<sup>3</sup> N. Hiemann,<sup>2</sup> R. Meyer,<sup>4</sup> R. Hetzer,<sup>2</sup> F. Berger,<sup>1</sup> <sup>1</sup>Pediatric Cardiology, German Heart Center, Berlin, Germany; <sup>2</sup>Thoracic and Cardiovascular Surgery, German Heart Center, Berlin, Germany; <sup>3</sup>Cardiology, German Heart Center, Berlin, Germany; <sup>4</sup>Pathology, German Heart Center, Berlin, Germany

**3:00 PM (212)** *Ultrasound Cardiac Output Monitor Measurements in Pediatric Cardiac Transplant Patients*; J.H. Eguchi, M. Mathur, R. Larsen, A. De-Amaya, L.L. Bailey, R. Chinnock, S.A. Abd-Allah, Pediatrics, Nursing, and Cardiothoracic Surgery, Loma Linda University Children's Hospital, Loma Linda, CA

**3:15 PM (213)** *Pediatric Heart Transplantation: Implications for 2 Hour Cyclosporin A Blood Levels Greater 600 ng/ml for Graft Protection Monitoring*; L. Ablonczy,<sup>1</sup> S. Schubert,<sup>2</sup> H. Lehmkuhl,<sup>2</sup> O. Miera,<sup>2</sup> M. H[ue]bler,<sup>2</sup> C. Knosalla,<sup>2</sup> O. Grauhan,<sup>2</sup> H. Abdul-Khaliq,<sup>2</sup> F. Berger,<sup>2</sup> R. Hetzer,<sup>2</sup> <sup>1</sup>Hungarian Institute of Cardiology, Budapest, Hungary; <sup>2</sup>Deutsches Herzzentrum, Berlin, Germany

**3:30 PM (214)** *Complement Fragments C4d and C3d Deposition Does Not Correlate with Rejection in Pediatric Heart Transplant Recipients with a Positive Crossmatch*; D.B. Holt,<sup>1</sup> H. Liapis,<sup>2</sup> D.R. Phelan,<sup>3</sup> S.K. Gandhi,<sup>4</sup> C.B. Huddleston,<sup>4</sup> C.E. Canter,<sup>1</sup> <sup>1</sup>Pediatrics, Washington University, St. Louis, MO; <sup>2</sup>Pathology, Washington University, St. Louis, MO; <sup>3</sup>Laboratory Medicine, Washington University, St. Louis, MO; <sup>4</sup>Surgery, Washington University, St. Louis, MO

**3:45 PM – 4:15 PM**

**Coffee Break/Poster Viewing (Continental Ballroom)**

**4:15 PM – 5:45 PM**

**CONCURRENT SESSION 19**

**Complication Amelioration: Prevention of Rejection, Restriction, and Renal Dysfunction (Grand Ballroom B)**

**\*Chairs:** \*Nicholas G. Smedira, MD and \*Mark J. Zucker, MD

**\*4:15 PM (215)** *Gene Expression Profiling in Patients with Antibody Mediated Rejection*; A.R. Gangadin,<sup>1</sup> M. Cadeiras,<sup>1</sup> A. Sinha,<sup>1</sup> M.P. Bayern,<sup>1</sup> A.S. Oz,<sup>1</sup> S. Memon,<sup>1</sup> C.C. Marboe,<sup>1</sup> N. Suci-Foca,<sup>1</sup> H. Baron,<sup>2</sup> R. Dedrick,<sup>2</sup> A. Califano,<sup>1</sup> M.C. Deng,<sup>1</sup> <sup>1</sup>Columbia University College of Physicians and Surgeons, New York, NY; <sup>2</sup>XDx Inc., South San Francisco, CA

**4:30 PM (216)** *Cell Death in Acute Cardiac Graft Rejection Is Mediated by Suppression of Apoptosis Inhibitor Apollon*; S. Aharinejad,<sup>1,2</sup> R. Schaefer,<sup>2</sup> P. Paulus,<sup>2</sup> K. Krenn,<sup>2,1</sup> A. Zuckermann,<sup>1</sup> A. Aliabadi,<sup>1</sup> E. Wolner,<sup>1</sup> M. Grimm,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria; <sup>2</sup>Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria

**4:45 PM (217)** *Predictors of Early Development of Chronic Kidney Disease Following Heart Transplantation*; G.D. Lewis,<sup>1</sup> D.S. Frankel,<sup>1</sup> R.N. Brown,<sup>2</sup> R.J. Rodeheffer,<sup>3</sup> A.L. Heroux,<sup>4</sup> B.M. Cabuay,<sup>5</sup> S.A. Keck,<sup>1</sup> J.K. Kirklin,<sup>2</sup> M.J. Semigran,<sup>1</sup> <sup>1</sup>Cardiology Division, Massachusetts General Hospital, Boston, MA; <sup>2</sup>Surgery Department and the Cardiac Transplant Research Database, University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>Cardiology Division, Mayo Clinic, Rochester, MN; <sup>4</sup>Cardiology Division, Loyola University Medical Center, Maywood, IL; <sup>5</sup>Cardiology Division, University of Iowa, Iowa City, IA

**5:00 PM (218)** *Replacement of Calcineurin-Inhibitors with Sirolimus to Preserve Renal Function in Stable Cardiac Transplant Recipients*; E. Raichlin,<sup>1</sup> Z. Khalpey,<sup>1</sup> A.L. Clavell,<sup>1</sup> B.S. Edwards,<sup>1</sup> R.P. Frantz,<sup>1</sup> J.A. Wagner,<sup>1</sup> R.J. Rodeheffer,<sup>1</sup> S.S. Kushwaha,<sup>1</sup> <sup>1</sup>Cardiovascular Diseases, Mayo Clinic, Rochester, MN

**5:15 PM (219)** *Widespread Fibrosis of Myocardial and Adjacent Tissues Causing Restrictive Cardiac Physiology in Patients Needing Re-Do Heart Transplant*; B.K. Itagaki,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> G.W. Wu,<sup>1</sup> J.K. Patel,<sup>1</sup> M.A. Kawano,<sup>1</sup> M.M. Kittleson,<sup>1</sup> M.C. Fishbein,<sup>2</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA; <sup>2</sup>Pathology and Laboratory Medicine, University of California at Los Angeles, Los Angeles, CA

**\*5:30 PM (220)** *Prognostic Impact of the Quilty Phenomenon for the Development of Stenotic Microvasculopathy after Heart Transplantation: Evidence from 9,713 Biopsies*; N.E. Hiemann,<sup>1</sup> E. Wellnhofer,<sup>2</sup> C. Knosalla,<sup>1</sup> H.B. Lehmkuhl,<sup>1</sup> R. Hetzer,<sup>1</sup> R. Meyer,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>2</sup>Department of Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany

4:15 PM – 5:45 PM

**CONCURRENT SESSION 20**

**GERD and Lung Transplantation (Grand Ballroom A)**

**Chairs:** Cecilia Chaparro, MD and David W. Zaas, MD

**4:15 PM (221) Exhaled Breath Condensate Pepsin: A New Noninvasive Marker of GERD after Lung Transplantation;** A. Krishnan,<sup>1</sup> S. Chow,<sup>2</sup> P.S. Thomas,<sup>2</sup> M.A. Malouf,<sup>1</sup> A.R. Glanville,<sup>1</sup> D.H. Yates,<sup>3</sup> <sup>1</sup>The Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia; <sup>2</sup>Thoracic Medicine, University of New South Wales, Sydney, NSW, Australia; <sup>3</sup>Thoracic Medicine, St. Vincent's Hospital, Sydney, NSW, Australia

**4:30 PM (222) Effect of Azithromycin on Gastroesophageal Reflux (Acid-Non Acid) and Pepsin in BALF of Lung Transplant Patients;** K. Blondeau,<sup>1</sup> V. Mertens,<sup>1</sup> B.M. Vanaudenaerde,<sup>2</sup> D.E. Van Raemdonck,<sup>2</sup> G.M. Verleden,<sup>2</sup> D. Sifrim,<sup>1</sup> L.J. Dupont,<sup>2</sup> <sup>1</sup>Center for Gastroenterological Research, Katholieke Universiteit Leuven, Leuven, Belgium; <sup>2</sup>Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium

**4:45 PM (223) Quantitative Assessment of Lipid Laden Macrophages with Oil Red O Stain Is an Effective Screening Test for GORD;** M.T. Musk,<sup>1</sup> P.M. Hopkins,<sup>1</sup> K. Kermeen,<sup>1</sup> J. Dunning,<sup>1</sup> J. Gradwell,<sup>2</sup> L. Whitfield,<sup>2</sup> C. Godinez,<sup>2</sup> K. McNeil,<sup>1</sup> <sup>1</sup>Queensland Heart-Lung Transplant Unit, Prince Charles Hospital, Brisbane, Queensland, Australia; <sup>2</sup>Pathology Department, Prince Charles Hospital, Brisbane, Queensland, Australia

**5:00 PM (224) Prevalence of Gastroparesis before and after Lung Transplant, and Association with Lung Allograft Outcomes;** Y. Raviv, A. Pierre, C. Chaparro, S. Keshavjee, L.G. Singer, Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada

**5:15 PM (225) Gastroesophageal Reflux Does Not Impact Survival after Lung Transplantation;** M. Macha,<sup>1</sup> E.J. Molina,<sup>1</sup> G. Monteiro,<sup>1</sup> S. Short,<sup>1</sup> J.P. Gaughan,<sup>1</sup> D. Beltramo,<sup>1</sup> J.B. McClurken,<sup>1</sup> S. Furukawa,<sup>1</sup> <sup>1</sup>Surgery, Temple University, Philadelphia, PA

**5:30 PM (226) Lung Transplant Recipients with Nocturnal Reflux Have an Increased Risk of Gastric Aspiration, Irrespective of the Presence of BOS;** K. Blondeau,<sup>1</sup> V. Mertens,<sup>1</sup> B.M. Vanaudenaerde,<sup>2</sup> D.E. Van Raemdonck,<sup>2</sup> G.M. Verleden,<sup>2</sup> D. Sifrim,<sup>1</sup> L.J. Dupont,<sup>2</sup> <sup>1</sup>Center for Gastroenterological Research, Katholieke Universiteit Leuven, Leuven, Belgium; <sup>2</sup>Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium

4:15 PM – 5:45 PM

**CONCURRENT SESSION 21**

**Ischemia Reperfusion Injury (Imperial Ballroom A)**

**\*Chairs:** \*Daniel Kreisel, MD and Seth D. Force, MD

**4:15 PM (227) Endothelin Axis Up-Regulation in a Murine Model of Brain Stem Death;** A.J. Sutherland,<sup>1</sup> F. Kermeen,<sup>1</sup> J. Dunning,<sup>1</sup> J.F. Fraser,<sup>1</sup> <sup>1</sup>Critical Care Research Group, The Prince Charles Hospital, Brisbane, Australia

**4:30 PM (228) Hypoxia-Reperfusion Injury Increases Cell Specific Endothelial Progenitor Cell Adhesion in an ICAM-1 Dependent Manner;** J.L. Jackman,<sup>1</sup> E. Partidge,<sup>1</sup> M. Ward,<sup>2</sup> L. Tumiaty,<sup>1</sup> M. Badiwala,<sup>1</sup> R. Sheshgiri,<sup>1</sup> D. Stewart,<sup>2</sup> V. Rao,<sup>1</sup> <sup>1</sup>Cardiovascular Surgery, University of Toronto, Toronto, ON, Canada; <sup>2</sup>Division of Cardiology, University of Toronto, Toronto, ON, Canada

**4:45 PM (229) Apoptosis Inhibition Improves Left Ventricular Function after Prolonged Cold Cardioplegic Arrest;** U.M. Fischer,<sup>1</sup> W.O. Monzon-Posadas,<sup>1</sup> J.H. Fischer,<sup>2</sup> H.J. Geissler,<sup>3</sup> K. Hekmat,<sup>4</sup> U. Mehlhorn,<sup>1</sup> W. Bloch,<sup>5</sup> <sup>1</sup>Department of Cardiac Surgery, University of Cologne, Cologne, Germany; <sup>2</sup>Institute for Experimental Medicine, University of Cologne, Cologne, Germany; <sup>3</sup>Department of Cardiac Surgery, University of Freiburg, Freiburg, Germany; <sup>4</sup>Department of Cardiac Surgery, University of Ulm, Ulm, Germany; <sup>5</sup>Institute for Molecular and Cellular Sports Medicine, German Sports Medicine, Cologne, Germany

**4:45 PM (230) Long-Term Ischemic Storage: A New Approach with Apoptosis Inhibition for Cardiac Allograft Protection;** U.M. Fischer,<sup>1</sup> W.O. Monzon-Posadas,<sup>1</sup> J.H. Fischer,<sup>2</sup> H.J. Geissler,<sup>3</sup> K. Hekmat,<sup>4</sup> U. Mehlhorn,<sup>1</sup> W. Bloch,<sup>5</sup> <sup>1</sup>Department of Cardiac Surgery, University of Cologne, Cologne, Germany; <sup>2</sup>Institute for Experimental Medicine, University of Cologne, Cologne, Germany; <sup>3</sup>Department of Cardiac Surgery, University of Freiburg, Freiburg, Germany; <sup>4</sup>Department of Cardiac Surgery, University of Ulm, Ulm, Germany; <sup>5</sup>Institute for Molecular and Cellular Sports Medicine, German Sports Medicine, Cologne, Germany

**5:00 PM (231) Synergistic Protection in Lung Ischemia Reperfusion Injury with Calcineurin and Thrombin Inhibition;** A.S. McCourtie,<sup>1</sup> H.E. Merry,<sup>1</sup> A.S. Farivar,<sup>1</sup> M.S. Mulligan,<sup>1</sup> <sup>1</sup>Division of Cardiothoracic Surgery, University of Washington, Seattle, WA

**5:15 PM (232) Donor Treatment with Simvastatin Abolishes Ischemia-Reperfusion Injury in Rat Cardiac Allografts;** R. Tuuminen,<sup>1</sup> A.I. Nykanen,<sup>1</sup> M.A.I. Keranen,<sup>1</sup> H. Sandelin,<sup>1</sup> R. Krebs,<sup>1</sup> P.K. Koskinen,<sup>1</sup> K.B. Lemstrom,<sup>1</sup> <sup>1</sup>Transplantation Laboratory, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland

**5:30 PM (233) Ectopic Expression of Bcl-3 Improves Lung Function and Selectively Inhibits NF- $\kappa$ B Driven Expression of Pro-Inflammatory Genes;** M. Okazaki,<sup>1</sup> J.M. Lai,<sup>1</sup> N.A. Das,<sup>1</sup> H.J. Huang,<sup>2</sup> A.S. Krupnick,<sup>1</sup> G.A. Patterson,<sup>1</sup> D. Kreisel,<sup>1</sup> A.E. Gelman,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, Washington University School of Medicine, Saint Louis, MO; <sup>2</sup>Division of Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine

4:15 PM – 5:45 PM

**CONCURRENT SESSION 22**

**Airways and Vessels in Rejection (Imperial Ballroom B)**

**\*Chairs:** \*Gerald J. Berry, MD and Margaret Burke, FRCPath

**\*4:15 PM (234) Morphologic Differences in Epicardial and Microvascular Alterations after Heart Transplantation – Intimal vs. Medial Disease;** N.E. Hiemann,<sup>1</sup> C. Knosalla,<sup>1</sup> E. Wellnhofer,<sup>2</sup> H.B. Lehmkuhl,<sup>1</sup> R. Hetzer,<sup>1</sup> R. Meyer,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>2</sup>Department of Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany

**4:30 PM (235) Transforming Growth Factor- $\beta$  (TGF- $\beta$ ) and Smad Mediated Epithelial Mesenchymal Transition (EMT) in Obliterative Bronchiolitis (OB);** M. Southwood,<sup>1</sup> D. Rassl,<sup>1</sup> P. Sivasothy,<sup>2</sup> J. Parameshwar,<sup>2</sup> K. Dhital,<sup>2</sup> N. Morrell,<sup>1</sup> S. Stewart,<sup>1</sup> S. Tsui,<sup>2</sup> J. Wallwork,<sup>2</sup> J. Parmar,<sup>2</sup>  
<sup>1</sup>Department of Pathology, Papworth Hospital NHS Trust, Cambridge, United Kingdom; <sup>2</sup>Transplant Unit, Papworth Hospital NHS Trust, Cambridge, United Kingdom

**4:45 PM (236) Preserved Microcirculation Allows Cardiomyocyte Engraftment in Human Sex-Mismatched Heart Transplantation;** A. Angelini,<sup>1</sup> F. Tona,<sup>2</sup> C. Castellani,<sup>1</sup> A.P. Caforio,<sup>2</sup> A. Gambino,<sup>3</sup> M. Della Barbera,<sup>3</sup> G. Feltrin,<sup>3</sup> M. Valente,<sup>1</sup> S. Ilicieto,<sup>2</sup> G. Gerosa,<sup>3</sup> G. Thiene,<sup>1</sup>  
<sup>1</sup>Department of Pathology, University of Padua, Padua, Italy; <sup>2</sup>Department of Cardiology, University of Padua, Padua, Italy; <sup>3</sup>Department of Cardiac Surgery, University of Padua, Padua, Italy

**5:00 PM (237) M2 Macrophages: Keyplayers in the Fibro-Proliferative Response in Cardiac Allograft Vasculopathy;** E. de Koning,<sup>1</sup> J. van Kuik,<sup>1</sup> D.F. van Wichen,<sup>1</sup> M.F.M. van Oosterhout,<sup>1</sup> F.H.J. Gmelig-Meyling,<sup>2</sup> N. de Jonge,<sup>3</sup> R.A. de Weger,<sup>1</sup>  
<sup>1</sup>Pathology, University Medical Center, Utrecht, Netherlands; <sup>2</sup>Immunology, University Medical Center, Utrecht, Netherlands; <sup>3</sup>Heart Lung Center, University Medical Center, Utrecht, Netherlands

**\*5:15 PM (238) Progression of Mild Rejection: Impact on New ISHLT Classification;** L. Potena,<sup>1</sup> G. Berry,<sup>2</sup> O. Leone,<sup>3</sup> F. Grigioni,<sup>1</sup> C. Holweg,<sup>4</sup> G. Magnani,<sup>1</sup> F. Coccolo,<sup>1</sup> F. Fallani,<sup>1</sup> A. Russo,<sup>1</sup> C. Magelli,<sup>1</sup> A. Branzi,<sup>1</sup> H. Valantine,<sup>4</sup>  
<sup>1</sup>Cardiovascular Diseases, University of Bologna, Bologna, Italy; <sup>2</sup>Pathology, Stanford University, Palo Alto, CA; <sup>3</sup>Pathology, University of Bologna, Bologna, Italy; <sup>4</sup>Cardiovascular Medicine, Stanford University, Palo Alto, CA

**5:30 PM Invited Lecture: Pathology of Chronic Rejection in Heart and Lung Transplantation,** Susan Stewart, FRCPath, Papworth Hospital, Cambridge, United Kingdom

**4:15 PM – 5:45 PM**

**CONCURRENT SESSION 23**

**CMV: Immunity and Damage Control (Plaza Ballroom A)**

**\*Chairs:** Margaret M. Hannan, MD and \*Martin R. Zamora, MD

**\*4:15 PM (239) Measurement of CMV-Specific Immunity to Risk Stratify Individual Lung Transplant Recipients with Regard to CMV Reactivation;** G.P. Westall,<sup>1</sup> N.A. Mifsud,<sup>1</sup> T.C. Kotsimbos,<sup>1</sup>  
<sup>1</sup>Lung Transplant Unit, Alfred Hospital, and Monash University Medical School, Melbourne, Vic, Australia

**4:30 PM (240) Acquisition of CMV-Specific CD8+ T Cell Memory during Primary CMV Infection in Lung Transplant Recipients;** M.R. Pipeling,<sup>1</sup> E.E. West,<sup>1</sup> C.M. Osborne,<sup>2</sup> S.A. Migueles,<sup>2</sup> M. Connors,<sup>2</sup> J.F. McDyer,<sup>1</sup>  
<sup>1</sup>Medicine, Johns Hopkins University, Baltimore, MD; <sup>2</sup>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

**4:45 PM (241) Asymptomatic CMV Viremia Is Associated with Adverse Outcomes Following Lung Transplantation;** D.M. Lyu,<sup>1</sup> M. Nicolls,<sup>1</sup> M.R. Zamora,<sup>1</sup>  
<sup>1</sup>Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO

**5:00 PM (242) Cytomegalovirus Replication Is Associated with Endothelial Dysfunction in Pediatric Heart Transplant Recipients;** J.D. Simmonds,<sup>1</sup> M.J. Fenton,<sup>1</sup> J.P.J. Halcox,<sup>2</sup> N.J. Klein,<sup>2</sup> L.M. Ellins,<sup>2</sup> C. Storry,<sup>2</sup> S. Omeagher,<sup>2</sup> L.M. Redmond,<sup>2</sup> A.E. Donald,<sup>2</sup> C.A. Scott,<sup>2</sup> M. Burch,<sup>1</sup>  
<sup>1</sup>Department of Paediatric Cardiology, Great Ormond Street Hospital, London, United Kingdom; <sup>2</sup>Vascular Physiology Department, Institute of Child Health, University College London, London, United Kingdom

**5:15 PM (243) Meta-Analysis of CMV-Hyperimmune Globulin Studies for the Prevention of CMV Infection and Disease in Solid Organ Transplant Recipients;** N. Bonaros,<sup>1</sup> A. Kocher,<sup>1</sup> B. Mayer,<sup>1</sup> G. Laufer,<sup>1</sup>  
<sup>1</sup>Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria

**5:30 PM (244) Predictive Value of Plasma CMV PCR for CMV Pneumonitis in Lung Transplant Recipients;** J.M. Magill,<sup>1</sup> S. Fernandez-Bussy,<sup>2</sup> O. Akindipe,<sup>2</sup> A.B. Deem,<sup>2</sup> E.D. Staples,<sup>3</sup> P.A. Drew,<sup>1</sup> M.A. Baz,<sup>2</sup>  
<sup>1</sup>Pathology, University of Florida, Gainesville, FL; <sup>2</sup>Medicine, University of Florida, Gainesville, FL; <sup>3</sup>Surgery, University of Florida, Gainesville, FL, United Kingdom

**4:15 PM – 5:45 PM**

**CONCURRENT SESSION 24**

**Growing Pains: Psychosocial Issues in Pediatric Transplant Recipients (Plaza Ballroom B)**

**Chairs:** Mary H. Freeman, MSW, LCSW and Alison Drabble, BSCN

**4:15 PM Invited Lecture: Little People, Big Concerns,** Alexandria Berg, RN, Children's Healthcare of Atlanta, GA

**4:35 PM Discussion**

**4:45 PM (245) Quality of Life as Perceived by 8-13 Yr Old Heart Transplant Recipients;** K. Uzark,<sup>1</sup> J. Johnston,<sup>2</sup> P. Murphy,<sup>3</sup> R. Rodriguez,<sup>4</sup> C. Nasman,<sup>5</sup> J. Slusher,<sup>1</sup>  
<sup>1</sup>Cincinnati Children's Hospital, Cincinnati, OH; <sup>2</sup>Loma Linda University Medical Center, Loma Linda, CA; <sup>3</sup>St Louis Children's Hospital, St. Louis, MO; <sup>4</sup>Children's Hospital of New York, New York, NY; <sup>5</sup>Cleveland Clinic Foundation, Cleveland, OH

**5:00 PM (246) Neurodevelopmental Outcomes in Pediatric Heart Transplant Recipients;** K. Uzark,<sup>1</sup> J. Slusher,<sup>1</sup> D. Beebe,<sup>2</sup> R. Spicer,<sup>1</sup>  
<sup>1</sup>Cardiology, Cincinnati Children's Hospital, Cincinnati, OH; <sup>2</sup>Psychology, Cincinnati Children's Hospital, Cincinnati, OH

**5:15 PM (247) Social Competence after Paediatric Transplantation – Should We Be Concerned?;** J. Wray,<sup>1</sup> B.K. Field,<sup>1</sup> T. Lunnon-Wood,<sup>1</sup>  
<sup>1</sup>Cardiothoracic Transplantation, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom

**5:30 PM (248) Symptoms of Post-Traumatic Stress Disorder in Children and Adolescents Undergoing Transplantation: A Complex Issue;** J. Wray,<sup>1</sup> B.K. Field,<sup>1</sup> T. Lunnon-Wood,<sup>1</sup>  
<sup>1</sup>Cardiothoracic Transplantation, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom

**5:45 PM – 6:45 PM**

**GENERAL POSTER SESSION 2/Wine and Cheese Reception (Continental Ballroom)**

**(249)** *Incidence of Intracardiac Thrombus and Spontaneous Echo Contrast in Asymptomatic Heart Tx Recipients*; S. Verstreken,<sup>1</sup> A. Feys,<sup>1</sup> M. Walravens,<sup>2</sup> M. Vanderheyden,<sup>1</sup> M. Goethals,<sup>1</sup> F. Wellens,<sup>2</sup> <sup>1</sup>Cardiology, OLV-Ziekenhuis, Aalst, Belgium; <sup>2</sup>Cardiovascular & Thoracic Surgery, OLV-Ziekenhuis, Aalst, Belgium

**(250)** *The Utility of Gene Expression Profiling To Facilitate Prednisone Weaning in a Diverse Population of Cardiac Transplant Recipients*; R.L. Scott,<sup>1</sup> F.A. Arabia,<sup>1</sup> D.E. Steidley,<sup>1</sup> D.L. Kasper,<sup>1</sup> P.A. DeValeria,<sup>1</sup> L.A. Lanza,<sup>1</sup> <sup>1</sup>Cardiology, Mayo Clinic Arizona, Scottsdale, AZ

**(251)** *Clinical Relevance of Crossmatch Results, HLA and Non-HLA Ab Antibodies for Cardiac Allograft Recipients*; R. Kerman,<sup>1</sup> S. Stepkowski,<sup>1</sup> A. Hoover,<sup>1</sup> T. Tu,<sup>1</sup> K. Hosek,<sup>1</sup> B. Victor,<sup>1</sup> S. Reverdin,<sup>2</sup> E. Varughese,<sup>2</sup> R. Radovancevic,<sup>2</sup> O. Frazier,<sup>2</sup> B. Radovancevic,<sup>2</sup> <sup>1</sup>Surgery, University of Texas Medical School-Houston, Houston, TX; <sup>2</sup>Surgery, Texas Heart Institute, Houston, TX

**(252)** *Nuclear Stress Myocardial Perfusion Imaging Compares Favorably to Dobutamine Stress Echocardiography in Detection of CAV*; B.T. Reddy,<sup>1</sup> M.B. Hagan,<sup>1</sup> N. Islam,<sup>1</sup> M.A. Movsesian,<sup>1</sup> R. Waxman,<sup>1</sup> F. Bader,<sup>1</sup> E.M. Gilbert,<sup>1</sup> D.A. Bull,<sup>1</sup> J. Stehlik,<sup>1</sup> <sup>1</sup>Cardiology, VA Salt Lake City Health Care System, Salt Lake City, UT

**(253)** *Gender Mismatch in Orthotopic Heart Transplantation Is Negatively Associated with Increased Numbers of Severe Rejections and Long Term Survival*; H. Welp,<sup>1</sup> J. Stypmann,<sup>2</sup> T. Spieker,<sup>3</sup> D. Camboni,<sup>1</sup> C. Schmid,<sup>1</sup> H.H. Scheld,<sup>1</sup> <sup>1</sup>Department of Thoracic and Cardiovascular Surgery, University Hospital Münster, Münster, Germany; <sup>2</sup>Department of Cardiology and Angiology, University Hospital Münster, Münster, Germany; <sup>3</sup>Institute of Pathology, University Hospital Münster, Münster, Germany

**(254)** *Clinical and Functional Determinants of Coronary Flow Reserve in Heart Transplantation: A Contrast-Enhanced Echocardiographic Study*; F. Tona,<sup>1</sup> A.L.P. Caforio,<sup>1</sup> R. Montisci,<sup>2</sup> A. Gambino,<sup>3</sup> G. Feltrin,<sup>3</sup> G. Dequal,<sup>1</sup> A. Ramondo,<sup>1</sup> A. Angelini,<sup>4</sup> G. Gerosa,<sup>3</sup> S. Illiceto,<sup>1</sup> <sup>1</sup>Cardiology, University of Padova, Padova, Italy; <sup>2</sup>Cardiology, University of Cagliari, Cagliari, Italy; <sup>3</sup>Cardiovascular Surgery, University of Padova, Padova, Italy; <sup>4</sup>Cardiovascular Pathology, University of Padova, Padova, Italy

**(255)** *Effect of Sympathetic Reinnervation on Exercise Tolerability and Quality of Life in Japanese Heart Transplant Patients*; K. Shitakura,<sup>1</sup> S. Nunoda,<sup>1</sup> K. Okajima,<sup>1</sup> O. Matsuoka,<sup>1</sup> S. Oinuma,<sup>1</sup> Y. Kubo,<sup>1</sup> K. Otsuka,<sup>1</sup> <sup>1</sup>Department of Medicine, Tokyo Women's Medical University Medical Center East, Tokyo, Japan

**(256)** *Mismatch of Donor and Recipient Cytomegalovirus Serostatus Is a Risk Factor for Long-Term Mortality but Not Development of Allograft Vasculopathy*; S. Arora,<sup>1</sup> A.K. Andreassen,<sup>1</sup> S. Simonsen,<sup>1</sup> O. Geiran,<sup>2,3</sup> L. Gullestad,<sup>1</sup> <sup>1</sup>Department of Cardiology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway; <sup>2</sup>Department of Cardiothoracic Surgery, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway; <sup>3</sup>Faculty Division Rikshospitalet, University of Oslo, Oslo, Norway

**(257)** *Outcome of Heart Transplants 15 to 20 Years Ago: Graft Survival, Post-Transplant Morbidity and Risk Factors for Mortality*; J.C. Roussel,<sup>1</sup> O. Baron,<sup>1</sup> S. Pattier,<sup>2</sup> T. Petit,<sup>2</sup> M. Treilhaud,<sup>2</sup> J.N. Trochu,<sup>3</sup> D. Duveau,<sup>1</sup> P.h Despins,<sup>1</sup> <sup>1</sup>Thoracic and Cardio-Vascular Surgery, Thorax Institut, Hôpital G&R Laënnec, Nantes, France; <sup>2</sup>Unit of Thoracic Transplantation, Thorax Institut, Hôpital G&R Laënnec, Nantes, France; <sup>3</sup>Department of Cardiology, Thorax Institut, Hôpital G&R Laënnec, Nantes, France

**(258)** *The Importance of Diabetes, Biventricular Failure and Cellular Infiltrates in Hemodynamically Compromising Rejection*; F. Haddad,<sup>1</sup> S. Khuppahally,<sup>1</sup> S. Virani,<sup>1</sup> D. Rosenthal,<sup>1</sup> M. Perloth,<sup>1</sup> G. Berry,<sup>1</sup> H. Parekh,<sup>2</sup> D. Weisshaar,<sup>2</sup> H. Valantine,<sup>1</sup> S.A. Hunt,<sup>1</sup> <sup>1</sup>Cardiovascular Medicine, Stanford University, Stanford, CA; <sup>2</sup>Heart Failure and Heart Transplant Service, Kaiser Santa Teresa Medical Center, San Jose, CA

**(259)** *Ibutilide Is Safe and Efficacious in Heart Transplant Recipients*; V. Franco,<sup>1</sup> J.A. Tallaj,<sup>1,2</sup> B.K. Rayburn,<sup>1</sup> S.V. Pamboukian,<sup>1</sup> R.L. Benza,<sup>1</sup> J.K. Kirklin,<sup>1</sup> D.C. McGiffin,<sup>1</sup> M. Smallfield,<sup>1</sup> R.C. Bourge,<sup>1</sup> <sup>1</sup>Division of Cardiovascular Medicine, University of Alabama at Birmingham, Birmingham, AL; <sup>2</sup>Department of Medicine, Birmingham VA Medical Center, Birmingham, AL

**(260)** *Clinico-Pathological Discrepancies: The Importance of Pathological Study on Native Lungs*; C. Giacometti,<sup>1</sup> M. Loy,<sup>2</sup> G. Marulli,<sup>2</sup> S. Rizzo,<sup>1</sup> F. Lunardi,<sup>1</sup> M. Valente,<sup>1</sup> F. Rea,<sup>2</sup> F. Calabrese,<sup>1</sup> <sup>1</sup>Department of Diagnostic and Medical Sciences and Special Therapies, University of Padua, Padua, Italy; <sup>2</sup>Department of Cardiothoracic Sciences, University of Padua, Padua, Italy

\* **(261)** *Microvasculopathy after Heart Transplantation – Character and Distribution of Myocardial Sequels Depend on Microvascular Phenomena*; N.E. Hiemann,<sup>1</sup> C. Knosalla,<sup>1</sup> E. Wellnhofer,<sup>2</sup> H.B. Lehmkühl,<sup>1</sup> R. Hetzer,<sup>1</sup> R. Meyer,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>2</sup>Department of Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany

**(262)** *Is Intramyocardial Macrophage Infiltration Beneficial in Heart Failure Secondary to Non-Ischemic Cardiomyopathy?*; R. Wojnicz,<sup>1</sup> M. Zakliczynski,<sup>2</sup> J. Nowak,<sup>1</sup> P. Trzeciak,<sup>1</sup> M. Zembala,<sup>2</sup> <sup>1</sup>Cardiology, Silesian Center for Heart Disease, Silesian Medical University, Zabrze, Poland; <sup>2</sup>Cardiac Surgery and Transplantation, Silesian Center for Heart Disease, Silesian Medical University, Zabrze, Poland

**(263)** *Cardiac Transplantation for Giant Cell Myocarditis: A Single Center Experience*; E.S. Shao,<sup>1</sup> T.E. Chen,<sup>1</sup> G.W. Wu,<sup>1</sup> J.K. Patel,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA

**(264)** *Low Yield of Silver Stain on BAL Fluid of Asymptomatic Lung Transplant Recipients*; S. Fernandez-Bussy,<sup>1</sup> J.M. Magill,<sup>2</sup> O. Akindipe,<sup>1</sup> A.B. Deem,<sup>1</sup> P. Drew,<sup>2</sup> E.D. Staples,<sup>3</sup> M.A. Baz,<sup>1</sup> <sup>1</sup>Medicine, University of Florida, Gainesville, FL; <sup>2</sup>Pathology, University of Florida, Gainesville, FL; <sup>3</sup>Surgery, University of Florida, Gainesville, FL

(265) *Cardiac Allograft Vasculopathy: Real or a Normal Morphologic Variant?*; S. Houser,<sup>1</sup> A. Muniappan,<sup>2</sup> J. Allan,<sup>2</sup> J. Madsen,<sup>2</sup> <sup>1</sup>Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA; <sup>2</sup>Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA

(266) *Pathoanatomical Diagnosis after Heart Transplant in Patients with Cardiomyopathy – Does It Match Pretransplant Diagnosis?*; M. Metawe, F. Gustafsson, J. Butany, D. Delgado, R. Smith, H. Ross, Department Cardiology and Heart Transplantation and Department of Pathology, Toronto General Hospital, Toronto, ON, Canada

\* (267) *Presence of Lipofuscin Deposition in Cardiomyocytes but Not Vascular Abnormalities Observed in Endomyocardial Biopsies (EMBs) Predicts Development of Transplanted Heart Coronary Artery Vasculopathy (CAV)*; M. Zakliczynski,<sup>1</sup> J. Nozynski,<sup>1</sup> D. Konecka-Mrowka,<sup>1</sup> M. Zembala,<sup>1</sup> <sup>1</sup>Department of Cardiac Surgery & Transplantation, Silesian Center for Heart Disease, Zabrze, Poland

(268) *The Real Estate of Cellular Cardiac Transplantation – Negative Remodeling Is Associated with Location*; J.D. McCue,<sup>1</sup> C.J. Swingen,<sup>4</sup> D.L. Gatlin,<sup>1</sup> T. Feldberg,<sup>3</sup> A. Kolb,<sup>3</sup> G. Caron,<sup>3</sup> B. Breviu,<sup>3</sup> S.J. Prabhu,<sup>2</sup> D.A. Taylor,<sup>3</sup> <sup>1</sup>Department of Surgery, University of Minnesota, Minneapolis, MN; <sup>2</sup>University of Minnesota Medical School, University of Minnesota, Minneapolis, MN; <sup>3</sup>Center for Cardiovascular Repair, University of Minnesota, Minneapolis, MN; <sup>4</sup>Department of Radiology, University of Minnesota, Minneapolis, MN

(269) *Granulocyte-Based Immune Response Against Decellularized Vascular Tissue: Activation of Complement and CD11b*; F. Bastian,<sup>1</sup> E. Rieder,<sup>1</sup> E. Eichmair,<sup>1</sup> M.T. Kasimir,<sup>1</sup> P. Simon,<sup>1</sup> G. Weigel,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria

(270) *Cultured Cardiomyocytes Expressed CD80 but Not CD86 Can Attenuate CTL*; N.W. Ke, J.J. Lei, Y.P. Li, T. Qiang, S.H.F. Li Key, Lab of Transplant Engineering and Immunology MOH, West China Hospital, Sichuan University, Chengdu, Sichuan, China

(271) *Magnetofection-Enhanced Lentiviral Mediated Gene Transfer to Cardiac Cells in a Heterotopic Heart Transplantation Model*; L. Burdorf,<sup>1</sup> A. Hofmann,<sup>2</sup> J. Postrach,<sup>1</sup> D. Messow,<sup>2</sup> B. Gleich,<sup>3</sup> T. Veyh,<sup>3</sup> E. Thein,<sup>4</sup> V. Mordstein,<sup>5</sup> B. Reichart,<sup>1</sup> A. Pfeifer,<sup>2</sup> M. Schmoekel,<sup>1</sup> <sup>1</sup>Department of Cardiac Surgery, Ludwig-Maximilians University, Munich, Germany; <sup>2</sup>Institute for Pharmacology and Toxicology, University of Bonn, Bonn, Germany; <sup>3</sup>The Heinz Nixdorf Chair for Medical Electronics, Technical University, Munich, Germany; <sup>4</sup>Institute of Pathology, Ludwig-Maximilians University, Munich, Germany; <sup>5</sup>Institute for Surgical Research, Ludwig-Maximilians University, Munich, Germany

(272) *Use of Tacrolimus, Sirolimus, and FK778 in Experimental Xenotransplantation – A Detailed Analysis of Drug Efficacy on Cellular and Humoral Xenorejection*; T. Deuse,<sup>1</sup> S. Schrepfer,<sup>2</sup> F. Koch-Nolte,<sup>3</sup> M.P. Fischbein,<sup>2</sup> M.P. Pelletier,<sup>2</sup> R.C. Robbins,<sup>2</sup> H. Reichenspurner,<sup>1</sup> <sup>1</sup>Cardiovascular Surgery, University Heart Center Hamburg gGmbH, Hamburg, Germany; <sup>2</sup>Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA; <sup>3</sup>Immunology, University Hospital Hamburg, Hamburg, Germany

(273) *National Transplantation Pregnancy Registry (NTPR): Pregnancy Outcomes in Female Thoracic Transplant Recipients*; L. Ohler,<sup>1</sup> L.A. Coscia,<sup>2</sup> C.H. McGroarty,<sup>2</sup> M.J. Moritz,<sup>3</sup> V.T. Armenti,<sup>2</sup> <sup>1</sup>Nursing, Virginia Commonwealth University/MCV, Richmond, VA; <sup>2</sup>Surgery, Temple University School of Medicine, Philadelphia, PA; <sup>3</sup>Surgery, Lehigh Valley Hospital, Allentown, PA

(274) *The Burdens Experienced by Caregivers of Candidates Waiting for Lung Transplant*; C.J. Whytehead,<sup>1</sup> <sup>1</sup>Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada

(275) *Television, Heart Transplantation and “On Line” National Donor Register Registrations*; S.A. Beer, P. Pocock, R.S. Bonser, Department of Heart & Lung Transplantation, Cardiothoracic Surgery, University Hospital of Birmingham NHSF Trust: Queen Elizabeth, Edgbaston, Birmingham, United Kingdom; Statistics and Audit Directorate, UK Transplant & Blood, Bristol, Avon, United Kingdom; Department of Heart & Lung Transplantation and Cardiothoracic Surgery, University Hospital of Birmingham:Queen Elizabeth, Edgbaston, Birmingham, United Kingdom

(276) *Teaching on Postoperative Day One: A Feasible Approach to Reduce Length of Stay in Ventricular Assist Device Patients*; M.A. Murray,<sup>1</sup> J.A. Hoffmann,<sup>2</sup> J. Drayton,<sup>3</sup> S. Osaki,<sup>1</sup> D. Murray,<sup>2</sup> M.R. Johnson,<sup>2</sup> N.M. Edwards,<sup>1</sup> T. Kohmoto,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, University of Wisconsin Hospital and Clinics, Madison, WI; <sup>2</sup>Heart Failure and Transplant Cardiology, University of Wisconsin Hospital and Clinics, Madison, WI; <sup>3</sup>Nursing Staff Development, University of Wisconsin Hospital and Clinics, Madison, WI

(277) *Challenges Associated with Development of a ‘Stand-Alone’ Donation after Cardiac Death (DCD) Lung Transplant (LTx) Program: Translating Research into Reality*; B. Levvey,<sup>1</sup> R. McEgan,<sup>2</sup> T. Oto,<sup>1</sup> A. Griffiths,<sup>1</sup> M. Mennen,<sup>2</sup> A. Davies,<sup>3</sup> D. Pilcher,<sup>3</sup> T. Williams,<sup>1</sup> F. Rosenfeldt,<sup>4</sup> G. Snell,<sup>1</sup> <sup>1</sup>Lung Transplant Service, Alfred Hospital, Melbourne, Victoria, Australia; <sup>2</sup>Cardiac Perfusion Services, Alfred Hospital, Melbourne, Victoria, Australia; <sup>3</sup>Intensive Care, Alfred Hospital, Melbourne, Victoria, Australia; <sup>4</sup>Cardiothoracic Surgical Research, Alfred Hospital, Melbourne, Victoria, Australia

(278) *Gender Differences in Symptom Experiences before and up to 6 Months after Lung Transplant (LT)*; D.M. Lanuza,<sup>1</sup> C.A. Lefaiver,<sup>2</sup> R.L. Brown,<sup>1</sup> S.M. Bhorade,<sup>2,3</sup> R. Love,<sup>4,2</sup> <sup>1</sup>School of Nursing, University of Wisconsin-Madison, Madison, WI; <sup>2</sup>Loyola University Medical Center, Maywood, IL; <sup>3</sup>Lung Transplant Program, University of Chicago, Chicago, IL; <sup>4</sup>Lung Transplant Program, University of Wisconsin Madison, Madison, WI

(279) *Quality of Life Surveys: Are Responders Different from Non-Responders?*; D. Naftel,<sup>1</sup> S. Myers,<sup>1</sup> J. Kirklin,<sup>1</sup> K. Grady,<sup>2</sup> <sup>1</sup>Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL; <sup>2</sup>Cardiac Surgery, Northwestern Memorial Hospital, Chicago, IL

\* (280) *Lung Allocation Score Is Not Associated with Health-Related Quality of Life in Lung Transplant Candidates*; A.J. Gurau,<sup>1,2</sup> N. Chowdhury,<sup>1</sup> L.G. Singer,<sup>1,2</sup> <sup>1</sup>Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada; <sup>2</sup>University of Toronto, Toronto, ON, Canada

- (281) *Congestive Heart Failure Offering Individualized Choice Evaluation Study (CHOICES)*; J. MacIver,<sup>1</sup> N. Desai,<sup>2</sup> D.H. Delgado,<sup>1</sup> V. Rao,<sup>2</sup> S. Abbey,<sup>3</sup> H.J. Ross,<sup>1</sup> <sup>1</sup>Department of Cardiology and Transplantation, Toronto General Hospital, Toronto, ON, Canada; <sup>2</sup>Division of Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada; <sup>3</sup>Department of Psychiatry and Transplantation, Toronto General Hospital, Toronto, ON, Canada
- (282) *Quality of Life Two or More Years Following LVAD Removal*; R.S. George,<sup>1,2</sup> P. Rogers,<sup>1</sup> C. Hallas,<sup>1</sup> M. Petrou,<sup>1</sup> N.R. Banner,<sup>1</sup> G. Dreyfus,<sup>1</sup> A. Khaghani,<sup>1</sup> M.H. Yacoub,<sup>2</sup> E.J. Birks,<sup>1,2</sup> <sup>1</sup>Transplant and Mechanical Circulatory Support, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom; <sup>2</sup>Heart Science Centre, Magdi Yacoub Institute, Imperial College, Harefield, Middlesex, United Kingdom
- (283) *Evaluation and Dissemination of the Electronic Version of the Questionnaire for Lung Transplant Patients (e-QLTP)*; A. DeVito Dabbs,<sup>1</sup> B.A. Johnson,<sup>2</sup> M.A. Dew,<sup>3</sup> M.Y. Song,<sup>1</sup> S.M. Studer,<sup>2</sup> <sup>1</sup>Acute & Tertiary Care, University of Pittsburgh School of Nursing, Pittsburgh, PA; <sup>2</sup>Pulmonary Allergy & Critical Care, University of Pittsburgh School of Medicine, Pittsburgh, PA; <sup>3</sup>Psychology, Psychiatry & Epidemiology, University of Pittsburgh School of Medicine, Pittsburgh, PA
- (284) *Improved Quality of Life and Functional Improvement in Patients Supported with the HeartMate II, an Axial Flow Left Ventricular Assist Device*; C. Gemmato, B. Radovancevic, S. Carranza, R. Radovancevic, R.M. Delgado, III, I. Gregoric, O.H. Frazier, Center for Cardiac Support, Texas Heart Institute/St. Luke's Episcopal Hospital, Houston, TX
- \* (285) *Pulmonary Rehabilitation Following Lung Transplantation*; G. Snell,<sup>1</sup> P.E. Munro,<sup>1</sup> M. Bailey,<sup>2</sup> B.M. Button,<sup>1</sup> <sup>1</sup>The Alfred Hospital, Melbourne, Australia; <sup>2</sup>Monash University, Melbourne, Australia
- (286) *Waiting for a New Heart: Early Experience from a Prospective Multi-Site Study of Psychosocial and Medical Predictors of Pre-Transplant Outcomes*; G. Weidner,<sup>1</sup> H. Spaderna,<sup>2</sup> D. Zahn,<sup>2</sup> J. Smits,<sup>3</sup> <sup>1</sup>Preventive Medicine Research Institute, Sausalito, CA; <sup>2</sup>Department of Psychology, Johannes Gutenberg University, Mainz, Germany; <sup>3</sup>Eurotransplant, Leiden, Netherlands
- (287) *Concordance: Defining the Heart Transplant Nurse-Patient Relationship*; H. Sobko, C. White-Williams, E. Buckner, Nursing, University of Alabama at Birmingham, Birmingham, AL; Nursing, University of Alabama at Birmingham, Birmingham, AL; School of Nursing, University of Alabama at Birmingham, Birmingham, AL
- (288) *Living with a Heart Transplantation. Experience and Support Needs One to Two Years Posttransplant*; Y. De Block,<sup>3</sup> M. Grypdonck,<sup>4</sup> F. Caes,<sup>3</sup> F. Wellens,<sup>2</sup> J. Vanhaecke,<sup>5</sup> S. Martin,<sup>5</sup> M. Walravens,<sup>2</sup> F. Dobbels,<sup>1,5</sup> E. Steeman,<sup>4</sup> <sup>1</sup>Center for Health Services and Nursing Research, School of Public Health, Leuven, Vlaams-Brabant, Belgium; <sup>2</sup>Department of Cardiovascular and Thoracic Surgery, Onze Lieve Vrouw Hospital, Aalst, Oost-Vlaanderen, Belgium; <sup>3</sup>Department of Cardiovascular and Thoracic Surgery, University Hospital Ghent, Ghent, Oost-Vlaanderen, Belgium; <sup>4</sup>Faculty of Medicine and Health Sciences, Department Public Health, University Ghent, Ghent, Oost-Vlaanderen, Belgium; <sup>5</sup>Leuven Heart Transplant Program, University Hospital Leuven, Leuven, Vlaams-Brabant, Belgium
- (289) *Donors with Bacterial Meningitis – Outcome after Intra-Thoracic Organ Transplantation: A Single Centre 20 Year Experience*; T. Bahrami,<sup>1</sup> H.A. Vohra,<sup>1</sup> K. Shaikhrezai,<sup>1</sup> J. Pepper,<sup>1</sup> N. Banner,<sup>1</sup> M. Yacoub,<sup>1</sup> M. Carby,<sup>1</sup> A. Khaghani,<sup>1</sup> G. Dreyfus,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic Surgery, Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Trust, London, United Kingdom
- (290) *Efficacy of Oral Ribavirin in Lung Transplant Patients with Respiratory Syncytial Virus*; A. Pelaez,<sup>1</sup> G.M. Lyon,<sup>1</sup> A. Ramirez,<sup>1</sup> S. Force,<sup>2</sup> D.C. Neujahr,<sup>1</sup> A. Gal,<sup>3</sup> E.C. Lawrence,<sup>1</sup> <sup>1</sup>Medicine, Emory University, Atlanta, GA; <sup>2</sup>Surgery, Emory University, Atlanta, GA; <sup>3</sup>Pathology, Emory University, Atlanta, GA
- (291) *Synergistic Activities of Temocillin and Tigecycline in Combination with 12 Antimicrobial Agents Against Strains of Burkholderia Cepacia Isolated Pre and Post Lung Transplantation*; A. Nicholson,<sup>1</sup> J.D. Perry,<sup>1</sup> M. Oliver,<sup>1</sup> S. Peart,<sup>1</sup> F.K. Gould,<sup>1</sup> <sup>1</sup>Microbiology Department, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
- (292) *Antagonism between Colistin and Meropenem in Pseudomonas Aeruginosa Isolates from Lung Transplant Patients*; G.R. Short,<sup>1</sup> J.D. Perry,<sup>1</sup> A. Nicholson,<sup>1</sup> S.R. Scheuler,<sup>2</sup> A.J. Fisher,<sup>2</sup> F.K. Gould,<sup>1</sup> <sup>1</sup>Microbiology Department, Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, United Kingdom; <sup>2</sup>Applied Immunology and Transplantation Group, Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, United Kingdom
- (293) *Synergistic Activities of Twelve Agents Tested as Triple Combinations Against 30 Strains of Multiresistant Pseudomonas aeruginosa and Burkholderia cepacia Isolated Pre and Post Lung Transplantation*; A. Nicholson,<sup>1</sup> J.D. Perry,<sup>1</sup> M. Oliver,<sup>1</sup> F.K. Gould,<sup>1</sup> M. Raza,<sup>1</sup> P. Corris,<sup>1</sup> A.J. Fisher,<sup>1</sup> <sup>1</sup>Microbiology, Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, United Kingdom
- (294) *Effect of Gram-Negative Bacterial Respiratory Infections on Development of Bronchiolitis Obliterans Syndrome*; G.S. Dhillon,<sup>1</sup> V.G. Valentine,<sup>2</sup> D.E. Taylor,<sup>2</sup> S.G. LaPlace,<sup>2</sup> G.A. Lombard,<sup>2</sup> R. Bonvillian,<sup>2</sup> D. Weill,<sup>1</sup> <sup>1</sup>Pulmonary and Critical Care Medicine, Stanford University Hospital, Stanford, CA; <sup>2</sup>Lung Transplantation, Ochsner Medical Center, New Orleans, LA
- (295) *Clinical Spectrum of Gram Positive Infections in Lung Transplantation*; J.E. Walker,<sup>1</sup> V.G. Valentine,<sup>1</sup> R.W. Bonvillian,<sup>2</sup> G.A. Lombard,<sup>1</sup> S.G. LaPlace,<sup>1</sup> D.E. Taylor,<sup>1</sup> <sup>1</sup>Lung Transplantation, Ochsner Medical Center, New Orleans, LA; <sup>2</sup>Medicine and Genetics, LSU Health Sciences Center, New Orleans, LA
- (296) *Ventricular Assist Device Related Infections. The Onassis Cardiac Surgery Experience*; A. Gouziouta,<sup>1</sup> L. Tsourelis,<sup>2</sup> D. Zarkalis,<sup>2</sup> T.H. Antoniou,<sup>3</sup> G. Saroglou,<sup>2</sup> P. Sfirakis,<sup>2</sup> P.A. Alivizatos,<sup>2</sup> <sup>1</sup>2nd Cardiology, Onassis Cardiac Surgery Center, Athens, Greece; <sup>2</sup>1st Cardiac Surgery & Transplantation, Onassis Cardiac Surgery Center, Athens, Greece; <sup>3</sup>Anesthesiology, Onassis Cardiac Surgery Center, Athens, Greece

- (297)** *A Comparison of the Efficacy of Nebulised Amphotericin (NAM) Against Oral Itraconazole (ITR) in Prophylaxis Against Infection with Aspergillus spp. (ASP) in Lung Transplantation (LTx);* A.C. Church,<sup>1</sup> P. Sivasothy,<sup>1</sup> J. Parmar,<sup>1</sup> J. Foweraker,<sup>1</sup> K. Venz,<sup>1</sup> <sup>1</sup>Transplant Unit, Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom
- (298)** *Single Centre Experience of Cystic Fibrosis Patients Colonized with Scedosporium Apiospermum Prior to Lung Transplantation;* S.N. Peart,<sup>1</sup> A. Nicholson,<sup>1</sup> F.K. Gould,<sup>1</sup> M.W. Raza,<sup>1</sup> J.H. Dark,<sup>1</sup> <sup>1</sup>Microbiology, Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, United Kingdom
- (299)** *Stenotrophomonas maltophilia in Lung Transplantation;* K.J. McAnally,<sup>1</sup> V.G. Valentine,<sup>1</sup> R.W. Bonvillain,<sup>2</sup> G.A. Lombard,<sup>1</sup> S.G. LaPlace,<sup>1</sup> L. Seoane,<sup>1</sup> D.E. Taylor,<sup>1</sup> <sup>1</sup>Lung Transplantation, Ochsner Medical Center, New Orleans, LA; <sup>2</sup>Medicine and Genetics, LSU Health Sciences Center, New Orleans, LA
- \* (300)** *Ex-Vivo Evaluation of Donor Hearts in the Beating Functioning State in The Organ Care System (OCS);* S. Schulte-Eistrup,<sup>1</sup> U. Schulz,<sup>1</sup> A. Elbetanony,<sup>2</sup> A. El-Banayosy,<sup>1</sup> G. Tenderich,<sup>1</sup> R. Koerfer,<sup>1</sup> <sup>1</sup>Department of Thoracic & Cardiovascular Surgery, Heart Center NRW, Bad Oeynhausen, Germany; <sup>2</sup>TransMedics Inc., Andover, MA
- (301)** *Increasing Organ Availability in Heart Transplantation with the Use of Warm Blood Perfusion for Organ Preservation;* G. Tenderich,<sup>1</sup> U. Schulz,<sup>1</sup> T. Khayal,<sup>2</sup> S. Schulte-Eistrup,<sup>1</sup> R. Koerfer,<sup>1</sup> <sup>1</sup>Thoracic and Cardiovascular Surgery, Heart Center North Rhine-Westphalia, Bad Oeynhausen, Germany; <sup>2</sup>TransMedics, Inc., Andover, MA
- (302)** *Female Gender Is Associated with Cardiac Dysfunction in Brain Dead Organ Donors;* K.K. Khush,<sup>1</sup> R.L. Menza,<sup>2</sup> W.D. Babcock,<sup>2</sup> C.W. Hoopes,<sup>3</sup> J.G. Zaroff,<sup>1</sup> <sup>1</sup>Medicine/Cardiology, University of California, San Francisco, CA; <sup>2</sup>California Transplant Donor Network, Oakland, CA; <sup>3</sup>Surgery, University of California, San Francisco, CA
- \* (303)** *Oxygenated Perfusion of Donor Hearts Reduces Ischemic Damage during Preservation;* A. Halldorsson,<sup>1</sup> H.A. Goolsby,<sup>2</sup> M.D. Tomison,<sup>2</sup> S.D. Prien,<sup>2</sup> <sup>1</sup>Surgery, Texas Tech University Health Sciences Center, Lubbock, TX; <sup>2</sup>Obstetrics and Gynecology, Texas Tech University Health Sciences Center, Lubbock, TX
- \* (304)** *Intermittent Antegrade Cardioplegia: Implications for Donor Heart Preservation;* A.L. Rivard,<sup>1,3</sup> C.M. Swingen,<sup>4</sup> F.D. Kamdar,<sup>5</sup> Z. Demorest,<sup>5</sup> E.J. Cordova,<sup>5</sup> J.E. Foker,<sup>2</sup> M. Jerosch-Herold,<sup>4,6</sup> R.W. Bianco,<sup>3</sup> R. John,<sup>3</sup> <sup>1</sup>Radiology, University of Florida, Gainesville, FL; <sup>2</sup>Surgery, Division of Cardiovascular and Thoracic, University of Minnesota, Minneapolis, MN; <sup>3</sup>Surgery, University of Minnesota, Minneapolis, MN; <sup>4</sup>Radiology, University of Minnesota, Minneapolis, MN; <sup>5</sup>Medical School, University of Minnesota, Minneapolis, MN; <sup>6</sup>Radiology, Oregon Health Sciences Center, Portland, OR
- (305)** *Increased Incidence of Rejection Early after Heart Transplantation Due to Donor-Recipient Ethnic Mismatch;* Y. Potashnik,<sup>1</sup> E.L. Shabtai,<sup>2</sup> Y. Har Zahav,<sup>1</sup> J. Lavee,<sup>3</sup> <sup>1</sup>Heart Institute, Sheba Medical Center, Tel Hashomer, Israel; <sup>2</sup>Statistics Services, Tel Aviv - Sourasky Medical Center, Tel Aviv, Israel; <sup>3</sup>Heart Transplantation Unit, Sheba Medical Center, Tel Hashomer, Israel
- (306)** *Ex Vivo Infrared Scanning for the Detection of Transmitted Coronary Disease in Human Donor Hearts;* R.S. Poston,<sup>1</sup> N. Burris,<sup>1</sup> C. Tang,<sup>1</sup> B.P. Griffith,<sup>1</sup> <sup>1</sup>Division of Cardiac Surgery, University of Maryland, Baltimore, MD
- (307)** *Erythropoietin May Improve Long Term Preservation of the Donor Heart;* S. Zangwill,<sup>1</sup> K. Mussatto,<sup>1</sup> J. Su,<sup>1</sup> J.E. Baker,<sup>1</sup> <sup>1</sup>Pediatrics - Children's Research Institute, Medical College of Wisconsin, Milwaukee, WI
- (308)** *Elevated IL-8 Levels in Retrograde Flush Effluent Is Associated with Unexpected Donor Pulmonary Embolism: A Novel Predictor for Primary Graft Dysfunction?;* T. Higuchi,<sup>1</sup> T. Oto,<sup>1</sup> L. Zheng,<sup>2</sup> G.P. Westall,<sup>1</sup> B.J. Levvey,<sup>1</sup> T.J. Williams,<sup>1</sup> G.I. Snell,<sup>1</sup> <sup>1</sup>Lung Transplant Service, The Alfred, Melbourne, Victoria, Australia; <sup>2</sup>Department of Medicine, Monash University, Melbourne, Victoria, Australia
- (309)** *Terbutaline Attenuates Reperfusion Injury in the Donor Lung from HBD and NHBS;* A.P. Neyrinck,<sup>1</sup> F.R. Rega,<sup>1</sup> C. Van De Wauwer,<sup>1</sup> N. Geudens,<sup>1</sup> G.M. Verleden,<sup>2</sup> P. Wouters,<sup>3</sup> T.E. Lerut,<sup>4</sup> D.E.M. Van Raemdonck,<sup>1,4</sup> <sup>1</sup>Laboratory for Experimental Thoracic Surgery, Katholieke Universiteit Leuven, Leuven, Belgium; <sup>2</sup>Laboratory for Pneumology, Katholieke Universiteit Leuven, Leuven, Belgium; <sup>3</sup>Center for Experimental Anesthesiology, Emergency and Intensive Care Medicine, Katholieke Universiteit Leuven, Leuven, Belgium; <sup>4</sup>Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium
- (310)** *Impact of the Lung Allocation Score on Disease Transplanted and Post-Transplant Survival;* C.J. De Ruiter-Gries,<sup>1</sup> J.R. Curtis,<sup>1</sup> M.S. Mulligan,<sup>1</sup> J.E. Edelman,<sup>1</sup> C.H. Goss,<sup>1</sup> <sup>1</sup>Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA
- (311)** *Expanded Thoracic Donors: Beyond Elderly, Hypertensive and Metabolic Disorders;* B. Mahillo,<sup>1</sup> B. Miranda,<sup>1</sup> E. Martin,<sup>1</sup> G. Garrido,<sup>1</sup> R. Matesanz,<sup>1</sup> <sup>1</sup>Medical Unit, Organizacion Nacional de Trasplantes, Madrid, Spain
- (312)** *Audit of 3 Months Data of Reasons for the Non-Use of Thoracic Organs in the United Kingdom;* W.N. Wrightson,<sup>1</sup> T. Wellman,<sup>2</sup> J.H. Dark,<sup>1</sup> <sup>1</sup>Cardio-Thoracic Transplant, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; <sup>2</sup>UKTSSA
- (313)** *Minimally Invasive Lung Transplantation in More Than 145 Patients with Emphysema: It Should Be the Standard Approach;* A.R. Simon,<sup>1</sup> J. Gottlieb,<sup>2</sup> B. Gohrbandt,<sup>1</sup> C. Hagl,<sup>1</sup> S. Fischer,<sup>1</sup> A. Meyer,<sup>1</sup> C. Kuehn,<sup>1</sup> A. Goerler,<sup>1</sup> Y. Li,<sup>1</sup> A. Haverich,<sup>1</sup> M. Strueber,<sup>1</sup> <sup>1</sup>Hannover Thoracic Transplant Program (Division of Thoracic- and Cardiovascular Surgery), Hannover Medical School, Hannover, Germany; <sup>2</sup>Division of Pneumology, Hannover Medical School, Hannover, Germany

- (314)** *Long-Term Results of Combined Heart-Lung Transplantation: Analysis of 325 First Transplants over Twenty-Two Years at a Single Centre*; J. Wallwork,<sup>1,2</sup> C.K. Choong,<sup>1,2</sup> L.D. Sharples,<sup>1</sup> J.S. Parmar,<sup>1</sup> P.R. Sivasothy,<sup>1</sup> S.S.L. Tsui,<sup>1</sup> <sup>1</sup>Transplant Unit, Papworth Hospital NHS Trust, Cambridge, England, United Kingdom; <sup>2</sup>Department of Surgery, University of Cambridge, Cambridge, England, United Kingdom
- (315)** *Interaction of Type of Transplant and Intraoperative Pulmonary Artery Pressures (PAP) in Patients with Idiopathic Pulmonary Fibrosis (IPF) Undergoing Lung Transplantation*; D. Hadjiliadis,<sup>1</sup> R. Lingaraju,<sup>1</sup> J.D. Christie,<sup>1</sup> J. Mendez,<sup>1</sup> N.P. Blumenthal,<sup>1</sup> J.Y. Woo,<sup>1</sup> V.N. Ahya,<sup>1</sup> J.S. Sager,<sup>1</sup> A. Pochettino,<sup>1</sup> R.M. Kotloff,<sup>1</sup> <sup>1</sup>Lung Transplant Program, University of Pennsylvania, Philadelphia, PA
- (316)** *The T Cell Infiltrate in Acute Cellular Rejection Biopsies Is a Temporally Homogeneous Restricted T Cell Repertoire*; C.M. Magro,<sup>1</sup> C. Morrison,<sup>2</sup> P. Ross,<sup>2</sup> A. Pope-Harmon,<sup>2</sup> <sup>1</sup>Pathology, Weill College of Medicine, New York, NY; <sup>2</sup>Pathology, Ohio State University, Columbus, OH; <sup>3</sup>Cardiothoracic Surgery, Ohio State University, Columbus, OH; <sup>4</sup>Pulmonary Medicine, Ohio State University, Columbus, OH
- (317)** *A Single-Institution Study Evaluating the Utility of Surveillance Bronchoscopy Following Lung Transplantation*; V.G. Valentine,<sup>1</sup> D. Weill,<sup>2</sup> G.A. Lombard,<sup>1</sup> S.G. LaPlace,<sup>1</sup> L. Seoane,<sup>1</sup> D.E. Taylor,<sup>1</sup> G.S. Dhillon,<sup>2</sup> <sup>1</sup>Lung Transplantation, Ochsner Medical Center, New Orleans, LA; <sup>2</sup>Medicine, Stanford University Hospital, Stanford, CA
- (318)** *Sleep Disordered Breathing before and after Lung Transplantation*; M.A. Malouf,<sup>1</sup> R.A. Milross,<sup>2</sup> R.R. Grunstein,<sup>2,3</sup> P.N. Chhajed,<sup>1</sup> D.M. Jankelson,<sup>3</sup> C.L. Aboyou,<sup>1</sup> P.T. Bye,<sup>2</sup> A.R. Glanville,<sup>1</sup> <sup>1</sup>The Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia; <sup>2</sup>The Woolcock Research Institute of Medical Research, University of Sydney, Sydney, NSW, Australia; <sup>3</sup>The Sleep Disorders Unit, St. Vincent's Hospital, Sydney, NSW, Australia
- (319)** *Differences in the Distribution of ISHLT Primary Graft Dysfunction Grades: Intubated vs Extubated Patients*; T. Oto,<sup>1</sup> B. Levvey,<sup>1</sup> A. Griffiths,<sup>1</sup> T. Higuchi,<sup>1</sup> T. Kotsimbos,<sup>1</sup> T. Williams,<sup>1</sup> G. Snell,<sup>1</sup> <sup>1</sup>Lung Transplant Service, Alfred Hospital & Monash University, Melbourne, Victoria, Australia
- (320)** *Thoracic Organ Transplantations in the Nordic Countries 1983-2005, Nordic Thoracic Transplantation Study Group. 1st Official Registry Report-2006*; B. Andersson,<sup>1</sup> for the Nordic Thoracic Transplantation Study Group, <sup>1</sup>Cardiology, Sahlgrenska University Hospital, Goteborg, Sweden
- (321)** *Correlation of Cylex ImmuKnow Assay with Lung Allograft Biopsy*; Y. Huang, I. Nizami Nazih Zuhdi, Transplantation Institute, Integris Baptist Medical Center, Oklahoma City, OK
- (322)** *A Randomized, Placebo Controlled Trial of Aprotinin to Reduce Primary Graft Dysfunction Following Lung Transplantation*; C.S. Herrington,<sup>1</sup> M.E. Prekker,<sup>1</sup> M.I. Hertz,<sup>1</sup> D.M. Radosovich,<sup>1</sup> R.F. Kelly,<sup>1</sup> V.V. Sullivan,<sup>1</sup> L.L. Studenski,<sup>1</sup> H.B. Bittner,<sup>2</sup> S.J. Shumway,<sup>1</sup> P.S. Dahlberg,<sup>1</sup> <sup>1</sup>Thoracic Transplantation, University of Minnesota, Minneapolis, MN; <sup>2</sup>Cardiovascular and Thoracic Surgery, University of Leipzig, Leipzig, Germany
- (323)** *Effect of IL-2 Induction Therapy on Reperfusion Edema after Lung Transplantation: A Radiographic Study*; E. Ruttman,<sup>1</sup> E.M. Gassner,<sup>2</sup> H.B. Hangler,<sup>1</sup> B. Bucher,<sup>3</sup> C. Geltner,<sup>3</sup> S. Semsroth,<sup>1</sup> R. Margreiter,<sup>4</sup> G. Laufer,<sup>1</sup> L.C. Mueller,<sup>1</sup> <sup>1</sup>Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Tyrol, Austria; <sup>2</sup>Department of Radiology, Innsbruck Medical University, Innsbruck, Tyrol, Austria; <sup>3</sup>Department of Pneumology, Innsbruck Medical University, Innsbruck, Tyrol, Austria; <sup>4</sup>Department of General and Transplant Surgery, Innsbruck Medical University, Innsbruck, Tyrol, Austria
- (324)** *Effect of HLA Antibodies Detected by Flow on Lung Transplant Outcomes at a Single Center*; R. Lingaraju,<sup>1</sup> J. Mendez,<sup>1</sup> V.N. Ahya,<sup>1</sup> R.M. Kotloff,<sup>1</sup> J.S. Sager,<sup>1</sup> J.D. Christie,<sup>1</sup> N.P. Blumenthal,<sup>1</sup> D. Isaia,<sup>1</sup> A. Pochettino,<sup>1</sup> D. Hadjiliadis,<sup>1</sup> <sup>1</sup>Lung Transplant Program, University of Pennsylvania, Philadelphia, PA
- (325)** *Survival and Functional Status in Patients 10 Years after Lung Transplantation in Lund, Sweden*; L. Eriksson,<sup>1</sup> K. Heimburg,<sup>1</sup> L. Mared,<sup>1</sup> <sup>1</sup>Department of Respiratory Medicine, University Hospital, Lund, Sweden
- (326)** *Ethnic Differences in Diagnoses and Outcomes of Lung Transplant (LTx) Recipients – Single Center Experience*; R. Lingaraju,<sup>1</sup> N.P. Blumenthal,<sup>1</sup> J. Mendez,<sup>1</sup> J.D. Christie,<sup>1</sup> R.M. Kotloff,<sup>1</sup> V.N. Ahya,<sup>1</sup> J.S. Sager,<sup>1</sup> J.Y. Woo,<sup>1</sup> A. Pochettino,<sup>1</sup> D. Hadjiliadis,<sup>1</sup> <sup>1</sup>Lung Transplant Program, University of Pennsylvania, Philadelphia, PA
- (327)** *Physiologic Outcomes of ARDS Ventilator Management Strategy in Lung Transplant Recipients*; J.D. McCue,<sup>1</sup> M.E. Prekker,<sup>2</sup> S.J. Prabhu,<sup>4</sup> C.S. Herrington,<sup>1</sup> M.I. Hertz,<sup>1</sup> P.S. Dahlberg,<sup>1</sup> <sup>1</sup>Thoracic Transplantation, University of Minnesota, Minneapolis, MN; <sup>2</sup>Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN; <sup>3</sup>University of Minnesota Medical School, University of Minnesota, Minneapolis, MN
- (328)** *Lung Function Tests for Prediction of BOS*; G. Martensson,<sup>1</sup> G. Riise,<sup>1</sup> A. Thylen,<sup>1</sup> F. Nilsson,<sup>2</sup> B. Bake,<sup>1</sup> <sup>1</sup>Respiratory Medicine, Medicine, Sahlgrenska Academy, Gothenburg, Sweden; <sup>2</sup>Thoracic Surgery, Medicine, Sahlgrenska Academy, Gothenburg, Sweden
- (329)** *Early "Surveillance" Biopsies Detect Lung Allograft Rejection and Lymphocytic Bronchiolitis*; D.J. Ross,<sup>1</sup> W.D. Wallace,<sup>2</sup> J.P. Lynch,<sup>1</sup> B. Kubak,<sup>3</sup> R. Sagar,<sup>1</sup> A. Ardehali,<sup>4</sup> R. Beygui,<sup>4</sup> M.C. Fishbein,<sup>2</sup> <sup>1</sup>Pulmonary and Critical Care, University of California, Los Angeles, Los Angeles, CA; <sup>2</sup>Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA; <sup>3</sup>Infectious Disease, University of California, Los Angeles, Los Angeles, CA; <sup>4</sup>Cardiothoracic Surgery, University of California, Los Angeles, Los Angeles, CA
- (330)** *Long-Term Outcome of Combined Heart-Lung Transplantation: Primary Pulmonary Hypertension Vs. Secondary Pulmonary Hypertension Due to Congenital Heart Diseases*; Y. Toyoda,<sup>1</sup> R. Santos,<sup>1</sup> J. Thacker,<sup>1</sup> J. Bhama,<sup>1</sup> D. Nguyen,<sup>1</sup> C. Bermudez,<sup>1</sup> B.G. Hattler,<sup>1</sup> R.L. Kormos,<sup>1</sup> J.

Pilewski,<sup>2</sup> D. McNamara,<sup>2</sup> K.R. McCurry,<sup>1</sup> <sup>1</sup>Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>2</sup>Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA

**6:15 PM – 7:45 PM**

**SATELLITE SYMPOSIUM 12**

**Malignancy in Thoracic Transplantation (Imperial Ballroom A)**

**\*Chairs:** \*Mandeep R. Mehra, MD and Richard E. Chinnock, MD

**\*6:15 PM** *How Does Immunosuppression Influence the Genesis and Propagation of Malignancy?* Howard Eisen, MD, Drexel University College of Medicine, Philadelphia, PA

**\*6:30 PM** *Post-Transplant Lymphoproliferative Disorders in the Thoracic Transplant Recipient*, Steven A. Webber, MD, Children's Hospital of Pittsburgh, Pittsburgh, PA

**6:45 PM** *Skin Cancers and Melanomas: Nuisance or a Determinant of Outcome?* Cynthia M. Magro, MD, Weill College of Medicine/Cornell University, New York, NY

**7:00 PM** *A German Nationwide Post-HTX Malignancy Registry*, Hans Lehmkuhl, MD, Deutsches Herzzentrum Berlin, Berlin, Germany

**7:15 PM** *A Perspective on Pre-existing Cancer in the Donor and Recipient*, Mark De Perrot, MD, Toronto General Hospital, Toronto, ON, Canada

**7:30 PM** *Discussion*

**6:15 PM – 7:15 PM**

**Scientific Council Meeting on Pathology and Basic Science (Plaza B)**

**Scientific Council Meeting on Infectious Diseases (Union Square 23/24)**

**Scientific Council Meeting on Pediatric Transplantation (Plaza A)**

**Scientific Council Meeting on Pulmonary Hypertension (Union Square 15/16)**

**6:45 PM – 8:00 PM**

General Poster Session 2 Removal (Continental Ballroom)

**FRIDAY, APRIL 27, 2007**

**24 Hours**

Internet Café Open (Continental Ballroom Foyer)

**6:00 AM – 6:00 PM**

Registration Desk Open (West Foyer)

**6:00 AM – 6:00 PM**

Slide Ready Room Open (Green Room)

**7:00 AM – 9:00 AM**

General Poster Session 3 Poster Mounting (Continental Ballroom)

**7:00 AM – 6:00 PM**

Press Office Open (Executive Boardroom)

**7:00 AM – 8:00 AM**

**SUNRISE SYMPOSIUM 5**

**Immunobiology for Clinicians: Principles of Therapy (Imperial Ballroom A)**

**\*Chairs:** \*David A. Baran, MD and George Tellides, MD

**\*7:00 AM** *Overview of Immunosuppression: Old and New*, Bruce R. Rosengard, MD, Massachusetts General Hospital, Boston, MA

**7:30 AM** *Overview of Tolerance*, Bill A. Pietra, MD, Children's Hospital, Littleton, CO

**7:00 AM – 8:00 AM**

**SUNRISE SYMPOSIUM 6**

**Novel Insights in Mechanisms of Bronchiolitis Obliterans (Imperial Ballroom B)**

**\*Chairs:** \*Annette Boehler, MD and \*Andrew J. Fisher, MRCP, PhD

**7:00 AM** *Mechanisms of Airway Inflammation*, Mark R. Nicolls, MD, University of Colorado Health Sciences Center, Denver, CO

**7:20 AM** *Chemokines and Airway Fibrosis*, John A. Belperio, MD, University of California at Los Angeles, Los Angeles, CA

**7:40 AM** *Antibody Mediated Airway Fibrosis*, Thalachallour Mohanakumar, PhD, Washington University School of Medicine, St. Louis, MO

**7:00 AM – 8:00 AM**

**SUNRISE SYMPOSIUM 7**

**From Observation to Research in Nursing and Social Sciences: Acting on Your Ideas (Plaza Ballroom A)**

**Chairs:** Annette J. DeVito Dabbs, RN, PhD and Connie White-Williams, MSN

**7:00 AM** *From Observation to Science: Realities of Clinical Research*, Bernice L. Coleman, PhD, RN, ACNP, Cedars Sinai Medical Center, Los Angeles, CA

**\*7:20 AM** *Panel Discussion*

- a) \*Mary Amanda Dew, PhD and \*Rachelle Zomak, RN
- b) Jeanne Salyer, PhD, RN and \*Maureen P. Flattery, RN, MSN, ANP

**7:00 AM – 8:00 AM**

**SUNRISE SYMPOSIUM 8**

**When Palliation Fails: Transplantation for the Adult with Congenital Heart Disease (Plaza Ballroom B)**

*Chairs:* James K. Kirklin, MD and Mark Boucek, MD

**7:00 AM** *How Big is the Problem: The Growing Population*, Dan J. Murphy, Jr., MD, Stanford University, Palo Alto, CA

**\*7:20 AM** *How Far Can Medicine Go: Predictors of Decline in Congenital Heart Disease*, F. Jay Fricker, MD, University of Florida, Gainesville, FL

**7:40 AM** *Is There Any Problem the Surgeon Can't Fix?* Asif Hasan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

**8:00 AM – 6:45 PM**

Mini Oral Sessions 1-4 Poster Viewing (Yosemite Ballroom)

**8:15 AM – 10:15 AM**

**PLENARY SESSION (Grand Ballroom B)**

*Chairs:* Joren C. Madsen, MD, D.Phil. and Axel Haverich, MD

**\*8:15 AM (331) Featured Abstract:** *Gene Expression Profiles in Peripheral Blood for the Noninvasive Diagnosis of Chronic Lung Allograft Rejection*; S.M. Studer,<sup>1</sup> T. Richards,<sup>1</sup> W. Wu,<sup>1</sup> K.R. McCurry,<sup>2</sup> N. Kaminski,<sup>1</sup> <sup>1</sup>Division of Pulmonary, Allergy, Critical Care, University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>Division of Thoracic Foregut Surgery, University of Pittsburgh, Pittsburgh, PA

**\*8:30 AM** *The Application of Genomics in Medicine and Transplantation*, Daniel Salomon, PhD, The Scripps Institute, La Jolla, CA

**9:00 AM (332) Featured Abstract:** *Does the UNOS Lung Allocation Score Predict Early Mortality in Lung Transplantation? Early Outcomes with the New US Allocation System*; A.S. Shah,<sup>1</sup> C.A. Merlo,<sup>2</sup> M.C. Borja,<sup>1</sup> M. Diener-West,<sup>3</sup> J.V. Conte,<sup>1</sup> J.B. Orens,<sup>2</sup> <sup>1</sup>Division of Cardiac Surgery, Johns Hopkins Medical Institutions, Baltimore, MD; <sup>2</sup>Division of Pulmonary and Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, MD; <sup>3</sup>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

**9:15 AM** *Controversies and Ethical Dilemmas in Thoracic Organ Allocation*, John Dark, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

**9:30 AM** *International Heart Allocation*, J. David Vega, MD, Emory Clinic, Atlanta, GA

**\*9:50 AM** *International Lung Allocation*, Walter Klepetko, MD, University of Vienna, Vienna, Austria

**9:30 AM – 6:45 PM**

Exhibit Hall Open (Continental Ballroom)

General Poster Session 3 Viewing (Continental Ballroom)

**10:15 AM – 10:45 AM**

**ANNUAL BUSINESS MEETING (Grand Ballroom B)**

**Coffee Break/Poster Viewing (Continental Ballroom)**

**10:45 AM – 12:15 PM**

**CONCURRENT SESSION 25**

**Permanent Mechanical Circulatory Support (Grand Ballroom B)**

**\*Chairs:** \*Yoshifumi Naka, MD, PhD and \*Carmelo Milano, MD

**10:45 AM (333)** *Center Experience and Outcomes of Left-Ventricular Assist Device (LVAD) Implantation as Destination Therapy (DT) – Analysis of Thoratec DT Registry 1998-2005*; K. Lietz,<sup>1</sup> J. Long,<sup>2</sup> A. Kfoury,<sup>2</sup> M. Slaughter,<sup>3</sup> M. Silver,<sup>3</sup> C. Milano,<sup>4</sup> J. Rogers,<sup>4</sup> Y. Naka,<sup>5</sup> D. Mancini,<sup>5</sup> L. Miller,<sup>1</sup> <sup>1</sup>Cardiovascular Division, Georgetown University - Washington Hospital Center, Washington, DC; <sup>2</sup>Cardiovascular and Cardiothoracic Divisions, LDS Hospital, Salt Lake City, UT; <sup>3</sup>Cardiovascular and Cardiothoracic Divisions, Advocate Christ Medical Center, Oak Lawn, IL; <sup>4</sup>Cardiovascular and Cardiothoracic Divisions, Duke University Medical Center, Durham, NC; <sup>5</sup>Cardiovascular and Cardiothoracic Divisions, Columbia-Presbyterian Medical Center, New York, NY

**11:00 AM (334)** *Causes for Hospital Readmission in Destination Therapy LVAD Patients*; C.J. Bishop,<sup>1</sup> C.N. Madsen,<sup>1</sup> K.M. Nelson,<sup>1</sup> D.M. Nelson,<sup>1</sup> K.E. Nelson,<sup>1</sup> A.G. Kfoury,<sup>1</sup> H.G. Smith,<sup>1</sup> D.G. Renlund,<sup>1</sup> J.W. Long,<sup>1</sup> <sup>1</sup>Utah Artificial Heart Program, LDS Hospital, Salt Lake City, UT

**\*11:15 AM (335)** *Improved Durability in Left Ventricular Assist Devices: An Urgent Need*; D.M. Nelson,<sup>1</sup> A.H. Healy,<sup>1</sup> K.M. Nelson,<sup>1</sup> M.R. Bonnell,<sup>1</sup> J.C. Child,<sup>1</sup> J.W. Long,<sup>1</sup> <sup>1</sup>Utah Artificial Heart Program, LDS Hospital, Salt Lake City, UT

**11:30 AM (336)** *Participation in End of Life Decisions with Destination Left Ventricular Assist Device Therapy*; S.J. Brush, A.G. Kfoury, A.H. Healy, B.Y. Rasmusson, D.G. Renlund, H.K. Smith, K.E. Nelson, M.R. Bonnell, D.M. Nelson, J.W. Long, Utah Artificial Heart Program, LDS Hospital, Salt Lake City, UT

**11:45 AM (337)** *MCS Out-of-Hospital Patients: Is There a Difference Between Pulsatile and Non-Pulsatile Devices?*; A. El-Banayosy,<sup>1</sup> L. Arusoglu,<sup>1</sup> M. Morshuis,<sup>1</sup> L. Kizner,<sup>1</sup> D. Cobaugh,<sup>1</sup> R. Koerfer,<sup>1</sup> <sup>1</sup>Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany

**\*NOON (338)** *A Low Hemolysis Rate Is Not a Sufficient Criterion for the Qualification of Rotary Blood Pumps*; J.H. Mueller,<sup>2</sup> M. Brodde,<sup>1</sup> K. Brandes,<sup>2</sup> P. Muesser,<sup>2</sup> J. Mueller,<sup>2</sup> K. Graichen,<sup>2</sup> B. Kehrel,<sup>1</sup> <sup>1</sup>Hematology, University of Muenster, Muenster, Germany; <sup>2</sup>Research and Development, Berlin Heart, Berlin, Germany

10:45 AM – 12:15 PM

CONCURRENT SESSION 26

**Clinical Heart Transplantation: Complications, Complications, Complications (Grand Ballroom A)**

**Chairs:** Stuart D. Russell, MD and J. Michael Dimairo, MD

**\*10:45 AM (339) Sudden Cardiac Death after Heart Transplant: Insights from the Cardiac Transplant Research Database;** J.M. Herre,<sup>1</sup> R.N. Brown,<sup>2</sup> P.P. Chang,<sup>3</sup> B.E. Jaski,<sup>4</sup> T.L. Stevens,<sup>5</sup> M.L. Hess,<sup>6</sup> B.M. Morril,<sup>1</sup> J.K. Kirklin,<sup>2</sup> the CTRD<sup>1</sup> Sentara Norfolk General Hospital, Norfolk, VA; <sup>2</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC; <sup>4</sup>Sharp Memorial Hospital, San Diego, CA; <sup>5</sup>Mid-America Heart Institute of St. Luke's Hospital, Kansas City, MO; <sup>6</sup>Medical College of Virginia, Richmond, VA

**11:00 AM (340) Sudden Cardiac Death in Heart Transplant Patients: Is There a Role for Defibrillators?;** M. Montpetit,<sup>1</sup> M. Singh,<sup>1</sup> E. Muller,<sup>1</sup> C. Feldman,<sup>1</sup> J. Sinacore,<sup>1</sup> B. Pavlovic-Surjancev,<sup>1</sup> A. Heroux,<sup>1</sup> <sup>1</sup>Heart Transplant/Heart Failure, Loyola University Medical Center, Maywood, IL

**\*11:15 AM (341) Monocenter Study of Percutaneous Coronary Interventions in 154 Cardiac Transplant Recipients with Chronic Allograft Vasculopathy;** E. Wellnhofer,<sup>1</sup> H. Lehmkuhl,<sup>1</sup> N. Hiemann,<sup>1</sup> S. Dreyses,<sup>1</sup> K. Graf,<sup>1</sup> R. Meyer,<sup>1</sup> M. Dandel,<sup>1</sup> C. Knosalla,<sup>1</sup> R. Hetzer,<sup>1</sup> E. Fleck,<sup>1</sup> <sup>1</sup>Deutsches Herzzentrum, Berlin, Germany

**11:30 AM (342) Predicting Death Due to Primary Graft Dysfunction in Adult Heart Transplantation;** J.S. Ganesh,<sup>1</sup> C.A. Rogers,<sup>1</sup> J.V.D. Meulen,<sup>1</sup> N.R. Banner,<sup>1</sup> R.S. Bonser,<sup>1</sup> <sup>1</sup>On Behalf of the Steering Group, UK Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom

**11:45 AM (343) The Stiffer the Heart, the Worse the Outcome after Heart Transplantation;** B.K. Itagaki,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> G.W. Wu,<sup>1</sup> W. Brubaker,<sup>1</sup> M.A. Kawano,<sup>1</sup> L. Gokanapudy,<sup>1</sup> M.M. Kittleston,<sup>1</sup> J.K. Patel,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA

**NOON (344) Utilization of Cardiac Allografts with Mild or Moderate LVH Is Safe and Can Expand the Donor Pool;** S. Goland,<sup>1</sup> L.S.C. Czer,<sup>1</sup> R.M. Kass,<sup>1</sup> R.J. Siegel,<sup>1</sup> J. Mirocha,<sup>1</sup> M. De Robertis,<sup>1</sup> J. Lee,<sup>1</sup> B. Coleman,<sup>1</sup> S. Raissi,<sup>1</sup> W. Cheng,<sup>1</sup> G. Fontana,<sup>1</sup> A. Trento,<sup>1</sup> <sup>1</sup>Cardiology and Cardiothoracic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA

10:45 AM – 12:15 PM

CONCURRENT SESSION 27

**Mechanisms of Rejection in Lung Transplantation (Imperial Ballroom A)**

**\*Chairs:** \*Kenneth R. McCurry, MD and Richard N. Pierson, III, MD

**(345) WITHDRAWN**

**10:45 AM (346) Three-Dimensional Matrix Embedding of Endothelial Cells Abates Alloimmunity Via Upregulation of CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> T Regulatory Cells;** H. Methe,<sup>1,2</sup> E.R. Edelman,<sup>1,3</sup> <sup>1</sup>Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA; <sup>2</sup>Department of Cardiology, University Hospital Grosshadern, Munich, Germany; <sup>3</sup>Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

**11:00 AM (347) The Pulmonary Milieu Facilitates Allograft Airway Rejection: A Possible Role for Bronchus Associated Lymphatic Tissue (BALT);** M. Sato,<sup>1</sup> P. Duchesneau,<sup>1</sup> C. Andrade,<sup>1</sup> S. Hirayama,<sup>1</sup> M. Liu,<sup>1</sup> T.K. Waddell,<sup>1</sup> S. Keshavjee,<sup>1</sup> <sup>1</sup>Thoracic Surgery Research Laboratory, Toronto General Research Institute, University Health Network, Toronto, ON, Canada

**11:15 AM (348) Dissecting the Intragraft Cytokine Networks of Chronic Inflammation: PDGF Stimulates MCP-1 Production by Intragraft Fibroblasts and Accordingly Recruits Tissue Macrophages in Cardiac Allografts Developing Chronic Rejection;** G.D. Wu,<sup>1</sup> H. Zhu,<sup>1</sup> Y. He,<sup>1</sup> A.S. Klein,<sup>1</sup> <sup>1</sup>Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

**11:30 AM (349) The Role of Indirect Recognition of MHC Class I and II Allopeptides in Lung Transplantation in Miniature Swine;** H. Sahara,<sup>1</sup> T. Shoji,<sup>1</sup> C.Y. Ng,<sup>1</sup> M.J. Weiss,<sup>1</sup> A. Muniappan,<sup>1</sup> D.A. Guenther,<sup>1</sup> S.L. Houser,<sup>1</sup> A.C. Pujara,<sup>1</sup> J.K. Sayer,<sup>1</sup> J.C. Wain,<sup>1</sup> D.H. Sachs,<sup>1</sup> J.C. Madsen,<sup>1</sup> J.S. Allan,<sup>1</sup> <sup>1</sup>Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA

**11:45 AM (350) CD4 T Lymphocytes Are Not Necessary for the Acute Rejection of Vascularized Orthotopic Allogeneic Mouse Lung Transplants;** M. Okazaki,<sup>1</sup> A.S. Krupnick,<sup>1</sup> C.G. Kornfeld,<sup>1</sup> J. Lai,<sup>1</sup> S.B. Richardson,<sup>1</sup> J.H. Ritter,<sup>1</sup> G.A. Patterson,<sup>1</sup> A.E. Gelman,<sup>1</sup> D. Kreisel,<sup>1</sup> <sup>1</sup>Department of Surgery, Washington University in St. Louis, St. Louis, MO

**\*NOON (351) Refining the Identification of Discriminatory Genes for Rejection in Lung Transplantation: The LARGO Study;** S. Keshavjee,<sup>1</sup> G. Berry,<sup>2</sup> C.C. Marboe,<sup>3</sup> J.S. Wilt,<sup>3</sup> E.P. Trulock,<sup>4</sup> P.A. Corris,<sup>5</sup> R.L. Doyle,<sup>2</sup> K.R. McCurry,<sup>6</sup> S.M. Arcasoy,<sup>3</sup> R.D. Davis,<sup>7</sup> J.G. Golden,<sup>8</sup> M. Strueber,<sup>9</sup> S. Sweet,<sup>4</sup> P. Jaksch,<sup>10</sup> A.C. Mehta,<sup>11</sup> M.S. Mulligan,<sup>12</sup> O.E. Pajaro,<sup>13</sup> J.T. Sun,<sup>15</sup> T.M. Klingler,<sup>15</sup> S. Rosenberg,<sup>15</sup> R.D. Dedrick,<sup>15</sup> H. Wolters,<sup>15</sup> K.C. Fang,<sup>15</sup> M.R. Zamora,<sup>14</sup> <sup>1</sup>University of Toronto, Toronto, Canada; <sup>2</sup>Stanford University, Stanford, CA; <sup>3</sup>Columbia University, New York, NY; <sup>4</sup>Washington University, St. Louis, MO; <sup>5</sup>University of Newcastle, Newcastle, United Kingdom; <sup>6</sup>University of Pittsburgh, Pittsburgh, PA; <sup>7</sup>Duke University, Durham, NC; <sup>8</sup>University of California, San Francisco, San Francisco, CA; <sup>9</sup>Hannover Medical School, Hannover, Germany; <sup>10</sup>University Hospital, Vienna, Austria; <sup>11</sup>Cleveland Clinic Foundation, Cleveland, OH; <sup>12</sup>University of Washington, Seattle, WA; <sup>13</sup>Mayo Clinic Jacksonville, Jacksonville, FL; <sup>14</sup>University of Colorado, Denver, CO; <sup>15</sup>XDx, South San Francisco, CA

10:45 AM – 12:15 PM

CONCURRENT SESSION 28

**Innovations in PAH (Imperial Ballroom B)**

**\*Chairs:** \*Reda Girgis, MB, BCH and \*Jean-Luc Vachieri, MD

**\*10:45 AM (352) Sequential Combination Therapy in Pulmonary Arterial Hypertension (PAH);** A. Keogh,<sup>1</sup> E. Kotlyar,<sup>1</sup> P. Macdonald,<sup>1</sup> C. Hayward,<sup>1</sup> C. Corrigan,<sup>1</sup> A. Pidoux,<sup>1</sup> K. Brown,<sup>1</sup> T. Williams,<sup>2</sup> E. Gabbay,<sup>3</sup> K. McNeil,<sup>4</sup> <sup>1</sup>Heart Transplant Unit, St Vincent's Hospital, Sydney,

Australia; <sup>2</sup>Lung Transplant Unit, Alfred Hospital, Melbourne, Australia; <sup>3</sup>Lung Transplant Service, Royal Perth Hospital, Perth, Australia;  
<sup>4</sup>Transplant Services, Prince Charles Hospital, Brisbane, Australia

**11:00 AM (353) Pulmonary Arterial Hypertension in End-Stage Pulmonary Sarcoidosis: Assessment of the Therapeutic Effect of Sildenafil;** N. Milman,<sup>1</sup> C.M. Burton,<sup>1</sup> M. Iversen,<sup>1</sup> R. Videbæk,<sup>1</sup> J. Carlsen,<sup>1</sup> <sup>1</sup>The Heart Centre, Rigshospitalet, Copenhagen, Denmark

**\*11:15 AM (354) Effects of Bosentan on Both Pulmonary Vascular Remodeling and Cardiac Function and Remodeling in Pulmonary Hypertension;** M.E. van Albeda,<sup>1</sup> R.G. Schoemaker,<sup>2</sup> R.M. Berger,<sup>1</sup> <sup>1</sup>Dept of Pediatric Cardiology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; <sup>2</sup>Dept of Experimental Cardiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

**11:30 AM (355) Increased Circulating Endothelial Microparticles Predict Hemodynamic Severity of Untreated Pulmonary Hypertension;** N. Amabile,<sup>1</sup> C. Heiss,<sup>1</sup> W.M. Real,<sup>1</sup> P. Minasi,<sup>1</sup> M.L. Springer,<sup>1</sup> D. McGoughlin,<sup>1</sup> E.J. Rame,<sup>1</sup> W. Grossman,<sup>1</sup> T. De Marco,<sup>1</sup> Y. Yeghiazarians,<sup>1</sup> <sup>1</sup>Division of Cardiology, UCSF, San Francisco, CA

**11:45 AM (356) Reduced Number and Function of Circulating Endothelial Progenitor Cells in Patients with Pulmonary Arterial Hypertension;** R.K. Rao,<sup>1</sup> J. Ye,<sup>1</sup> W.M. Real,<sup>1</sup> M. Springer,<sup>1</sup> W. Grossman,<sup>1</sup> T. De Marco,<sup>1</sup> Y. Yeghiazarians,<sup>1</sup> <sup>1</sup>Medicine - Cardiology, University of California, San Francisco, San Francisco, CA

**NOON (357) Augmentation of Type 1 Immune Response Cytokines/Chemokines Is Associated with Pulmonary Arterial Hypertension;** D.J. Ross,<sup>1</sup> J.A. Belperio,<sup>1</sup> M.D. Burdick,<sup>2</sup> S. Shapiro,<sup>3</sup> R. Saggat,<sup>1</sup> D. Zisman,<sup>1</sup> J.P. Lynch,<sup>1</sup> A. Ardehali,<sup>4</sup> R.M. Strieter,<sup>2</sup> <sup>1</sup>Pulmonary and Critical Care, University of California, Los Angeles, Los Angeles, CA; <sup>2</sup>MD-Inmd Pulmonary, University of Virginia, Charlottesville, VA; <sup>3</sup>Cardiology, University of California, Los Angeles, Los Angeles, CA; <sup>4</sup>Cardiothoracic Surgery, University of California, Los Angeles, Los Angeles, CA

**10:45 AM – 12:15 PM  
CONCURRENT SESSION 29**

**Organ Allocation in the 21<sup>st</sup> Century (Plaza Ballroom A)**

**Chairs:** Edward R. Garrity, Jr., MD and Ashish S. Shah, MD

**10:45 AM (358) Prevalence and Extent of Coronary Atherosclerosis in the Donor Pool;** O. Grauhan,<sup>1</sup> G. Schmidt,<sup>1</sup> R. Krueger,<sup>2</sup> F. Polster,<sup>2</sup> C. Wesslau,<sup>2</sup> R. Hetzer,<sup>1</sup> <sup>1</sup>Thoracic and Cardiovascular Surgery, German Heart Institute, Berlin, Germany; <sup>2</sup>Deutsche Stiftung Organtransplantation, Berlin, Germany

**11:00 AM (359) Virtual Crossmatch Improves Organ Allocation in Sensitized Patients;** N. Islam,<sup>1</sup> J. Stehlik,<sup>1</sup> D. Hurst,<sup>1</sup> M.A. Movsesian,<sup>1</sup> B.T. Reddy,<sup>1</sup> E.M. Gilbert,<sup>1</sup> A.G. Kfoury,<sup>1</sup> D.G. Renlund,<sup>1</sup> F.M. Bader,<sup>1</sup> D.A. Bull,<sup>1</sup> A. Fuller,<sup>1</sup> M.E.H. Hammond,<sup>1</sup> D. Eckels,<sup>1</sup> <sup>1</sup>U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT

**11:15 AM (360) Impact of Donor-Recipient Race-Mismatch on Outcomes of Cardiac Transplantation;** G.V. Moukarbel,<sup>1</sup> H. Jneid,<sup>1</sup> H.K. Hoyer,<sup>1</sup> E.W. Kuhn,<sup>1</sup> K.M. Gonczarek,<sup>1</sup> S.A. Keck,<sup>1</sup> C.D. Haggan,<sup>1</sup> M.J. Semigran,<sup>1</sup> <sup>1</sup>Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

**11:30 AM (361) The Lung Allocation Score (LAS) and Its Components Predict Transplant Survival Well for Groups, but Not for Individual Patients;** R. Lingaraju,<sup>1</sup> J. Mendez,<sup>1</sup> R.M. Kotloff,<sup>1</sup> J.S. Sager,<sup>1</sup> V.N. Ahya,<sup>1</sup> J.D. Christie,<sup>1</sup> A. Pochettino,<sup>1</sup> D. Hadjiliadis,<sup>1</sup> <sup>1</sup>Lung Transplant Program, University of Pennsylvania, Philadelphia, PA

**11:45 AM (362) Effect of Lung Allocation Score (LAS) on Actual Post-Transplant Survival: Early 1-Year Results;** D. Hadjiliadis,<sup>1</sup> J. Mendez,<sup>1</sup> N.P. Blumenthal,<sup>1</sup> D. Isaia,<sup>1</sup> K. Carney,<sup>1</sup> V.N. Ahya,<sup>1</sup> R.M. Kotloff,<sup>1</sup> J. Woo,<sup>1</sup> J.S. Sager,<sup>1</sup> J.D. Christie,<sup>1</sup> A. Pochettino,<sup>1</sup> <sup>1</sup>Lung Transplant Program, University of Pennsylvania, Philadelphia, PA

**NOON (363) Is UNOS Rejection of a Donor Heart or Lung a Risk Factor for Successful Transplantation?;** J.C. Mullen,<sup>1</sup> A. Oreopoulos,<sup>1</sup> D.L. Modry,<sup>1</sup> A. Koshal,<sup>1</sup> S. Wang,<sup>1</sup> D.B. Ross,<sup>1</sup> I.R. Rebeyka,<sup>1</sup> R. MacArthur,<sup>1</sup> <sup>1</sup>Surgery, University of Alberta Hospital, Edmonton, AB, Canada

**(364) WITHDRAWN**

**10:45 AM – 12:15 PM  
CONCURRENT SESSION 30**

**Beyond Surviving: Thriving Post-Transplant (Plaza Ballroom B)**

**Chairs:** Diane V. Skojec, NP and Christiane Kugler, PhD, MSc, RN

**10:45 AM (365) Prospective, Randomized Intervention on Physical Functioning and HRQoL after Lung Transplantation;** C. Kugler,<sup>1</sup> U. Tegtbur,<sup>2</sup> J. Gottlieb,<sup>3</sup> A. Simon,<sup>1</sup> M. Dierich,<sup>3</sup> T. Welte,<sup>3</sup> A. Haverich,<sup>1</sup> M. Strueber,<sup>1</sup> <sup>1</sup>Hannover Thoracic Transplant Program; Division of Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany; <sup>2</sup>Sportsphysiology/Medicine, Hannover Medical School, Hannover, Germany; <sup>3</sup>Division of Pulmonary Medicine, Hannover Medical School, Hannover, Germany

**11:00 AM (366) Patterns and Predictors of Physical Functional Disability at 5-10 Years after Heart Transplantation;** K.L. Grady,<sup>1</sup> D.C. Naftel,<sup>2</sup> J.B. Young,<sup>3</sup> D. Pelegrin,<sup>3</sup> J. Czerr,<sup>3</sup> R. Higgins,<sup>4</sup> A. Heroux,<sup>5</sup> M. McLeod,<sup>4</sup> B. Rybarczyk,<sup>6</sup> J. Kobashigawa,<sup>7</sup> J. Chait,<sup>7</sup> C. White-Williams,<sup>2</sup> S. Myers,<sup>2</sup> J.K. Kirklin,<sup>2</sup> <sup>1</sup>Cardiothoracic Surgery, Northwestern Memorial Hospital, Chicago, IL; <sup>2</sup>Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, OH; <sup>4</sup>Cardiovascular and Thoracic Surgery, Rush University Medical Center, Chicago, IL; <sup>5</sup>Cardiology, Loyola University Medical Center, Maywood, IL; <sup>6</sup>Psychology, Virginia Commonwealth University, Richmond, VA; <sup>7</sup>UCLA Heart and Lung Transplant Program, UCLA Medical Center, Los Angeles, CA

**11:15 AM (367) Posttransplant Infections after Lung Transplantation Reduce HRQoL in the Long-Term: Results of a Prospective Cohort Study;** C. Kugler,<sup>1</sup> F. Mattner,<sup>2</sup> A. Simon,<sup>1</sup> J. Gottlieb,<sup>3</sup> T. Welte,<sup>3</sup> A. Haverich,<sup>1</sup> M. Strueber,<sup>1</sup> <sup>1</sup>Hannover Thoracic Transplant Program; Division of

Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany; <sup>2</sup>Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany; <sup>3</sup>Division of Pulmonary Medicine, Hannover Medical School, Hannover, Germany

**\*11:30 AM (368) Rates and Risk Factors for Nonadherence to the Medical Regimen after Transplantation;** M.A. Dew,<sup>1</sup> A.F. DiMartini,<sup>2</sup> A. De Vito Dabbs,<sup>3</sup> R. Zomak,<sup>4</sup> R.L. Kormos,<sup>5</sup> <sup>1</sup>Psychiatry, Psychology and Epidemiology, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA; <sup>2</sup>Psychiatry and Surgery, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA; <sup>3</sup>Acute and Tertiary Care Nursing, University of Pittsburgh School of Nursing, Pittsburgh, PA; <sup>4</sup>Cardiothoracic Transplantation, University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>5</sup>Surgery, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA

**11:45 AM (369) Time Course and Determinants of Functional Recovery the First Year after Lung Transplantation;** J.C.A. Trappenburg,<sup>2</sup> E.A. van de Graaf,<sup>1</sup> K. Valkenet,<sup>2</sup> G.D. Nossent,<sup>1</sup> E. Lindeman,<sup>2</sup> <sup>1</sup>University Medical Center Utrecht, Heart Lung Center, Utrecht, Netherlands; <sup>2</sup>University Medical Center Utrecht, Department of Rehabilitation and Sports Medicine, Utrecht, Netherlands

**NOON (370) Physical Activity in Patients Newly Listed for Heart Transplantation: Results from the "Waiting for a New Heart Study";** H. Spaderna,<sup>1</sup> G. Weidner,<sup>2</sup> A. Becker,<sup>1</sup> D. Zahn,<sup>1</sup> J.M.A. Smits,<sup>3</sup> <sup>1</sup>Department of Psychology, Johannes Gutenberg University, Mainz, Germany; <sup>2</sup>Preventive Medicine Research Institute, Sausalito, CA; <sup>3</sup>Eurotransplant International Foundation, Leiden, Netherlands

**12:15 PM – 12:30 PM**

Box Lunch Pick-up (ticket required) (Yosemite Ballroom)

**12:30 PM – 2:00 PM**

**LUNCHEON SYMPOSIUM: Beyond the Biopsy: Strengths and Pitfalls of Non-Invasive Diagnostics in Heart Transplantation (Grand Ballroom B)**

**Supported by an Unrestricted Educational Grant from XDX**

**\*Chairs:** \*Andreas O. Zuckermann, MD and \*Nicholas R. Banner, FRCP

**12:30 PM Endomyocardial Biopsy: Is it the Gold Standard in the Diagnosis of Rejection?** Michael C. Fishbein, MD, University of California, Los Angeles, Los Angeles, CA

**12:40 PM The Role of Echocardiography and MRI in Diagnosing Acute Rejection,** Hannah A. Valantine, MD, Stanford University School of Medicine, Stanford, CA

**12:55 PM Monitoring Global Immune Function,** Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA

**\*1:10 PM Protein Biomarkers in Heart Transplantation,** Mandeep R. Mehra, MD, University of Maryland, Baltimore, MD

**\*1:20 PM Clinical Application of Peripheral Blood Gene Profiling in the Management of Heart Transplant Recipients,** Randall C. Starling, MD, Cleveland Clinic Foundation, Cleveland, OH

**1:35 PM Incorporating Noninvasive Monitoring into Management Protocols,** Thomas P. Cappola, MD, ScM, University of Pennsylvania Hospital System, Philadelphia, PA

**1:50 PM Discussion**

**12:30 PM – 2:00 PM**

Second Summit on Mechanical Circulatory Support for Advanced Heart Failure (Union Square 19/20)

**12:30 PM – 2:00 PM**

**MINI ORAL SESSION 3 (Imperial Ballroom A)**

**\*Chairs:** \*Richard N. Pierson III, MD and Kenneth R. McCurry, MD

**12:30 PM (371) Endothelial Progenitor Cells Possess Monocyte-Like Antigen-Presenting and T Cell-Activating Capacity;** P.C. Raemer,<sup>1</sup> S. Haemmerling,<sup>1</sup> T. Giese,<sup>2</sup> T.J. Dengler,<sup>1</sup> S. Vijayshankar,<sup>1</sup> <sup>1</sup>Department of Cardiology, Heidelberg University, Heidelberg, Germany; <sup>2</sup>Institute of Immunology, Heidelberg University, Heidelberg, Germany

**12:35 PM (372) IL-10 Inhibits Endothelium-Dependent T-Cell Costimulation by Upregulation of ILT3/4 in Human Vascular Endothelial Cells;** C.A. Gleissner,<sup>1</sup> M.H. Konstandin,<sup>1</sup> S. Celik,<sup>1</sup> R. Klingenberg,<sup>1</sup> T. Giese,<sup>2</sup> T.J. Dengler,<sup>1</sup> <sup>1</sup>Department of Cardiology, University of Heidelberg, Heidelberg, Germany; <sup>2</sup>Department of Immunology, University of Heidelberg, Heidelberg, Germany

**12:40 PM (373) Alloimmune Response Induces HIF-1 Activation in Vascular and Inflammatory Cells of Transplanted Hearts – Possible Link to Cardiac Allograft Vasculopathy;** M.A.I. Keränen,<sup>1</sup> A.I. Nykänen,<sup>1</sup> R. Krebs,<sup>1</sup> H. Sandelin,<sup>1</sup> R. Tuuminen,<sup>1</sup> P.K. Koskinen,<sup>1,2</sup> K.B. Lemström,<sup>1,3</sup> <sup>1</sup>Transplantation Laboratory, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; <sup>2</sup>Department of Medicine, Division of Nephrology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; <sup>3</sup>Department of Cardiothoracic Surgery, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland

**12:45 PM (374) Thymectomy Does Not Abrogate Long-Term Acceptance of MHC Class I-Disparate Lung Allografts;** H. Sahara,<sup>1</sup> M.J. Weiss,<sup>1</sup> C.Y. Ng,<sup>1</sup> S.L. Houser,<sup>1</sup> A.C. Pujara,<sup>1</sup> J.K. Sayer,<sup>1</sup> J.C. Wain,<sup>1</sup> D.H. Sachs,<sup>1</sup> J.C. Madsen,<sup>1</sup> J.S. Allan,<sup>1</sup> <sup>1</sup>Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA

**12:50 PM (375) Increased Serum Concentrations of Th1 Chemokines Are Associated with Acute Rejection Following Heart Transplantation;** N.U. Khan,<sup>1</sup> J.E. Fildes,<sup>1</sup> M. Al-Aloul,<sup>1</sup> A. Baynes,<sup>1</sup> C.T. Leonard,<sup>1</sup> N. Yonan,<sup>1</sup> <sup>1</sup>The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom

**12:55 PM (376) Anti-Proliferative Properties of CMV Hyperimmunoglobulin Are Related to Activation Induced Cell Death In Vitro: Possible Role in Tolerance Induction;** K. Hoetzenecker,<sup>1</sup> S. Hacker,<sup>1</sup> W. Hoetzenecker,<sup>2</sup> K. Sadeghi,<sup>1</sup> A. Pollreis,<sup>1</sup> A. Mangold,<sup>1</sup> B. Moser,<sup>3</sup> M. Grimm,<sup>1</sup> F. Muehlbacher,<sup>1</sup> W. Klepetko,<sup>1</sup> E. Wolner,<sup>1</sup> H.J. Ankersmit,<sup>1</sup> <sup>1</sup>Department of Surgery, Medical University of Vienna, Vienna, Austria; <sup>2</sup>Department of Dermatology, Medical University Tübingen, Tübingen, Germany; <sup>3</sup>Department of Surgery, Columbia University, New York

**1:00 PM (377) An Innovative Chimeric Gene Construct Targeting p21 Gene Transfer into T Lymphocytes; A.K. Khanna,<sup>1</sup> M.R. Mehra,<sup>1</sup> <sup>1</sup>Medicine (Cardiology), University of Maryland, Baltimore, MD**

**\*1:05 PM (378) Anti-Vimentin Antibodies Induce Formation of Platelet-Leukocyte Conjugates and Whole-Blood Agglutination Via Platelet-Activating Factor; H.S. Leong,<sup>1</sup> B. Mahesh,<sup>1</sup> J.R. Day,<sup>2</sup> J.D. Smith,<sup>1</sup> A.M. McCormack,<sup>1</sup> T.J. Podor,<sup>3</sup> M.L. Rose,<sup>1</sup> <sup>1</sup>Transplant Immunology, Harefield Hospital, Harefield, Middlesex, United Kingdom; <sup>2</sup>Eric Bywaters Center, BHF Cardiovascular Department, Hammersmith Hospital, London, United Kingdom; <sup>3</sup>James Hogg iCAPTURE Center, St. Paul's Hospital, Vancouver, Canada**

**1:10 PM (379) Donor Class I Peptide Immunization Affects the Induction but Not Maintenance Phase of Tolerance; M.J. Weiss,<sup>1</sup> D.A. Guenther,<sup>1</sup> J.D. Mezrich,<sup>1</sup> H. Sahara,<sup>1</sup> C.Y. Ng,<sup>1</sup> A.J. Meltzer,<sup>1</sup> W. Oriyanhan,<sup>1</sup> J.K. Sayre,<sup>1</sup> A.C. Pujara,<sup>1</sup> M.E. Cochrane,<sup>1</sup> S.L. Houser,<sup>1</sup> D.H. Sachs,<sup>1</sup> J.S. Allan,<sup>1,2</sup> J.C. Madsen,<sup>1,3</sup> <sup>1</sup>Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA; <sup>2</sup>Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA; <sup>3</sup>Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA**

**1:15 PM (380) Chronic Aspiration in Lung Allografts Induces a Donor-Specific Hyperimmune State; E.L. Bush,<sup>1</sup> J.Z. Appel,<sup>1</sup> B. Li,<sup>1</sup> K.R. Balsara,<sup>1</sup> M. Hartwig,<sup>1</sup> E. Cantu, III,<sup>1</sup> W. Parker,<sup>1</sup> R.D. Davis,<sup>2</sup> S.S. Lin,<sup>2,3</sup> <sup>1</sup>Department of Surgery, Duke University Medical Center, Durham, NC; <sup>2</sup>Department of Surgery, Division of Cardiovascular and Thoracic Surgery, Duke University Medical Center, Durham, NC; <sup>3</sup>Department of Immunology, Duke University Medical Center, Durham, NC**

**1:20 PM (381) Coronary Plaque Characterization in Heart Transplant Recipients Using Intravascular Ultrasound Radiofrequency Data Analysis; M. Walravens,<sup>1</sup> G. Sarno,<sup>2</sup> S. Verstreken,<sup>2</sup> M. Goethals,<sup>2</sup> F. Wellens,<sup>1</sup> M. Vanderheyden,<sup>2</sup> <sup>1</sup>Cardiovascular & Thoracic Surgery, OLV-Ziekenhuis, Aalst, Belgium; <sup>2</sup>Cardiology, OLV-Ziekenhuis, Aalst, Belgium**

**1:25 PM (382) Chronic Alcohol Ingestion by Donors Amplifies Obliterative Bronchiolitis in a Rodent Model of Lung Transplantation; P.O. Mitchell,<sup>1,2</sup> D.M. Guidot,<sup>1,2</sup> <sup>1</sup>Atlanta Veterans Affairs Medical Center, Decatur, GA; <sup>2</sup>Division of Pulmonary, Allergy & Critical Care Medicine, Emory University School of Medicine, Atlanta, GA**

**1:30 PM (383) Relationship between u-PA and TGF Genotype and Allograft Coronary Disease; D.M. Pekarek,<sup>1</sup> C.S. Coffey,<sup>2</sup> J.A. Barchue,<sup>3</sup> H.E. Grenett,<sup>3</sup> J.A. Tallaj,<sup>3</sup> B.K. Rayburn,<sup>3</sup> R.L. Benza,<sup>3</sup> <sup>1</sup>Genetics, University of Alabama at Birmingham, Birmingham, AL; <sup>2</sup>Biostatistics, University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>Medicine/Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL**

**12:30 PM – 2:00 PM**

**MINI ORAL SESSION 4 (Imperial Ballroom B)**

**Chairs:** Christof Schmid, MD and Mark S. Slaughter, MD

**12:30 PM (384) Stem Cell Factor mRNA Expression during Mechanical Circulatory Support with Left Ventricular Assist Devices Correlates with Cardiac Mast Cell Populations in the Failing Human Heart; J. Jahanyar,<sup>1</sup> K.A. Youker,<sup>2</sup> M. Loebe,<sup>1</sup> H. Chai,<sup>1</sup> C. Assad-Kottner,<sup>2</sup> G. Torre-Amione,<sup>2</sup> G.P. Noon,<sup>1</sup> <sup>1</sup>Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX; <sup>2</sup>Methodist DeBakey Heart Center, The Methodist Hospital, Houston, TX**

**\*12:35 PM (385) Molecular Recovery of the Failing Canine Left Ventricular Myocardium Following Extended Therapy with the Orqis Medical Cardiac Recovery System; H.N. Sabbah,<sup>1</sup> R. Brewer,<sup>1</sup> S. Rastogi,<sup>1</sup> M.S. Sabbah,<sup>1</sup> T. Viole,<sup>2</sup> M.A. Konstam,<sup>2</sup> <sup>1</sup>Medicine and Surgery, Henry Ford Health System, Detroit, MI; <sup>2</sup>Orqis Medical, Inc., Lake Forest, CA**

**12:40 PM (386)  $\beta$ -Adrenergic Respose Is Preserved in Partially Unloaded, but Not in Completely Unloaded Rat Heart; M. Tsukashita,<sup>1</sup> T. Nishina,<sup>1</sup> A. Marui,<sup>1</sup> E. Yoshikawa,<sup>1</sup> J. Wang,<sup>1</sup> T. Ikeda,<sup>1</sup> M. Komeda,<sup>1</sup> <sup>1</sup>Cardiovascular Surgery, Kyoto University, Kyoto, Japan**

**12:45 PM (387) Non-sternotomy Approach for Left Ventricular Assist Device Implantation, Exchange or Explantation; K.K. Liao,<sup>1</sup> A. Barksdale,<sup>1</sup> S.J. Park,<sup>1</sup> L. Macho,<sup>1</sup> L.W. Miller,<sup>2</sup> E. Missov,<sup>2</sup> M. Colvin-Adams,<sup>2</sup> <sup>1</sup>Division of Cardiac Surgery, University of Minnesota, Minneapolis, MN; <sup>2</sup>Division of Cardiology, University of Minnesota, Minneapolis, MN**

**\*12:50 PM (388) Management of Life-Threatening LVAD Pocket and Mediastinal Infections with Omental and Myocutaneous Flaps; D.Q. Nguyen,<sup>1</sup> J.K. Bhama,<sup>1</sup> C. Bermudez,<sup>1</sup> Y. Toyoda,<sup>1</sup> K.M. McCurry,<sup>1</sup> R.L. Kormos,<sup>1</sup> <sup>1</sup>Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA**

**\*12:55 PM (389) Impact of Concomitant Operative Procedures on Left Ventricular Assist Device Implantation Outcomes; D.M. Nelson,<sup>1</sup> K.M. Nelson,<sup>1</sup> I.E. Lloyd,<sup>1</sup> A.G. Kfoury,<sup>1</sup> K.E. Nelson,<sup>1</sup> B.Y. Rasmusson,<sup>1</sup> S.E. Clayton,<sup>1</sup> B.B. Reid,<sup>1</sup> J.W. Long,<sup>1</sup> <sup>1</sup>Utah Artificial Heart Program, LDS Hospital, Salt Lake City, UT**

**1:00 PM (390) Improved Survival in Patients with Ventricular Assist Device Therapy: The University of Wisconsin Experience; S. Osaki,<sup>1</sup> N.M. Edwards,<sup>1</sup> M. Velez,<sup>2</sup> M.R. Johnson,<sup>2</sup> W.G. Kao,<sup>2</sup> E.M. Winkel,<sup>2</sup> M.A. Murray,<sup>1</sup> J.A. Hoffmann,<sup>2</sup> T. Kohmoto,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI; <sup>2</sup>Heart Failure and Transplant Cardiology, University of Wisconsin School of Medicine and Public Health, Madison, WI**

**1:05 PM (391) Outcome Evaluation of the Bridge to Bridge Concept in Patients with Cardiogenic Shock; D. Hoefler,<sup>1</sup> E. Ruttman-Ulmer,<sup>1</sup> J. Kilo,<sup>1</sup> G. Poelzl,<sup>2</sup> C. Hoermann,<sup>3</sup> G. Laufer,<sup>1</sup> H. Antretter,<sup>1</sup> <sup>1</sup>Department of Cardiac Surgery, Medical University Innsbruck, Innsbruck, Austria; <sup>2</sup>Department of Cardiology, Medical University Innsbruck, Innsbruck, Austria; <sup>3</sup>Department of Anaesthesia, Medical University Innsbruck, Innsbruck, Austria**

**1:10 PM (392) Impact of Continuous Versus Pulsatile Left Ventricular Assist Devices on Renal Function; S.E. Sandner,<sup>1</sup> D. Zimpfer,<sup>1</sup> P. Zrunek,<sup>1</sup> H. Schima,<sup>1</sup> A. Rajek,<sup>2</sup> M. Grimm,<sup>1</sup> E. Wolner,<sup>1</sup> G.M. Wieselthaler,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria; <sup>2</sup>Cardiothoracic Anesthesiology, Medical University of Vienna, Vienna, Austria**

**1:15 PM (393) Patient Outcome Following LVAD Bridge to Recovery Compared to Bridge to Transplantation; E.J. Birks,<sup>1,2</sup> R.S. George,<sup>1,2</sup> P. Rogers,<sup>1</sup> J.R. Pepper,<sup>1</sup> G. Dreyfus,<sup>1</sup> M.H. Yacoub,<sup>2</sup> A. Khaghani,<sup>1,2</sup> <sup>1</sup>Department of Transplantation and Mechanical Circulatory Support, Royal**

Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom; <sup>2</sup>Heart Science Centre, Harefield Hospital, Harefield, Middlesex, United Kingdom

**1:20 PM (394) Portable Drivers for a Total Artificial Heart; A. El-Banayosy,<sup>1</sup> L. Arusoglu,<sup>1</sup> M. Morshuis,<sup>1</sup> L. Kizner,<sup>1</sup> D. Roefe,<sup>1</sup> C. Raddatz,<sup>1</sup> D. Coughan,<sup>1</sup> R. Koerfer,<sup>1</sup> <sup>1</sup>Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany**

**1:25 PM (395) Bridge to Recovery with Pulsatile Pump Support in Children under Two Years of Age; J.G. Copeland,<sup>1</sup> R.G. Smith,<sup>1</sup> P.E. Nolan,<sup>2</sup> B. Barber,<sup>3</sup> R. Samson,<sup>3</sup> <sup>1</sup>Surgery, University of Arizona, Tucson, AZ; <sup>2</sup>Pharmacy, University of Arizona, Tucson, AZ; <sup>3</sup>Pediatrics, University of Arizona, Tucson, AZ**

**(396) SEE WEDNESDAY LUNCHEON SYMPOSIUM**

**(397) SEE WEDNESDAY LUNCHEON SYMPOSIUM**

**\*1:30 PM (398) Premature Termination of a Prospective, Open Label, Randomized, Multicenter Study of Sirolimus to Replace Calcineurin Inhibitors (CNI) in a Standard Care Regimen of CNI, MMF and Corticosteroids Early after Heart Transplantation; J. Hunt,<sup>1</sup> H. Bedánová,<sup>2</sup> R.C. Starling,<sup>3</sup> G. Rabágo,<sup>4</sup> N.R. Banner,<sup>5</sup> J. Kobashigawa,<sup>6</sup> A. Keogh,<sup>7</sup> R. Kormos,<sup>8</sup> M. Mehra,<sup>9</sup> T. Wahlers,<sup>10</sup> J. Noeldeke,<sup>11</sup> <sup>1</sup>Medical City Hospital, Dallas, TX; <sup>2</sup>CKTCH, Brno, Czech Republic; <sup>3</sup>Cleveland Clinic Foundation, Cleveland, OH; <sup>4</sup>Clinica Universitaria, Navarra, Pamplona, Spain; <sup>5</sup>Royal Brompton and Harefield NHS Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom; <sup>6</sup>The David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>7</sup>St. Vincent's Hospital, Darlinghurst, NSW, Australia; <sup>8</sup>University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>9</sup>University of Maryland School of Medicine, Baltimore, MD; <sup>10</sup>Universitätsklinik Köln, Cologne, Germany; <sup>11</sup>Pharmaceuticals Division, F. Hoffmann-LaRoche Ltd, Basel, Switzerland**

**1:35 PM (399) Therapeutic Monitoring of Mycophenolate Mofetil Dose by Twelve-Hour-Area under the Curve to Avoid Acute Rejection in Heart Transplant Recipients; K. Wada,<sup>1</sup> T.S. Kato,<sup>2</sup> N. Oda,<sup>2</sup> I. Ochi,<sup>1</sup> Y. Maeda,<sup>1</sup> A. Mano,<sup>2</sup> T. Kotake,<sup>1</sup> T. Nakatani,<sup>2</sup> <sup>1</sup>Department of Pharmacy, National Cardiovascular Center, Suita, Osaka, Japan; <sup>2</sup>Department of Organ Transplantation, National Cardiovascular Center, Suita, Osaka, Japan**

**1:40 PM (400) A French Multicenter Prospective Randomized Study Evaluating the Benefit, on Renal Function, of Two Doses of Cyclosporine: Low Dose Versus Usual Dose, in Association with Mycophenolate Mofetil and Corticoids, in De Novo Cardiac Transplant: Results at 6 Months; P. Boissonnat,<sup>1</sup> S. Gaillard,<sup>2</sup> F. Noel-Baron,<sup>2</sup> C. Mercier,<sup>3</sup> A. Roussoulières,<sup>1</sup> O. Bastien,<sup>1</sup> L. Sebbag,<sup>1</sup> <sup>1</sup>Unité de Transplantation Cardiaque, Hôpital Cardiovasculaire et Pneumologique - CHU de Lyon, Bron, France, Metropolitan; <sup>2</sup>INSERM - CHU de Lyon, Bron, France, Metropolitan; <sup>3</sup>Service de Biostatistique - UMR CNRS 5558, CHU de Lyon, Lyon, France, Metropolitan**

**1:45 PM (401) Novel Short-Course Total Lymphoid Irradiation Protocol for Refractory Cardiac Rejection; T.S. Lee,<sup>1</sup> J. Freund,<sup>1</sup> V. Petersen,<sup>1</sup> J. Heywood,<sup>1</sup> G. O'Driscoll,<sup>2,3</sup> <sup>1</sup>Perth Radiation Oncology, Royal Perth Hospital, Perth, Western Australia, Australia; <sup>2</sup>Advanced Heart Failure & Cardiac Transplant Services, Royal Perth Hospital, Perth, Western Australia, Australia; <sup>3</sup>School of Medicine, University of Notre Dame, Fremantle, Western Australia, Australia**

**2:15 PM – 3:45 PM**

**CONCURRENT SESSION 31**

**Clinical Heart Transplantation: Will You Still Love me 20 Years Later? (Grand Ballroom A)**

**\*Chairs: Ari L. J. Harjula, MD and \*Barry K. Rayburn, MD**

**2:15 PM (402) Outcomes in Bicaval Versus Biatial Techniques in Heart Transplantation: An Analysis of the UNOS Database; E.S. Weiss,<sup>1</sup> L.U. Nwakanma,<sup>1</sup> S.D. Russell,<sup>2</sup> J.V. Conte,<sup>1</sup> A.S. Shah,<sup>1</sup> <sup>1</sup>Department of Surgery, Division of Cardiac Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD; <sup>2</sup>Department of Medicine, Division of Cardiology, The Johns Hopkins University School of Medicine, Baltimore, MD**

**2:30 PM (403) The Effect of Body Mass Index on Survival Following Heart Transplantation: A Critique of the ISHLT's Revised Listing Criteria for Heart Transplantation; M.J. Russo,<sup>1,2</sup> J.M. Chen,<sup>1</sup> A. Moskowitz,<sup>2</sup> K.N. Hong,<sup>2</sup> R.R. Davies,<sup>1</sup> F. Cheema,<sup>1</sup> D.D. Ascheim,<sup>2,3</sup> M. Argenziano,<sup>1</sup> M.C. Oz,<sup>1</sup> A.C. Gelijs,<sup>2</sup> Y. Naka,<sup>1</sup> <sup>1</sup>Division of Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, NY, NY; <sup>2</sup>International Center for Health Outcomes and Innovation Research, Columbia University College of Physicians and Surgeons, NY, NY; <sup>3</sup>Division of Cardiology, Columbia University College of Physicians and Surgeons, NY, NY**

**2:45 PM (404) Twenty-Five Years of Heart Transplantation at a Single Centre: Changes in Factors Influencing Short- and Long-Term Survival over Time; K. Goldsmith,<sup>2,3</sup> L. Sharples,<sup>2,3</sup> C. Sudarshan,<sup>1</sup> J. Parameshwar,<sup>1</sup> S. Tsui,<sup>1</sup> J. Wallwork,<sup>1</sup> S. Large,<sup>1</sup> <sup>1</sup>Transplant Unit, Papworth Hospital, Papworth Everard, Cambridge, United Kingdom; <sup>2</sup>Research & Development Department, Papworth Hospital, Papworth Everard, Cambridge, United Kingdom; <sup>3</sup>MRC Biostatistics Unit, Cambridge, United Kingdom**

**3:00 PM (405) 129 Cardiac Transplantations with Hearts from Donors Older Than 50: A Five Years Single Center Experience; C. D'Alessandro,<sup>1</sup> P. Leprince,<sup>1</sup> S. Varnous,<sup>1</sup> E. Vaissier,<sup>2</sup> M. Landi,<sup>2</sup> E. Barreda,<sup>1</sup> A. Rama,<sup>1</sup> I. Gandjbakhch,<sup>1</sup> A. Pavie,<sup>1</sup> N. Bonnet,<sup>1</sup> <sup>1</sup>CT Surgery Department, University Paris VI, AP-HP, Hospital Pitie Salpetriere, Paris, France; <sup>2</sup>Anesthesiology Department, University Paris VI, AP-HP, Hospital Pitie Salpetriere, Paris, France**

**3:15 PM (406) Estimated GFR Predicts Survival Following Heart Transplantation; M.J. Russo,<sup>1,2</sup> J.M. Chen,<sup>1</sup> K.N. Hong,<sup>2</sup> F.H. Cheema,<sup>1</sup> R.R. Davies,<sup>1</sup> D.D. Ascheim,<sup>2,3</sup> M. Argenziano,<sup>1</sup> A.J. Moskowitz,<sup>2</sup> M.C. Oz,<sup>1</sup> A.C. Gelijs,<sup>2</sup> Y. Naka,<sup>1</sup> <sup>1</sup>Division of Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, NY, NY; <sup>2</sup>International Center for Health Outcomes and Innovation Research, Columbia University College of Physicians and Surgeons, NY, NY; <sup>3</sup>Division of Cardiology, Columbia University College of Physicians and Surgeons, NY, NY**

**3:30 PM (407) Outcomes in Patients Older Than Sixty Undergoing Orthotopic Heart Transplantation: An Analysis of UNOS Data; E.S. Weiss,<sup>1</sup> L.U. Nwakanma,<sup>1</sup> D.D. Yuh,<sup>1</sup> <sup>1</sup>Division of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, MD**

**2:15 PM – 3:45 PM**

**CONCURRENT SESSION 32**

## **Lung Retransplantation (Imperial Ballroom A)**

**Chairs:** Jason Christie, MD and Christine Fegbeutel, MD

**2:15 PM (408)** *A UNOS Registry Analysis of Lung Retransplantation (ReTxp) in the Modern Era*; S.M. Kawut,<sup>1</sup> D.J. Lederer,<sup>1</sup> J.S. Wilt,<sup>1</sup> F. D'Ovidio,<sup>2</sup> J.R. Sonett,<sup>2</sup> S.M. Arcasoy,<sup>1</sup> S. Keshavjee,<sup>3</sup> M.L. Barr,<sup>4</sup> <sup>1</sup>Medicine, Columbia University, New York City, NY; <sup>2</sup>Surgery, Columbia University, New York City, NY; <sup>3</sup>Surgery, University of Toronto, Toronto, ON, Canada; <sup>4</sup>Cardiothoracic Surgery, University of Southern California, Los Angeles, CA

**2:30 PM (409)** *Pulmonary Retransplantation – Is It Worth the Effort? A Long Term Analysis of 46 Cases*; C. Aigner,<sup>1</sup> P. Jaksch,<sup>1</sup> S. Taghavi,<sup>1</sup> G. Lang,<sup>1</sup> A. Hoda,<sup>1</sup> W. Wisser,<sup>1</sup> W. Klepetko,<sup>1</sup> <sup>1</sup>Department of Cardio-Thoracic Surgery, Medical University of Vienna, Vienna, Austria

**2:45 PM (410)** *Repeat Heart-Lung Transplantation Outcome United States: An Update from the UNOS Registry*; J.H. Shuhaiber, J.B. Kim, R. Gibbons, Thoracic and Cardiovascular Surgery, Loyola University Stritch School of Medicine, Chicago, IL; Department of Biostatistics, University of Illinois, Chicago, IL; Department of Biostatistics, University of Illinois, Chicago, IL

**\*3:00 PM DEBATE:** *Retransplantation Should Not be Performed*

*PRO:* Keith McNeil, FRACP, Prince Charles Hospital, Brisbane, Australia

*\*CON:* Thomas M. Egan, MD, MSC, University of North Carolina School of Medicine, Chapel Hill, NC

**2:15 PM – 3:45 PM**

### **CONCURRENT SESSION 33**

#### **Sex, Drugs, and Devices in Heart Failure (Imperial Ballroom B)**

**\*Chairs:** Edoardo G. Gronda, MD and \*Paul J. Mather, MD

**2:15 PM Invited Lecture:** *Optimal Heart Failure Management: The ISHLT Guidelines*, Mariell Jessup, MD, Hospital of the University of Pennsylvania, Philadelphia, PA

**\*2:30 PM (411)** *Women Are at Higher Risk for Recurrence of Cardiomyopathy*; E.A. Carraway,<sup>1</sup> B.K. Rayburn,<sup>1</sup> J.A. Tallaj,<sup>1</sup> S.V. Pamboukian,<sup>1</sup> R.L. Benza,<sup>1</sup> R.C. Bourge,<sup>1</sup> <sup>1</sup>Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL

**2:45 PM (412)** *Gender Related Considerations in Patients Referred for Heart Transplant Evaluation*; S.M. Yala,<sup>1</sup> M. Cadeiras,<sup>1</sup> M.P. Bayern,<sup>1</sup> A.R. Gangadin,<sup>1</sup> Y. Naka, D.M. Mancini, E.V. Giardina, M.C. Deng <sup>1</sup>Medicine, Columbia University, New York, NY

**3:00 PM (413)** *Whole Transcriptome Analysis of Heart Transplantation Candidates Supported by Pulsatile and Non-Pulsatile Ventricular Assist Devices*; H. Milting,<sup>1</sup> P. Ellinghaus,<sup>2</sup> D. D'Urso,<sup>2</sup> M. Seewald,<sup>2</sup> R. Cebulla,<sup>1</sup> A. Kassner,<sup>1</sup> M. Morshuis,<sup>1</sup> L. Arusoglu,<sup>1</sup> R. Koerfer,<sup>1</sup> A. El Banayosy,<sup>1</sup> <sup>1</sup>Erich und Hanna Klessmann-Institut fuer Kardiovaskulaere Forschung und Entwicklung, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany; <sup>2</sup>Target Research, Bayer Healthcare AG, Wuppertal, NRW, Germany

**\*3:15 PM (414)** *The Effect of Clenbuterol on Skeletal Muscle, Cardiac Function and Exercise Capacity in Patients with Chronic Heart Failure*; S. Maybaum,<sup>1</sup> I. George,<sup>2</sup> C. Petrilli,<sup>1</sup> E. Shane,<sup>2</sup> G. Kamalakkannan,<sup>1</sup> D. Rossi,<sup>1</sup> J. LaManca,<sup>2</sup> D.M. Mancini,<sup>2</sup> <sup>1</sup>Montefiore Medical Center, Bronx, NY; <sup>2</sup>Columbia University Medical Center, New York, NY

**\*3:30 PM (415)** *Seeing the Future: Strategic Decision Support for Heart Transplant*; M.S. Sharma,<sup>2</sup> K.J. Hoercher,<sup>1</sup> R.C. Starling,<sup>1,4</sup> J.M. Alster,<sup>3</sup> I. Deglurkar,<sup>2</sup> E.H. Blackstone,<sup>2,3</sup> G.V. Gonzalez-Stawinski,<sup>1,2</sup> N.G. Smedira,<sup>1,2</sup> <sup>1</sup>Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, OH; <sup>2</sup>Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH; <sup>3</sup>Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; <sup>4</sup>Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

**2:15 PM – 3:45 PM**

### **CONCURRENT SESSION 34**

#### **Immunosuppressive Jumble Sale (Plaza Ballroom A)**

**Chairs:** Geert M. Verleden, MD, PhD and David Weill, MD

**\*2:15 PM (416)** *A Longitudinal Study of Airway Vascularity Post-Lung Transplantation (LTx): Everolimus (ERL) vs Azathioprine (AZA)*; B.J. Levvey,<sup>1</sup> L. Zheng,<sup>2</sup> B. Orsida,<sup>2</sup> M. Bailey,<sup>3</sup> T.J. Williams,<sup>1</sup> G.I. Snell,<sup>1</sup> <sup>1</sup>Lung Transplant Service, The Alfred, Melbourne, Victoria, Australia; <sup>2</sup>Department of Medicine, Monash University, Melbourne, Victoria, Australia; <sup>3</sup>Epidemiology and Preventative Medicine, Monash University, Melbourne, Victoria, Australia

**2:30 PM (417)** *Cyclosporine Does Not Penetrate, but Accumulates at High Concentrations within, Differentiated Human Airway Epithelial Cells In Vitro: Possible Implications for the Use of Inhaled Cyclosporine*; R. Aris,<sup>1</sup> P. McNeillie,<sup>1</sup> O. Olusesi,<sup>1</sup> S. Thomas,<sup>1</sup> M. Paine,<sup>2</sup> C. Hammett-Stabler,<sup>3</sup> I. Neuringer,<sup>1</sup> <sup>1</sup>Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; <sup>2</sup>School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC; <sup>3</sup>Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC

**2:45 PM (418)** *Mycophenolate Mofetil Is Associated with Decreased De Novo Anti-HLA Alloantibodies in the First Year after Lung Transplantation*; A.L. Girmita,<sup>1</sup> A. Zeevi,<sup>1</sup> S.A. Yousem,<sup>1</sup> J. Pilewski,<sup>1</sup> G. Zdanowicz,<sup>1</sup> K.J. Spichty,<sup>1</sup> J. Howe,<sup>1</sup> D. Zaldonis,<sup>1</sup> K.R. McCurry,<sup>1</sup> <sup>1</sup>University of Pittsburgh Medical Center, Pittsburgh, PA

**3:00 PM (419)** *Initial Cyclosporin C2 Monitoring Following Lung Transplantation Provides Long-Term Clinical Benefits: A Prospective Randomised Study*; J. Cornelissen,<sup>1</sup> M. Goddard,<sup>1</sup> A. Wood,<sup>2</sup> J. Wallwork,<sup>3</sup> P. Sivasothy,<sup>3</sup> <sup>1</sup>Department of Pathology, Papworth NHS Trust Hospital, Cambridge, United Kingdom; <sup>2</sup>MRC Biostatistics Unit, Institute of Public Health, Cambridge, United Kingdom; <sup>3</sup>Transplant Unit, Papworth NHS Trust Hospital, Cambridge, United Kingdom

**\*3:15 PM (420) Final 3 Year Analysis of a Prospective Randomized International Multicenter Investigator Driven Study Comparing Tac and CsA (+ MMF/Steroids) after Lung Transplantation in 274 Patients;** H. Reichenspurner, W. Klepetko, C. Aboyoun, C. Bravo, M. Estenne, S. Hirt, J. Aubert, H. Treede, A. Glanville, the European and Australian Investigators in Lung Transplantation, Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; University of Vienna, Vienna, Austria; Alfreds Hospital, University of Sydney, Sydney, Australia; University of Barcelona, Barcelona, Spain; University of Brussels, Brussels, Belgium; University of Kiel, Kiel, Germany; University of Lausanne, Lausanne, Switzerland; University Heart Center Hamburg, Hamburg, Germany; Alfreds Hospital, University of Sydney, Sydney, Australia

**\*3:30 PM (421) Effect of Induction Therapy on the Peripheral Blood Genomic Signature in the LARGO Lung Transplant Study;** S. Keshavjee,<sup>1</sup> K.R. McCurry,<sup>2</sup> R.D. Davis,<sup>3</sup> J.M. Pilewski,<sup>2</sup> P.A. Corris,<sup>4</sup> A. Zeevi,<sup>2</sup> T.K. Waddell,<sup>1</sup> S.M. Arcasoy,<sup>5</sup> J.G. Golden,<sup>6</sup> M. Strueber,<sup>7</sup> R.L. Doyle,<sup>8</sup> P. Jaksch,<sup>9</sup> A.C. Mehta,<sup>10</sup> M.S. Mulligan,<sup>11</sup> O.E. Pajaro,<sup>12</sup> M.R. Zamora,<sup>13</sup> S. Sweet,<sup>14</sup> R.N. Woodward,<sup>15</sup> R.D. Dedrick,<sup>15</sup> H. Wolters,<sup>15</sup> K.C. Fang,<sup>15</sup> E.P. Trulock,<sup>14</sup> <sup>1</sup>University of Toronto, Toronto, ON, Canada; <sup>2</sup>University of Pittsburgh, Pittsburgh, PA; <sup>3</sup>Duke University, Durham, NC; <sup>4</sup>University of Newcastle, Newcastle Upon Tyne, MO, United Kingdom; <sup>5</sup>Columbia University, New York, NY; <sup>6</sup>University of California, San Francisco, San Francisco, CA; <sup>7</sup>Hannover Medical School, Hannover, Germany; <sup>8</sup>Stanford University, Stanford, CA; <sup>9</sup>University Hospital, Vienna, Austria; <sup>10</sup>Cleveland Clinic Foundation, Cleveland, OH; <sup>11</sup>University of Washington, Seattle, WA; <sup>12</sup>Mayo Clinic Jacksonville, Jacksonville, FL; <sup>13</sup>University of Colorado, Denver, CO; <sup>14</sup>Washington University, St. Louis, MO; <sup>15</sup>XDx, South San Francisco, CA

**2:15 PM – 4:15 PM**

**CONCURRENT SESSION 35**

**Caves Candidate Award Presentations (Plaza Ballroom B)**

**Chairs:** Mark L. Barr, MD and Bruno Reichart, MD

**2:15 PM (422) CXCR3 and CCR5 Blockade Prevents Acute Rejection Via Induction of Regulatory CD4 Lymphocytes;** S. Bastani,<sup>1,2</sup> G.T. Schnickel,<sup>1</sup> G.R. Hsieh,<sup>1,2</sup> C. Garcia,<sup>1</sup> M.C. Fishbein,<sup>3</sup> A. Ardehali,<sup>1,2</sup> <sup>1</sup>Department of Surgery, Division of Cardiac Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA; <sup>2</sup>Department of Surgery, Division of Cardiac Surgery, West Los Angeles VA Medical Center, Los Angeles, CA; <sup>3</sup>Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA

**2:30 PM (423) Adenoviral Mediated Interleukin 10(AdhIL-10) Gene Therapy in Normothermic Ex-Vivo Lung Perfusion;** M. Cypel, M. Rubacha, M. Sato, S. Hirayama, S. Fischer, K. McRae, M. Liu, T.K. Waddell, M. dePerrot, S. Keshavjee, Thoracic Surgery Research Laboratory, Toronto Lung Transplant Program, Toronto General Research Institute, University of Toronto, Toronto, ON, Canada

**2:45 PM (424) Anti-CD20 Prevents Alloantibody Production and Attenuates Cardiac Allograft Vasculopathy in Monkeys Treated with Anti-CD154;** S.S. Kelishadi,<sup>1</sup> T. Zhang,<sup>1</sup> B.N. Nguyen,<sup>1</sup> G. Wu,<sup>1</sup> E. Welty,<sup>1</sup> C.J. Avon,<sup>1</sup> S. Pfeiffer,<sup>1</sup> C. Schroder,<sup>1</sup> A. Azimzadeh,<sup>1</sup> R.N. Pierson, III,<sup>1</sup> <sup>1</sup>Cardiac Surgery, University of Maryland School of Medicine and Baltimore VAMC, Baltimore, MD

**3:00 PM (425) VAD-Associated Thromboembolism: Possible Role for Intrinsic Coagulation Cascade;** S. Kallam,<sup>1</sup> R.N. Sangrampurkar,<sup>1</sup> Z. Kon,<sup>1</sup> R.N. Pierson,<sup>1</sup> B.P. Griffith,<sup>1</sup> R.S. Poston,<sup>1</sup> <sup>1</sup>Cardiac Surgery, University of Maryland Medical Center, Baltimore, MD

**3:15 PM (426) Vascular Endothelial Growth Factor-C Enhances Experimental Obliterative Bronchiolitis by Inducing Lymphangiogenesis;** R. Krebs,<sup>1</sup> J.M. Tikkanen,<sup>1</sup> A.I. Nykänen,<sup>1</sup> S. Ylä-Herttuala,<sup>2</sup> P.K. Koskinen,<sup>1</sup> K.B. Lemström,<sup>1</sup> <sup>1</sup>Transplantation Laboratory, University of Helsinki, Helsinki, Finland; <sup>2</sup>A.I. Virtanen Institute for Molecular Sciences, University of Kuopio, Kuopio, Finland

**3:30 PM (427) The Effects of Hormone Resuscitation on Transplantable Organs in the Brain Dead Donor;** A. Hing,<sup>1</sup> M. Hicks,<sup>1</sup> L. Gao,<sup>1</sup> S.C. Faddy,<sup>1</sup> P. Tran,<sup>2</sup> S.H. Kesteven,<sup>3</sup> A.F. Sharland,<sup>2</sup> G.J. Stewart,<sup>2</sup> P.S. Macdonald,<sup>1</sup> <sup>1</sup>Transplant Program, The Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; <sup>2</sup>The Collaborative Transplant Research Group, The University of Sydney, Sydney, NSW, Australia; <sup>3</sup>Cardiovascular Mechanics Program, The Victor Chang Cardiac Research Institute, Sydney, NSW, Australia

**3:45 PM (428) Lipopolysaccharide Preconditioning Is Protective in Lung Ischemia Reperfusion Injury;** H.E. Merry,<sup>1</sup> A.S. McCourtie,<sup>1</sup> P.S. Wolf,<sup>1</sup> A.S. Farivar,<sup>1</sup> M.S. Mulligan,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, University of Washington, Seattle, WA

**\*4:00 PM (429) B-Type Natriuretic Peptide Is a Sensitive Screening Tool for Acute Rejection in Pediatric Heart Transplant Patients;** J.W. Rossano,<sup>1</sup> S.W. Denfield,<sup>1</sup> J.J. Kim,<sup>1</sup> J.L. Jefferies,<sup>1</sup> J.F. Price,<sup>1</sup> J.A. Decker,<sup>1</sup> S.K. Clunie,<sup>1</sup> J.A. Towbin,<sup>1</sup> W.J. Dreyer,<sup>1</sup> <sup>1</sup>Cardiology, Texas Children's Hospital and Baylor College of Medicine, Houston, TX

**3:45 PM – 4:15 PM**

**Coffee Break/Poster Viewing (Continental Ballroom)**

**4:15 PM – 5:45 PM**

**CONCURRENT SESSION 36**

**Whom To Transplant or Not to Transplant: That is the Question (Grand Ballroom A)**

**\*Chairs:** \*Leway Chen, MD, MPH and \*Nicholaas De Jonge, MD

**4:15 PM (430) Clinical Outcomes after Cardiac Transplantation in Muscular Dystrophy Patients;** R.S. Wu,<sup>1</sup> R.N. Brown,<sup>2</sup> C.W. Yancy,<sup>1</sup> J.W. Wald,<sup>3</sup> P. Kaiser,<sup>1</sup> N.M. Kirklin,<sup>2</sup> D.J. Garry,<sup>1,4,5</sup> P.P.A. Mammen,<sup>1,5</sup> <sup>1</sup>Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX; <sup>2</sup>Cardiac Transplant Research Database, University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>Department of Internal Medicine, Temple University, Philadelphia, PA; <sup>4</sup>Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX; <sup>5</sup>Donald W. Reynolds Cardiovascular Clinical Research Center, UT Southwestern Medical Center, Dallas, TX

**4:30 PM (431) Heart Transplantation for AL Amyloidosis;** C.G.A. McGregor,<sup>1</sup> B.S. Edwards,<sup>1</sup> R.J. Rodeheffer,<sup>1</sup> R.P. Frantz,<sup>1</sup> S.S. Kushwaha,<sup>1</sup> A.L. Clavell,<sup>1</sup> J.A. Dearani,<sup>1</sup> T.M. Sundt,<sup>1</sup> R.C. Daly,<sup>1</sup> <sup>1</sup>Mayo Clinic-Rochester William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN

**4:45 PM (432) Long-Term Results of Combined Heart and Kidney Transplantation: A French Multicenter Study;** E. Vermes,<sup>1</sup> L. Sebbag,<sup>2</sup> B. Barrou,<sup>3</sup> A. Pavie,<sup>3</sup> D. Loisançe,<sup>1</sup> M. Kirsch,<sup>1</sup> <sup>1</sup>Cardiac Surgery, Henri Mondor Hospital, Creteil, France; <sup>2</sup>Cardiac Surgery, Lyon, France; <sup>3</sup>Cardiac Surgery, Renal Transplantation, Pitie Salpetriere Hospital, Paris, France

**5:00 PM (433) Outcomes in Simultaneous Heart and Kidney Transplantation: The University of Wisconsin Experience;** J.L. Hermsen,<sup>1</sup> D.S. Nath,<sup>1</sup> J.D. Lindsey,<sup>1</sup> C.H. Wigfield,<sup>1</sup> N.M. Edwards,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, University of Wisconsin, Madison, WI

**5:15 PM (434) Infections in Alternate Versus Standard List Heart Transplant Patients: Implications for Immunosuppression;** B. Lima,<sup>1</sup> K. Rajagopal,<sup>1</sup> R.G. Mesis,<sup>1</sup> R.P. Petersen,<sup>1</sup> B. Soule,<sup>1</sup> G.M. Felker,<sup>1</sup> J.G. Rogers,<sup>1</sup> A.J. Lodge,<sup>1</sup> C.A. Milano,<sup>1</sup> <sup>1</sup>Department of Surgery, Duke University Medical Center, Durham, NC

**5:30 PM (435) Long-Term Outcomes of Transplantation for Peripartum Cardiomyopathy. A Multiinstitutional Analysis;** K.D. Rasmusson,<sup>1</sup> J. Stehlik,<sup>2</sup> R.N. Brown,<sup>3</sup> D.G. Renlund,<sup>1</sup> L.E. Wagoner,<sup>4</sup> G. Torre-Amione,<sup>5</sup> J.W. Folsom,<sup>1</sup> D.H. Silber,<sup>6</sup> J.K. Kirklin,<sup>3</sup> <sup>1</sup>LDS Hospital, Utah Transplant Affiliated Hospitals, Salt Lake City, UT; <sup>2</sup>VA Salt Lake City HCS, Utah Transplant Affiliated Hospitals, Salt Lake City; <sup>3</sup>University of Alabama at Birmingham, Birmingham; <sup>4</sup>University of Cincinnati Medical Center, Cincinnati; <sup>5</sup>Baylor College of Medicine, The Methodist Hospital, Houston; <sup>6</sup>Hershey Medical Center, Penn State University, Hershey; <sup>7</sup>Cardiac Transplant Research Database

**4:15 PM – 5:45 PM**

**CONCURRENT SESSION 37**

**Mechanisms and Treatment of Lung Rejection (Imperial Ballroom A)**

**\*Chairs:** \*Scott M. Palmer, MD and Christine L. Lau, MD

**4:15 PM (436) The Involvement of the IL23/IL17 Pathway in the Development of Bronchiolitis Obliterans Syndrome after Lung Transplantation;** B.M. Vanaudenaerde,<sup>1</sup> R. Vos,<sup>1</sup> N. Geudens,<sup>2</sup> L.J. Dupont,<sup>1,2</sup> D.E. Van Raemdonck,<sup>2</sup> G.M. Verleden,<sup>1,2</sup> <sup>1</sup>Laboratory of Pneumology, KU Leuven, Leuven, Belgium; <sup>2</sup>Lung Transplant Unit, UZ Gasthuisberg, Leuven, Belgium

**4:30 PM (437) Azithromycin Inhibits IL17-Induced 8-Isoprostane Production in Human Airway Smooth Muscle Cells: A Role for Anti-Oxidative Effects in Bronchiolitis Obliterans Syndrome after Lung Transplantation?;** R. Vos,<sup>1</sup> B.M. Vanaudenaerde,<sup>1</sup> W.A. Wuyts,<sup>1,3</sup> N. Geudens,<sup>1</sup> L.J. Dupont,<sup>1,2,3</sup> D.E. Van Raemdonck,<sup>2,4</sup> G.M. Verleden,<sup>1,2,3</sup> <sup>1</sup>Laboratory of Pneumology, Katholieke Universiteit, Leuven, Belgium; <sup>2</sup>Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium; <sup>3</sup>Respiratory Disease, University Hospital Gasthuisberg, Leuven, Belgium; <sup>4</sup>Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium

**4:45 PM (438) Comparative Broncho-Alveolar Lavage Fluid (BAL-f) and Plasma Proteome Analysis in Lung Transplant Recipients with Bronchiolitis Obliterans Syndrome (BOS);** F. Meloni,<sup>1</sup> R. Salvini,<sup>2</sup> I. Passadore,<sup>1</sup> C. Di Poto,<sup>2</sup> A.M. Bardoni,<sup>2</sup> P. Vitulo,<sup>3</sup> A.M. Fietta,<sup>1</sup> <sup>1</sup>Dept Hematol Pneumol Cardiovasc Sc - Sect Pneumology, University of Pavia & Pol San Matteo, Pavia, Italy; <sup>2</sup>Dept of Biochemistry, University of Pavia, Pavia, Italy; <sup>3</sup>ISMETT, Palermo, Italy

**5:00 PM (439) Efficacy of Combination Therapy with High Dosages of IVIG and Anti-CD25<sup>+</sup> (Basiximab) for Acute Lung Allograft Rejection or Organizing Pneumonia: A Pilot Study;** D.J. Ross,<sup>1</sup> J.P. Lynch,<sup>1</sup> R. Sagar,<sup>1</sup> B. Kubak,<sup>2</sup> J.A. Belperio,<sup>1</sup> R. Beygui,<sup>4</sup> W.D. Wallace,<sup>3</sup> M.C. Fishbein,<sup>3</sup> A. Ardehali,<sup>4</sup> <sup>1</sup>Pulmonary and Critical Care, University of California, Los Angeles, Los Angeles, CA; <sup>2</sup>Infectious Disease, University of California, Los Angeles, Los Angeles, CA; <sup>3</sup>Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA; <sup>4</sup>Cardiothoracic Surgery, University of California, Los Angeles, Los Angeles, CA

**5:15 PM (440) Decreasing Regulatory T-Cell Dynamics Early Post Lung Transplant Is Associated with Histopathological Acute Rejection;** T. Higuchi,<sup>1</sup> N.A. Mifsud,<sup>2</sup> G.P. Westall,<sup>1</sup> T.J. Williams,<sup>1</sup> G.I. Snell,<sup>1</sup> T.C. Kotsimbos,<sup>1</sup> <sup>1</sup>Lung Transplant Service, The Alfred, Melbourne, Victoria, Australia; <sup>2</sup>Department of Medicine, Monash University, Melbourne, Victoria, Australia

**\*5:30 PM (441) Defining Humoral Rejection: A Detailed Longitudinal Study of Lung Transplant Recipients;** G.P. Westall,<sup>1</sup> T.C. Kotsimbos,<sup>1</sup> G.I. Snell,<sup>1</sup> C. McLean,<sup>1</sup> C.M. Magro,<sup>2</sup> <sup>1</sup>Lung Transplant Service, Alfred Hospital, Melbourne, Victoria, Australia; <sup>2</sup>Weill College of Medicine, Cornell University, New York, NY

**4:15 PM – 5:45 PM**

**CONCURRENT SESSION 38**

**Mechanisms of Rejection in Heart Transplantation (Imperial Ballroom B)**

**\*Chairs:** Suzanne Roedler, MD and \*David S. Feldman, MD, PhD

**4:15 PM (442) Viral Interleukin-10 Gene Therapy Via Mesenchymal Stem Cells Prolonged Cardiac Transplant Survival;** S. Salgar,<sup>1</sup> S. Li,<sup>1</sup> M. Hernandez,<sup>1</sup> Y. Wei,<sup>1</sup> D. Mateu,<sup>1</sup> J. Mathew,<sup>1</sup> S. Pham,<sup>1</sup> <sup>1</sup>Surgery, University of Miami, Miami, FL

**4:30 PM (443) VEGFR-3 Mediates Lymphangiogenesis and Alloimmune Responses in Cardiac Allografts;** H. Sandelin,<sup>1</sup> A.I. Nykanen,<sup>1</sup> M.A.I. Keranen,<sup>1</sup> R. Tuuminen,<sup>1</sup> P.K. Koskinen,<sup>1</sup> K. Alitalo,<sup>2</sup> K.B. Lemstrom,<sup>1</sup> <sup>1</sup>Transplantation Laboratory, University of Helsinki, Helsinki, Finland; <sup>2</sup>Molecular Cancer Laboratory, University of Helsinki, Helsinki, Finland

**4:45 PM (444) Persistent PDGF-A, -C, -D Transgene Expression Enhances Cardiac Allograft Vasculopathy and Fibrosis, but PDGF-B Induces Myocardial Angiogenesis;** R. Tuuminen,<sup>1</sup> M.A.I. Keranen,<sup>1</sup> A.I. Nykanen,<sup>1</sup> R. Krebs,<sup>1</sup> K. Alitalo,<sup>2</sup> P.K. Koskinen,<sup>1</sup> K.B. Lemstrom,<sup>1</sup> <sup>1</sup>Transplantation Laboratory, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; <sup>2</sup>Molecular Cancer Biology Laboratory, University of Helsinki, Helsinki, Finland

**5:00 PM (445) Preferential Expression of CD44 V1 Isoforms by Intra-graft Fibroblasts from Cardiac Allografts with Chronic Rejection;** G.D. Wu,<sup>1</sup> H. Zhu,<sup>1</sup> Y. He,<sup>1</sup> M. Barr,<sup>2</sup> A.S. Klein,<sup>1</sup> <sup>1</sup>Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; <sup>2</sup>Cardiothoracic Surgery, Keck School of Medicine, USC, Los Angeles, CA

**5:15 PM (446) Antivimentin Antibodies Mediate Acute and Chronic Damage in MHC-Matched Allografts;** B. Mahesh,<sup>1</sup> H.S. Leong,<sup>1</sup> P. Sarathchandra,<sup>1</sup> A.M. McCormack,<sup>1</sup> A.L. Holder,<sup>1</sup> J.D. Smith,<sup>1</sup> M.L. Rose,<sup>1</sup> <sup>1</sup>Transplant Immunology, Heart Science Center, Harefield Hospital, Harefield, United Kingdom

**5:30 PM (447) *The Role of Interleukin-7 in Acute Rejection Following Heart Transplantation***; J.E. Fildes,<sup>1</sup> N.U. Khan,<sup>1</sup> M. Al-Aloul,<sup>1</sup> S.G. Williams,<sup>1</sup> C.T. Leonard,<sup>1</sup> N. Yonan,<sup>1</sup> <sup>1</sup>The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom

**4:15 PM – 5:45 PM**

**CONCURRENT SESSION 39**

**Post-Transplant Infections: Bacteria, Moulds, and Parasites (Plaza Ballroom A)**

\*Chairs: Martha L. Mooney, MD and \*Kate Gould, FRCPATH

**4:15 PM (448) *Infections in Lung Allograft Recipients: Ganciclovir Era***; V.G. Valentine,<sup>1</sup> R.W. Bonvillain,<sup>2</sup> G.A. Lombard,<sup>1</sup> S.G. LaPlace,<sup>1</sup> G.S. Dhillon,<sup>3</sup> G. Wang,<sup>2</sup> <sup>1</sup>Lung Transplantation, Ochsner Medical Center, New Orleans, LA; <sup>2</sup>Medicine and Genetics, LSU Health Sciences Center, New Orleans, LA; <sup>3</sup>Medicine, Stanford University Hospital, Stanford, CA

**\*4:30 PM (449) *Aspergillus Infection in Lung Transplant Patients: Incidence and Prognosis***; M. Iversen,<sup>1</sup> C.M. Burton,<sup>1</sup> S. Vand,<sup>2</sup> L. Skovfoged,<sup>2</sup> N. Milman,<sup>1</sup> J. Carlsen,<sup>1</sup> M. Rasmussen,<sup>2</sup> <sup>1</sup>Division of Lung Transplantation, The Heart Centre, Rigshospitalet, Copenhagen, Denmark; <sup>2</sup>Department of Pharmacology and Pharmacotherapy, Danish University of Pharmaceutical Sciences, Copenhagen, Denmark

**\*4:45 PM (450) *Invasive Aspergillosis in Lung Transplant Recipients: The Impact of Pretransplant Colonization***; F. Mattner,<sup>1</sup> S. Fischer,<sup>2</sup> H. Weissbrodt,<sup>1</sup> B. Haubitz,<sup>3</sup> J. Gottlieb,<sup>4</sup> I.F. Chaberny,<sup>1</sup> A. Simon,<sup>5</sup> P. Gastmeier,<sup>1</sup> M. Strueber,<sup>5</sup> <sup>1</sup>Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany; <sup>2</sup>Division of Thoracic Surgery, University Toronto, Toronto, Canada; <sup>3</sup>Neuroradiology, Hannover Medical School, Hannover, Germany; <sup>4</sup>Respiratory Medicine, Hannover Medical School, Hannover, Germany; <sup>5</sup>Division of Thoracic Surgery, Hannover Medical School, Hannover, Germany

**5:00 PM (451) *Epidemiology of Late Bacterial Pneumonia in a Prospective Cohort of Lung Transplant Recipients (LTRs)***; K. Raza,<sup>1</sup> S. Studer,<sup>2</sup> D.L. Paterson,<sup>1</sup> M. Crespo,<sup>2</sup> D.L. Pakstis,<sup>1</sup> M.E. Carey,<sup>1</sup> A. Zeevi,<sup>3</sup> J. Pilewski,<sup>2</sup> K.R. McCurry,<sup>3</sup> S. Husain,<sup>1</sup> <sup>1</sup>Div of Infect Dis, Univ of Pitt, Pittsburgh, PA; <sup>2</sup>Div of Pulm & Crit Care, Univ of Pitt, Pittsburgh, PA; <sup>3</sup>Dept of Surgery, Univ of Pitt, Pittsburgh, PA

**5:15 PM (452) *Effectiveness and Safety of Epstein-Barr Virus DNA-Load Guided Reduction of Immunosuppression Late after Lung Transplantation***; N.A. Bakker,<sup>1</sup> E.A.M. Verschuuren,<sup>2</sup> M.E. Erasmus,<sup>3</sup> B.G. Hepkema,<sup>4</sup> N.J.G.M. Veeger,<sup>5</sup> C.G.M. Kallenberg,<sup>6</sup> W. van der Bij,<sup>2</sup> <sup>1</sup>Hematology, University Medical Center, Groningen, Netherlands; <sup>2</sup>Pulmonary Diseases, University Medical Center, Groningen, Netherlands; <sup>3</sup>Cardiothoracic Surgery, University Medical Center, Groningen, Netherlands; <sup>4</sup>Pathology and Laboratory Medicine, University Medical Center, Groningen, Netherlands; <sup>5</sup>Clinical Epidemiology, University Medical Center, Groningen, Netherlands; <sup>6</sup>Clinical Immunology, University Medical Center, Groningen, Netherlands

**5:30 PM (453) *Usefulness of Polymerase Chain Reaction Strategies for Early Diagnosis of Chagas Disease Reactivation and Treatment Follow-Up in Heart Transplantation***; M. Diez,<sup>1</sup> L. Favaloro,<sup>1</sup> J.M. Burgos,<sup>2</sup> M. Peradejordi Lastras,<sup>1</sup> A. Bertolotti,<sup>1</sup> C. Vigliano,<sup>1</sup> A.G. Schijman,<sup>1</sup> R.R. Favaloro,<sup>1</sup> <sup>1</sup>Intrathoracic Transplant Unit, Fundacion Favaloro, Buenos Aires, Argentina; <sup>2</sup>Laboratorio de Biologia Molecular de la Enfermedad de Chagas, INGEBI-CONICET, Buenos Aires, Argentina

**5:45 PM – 6:45 PM**

**GENERAL POSTER SESSION 3/Wine and Cheese Reception (Continental Ballroom)**

**(454) *First Human Application of Right Ventricular Endocardial Thermography in Transplanted and Coronary Artery Disease Patients***; A. Manginas, E. Andreanidis, E. Leontiadis, P. Sfirakis, D.V. Kokkinos, P.A. Alivizatos, <sup>1</sup>1st Cardiology, Onassis Cardiac Surgery Center, Athens, Greece; <sup>2</sup>1st Cardiology, Onassis Cardiac Surgery Center, Athens, Greece; <sup>3</sup>1st Cardiology, Onassis Cardiac Surgery Center, Athens, Greece; <sup>4</sup>1st Cardiothoracic Surgery & Transplantation, Onassis Cardiac Surgery Center, Athens, Greece; <sup>5</sup>1st Cardiology, Onassis Cardiac Surgery Center, Athens, Greece; <sup>6</sup>1st Cardiothoracic Surgery & Transplantation, Onassis Cardiac Surgery Center, Athens, Greece

**(455) *Mid-Term Results of Cardiac Transplantation in Adults with Congenital Heart Disease***; J.K. Bhama,<sup>1</sup> D.Q. Nguyen,<sup>1</sup> C. Benjamin,<sup>1</sup> R.L. Kormos,<sup>1</sup> K.R. McCurry,<sup>1</sup> S.A. Webber,<sup>2</sup> C.A. Bermudez,<sup>1</sup> <sup>1</sup>Heart, Lung & Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>2</sup>Pediatric Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA

**(456) *Hyperhomocysteinemia Accelerates Cardiac Allograft Vasculopathy***; S. Nunoda,<sup>1</sup> O. Matsuoka,<sup>1</sup> K. Okajima,<sup>1</sup> K. Shitakura,<sup>1</sup> S. Oinuma,<sup>1</sup> Y. Kubo,<sup>1</sup> K. Otsuka,<sup>1</sup> <sup>1</sup>Department of Medicine, Tokyo Women's Medical University Medical Center East, Tokyo, Japan

**(457) *Absence of Sinus Rhythm or Its Loss as Risk Factors for Cardiac Graft Failure after Heart Transplantation***; R. Baretti,<sup>1</sup> B. Debus,<sup>1</sup> D. Kemper,<sup>1</sup> C. Knosalla,<sup>1</sup> S. Buz,<sup>1</sup> H. Lehmkuhl,<sup>1</sup> R. Hetzer,<sup>1</sup> <sup>1</sup>Deutsches Herzzentrum Berlin, Berlin, Germany

**(458) *A Single-Centre Retrospective Study on Human Leukocyte Antigen-G Expression in Heart Transplant Recipients Prior To, During, and Following Episodes of Rejection***; R. Sheshgiri,<sup>1</sup> D. Ramzy,<sup>1</sup> J. Jackman,<sup>1</sup> E.D. Carosella,<sup>2</sup> N. Rouas-Freiss,<sup>2</sup> J. Butany,<sup>3</sup> H. Ross,<sup>4</sup> V. Rao,<sup>1</sup> D. Delgado,<sup>4</sup> <sup>1</sup>Division of Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada; <sup>2</sup>Research Institute for Hemato-Immunology, Saint-Louis Hospital, Paris, France; <sup>3</sup>Department of Pathology, Toronto General Hospital, Toronto, ON, Canada; <sup>4</sup>Divisions of Cardiology and Transplantation, Toronto General Hospital, Toronto, ON, Canada

**(459) *Reduced Systolic Strain and Systolic Strain Rate Could Detect Sub-Clinical Acute Rejection in Heart Transplant Recipients***; C. Kamiya,<sup>1</sup> T.S. Kato,<sup>1</sup> N. Oda,<sup>1</sup> A. Mano,<sup>1</sup> K. Hashimura,<sup>1</sup> S. Hashimoto,<sup>1</sup> K. Komamura,<sup>1</sup> M. Kitakaze,<sup>1</sup> S. Kitamura,<sup>2</sup> T. Nakatani,<sup>3</sup> <sup>1</sup>Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan; <sup>2</sup>Department of Cardiovascular Surgery, National Cardiovascular Center, Suita, Osaka, Japan; <sup>3</sup>Department of Organ Transplantation, National Cardiovascular Center, Suita, Osaka, Japan

**(460)** *Ezetimibe Effectively Lowers LDL Cholesterol in Cardiac Allograft Recipients on Stable Statin Therapy*; M.H. Konstandin,<sup>1</sup> S. Celik,<sup>1</sup> A. Dösch,<sup>1</sup> A. Koch,<sup>2</sup> F.-U. Sack,<sup>2</sup> H.A. Katus,<sup>1</sup> T.J. Dengler,<sup>1</sup> <sup>1</sup>Cardiology, Universitätsklinik Heidelberg, Heidelberg, Germany; <sup>2</sup>Cardiac Surgery, Universitätsklinik Heidelberg, Heidelberg, Germany

\* **(461)** *Recurrent Mild Rejection in the First Year after Heart Transplantation Does Not Affect Outcomes: Validation of the Revised ISHLT Grading System*; J.K. Patel,<sup>1</sup> J.C. Kawano,<sup>1</sup> G.W. Wu,<sup>1</sup> L. Chinakarn,<sup>1</sup> M.A. Kawano,<sup>1</sup> B.I. Kobashigawa,<sup>1</sup> M.M. Kittleson,<sup>1</sup> A.L. Gordon,<sup>1</sup> S.M. Kagimoto,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA

**(462)** *Evolution of Renal Function and Prognostic Implications of Impaired Renal Function One Year after Heart Transplantation*; S. Arora,<sup>1</sup> A.K. Andreassen,<sup>1</sup> S. Simonsen,<sup>1</sup> A. Relbo,<sup>1</sup> O. Geiran,<sup>2,3</sup> L. Gullestad,<sup>1</sup> <sup>1</sup>Department of Cardiology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway; <sup>2</sup>Department of Cardiothoracic Surgery, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway; <sup>3</sup>Faculty Division Rikshospitalet, University of Oslo, Oslo, Norway

**(463)** *Impact of Donor Left Ventricular Hypertrophy on Survival after Cardiac Transplantation*; K. Sharma,<sup>1</sup> M.P. Pelletier,<sup>1</sup> R. Menza,<sup>2</sup> J.G. Zaroff,<sup>3</sup> S.C. Malaisrie,<sup>1</sup> T.A. Timek,<sup>1</sup> E.L. Houston,<sup>2</sup> E.P. Oyer,<sup>1</sup> B.A. Reitz,<sup>1</sup> R.C. Robbins,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic Surgery, Stanford University, Stanford, CA; <sup>2</sup>California Transplant Donor Network, Oakland, CA; <sup>3</sup>Department of Medicine, University of California - San Francisco (UCSF), San Francisco, CA

**(464)** *Donor Age Influences Orthotopic Heart Transplant (OHTX) Outcome Independent of Traditional Risk Factors*; D. Nguyen,<sup>1</sup> J. Bhamra,<sup>1</sup> C. Bermudez,<sup>1</sup> Y. Toyoda,<sup>1</sup> Y. Thacker,<sup>1</sup> J. Teuteberg,<sup>1</sup> K. McCurry,<sup>1</sup> R. Kormos,<sup>1</sup> <sup>1</sup>Heart Lung and Esophageal Institute, University of Pittsburgh, Pittsburgh, PA

\* **(465)** *Influence of CNI-Free Versus CNI-Based Immunosuppression on Rejection and Infection after Heart Transplantation*; A.S. Leet,<sup>1</sup> R. Martin,<sup>1</sup> M. Richardson,<sup>1</sup> P. Bergin,<sup>1</sup> D. Esmore,<sup>1</sup> D.M. Kaye,<sup>1</sup> <sup>1</sup>Heart Transplant Unit, The Alfred Hospital, Melbourne, Australia

\* **(466)** *First-Year Mycophenolate Mofetil Dose Reductions: Do They Portend Poor Outcome?*; J.A. Kobashigawa,<sup>1</sup> M.A. Kawano,<sup>1</sup> G.W. Wu,<sup>1</sup> J.C. Kawano,<sup>1</sup> M. Yajnik,<sup>1</sup> M.M. Kittleson,<sup>1</sup> J.K. Patel,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA

**(467)** *Sirolimus Dose Adjustment in Heart and Lung Transplant Recipients on Voriconazole Therapy*; H. Windham,<sup>1</sup> J.Y. Lee,<sup>1</sup> S.R. Hays,<sup>2</sup> L.E. Leard,<sup>2</sup> J.A. Golden,<sup>2</sup> T. De Marco,<sup>3</sup> C. Hoopes,<sup>4</sup> R.F. Boettger,<sup>1</sup> <sup>1</sup>Department of Clinical Pharmacy, University of California, San Francisco Medical Center, San Francisco, CA; <sup>2</sup>Department of Medicine, University of California, San Francisco Medical Center, San Francisco, CA; <sup>3</sup>Department of Cardiology, University of California, San Francisco Medical Center, San Francisco, CA; <sup>4</sup>Department of Surgery, University of California, San Francisco Medical Center, San Francisco, CA

\* **(468)** *Discontinued Use of Mycophenolate Mofetil and Graft Loss in Heart Transplant Recipients*; A.P. Legorreta,<sup>1</sup> A.S. Gilmore,<sup>2</sup> J. Marehbian,<sup>2</sup> G. Machnicki,<sup>3</sup> <sup>1</sup>UCLA School of Public Health, Los Angeles, CA; <sup>2</sup>Health Benchmarks, Inc., Woodland Hills, CA; <sup>3</sup>Novartis Pharma AG, Basel, Switzerland

\* **(469)** *Prospective, Randomized, Multicenter Trial Comparing Conversion to a CNI-Free Regimen (MMF & Sirolimus) vs. a CNI-Reduced, MMF-Based Immunosuppression to Improve Renal Function in Late Cardiac Transplant Recipients*; J. Groetzner,<sup>1</sup> U. Schulz,<sup>2</sup> I. Kaczmarek,<sup>1</sup> E. Stegemann,<sup>3</sup> K. Kaiser,<sup>4</sup> M. Voss,<sup>5</sup> T. Wittwer,<sup>6</sup> T.H. Wahlers,<sup>7</sup> J. Schirmer,<sup>8</sup> H.Y. Sohn,<sup>1</sup> H. Welp,<sup>9</sup> C. Schmid,<sup>9</sup> B. Meiser,<sup>1</sup> B. Reichart,<sup>1</sup> the VENINAHTx-Study-Group,<sup>10</sup> <sup>1</sup>Department of Cardiac Surgery, Ludwig-Maximilians-University Grosshadern, Munich, Germany; <sup>2</sup>Department of Cardiac Surgery, Bad Oeynhausen Heart Center, Bad Oeynhausen, Germany; <sup>3</sup>Department of Cardiology, RWTH Aachen, Aachen, Germany; <sup>4</sup>Department of Cardiology, Johannes Gutenberg University Mainz, Mainz, Germany; <sup>5</sup>Department of Cardiothoracic & Vascular Surgery, University Hospital Goettingen, Goettingen, Germany; <sup>6</sup>Department of Cardio-Thoracic Surgery, Cologne University Hospital, Cologne, Germany; <sup>7</sup>Department of Cardio-Thoracic Surgery, Friedrich Schiller University, Jena, Germany; <sup>8</sup>Department of Cardiovascular Surgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany; <sup>9</sup>Department of Cardiothoracic & Vascular Surgery, Westfaelische Wilhelms University Hospital Muenster, Muenster, Germany

\* **(470)** *Daclizumab Induction Therapy in Clinical Lung Transplantation – A Prospective, Double-Blinded, Randomized Trial*; M. Strueber,<sup>1</sup> J. Gottlieb,<sup>2</sup> A.R. Simon,<sup>1</sup> B. Gohrbandt,<sup>1</sup> S. Fischer,<sup>1</sup> A. Goerler,<sup>1</sup> A. Haverich,<sup>1</sup> T. Welte,<sup>2</sup> <sup>1</sup>Hannover Thoracic Transplant Program, Division Thoracic and Cardiovasc. Surg, Hannover Medical School, Hannover, Germany; <sup>2</sup>Respiratory Medicine, Hannover Medical School, Hannover, Germany

**(471)** *Transition to Sirolimus from Calcineurin Inhibitor for Renal Impairment Is Not Associated with an Increase in Brochiolitis Obliterans Syndrome or Acute Rejection*; S.R. Hays,<sup>1</sup> L.E. Leard,<sup>1</sup> G. Horns,<sup>2</sup> M. Sweet,<sup>2</sup> C. Hoopes,<sup>2</sup> J.A. Golden,<sup>1</sup> <sup>1</sup>Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, CA; <sup>2</sup>Cardiothoracic Surgery, University of California, San Francisco, San Francisco, CA

**(472)** *Predictors of Mycophenolate Mofetil Adverse Effects in Thoracic Transplant Recipients*; L.S.L. Ting,<sup>1</sup> N. Partovi,<sup>1,4,5</sup> M. Fritz,<sup>1</sup> K.W. Riggs,<sup>1</sup> R.D. Levy,<sup>2,4,5</sup> C. Imai,<sup>3,5</sup> A.P. Ignaszewski,<sup>2,3,5</sup> M.H.H. Ensom,<sup>1</sup> <sup>1</sup>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada; <sup>2</sup>Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; <sup>3</sup>Heart Transplant Program, St. Paul's Hospital, Vancouver, BC, Canada; <sup>4</sup>Lung Transplant Program, Vancouver General Hospital, Vancouver, BC, Canada; <sup>5</sup>Lung and Heart Transplant Programs, British Columbia Transplant Society, Vancouver, BC, Canada

**(473)** *Superiority of Antithymocyte-Globulin Induction Therapy in Lung Transplant Recipients with Cystic Fibrosis*; P. Jaksch,<sup>1</sup> B. Zweytick,<sup>1</sup> G. Lang,<sup>1</sup> C. Aigner,<sup>1</sup> G. Dekan,<sup>2</sup> W. Wisser,<sup>1</sup> W. Klepetko,<sup>1</sup> <sup>1</sup>Department of Cardio-Thoracic Surgery, Medical University of Vienna, Vienna, Austria; <sup>2</sup>Department of Clinical Pathology, Medical University of Vienna, Vienna, Austria

\* (474) *Assessing Safety and Efficacy of Neoral®/Everolimus Maintenance Therapy in Cardiac Transplant Recipients: 12 Month Data*; H. Ross,<sup>1</sup> J. Burton,<sup>2</sup> P. Pflugfelder,<sup>3</sup> M. Cantarovich,<sup>4</sup> A. Ignaszewski,<sup>5</sup> J. Howlett,<sup>6</sup> M. White,<sup>7</sup> H. Haddad,<sup>8</sup> R. Dorent,<sup>9</sup> C. Sips,<sup>10</sup> M. Vaillancourt,<sup>11</sup> <sup>1</sup>Toronto General Hospital, Toronto, Canada; <sup>2</sup>Walter Mackenzie Center, Edmonton, Canada; <sup>3</sup>London HSC - University Campus Site, London, Canada; <sup>4</sup>Mc Gill University Health Centre, Montreal, Canada; <sup>5</sup>St. Paul's Hospital, Vancouver, Canada; <sup>6</sup>Queen Elizabeth II Health Sciences Centre - New Halifax Infirmary, Halifax, Canada; <sup>7</sup>Institut de Cardiologie de Montreal, Montreal, Canada; <sup>8</sup>University of Ottawa Heart Institute, Ottawa, Canada; <sup>9</sup>Service de Médecine Interne, Centre Hospitalier Universitaire Pitie-Salpetriere, Paris, France; <sup>10</sup>Novartis Pharma AG, Basel, Switzerland; <sup>11</sup>Novartis Pharma, Dorval, Canada

\* (475) *Sirolimus vs Azathiopine from the Time of Heart Transplantation: 65 Month Followup for Vascular (MACE) and Malignant Events*; A. Keogh,<sup>1</sup> M. Richardson,<sup>2</sup> P. Ruygrok,<sup>3</sup> P. Macdonald,<sup>1</sup> L. Schneider,<sup>1</sup> G. O'Driscoll,<sup>4</sup> A. Galbraith,<sup>5</sup> <sup>1</sup>St Vincent's Hospital, Sydney, Australia; <sup>2</sup>Alfred Hospital, Melbourne, Australia; <sup>3</sup>Auckland City Hospital, Auckland, New Zealand; <sup>4</sup>Royal Perth Hospital, Perth, Australia; <sup>5</sup>Prince Charles Hospital, Brisbane, Australia

(476) *Steroid-Free Maintenance Immunosuppression with Campath-1H Induction in Cardiac Transplantation*; S. Aggarwal,<sup>1</sup> S. Pagni,<sup>1</sup> D. Pidwell,<sup>2</sup> R.D. Dowling,<sup>1</sup> <sup>1</sup>Surgery, University of Louisville, Louisville, KY; <sup>2</sup>Immunology, University of Louisville, Louisville, KY

\* (477) *The Daily Steroid Dose Correlates More Strongly Than the Time Since Heart Transplant with a Gene Expression Profile Assessment of Immune Activation*; D.F. Pauly,<sup>1</sup> J.M. Aranda,<sup>1</sup> R.S. Schofield,<sup>1</sup> S.J. Normann,<sup>2</sup> J.A. Hill,<sup>1</sup> <sup>1</sup>Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, FL; <sup>2</sup>Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL

\* (478) *Pharmacokinetics of Tacrolimus and Everolimus When Used Concomitantly in De Novo Heart Transplantation Patients*; C. van Kesteren,<sup>1</sup> N. de Jonge,<sup>2</sup> J.H. Kirkels,<sup>2</sup> C. Klöpping,<sup>2</sup> F.F.T. Ververs,<sup>1</sup> <sup>1</sup>Department of Clinical Pharmacy, University Medical Centre, Utrecht, Netherlands; <sup>2</sup>Heart Lung Centre, University Medical Centre, Utrecht, Netherlands

(479) *Induction Therapy with Thymoglobulin after Heart Transplantation: Impact of Therapy Duration on Lymphocyte Depletion and Recovery, Rejection and CMV Infection Rates*; L.S.C. Czer,<sup>1</sup> S. Goland,<sup>1</sup> R.M. Kass,<sup>1</sup> M. De Robertis,<sup>1</sup> J. Mirocha,<sup>1</sup> K. Zivari,<sup>1</sup> J. Lee,<sup>1</sup> B. Coleman,<sup>1</sup> A. Trento,<sup>1</sup> <sup>1</sup>Cardiology, Cedars Sinai Medical Center, Los Angeles, CA

(480) *High Rates of Acute Rejection with a CNI Sparing Regimen of Everolimus and Mycophenolate in Long Term Lung Transplant Recipients*; P.M. Hopkins,<sup>1</sup> F. Kermeen,<sup>1</sup> J. Dunning,<sup>1</sup> K. McNeil,<sup>1</sup> <sup>1</sup>Queensland Heart-Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Queensland, Australia

\* (481) *Is IL-17 Attenuated by Everolimus (ERL)?: A Longitudinal Airway Biopsy (EBB) Study Post Lung Transplant (LTx)*; G.I. Snell,<sup>1</sup> B.J. Levvey,<sup>1</sup> L. Zheng,<sup>2</sup> B. Orsida,<sup>2</sup> M. Bailey,<sup>3</sup> T. Kotsimbos,<sup>1</sup> T. Williams,<sup>1</sup> <sup>1</sup>Lung Transplant Service, The Alfred Hospital, Melbourne, Victoria, Australia; <sup>2</sup>Department of Medicine, Monash University, Melbourne, Victoria, Australia; <sup>3</sup>Epidemiology & Preventative Medicine, Monash University, Melbourne, Victoria, Australia

(482) *Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Development of Cardiac Allograft Vasculopathy and Cardiac Adverse Events in Heart Transplant Patients*; E.R. Raichlin,<sup>1</sup> J.H. Bae,<sup>1</sup> J.P. McConnell,<sup>2</sup> W.R. Kremers,<sup>3</sup> R.P. Frantz,<sup>1</sup> A. Lerman,<sup>1</sup> <sup>1</sup>Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN; <sup>2</sup>Laboratory Medicine, Mayo Clinic College of Medicine, Rochester, MN; <sup>3</sup>Biostatistics, Mayo Clinic College of Medicine, Rochester, MN

(483) *Calcineurin-Inhibitor Associated Nephrotoxicity after Orthotopic Heart Transplantation Associated with Single Nucleotide Polymorphisms (SNP)*; H. Milting,<sup>1</sup> A. Wirth,<sup>1</sup> B. Klauke,<sup>1</sup> G. Tenderich,<sup>1</sup> B. Bohms,<sup>1</sup> A. Zittermann,<sup>1</sup> R. Koerfer,<sup>1</sup> <sup>1</sup>Erich und Hanna Klessmann-Institut fuer Kardiovaskulaere Forschung und Entwicklung, Herz- und Diabeteszentrum NRW, Bad Oeynhaus, NRW, Germany

(484) *Quinolone-Related Achilles Tendinopathy in Heart Transplant Recipients: Incidence and Risk Factors*; E. Barge-Caballero,<sup>1</sup> M.G. Crespo-Leiro,<sup>1</sup> M.J. Paniagua-Martin,<sup>1</sup> J. Muñoz,<sup>1</sup> A. Bouzas-Mosquera,<sup>1</sup> R. Marzoa-Rivas,<sup>1</sup> P. Piñon-Esteban,<sup>1</sup> P. Pazos,<sup>1</sup> A. Juffé-Stein,<sup>1</sup> A. Castro-Beiras,<sup>1</sup> <sup>1</sup>Heart Transplantation Unit, Hospital Juan Canalejo, La Coruña, Spain

(485) *Influence of Levosimendan, a Ca<sup>2+</sup>-Sensitizer, on Acute Graft Failure after Heart Transplantation: A Pilot Study*; A. Beiras-Fernandez,<sup>1</sup> I. Kaczmarek,<sup>1</sup> F. Weis,<sup>2</sup> B.M. Meiser,<sup>1</sup> M. Weis,<sup>2</sup> B. Reichart,<sup>1</sup> <sup>1</sup>Department of Cardiac Surgery, University Hospital Grosshadern; LM-University, Munich, Germany; <sup>2</sup>Department of Anesthesiology, University Hospital Grosshadern; LM-University, Munich, Germany

(486) *Does the Presence of Adiposity or the Metabolic Syndrome in Transplant Donor or Recipient Increase the Progression of Cardiac Allograft Vasculopathy?*; A.M. Wilson,<sup>1</sup> S.A. Virani,<sup>1</sup> H.A. Valentine,<sup>1</sup> M.X. Pham,<sup>1</sup> W.F. Fearon,<sup>1</sup> J.P. Cooke,<sup>1</sup> <sup>1</sup>Cardiovascular Medicine, Stanford University, Stanford, CA

(487) *Outcomes of Percutaneous Coronary Interventions and Surgical Revascularization in the Treatment of Cardiac Allograft Vasculopathy*; D.Q. Nguyen,<sup>1</sup> J.K. Bhama,<sup>1</sup> K. Sun,<sup>2</sup> Y. Toyoda,<sup>1</sup> S. Zomak,<sup>1</sup> C. Yost,<sup>1</sup> K.M. McCurry,<sup>1</sup> R.L. Kormos,<sup>1</sup> C. Bermudez,<sup>1</sup> <sup>1</sup>Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>2</sup>Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA

(488) *Increased Infection Risk of Non-Cardiac Surgeries after Heart Transplantation*; O. Aye,<sup>1</sup> J.K. Patel,<sup>1</sup> A. Seid,<sup>1</sup> L. Chinakarn,<sup>1</sup> M.M. Kittleson,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA

(489) *Evolution of Endothelial-Dependent Forearm Vasodilatation after Heart Transplantation and Its Relationship with Early Graft Vasculopathy*; E. Roig,<sup>1</sup> A. Cuppoletti,<sup>1</sup> R. Kiamco,<sup>1</sup> M. Sitges,<sup>1</sup> M. Masotti,<sup>1</sup> C. Pare,<sup>1</sup> I. Vallejos,<sup>1</sup> F. Perez Villa,<sup>1</sup> <sup>1</sup>Cardiology - Thorax Institute, Hospital Clinic, Barcelona, Spain

\* (490) *Pharmacologic Myocardial Perfusion Stress Testing to Detect Significant Cardiac Allograft Vasculopathy – Is It Worthwhile?*; J.K. Patel,<sup>1</sup> M.A. Kawano,<sup>1</sup> M.M. Kittleson,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA

(491) *The Use of ECMO/Intra-Aortic Balloon Pump to Support Hemodynamics in Patients with Cardiogenic Shock Due to Severe Rejection*; S.J. Miller,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> M.M. Kittleson,<sup>1</sup> J.K. Patel,<sup>1</sup> M.A. Kawano,<sup>1</sup> A. Ardehali,<sup>2</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA; <sup>2</sup>Cardiothoracic Surgery, University of California at Los Angeles, Los Angeles, CA

(492) *Short and Long-Term Survival after Surgery for Lung Cancer in Heart Transplant Recipients*; G. Bruschi,<sup>1</sup> T. Colombo,<sup>1</sup> S. Conforti,<sup>2</sup> A. Rinaldo,<sup>2</sup> S. Fieschi,<sup>2</sup> G. Pedrazzini,<sup>1</sup> S. Campisi,<sup>1</sup> F. Turazza,<sup>1</sup> F. Oliva,<sup>1</sup> M. Frigerio,<sup>1</sup> M. Ravini,<sup>2</sup> E. Vitali,<sup>1</sup> <sup>1</sup>Cardiology & Cardiac Surgery “A. De Gasperis”, Niguarda Ca’ Granda Hospital, Milan, Italy; <sup>2</sup>Division of Thoracic Surgery, Niguarda Ca’ Granda Hospital, Milan, Italy

(493) *Re-Transplantation for Heart Failure with Preserved Systolic Function*; B.K. Itagaki,<sup>1</sup> J.K. Kobashigawa,<sup>1</sup> G.W. Wu,<sup>1</sup> W. Brubaker,<sup>1</sup> M.A. Kawano,<sup>1</sup> L. Gokanapudy,<sup>1</sup> M.M. Kittleson,<sup>1</sup> J.K. Patel,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA

(494) *What Is the Prognostic Value of a Normal Adenosine Myocardial Perfusion Imaging in Cardiac Transplant Patients?*; M. Arida,<sup>1</sup> E. Garcia-Sayan,<sup>1</sup> M. Al-Mallah,<sup>2</sup> C. Assal,<sup>1</sup> G. Tapia Zegarra,<sup>1</sup> B. Czerna,<sup>1</sup> K. Ananthsubramaniam,<sup>1</sup> <sup>1</sup>Cardiology, Henry Ford Hospital, Detroit, MI; <sup>2</sup>Cardiology, Brigham and Women’s Hospital, Boston, MA

(495) *Cardiac Allograft Vasculopathy Is Associated with Endothelial Dysfunction but Not Endothelial Progenitor Cell Numbers*; P.P. Chang,<sup>1</sup> R.V. Kelly,<sup>1</sup> M. Caughey,<sup>1</sup> K.R. Smith,<sup>1</sup> S.S. Smyth,<sup>2</sup> M.G. Cohen,<sup>1</sup> G.A. Stouffer,<sup>1</sup> W.A. Tan,<sup>3</sup> D. Tate,<sup>1</sup> S.C. Smith, Jr.,<sup>1</sup> S.L. Kowalczyk,<sup>1</sup> C. Patterson,<sup>1</sup> A.L. Hinderliter,<sup>1</sup> <sup>1</sup>Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC; <sup>2</sup>Medicine, University of Kentucky, Lexington, KY; <sup>3</sup>Medicine, East Carolina University, Greenville, NC

(496) *Negative Impact of Nesiritide in Combination with Inotropic Therapy among Patients Admitted with Acute Heart Failure*; D. Putney, L. Matura, K. Daniels, V. Thohan, Pharmacy, Methodist Hospital, Houston, TX; Nursing Education, Methodist Hospital, Houston, TX; Cardiology, Wake Forest University, Winston Salem, NC; Cardiology, Wake Forest University, Winston Salem, NC

(497) *2D Strain Echocardiography a Novel Non-Invasive Tool for Pre-Transplant Evaluation of Patients with Dilated Cardiomyopathy*; M. Dandel,<sup>1</sup> N. Suramelashvili,<sup>1</sup> H.B. Lehmkuhl,<sup>1</sup> C. Knosalla,<sup>1</sup> O. Grauhan,<sup>1</sup> R. Hetzer,<sup>1</sup> <sup>1</sup>Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

\* (498) *The Chronicle<sup>®</sup> Implantable Hemodynamic Monitor in Patients on the Heart Transplant Waiting List: One Year Results*; M. Schmoeckel,<sup>1</sup> P. Lamm,<sup>1</sup> M. Wolf,<sup>1</sup> I. Kaczmarek,<sup>1</sup> P. Reiters,<sup>2</sup> M.R. Hill,<sup>2</sup> B. Reichart,<sup>1</sup> <sup>1</sup>Department of Cardiac Surgery, Ludwig-Maximilians-University, Munich, Bavaria, Germany; <sup>2</sup>Bakken Research Centre, Medtronic Inc., Maastricht, Netherlands

(499) *Is Screening Computed Tomography of the Chest, Abdomen, and Pelvis in Potential Heart Transplant Recipients Necessary?*; M. Montpetit,<sup>1</sup> S. Pauwaa,<sup>1</sup> G. Macaluso,<sup>1</sup> B. Pavlovic-Surjanec,<sup>1</sup> J. Sinacore,<sup>1</sup> A. Heroux,<sup>1</sup> <sup>1</sup>Heart Transplant/Heart Failure, Loyola University Medical Center, Maywood, IL

(500) *Serial Changes in BNP Are Not Associated with Changes in Submaximal or Maximal Exercise or Quality of Life*; A.H. Wu,<sup>1</sup> J.C. Matthews,<sup>1</sup> D.B. Dyke,<sup>1</sup> S.M. Zick,<sup>2</sup> K.D. Aaronson,<sup>1</sup> <sup>1</sup>Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI; <sup>2</sup>Department of Family Medicine, University of Michigan, Ann Arbor, MI

\* (501) *Weight of Age in the Selection of Candidates for Heart Transplantation*; L. Potena, F. Grigioni, I.G. Bianchi, M. Masetti, F. Fabbri, G. Magnani, F. Coccolo, F. Fallani, A. Russo, C. Magelli, G. Arpesella, A. Branzi, Cardiovascular Diseases, University of Bologna, Bologna, Italy

(502) *Rapid Progression of Left Ventricular Wall Thickness Predicts Mortality in Cardiac Light-Chain Amyloidosis*; A.V. Kristen,<sup>1</sup> J.B. Perz,<sup>2</sup> S.O. Schonland,<sup>2</sup> F.U. Sack,<sup>3</sup> H.A. Katus,<sup>1</sup> T.J. Dengler,<sup>1</sup> <sup>1</sup>Department of Cardiology, Medical University of Heidelberg, Heidelberg, Germany; <sup>2</sup>Department of Haematology, Medical University of Heidelberg, Heidelberg, Germany; <sup>3</sup>Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany

(503) *Mechanical Dyssynchrony in Pediatric Cardiomyopathy*; M.K. Friedberg,<sup>1</sup> N.H. Silverman,<sup>1</sup> A.M. Dubin,<sup>1</sup> D.N. Rosenthal,<sup>1</sup> <sup>1</sup>Division of Pediatric Cardiology, Stanford University, Palo Alto, CA

(504) *Left Ventricular Systolic Asynchrony in Pediatric and Adolescent Patients with Congestive Heart Failure*; G. Srinath,<sup>1</sup> A. Ali,<sup>2</sup> G. Rosenthal,<sup>1</sup> R. Grimm,<sup>2</sup> R. Sterba,<sup>1</sup> E. Saarel,<sup>4</sup> A. Younoszai,<sup>3</sup> G. Boyle,<sup>1</sup> <sup>1</sup>Pediatric Cardiology, The Cleveland Clinic Foundation, Cleveland, OH; <sup>2</sup>Adult Cardiology, The Cleveland Clinic Foundation, Cleveland, OH; <sup>3</sup>Pediatric Cardiology, Children’s Hospital, Denver, CO; <sup>4</sup>Pediatric Cardiology, Primary Childrens Medical Center, Salt Lake City, UT

(505) *Perceptions of Transitional Care Needs and Experiences in Paediatric Heart Transplantation: An Exploratory Study*; S.J. Anthony,<sup>1</sup> K.A. Martin,<sup>1</sup> A. Drabble,<sup>1</sup> M. Seifert-Hansen,<sup>1</sup> A.I. Dipchand,<sup>2</sup> M. Kaufman,<sup>1</sup> <sup>1</sup>Paediatric Academic Multi-Organ Transplant Program, The Hospital for Sick Children, Toronto, ON, Canada; <sup>2</sup>Cardiology, The Hospital for Sick Children, Toronto, ON, Canada

(506) *Primary Graft Dysfunction Does Not Increase the Risk of Acute Rejection in Pediatric Lung Transplant Recipients*; M.G. Schecter,<sup>1</sup> J.M. Robertson,<sup>1</sup> M.L. Doan,<sup>1</sup> E.D. McKenzie,<sup>2</sup> J.S. Heinle,<sup>2</sup> G.B. Mallory,<sup>1</sup> O. Elidemir,<sup>1</sup> <sup>1</sup>Pediatric Pulmonology, Baylor College of Medicine, Houston, TX; <sup>2</sup>Congenital Heart Surgery, Baylor College of Medicine, Houston, TX

- \* **(507)** *Effect of Body Mass Index on Outcome in Pediatric Heart Transplant Patients*; J.W. Rossano,<sup>1</sup> M.A. Grenier,<sup>1</sup> W.J. Dreyer,<sup>1</sup> J.J. Kim,<sup>1</sup> J.F. Price,<sup>1</sup> J.L. Jefferies,<sup>1</sup> S.K. Clunie,<sup>1</sup> M. Mouluk,<sup>1</sup> J.A. Decker,<sup>1</sup> J.P. Breinholt,<sup>1</sup> D.L. Morales,<sup>2</sup> E.D. McKenzie,<sup>2</sup> J.A. Towbin,<sup>1</sup> S.W. Denfield,<sup>1</sup> <sup>1</sup>Cardiology, Baylor College of Medicine/Texas Children's Hospital, Houston, TX; <sup>2</sup>Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX
- (508)** *Cardiac Structure and Function in Long-Term Pediatric Heart Transplant Survivors*; A. Kulikowska,<sup>1</sup> S.E. Boslaugh,<sup>1</sup> S. Foerster,<sup>1</sup> C.H. Gumbiner,<sup>2</sup> K.E. Ward,<sup>3</sup> C. Ong Simon,<sup>4</sup> M. Kimberling,<sup>5</sup> S.K. Gandhi,<sup>6</sup> C.E. Huddleston,<sup>6</sup> C.E. Canter,<sup>1</sup> <sup>1</sup>Department of Pediatrics, St Louis Children's Hospital, St. Louis, MO; <sup>2</sup>Department of Pediatrics, Children's Hospital of Omaha, Omaha, NE; <sup>3</sup>Department of Pediatrics, The Children's Hospital at University of Oklahoma, Oklahoma City, OK; <sup>4</sup>Department of Pediatrics, Children's Mercy Hospitals and Clinics, Kansas City, MO; <sup>5</sup>Department of Pediatrics, The Children's Hospital at Saint Francis, Tulsa, OK; <sup>6</sup>Department of Surgery, St Louis children's Hospital, St. Louis, MO
- \* **(509)** *The Predictive Value of Donor Specific Antibody Responses in Pediatric Heart Recipients: A Pilot Study*; R.J. Boucek, Jr.,<sup>1</sup> D. Yung,<sup>1</sup> K. Nelson,<sup>2</sup> P. Hopkins,<sup>1</sup> L. Permut,<sup>3</sup> G. Cohen,<sup>3</sup> <sup>1</sup>Pediatrics, U of Wash/Seattle Children's Hospital, Seattle, WA; <sup>2</sup>Puget Sound Blood Center, Seattle, WA; <sup>3</sup>Surgery, U of Wash, Seattle, WA
- (510)** *Quality of Life and Psychological Functioning in Paediatric Patients at 1 Year Post Lung Transplant – A Single Centre Experience*; T. Lunnon-Wood,<sup>1</sup> B.K. Field,<sup>1</sup> J. Wray,<sup>1</sup> P. Aurora,<sup>1</sup> <sup>1</sup>Dept of Cardiothoracic Transplantation, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
- (511)** *Associations between Markers of Inflammatory Activation and Heart Failure in Children*; C. Ratnasamy,<sup>1</sup> D.D. Kinnamon,<sup>1</sup> S.E. Lipshultz,<sup>1</sup> P.G. Rusconi,<sup>1</sup> <sup>1</sup>Pediatrics, Miller School of Medicine University of Miami, Miami, FL
- \* **(512)** *Dobutamine Stress Echocardiography for the Assessment of Coronary Artery Disease in Paediatric Heart Transplant Recipients*; A.I. Dipchand,<sup>1</sup> W. Bharat,<sup>1</sup> C. Manlihot,<sup>1</sup> M. Safi,<sup>1</sup> N. Lobach,<sup>1</sup> B.W. McCrindle,<sup>1</sup> <sup>1</sup>Cardiology, Hospital for Sick Children, Toronto, ON, Canada
- (513)** *Heart Rate Recovery from Maximal Exercise in Children One-Year after Heart Transplantation – Effect of Autonomic Denervation*; T.P. Singh,<sup>1</sup> J. Rhodes,<sup>1</sup> H.J. Bastardi,<sup>1</sup> E.D. Blume,<sup>1</sup> <sup>1</sup>Cardiology, Children's Hospital, Boston, MA
- (514)** *Donor (+)/Recipient (-) EBV Mismatch Leads to a High Incidence of Post-Transplant Lymphoproliferative Disorder in Pediatric Lung Transplant Recipients*; O. Elidemir,<sup>1</sup> M.G. Schechter,<sup>1</sup> E.D. McKenzie,<sup>2</sup> J.S. Heinle,<sup>2</sup> G.B. Mallory,<sup>1</sup> <sup>1</sup>Pediatric Pulmonology, Baylor College of Medicine, Houston, TX; <sup>2</sup>Congenital Heart Surgery, Baylor College of Medicine, Houston, TX
- (515)** *Outcomes of Fetal, Neonate and Infant Candidates for Heart Transplantation*; S.M. Pollock-BarZiv,<sup>1</sup> B.W. McCrindle,<sup>1</sup> L.J. West,<sup>2</sup> M. VanderVliet,<sup>1</sup> A.I. Dipchand,<sup>1</sup> <sup>1</sup>Cardiology, Hospital for Sick Children, Toronto, ON, Canada; <sup>2</sup>Heart Transplantation Research, University of Alberta, Edmonton, AB, Canada
- (516)** *Use of Endomyocardial Biopsy for Rejection Surveillance in Pediatric Heart Transplant Patients*; D.A. Dodd,<sup>1</sup> J. Burger,<sup>1</sup> <sup>1</sup>Pediatric Cardiology, Vanderbilt University Medical Center, Nashville, TN
- (517)** *Transplantation in Children with Idiopathic Pulmonary Arterial Hypertension*; A.E. Lammers,<sup>1</sup> M. Burch,<sup>1</sup> S.G. Haworth,<sup>2</sup> M.J. Elliott,<sup>3</sup> P. Aurora,<sup>1</sup> <sup>1</sup>Paediatric Cardiothoracic Transplantation, Great Ormond Street Hospital for Children, London, United Kingdom; <sup>2</sup>UK Pulmonary Hypertension Service for Children, Great Ormond Street Hospital for Children, London, United Kingdom; <sup>3</sup>Paediatric Cardiothoracic Surgery, Great Ormond Street Hospital for Children, London, United Kingdom
- (518)** *Medium Term Renal Function of Pediatric Heart Transplant Patients on Reduced Calcineurin Inhibitor and Rapamycin*; M.S. Zahra,<sup>1</sup> S.W. Srun,<sup>2</sup> C.W. Belsha,<sup>3</sup> D.L. Marshall,<sup>2</sup> P.J. Hauptman,<sup>4</sup> K.O. Schowengerdt,<sup>2</sup> I.C. Balfour,<sup>2</sup> <sup>1</sup>Division of Critical Care, Dept of Pediatrics, University of Miami School of Medicine, Miami, FL; <sup>2</sup>Division of Cardiology, Dept of Pediatrics, St Louis University Health Sciences Center, St. Louis, MO; <sup>3</sup>Division of Nephrology, Dept of Pediatrics, St Louis University Health Sciences Center, St. Louis, MO; <sup>4</sup>Division of Cardiology, Dept Internal Medicine, St Louis University Health Sciences Center, St. Louis, MO
- (519)** *Campath-1H Therapy for Resistant Rejection in Pediatric Heart Transplant Patients*; S.D. Miyamoto,<sup>1</sup> D. Gilbert,<sup>1</sup> A. Ballard,<sup>1</sup> S. Anderson,<sup>1</sup> P.N. Le,<sup>1</sup> M.B. Mitchell,<sup>2</sup> D.N. Campbell,<sup>2</sup> B.A. Pietra,<sup>1</sup> <sup>1</sup>Pediatric Cardiology, The Children's Hospital, Denver, CO; <sup>2</sup>Pediatric Cardiovascular Surgery, The Children's Hospital, Denver, CO
- (520)** *Value of the Natriuretic Peptide proANP as a Prognostic Marker in Pediatric Heart Transplantation*; G. Heise,<sup>1</sup> H. Lehmkuhl,<sup>1</sup> B. Stiller,<sup>1</sup> J. Lemmer,<sup>1</sup> S. Schubert,<sup>1</sup> M. Redlin,<sup>1</sup> C. Knosalla,<sup>1</sup> R. Hetzer,<sup>1</sup> F. Berger,<sup>1</sup> <sup>1</sup>Deutsches Herzzentrum, Berlin, Germany
- (521)** *Pediatric Heart Transplantation in the New Millennium*; C. Ravishankar,<sup>1</sup> B.D. Hanna,<sup>1</sup> B. Kaufman,<sup>1</sup> S.M. Paridon,<sup>1</sup> N. Bitterman,<sup>1</sup> H. Melusky,<sup>1</sup> S.C. Nicolson,<sup>2</sup> P.J. Gruber,<sup>3</sup> W.J. Gaynor,<sup>3</sup> T.L. Spray,<sup>3</sup> M.K. Chrisant,<sup>1</sup> <sup>1</sup>Pediatrics, Division of Cardiology, The Children's Hospital of Philadelphia, Philadelphia, PA; <sup>2</sup>Anesthesiology, The Children's Hospital of Philadelphia, Philadelphia, PA; <sup>3</sup>Cardiothoracic Surgery, The Children's Hospital of Philadelphia, Philadelphia, PA
- (522)** *Single Institution Experience of Paediatric Heart Transplant Following Anthracycline Cardiomyopathy Including Early Use of Mechanical Support*; S. Janakiraman,<sup>1</sup> D.S. Crossland,<sup>1</sup> A. Hasan,<sup>1</sup> J.R.L. Hamilton,<sup>1</sup> G. Parry,<sup>1</sup> C.R. Kirk,<sup>1</sup> <sup>1</sup>Paediatric Cardiothoracic Unit, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
- (523)** *Erythropoietin Reverses Pulmonary Vascular Remodelling in Experimental Flow-Associated Pulmonary Hypertension*; M.E. van Albada,<sup>1</sup> R.M. Berger,<sup>1</sup> R.G. Schoemaker,<sup>2</sup> <sup>1</sup>Dept of Pediatric Cardiology, Beatrix Children's Hospital, University Medical Center Groningen, University of

Groningen, Groningen, Netherlands; <sup>2</sup>Dept of Experimental Cardiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

\* **(524)** *Serial NT-proBrain Natriuretic Peptide (NT-proBNP) Levels in Patients with Pulmonary Arterial Hypertension (PAH)*; L.S. Mackay,<sup>1</sup> R. Hughes,<sup>1</sup> R. Peaston,<sup>1</sup> G. MacGowan,<sup>1</sup> G. Parry,<sup>1</sup> A.J. Fisher,<sup>1</sup> J. Lordan,<sup>1</sup> P.A. Corris,<sup>1</sup> <sup>1</sup>Northern Pulmonary Vascular Unit, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

**(525)** *Novel Therapies for Pediatric Patients with Elevated Pulmonary Vascular Resistance Undergoing Heart Transplantation*; B. Daftari,<sup>1</sup> G.S. Perens,<sup>1</sup> N.J. Halnon,<sup>1</sup> J.C. Alejos,<sup>1</sup> <sup>1</sup>Pediatrics, UCLA Medical Center, Los Angeles, CA

**(526)** *Resting Heart Rate Predicts Mortality in Patients with Isolated Right Ventricular Failure and Pulmonary Hypertension*; A.K. Andreassen,<sup>1</sup> S. Arora,<sup>1</sup> E. Gude,<sup>1</sup> S. Simonsen,<sup>1</sup> O.R. Geiran,<sup>2</sup> L. Gullstad,<sup>1</sup> <sup>1</sup>Cardiology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway; <sup>2</sup>Thoracic Surgery, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway

**(527)** *Transplantability and Bridge to Heart Transplant Using Intra-Aortic Balloon Pumping in High-Urgency Candidates with Pulmonary Hypertension*; H. Guelmez, G. Tenderich, U. Schulz, A. Zittermann, S. Schulte-Eistrup, U. Fuchs, W. Deyerling, R. Koerfer, Department of Cardio-Thoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany; Department of Cardio-Thoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany; Department of Cardio-Thoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany; Department of Cardio-Thoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany; Department of Cardio-Thoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany; Department of Cardio-Thoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany; Department of Cardio-Thoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany; Department of Cardio-Thoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany

**(528)** *Three Different Approaches for Non-Invasive Estimation of Pulmonary Artery Mean Pressure in Patients with Pulmonary Arterial Hypertension*; N. Selimovic,<sup>1</sup> B. Rundqvist,<sup>1</sup> C.-H. Bergh,<sup>1</sup> B. Andersson,<sup>1</sup> S. Petersson,<sup>2</sup> O. Bech-Hanssen,<sup>2</sup> <sup>1</sup>Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; <sup>2</sup>Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden

#### **(529) WITHDRAWN**

\* **(530)** *Correlation of NT-proBrain Natriuretic Peptide (NT-proBNP) and Haemodynamics in Patients with Pulmonary Arterial Hypertension (PAH)*; L.S. Mackay,<sup>1</sup> R. Hughes,<sup>1</sup> R. Peaston,<sup>1</sup> G. MacGowan,<sup>1</sup> G. Parry,<sup>1</sup> A.J. Fisher,<sup>1</sup> J. Lordan,<sup>1</sup> P.A. Corris,<sup>1</sup> <sup>1</sup>Northern Pulmonary Vascular Unit, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

**(531)** *Imatinib-Mesylate in Combination with RAD Reduces Significantly Chronic Rejection (CR) after Orthotopic Lung Transplantation (LTX) in an Experimental Rat Model*; S. Hirt,<sup>1</sup> T. Puehler,<sup>1</sup> E. Lesser,<sup>1</sup> C. Hass,<sup>1</sup> M. Ernst,<sup>1</sup> B. Bewig,<sup>2</sup> U. Wottge,<sup>3</sup> J. Cremer,<sup>1</sup> <sup>1</sup>Cardiovascular Surgery, University Hospital SH Campus Kiel, Kiel, SH, Germany; <sup>2</sup>Pneumology, University Hospital SH Campus Kiel, Kiel, SH, Germany; <sup>3</sup>Immunology, University Hospital SH Campus Kiel, Kiel, SH, Germany

**(532)** *The Immunosuppressant Everolimus Significantly Prevents Atherosclerosis in LDLR<sup>-/-</sup> Mice Despite Severe Hypercholesterolemia*; M.A. Mueller,<sup>1</sup> F. Beutner,<sup>1</sup> D. Teupser,<sup>1</sup> U. Ceglarek,<sup>1</sup> F. Jeromin,<sup>1</sup> W. Wilfert,<sup>1</sup> J. Thiery,<sup>1</sup> <sup>1</sup>Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Leipzig, Germany

**(533)** *Immunosuppressive Properties of Cordyceps*; J.L. Jordan, B. Ross, G.M. Hirsch, T.D.G. Lee, Pathology, Dalhousie University, Halifax, NS, Canada; Surgery, Dalhousie University, Halifax, NS, Canada; Surgery, Dalhousie University, Halifax, NS, Canada; Microbiology & Immunology, Dalhousie University, Halifax, NS, Canada

**(534)** *Important Role of Hematopoietic Chimerism for the Induction, but Not for the Maintenance of Tolerance after Pulmonary Transplantation in Pigs*; B. Kruse,<sup>1</sup> S. Thissen,<sup>1</sup> G. Warnecke,<sup>1</sup> M. Avsar,<sup>1</sup> R. Reinhard,<sup>1</sup> A.R. Simon,<sup>1</sup> A. Haverich,<sup>1</sup> M. Strueber,<sup>1</sup> <sup>1</sup>Division of Thoracic and CV Surgery, Hannover Medical School, Hannover, Germany

**(535)** *Is the Malononitrilamide FK778 Better for Prevention of Acute or Chronic Rejection?*; T. Deuse,<sup>1</sup> S. Schrepfer,<sup>2</sup> F. Koch-Nolte,<sup>3</sup> M.P. Pelletier,<sup>2</sup> M.P. Fischbein,<sup>2</sup> R.C. Robbins,<sup>2</sup> H. Reichenspurner,<sup>1</sup> <sup>1</sup>Cardiovascular Surgery, University Heart Center gGmbH, Hamburg, Germany; <sup>2</sup>Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA; <sup>3</sup>Immunology, University Hospital Hamburg, Hamburg, Germany

**(536)** *Suppression of De Novo Synthesis of MHC Class-II by Pravastatin Prolongs Graft Survival in a Congenic Rat Model of Orthotopic Single Lung Transplantation*; Y. Li,<sup>1</sup> F. Laenger,<sup>2</sup> S. Koertner,<sup>1</sup> A. Meyer,<sup>1</sup> C. Moerike,<sup>1</sup> A. Haverich,<sup>1</sup> A.R. Simon,<sup>1</sup> <sup>1</sup>Hannover Thoracic Transplant Program (Division of Thoracic- and Cardiovascular Surgery), Hannover Medical School, Hannover, Germany; <sup>2</sup>Division of Pathology, Hannover Medical School, Hannover, Germany

**6:15 PM – 7:15 PM**

**Scientific Council Meeting on Cell Transplantation/Tissue Engineering (Union Square 15/16)**

**Scientific Council Meeting on Nursing and Social Sciences (Union Square 23/24)**

**Scientific Council Meeting on Pulmonary Transplantation (Plaza A)**

**Scientific Council Meeting on Heart Failure and Transplant Medicine (Plaza B)**

**6:45 PM – 7:15 PM**

**Joint Scientific Council Meeting: Pathology/Basic Science and Pulmonary Transplantation (Plaza A)**

**6:45 PM – 8:00 PM**

General Poster Session 3 Removal (Continental Ballroom)

Mini Oral Sessions 1-4 Poster Removal (Yosemite Ballroom)

**7:00 PM – MIDNIGHT**

Exhibit Hall Strike

**SATURDAY, APRIL 28, 2007**

**24 Hours - Noon**

Internet Café Open (Continental Ballroom Foyer)

**7:00 AM – 10:00 AM**

Exhibit Hall Strike (Continental Ballroom)

**7:00 AM – NOON**

Slide Ready Room Open (Green Room)

**7:00 AM – NOON**

Press Office Open (Executive Boardroom)

**7:30 AM – 10:00 AM**

Registration Desk Open (West Foyer)

**8:00 AM – 9:30 AM**

**CONCURRENT SESSION 40: Frontiers in MCS Therapy (Grand Ballroom B)**

**\*Chairs:** \*Steven S. L. Tsui, MD, FRCS and \*Bartley P. Griffith, MD

**8:00 AM (537) *Clinical Outcome of the European Multicenter Trial with the DuraHeart® Mag-Lev Centrifugal Left Ventricular Assist System;*** A. El-Banayosy,<sup>1</sup> R. Koerfer,<sup>1</sup> R. Hetzer,<sup>2</sup> G. Wieselthaler,<sup>3</sup> A. Pavie,<sup>4</sup> <sup>1</sup>Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany; <sup>2</sup>Thoracic and Cardiovascular Surgery, German Heart Center Berlin, Berlin, Germany; <sup>3</sup>Thoracic and Cardiovascular Surgery, University of Vienna, Vienna, Austria; <sup>4</sup>Thoracic and Cardiovascular Surgery, Pitie Salpetriere Hospital, Paris, France

**8:15 AM (538) *Bridge to Heart Transplantation with Second and Third Generation Continuous-Flow Left Ventricular Assist Devices;*** M.J. Jurmann,<sup>1</sup> Y. Weng,<sup>1</sup> T. Drews,<sup>1</sup> M. Pasic,<sup>1</sup> E. Hennig,<sup>1</sup> F. Kaufmann,<sup>1</sup> E. Potapov,<sup>1</sup> R. Hetzer,<sup>1</sup> <sup>1</sup>Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

**8:30 AM (539) *Low Thromboembolic Risk with the Heartmate II Left Ventricular Assist Device;*** R. John,<sup>1</sup> F. Kamdar,<sup>1</sup> C. Toninato,<sup>1</sup> A. Boyle,<sup>2</sup> M. Colvin-Adams,<sup>2</sup> K. Liao,<sup>1</sup> L. Miller,<sup>2</sup> L. Joyce,<sup>1</sup> <sup>1</sup>Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN; <sup>2</sup>Division of Cardiology, University of Minnesota, Minneapolis, MN

**\*8:45 AM (540) *Early Experience with Off Pump Placement of Implantable Mechanical Circulatory Support Devices (MCSD);*** B. Sun,<sup>1</sup> L. Louis,<sup>1</sup> A. Panza,<sup>1</sup> C. Sai-Sudhakar,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, The Ohio State University Medical Center, Columbus, OH

**9:00 AM *Invited Lecture: The Role of INTERMACS in Patient Selection for Longer Term Mechanical Circulatory Support,*** Lynne Warner Stevenson, MD, Brigham and Women's Hospital, Boston, MA

**9:15 AM (541) *Pneumatic Paracorporeal Ventricular Assist Device in Infants and Children: Initial Stanford Experience;*** S.C. Malaisrie,<sup>1</sup> M.P. Pelletier,<sup>1</sup> J.J. Yun,<sup>1</sup> K. Sharma,<sup>1</sup> T.A. Timek,<sup>1</sup> D.N. Rosenthal,<sup>2</sup> G.E. Wright,<sup>2</sup> R.C. Robbins,<sup>1</sup> B.A. Reitz,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA; <sup>2</sup>Division of Pediatric Cardiology, Stanford University Medical Center, Stanford, CA

**8:00 AM – 9:30 AM**

**CONCURRENT SESSION 41**

**Pre-Transplant Matters on Post-Transplant Outcomes (Grand Ballroom A)**

**\*Chairs:** \*Roberto R. Favaloro, MD and \*Angeline S. Leet, MBBS, FRACP

**\*8:00 AM (542) *Naturally Occurring Leukopenia as a Marker for Good Outcome after Cardiac Transplantation;*** M.M. Kittleson,<sup>1</sup> H. Song,<sup>1</sup> M. Yajnik,<sup>1</sup> G.W. Wu,<sup>1</sup> B.I. Kobashigawa,<sup>1</sup> J.K. Patel,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA

**8:15 AM (543) *Negative Impact of Pre Transplant Blood Transfusions on Post Heart Transplant Outcomes – Analysis of the UNOS Database;*** L.U. Nwakanma,<sup>1</sup> E.S. Weiss,<sup>1</sup> W.A. Baumgartner,<sup>1</sup> S.B. Russell,<sup>2</sup> J.V. Conte,<sup>1</sup> <sup>1</sup>Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD; <sup>2</sup>Cardiology, The Johns Hopkins Medical Institutions, Baltimore, MD

**8:30 AM (544) *Management and Outcomes of Heparin-Induced Thrombocytopenia in Ventricular Assist Device and Cardiac Transplant Patients;*** L. Wang,<sup>1</sup> J.R. Smith,<sup>2</sup> M. Cornell,<sup>1</sup> T.J. Guthrie,<sup>1</sup> M.K. Pasque,<sup>1</sup> M.S. Avidan,<sup>3</sup> C.J. de Wet,<sup>3</sup> L.L. Hill,<sup>3</sup> N. Moazami,<sup>1</sup> <sup>1</sup>Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO; <sup>2</sup>Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO; <sup>3</sup>Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO

**8:45 AM (545) *Impact of Pretransplant Statin Treatment on Sensitization and Crossmatch Results of Cardiac Allograft Recipients;*** S. Reverdin,<sup>1</sup> E. Varughese,<sup>1</sup> R. Radovancevic,<sup>1</sup> A. Hoover,<sup>2</sup> T. Tu,<sup>2</sup> K. Hosek,<sup>2</sup> B. Victor,<sup>2</sup> S. Stepkowski,<sup>2</sup> B. Radovancevic,<sup>1</sup> O. Frazier,<sup>1</sup> R. Kerman,<sup>2</sup> <sup>1</sup>Surgery, Texas Heart Institute, Houston, TX; <sup>2</sup>Surgery, University of Texas Medical School, Houston, TX

**9:00 AM (546)** No Harm, No Foul? The Prospective Treatment of Sensitized Heart Transplant Recipients with Plasmapheresis and IVIG – Three Year Follow-Up; M.W. Weston,<sup>1</sup> M. Lopez-Cepero,<sup>2</sup> L. DiChiara,<sup>3</sup> <sup>1</sup>Cardiology, LifeLink HealthCare Institute, Tampa, FL; <sup>2</sup>Immunology, LifeLink Immunology Laboratory, Tampa, FL; <sup>3</sup>Cardiology, Tampa General Hospital, Tampa, FL

**9:15 AM (547)** *The Effect of Body Mass Index on Postoperative Length of Stay and Survival in Heart Transplant Recipients*; J.C. Mullen,<sup>1</sup> A. Oreopoulos,<sup>1</sup> S. Becker,<sup>1</sup> M.J. Bentley,<sup>1</sup> D.L. Modry,<sup>1</sup> S. Wang,<sup>1</sup> R. MacArthur,<sup>1</sup> D.B. Ross,<sup>1</sup> E.T. Gelfand,<sup>1</sup> <sup>1</sup>Surgery, University of Alberta, Edmonton, AB, Canada

**8:00 AM – 9:30 AM**

**CONCURRENT SESSION 42**

**Regulation of Bronchiolitis Obliterans (Imperial Ballroom A)**

\*Chairs: \*Erik A.M. Verschuuren, MD and Mark R. Nicolls, MD

**8:00 AM (548)** *Regression of Established Post-Transplant Allograft Airway Obliteration by Targeting Interaction of Fibrosis and Immune System*; M. Sato,<sup>1</sup> M. Anraku,<sup>1</sup> M. Cypel,<sup>1</sup> S. Hirayama,<sup>1</sup> T.K. Waddell,<sup>1</sup> M. Liu,<sup>1</sup> S. Keshavjee,<sup>1</sup> <sup>1</sup>Thoracic Surgery Research Laboratory, Toronto General Research Institute, University Health Network, Toronto, ON, Canada

**8:15 AM (549)** *Lipopolysaccharide Induced IL-8 Release from Alveolar Macrophages in Lung Transplant Recipients with Chronic Rejection Is Not Suppressed by Glucocorticoids*; L.G. Spencer,<sup>1</sup> D. Singh,<sup>2</sup> C.T. Leonard,<sup>1</sup> <sup>1</sup>Transplant Unit, Wythenshawe Hospital, Wythenshawe, Manchester, United Kingdom; <sup>2</sup>North West Lung Centre, Wythenshawe Hospital, Wythenshawe, Manchester, United Kingdom

**8:30 AM (550)** *Airway Changes after Vascularized Aerated Orthotopic Mouse Lung Transplantation Differ Markedly from Those after Heterotopic Tracheal Transplantation*; M. Okazaki,<sup>1</sup> A.S. Krupnick,<sup>1</sup> C.G. Kornfeld,<sup>1</sup> S.B. Richardson,<sup>1</sup> J. Lai,<sup>1</sup> J.H. Ritter,<sup>1</sup> G.A. Patterson,<sup>1</sup> A.E. Gelman,<sup>1</sup> D. Kreisel,<sup>1</sup> <sup>1</sup>Department of Surgery, Washington University in St. Louis, St. Louis, MO

**8:45 AM (551)** *An MHC Class II Disparity Raises the Threshold for Tolerance Induction in Pulmonary Allografts in Miniature Swine*; T. Shoji,<sup>1</sup> H. Sahara,<sup>1</sup> A. Muniappan,<sup>1</sup> D.A. Guenther,<sup>1</sup> S.L. Houser,<sup>1</sup> A.C. Pujara,<sup>1</sup> M.A. Bravard,<sup>1</sup> J.C. Wain,<sup>1</sup> D.H. Sachs,<sup>1</sup> J.C. Madsen,<sup>1</sup> J.S. Allan,<sup>1</sup> <sup>1</sup>Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA

**9:00 AM (552)** *Natural Killer Lymphocytes Migrate to the Lung during Bronchiolitis Obliterans Syndrome*; J.E. Fildes,<sup>1</sup> K. Tunstall,<sup>1</sup> L. Griffiths-Davies,<sup>2</sup> A.H. Walker,<sup>1</sup> M. Al-Aloul,<sup>1</sup> N. Yonan,<sup>1</sup> P. Bishop,<sup>2</sup> C.T. Leonard,<sup>1</sup> <sup>1</sup>The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom; <sup>2</sup>Department of Pathology, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom

**9:15 AM (553)** *Inhaled Immunosuppression with Tacrolimus after Airway Transplantation*; S. Schrepfer,<sup>1</sup> T. Deuse,<sup>2</sup> J. Hoffmann,<sup>1</sup> M.P. Pelletier,<sup>1</sup> M.P. Fischbein,<sup>1</sup> H. Reichenspurner,<sup>2</sup> R.C. Robbins,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA; <sup>2</sup>Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany

**8:00 AM – 9:30 AM**

**CONCURRENT SESSION 43**

**Mechanic Insights into Ischemia/Reperfusion (Imperial Ballroom B)**

\*Chairs: Stephen C. Clark, MD and \*Thomas M. Egan, MD, MSC

**8:00 AM (554)** *Donor Myocardial Hypoxia Inducible Factor (HIF)-1 $\alpha$  Expression Predicts Cardiac Allograft Dysfunction: Results of a 7-Year Prospective Study*; S. Aharinejad,<sup>1,2</sup> K. Krenn,<sup>1,2</sup> R. Schaefer,<sup>2</sup> E. Wolner,<sup>1</sup> A. Aliabadi,<sup>1</sup> A. Zuckermann,<sup>1</sup> M. Grimm,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria; <sup>2</sup>Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria

**8:15 AM (555)** *Delayed Pulmonary Graft Function: The Role of CD26/Dipeptidylpeptidase IV*; W. Zhai,<sup>1,2</sup> I. Inci,<sup>1</sup> S. Arni,<sup>1</sup> I.D. Meester,<sup>3</sup> S. Hillinger,<sup>1</sup> M. Cardell,<sup>1</sup> W. Jungraithmayr,<sup>1</sup> B. Oberreiter,<sup>1</sup> W. Weder,<sup>1</sup> S. Korom,<sup>1</sup> <sup>1</sup>Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland; <sup>2</sup>Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; <sup>3</sup>Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium

**8:30 AM (556)** *The Lectin-Like Domain of Thrombomodulin Suppresses Leukocyte Infiltration in a Murine Lung Ischemia-Reperfusion Injury Model*; N. Geudens,<sup>1</sup> M. Van de Wouwer,<sup>2</sup> B.M. Vanaudenaerde,<sup>3</sup> C. Van De Wauwer,<sup>1</sup> T. Lerut,<sup>4</sup> E. Verbeken,<sup>5</sup> G.M. Verleden,<sup>5</sup> E. Conway,<sup>2</sup> D.E.M. Van Raemdonck,<sup>1,4</sup> <sup>1</sup>Experimental Thoracic Surgery, Katholieke Universiteit, Leuven, Belgium; <sup>2</sup>Center for Transgene Technology and Gene Therapy, Katholieke Universiteit, Leuven, Belgium; <sup>3</sup>Laboratory of Pneumology, Katholieke Universiteit, Leuven, Belgium; <sup>4</sup>Department of Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium; <sup>5</sup>Department of Pathology, University Hospital Gasthuisberg, Leuven, Belgium

**8:45 AM (557)** *FP15, a Novel Peroxynitrite Decomposition Catalyst Reduces Reperfusion Injury in a Rat Heart Transplantation Model*; G. Szabó,<sup>1</sup> T. Radovits,<sup>1</sup> A. Koch,<sup>1</sup> C. Szabó,<sup>2</sup> <sup>1</sup>Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; <sup>2</sup>Cellscreen Applied Research Center, Semmelweis University, Budapest, Hungary

**9:00 AM (558)** *Human Atrial Natriuretic Peptide Ameliorates Warm Ischemia-Reperfusion Injury of the Lung*; A. Aoyama,<sup>1</sup> F. Chen,<sup>1</sup> T. Nakamura,<sup>2</sup> T. Fujinaga,<sup>2</sup> J. Zhang,<sup>1</sup> T. Okamoto,<sup>1</sup> N. Satoda,<sup>1</sup> A. Takahashi,<sup>1</sup> H. Hamakawa,<sup>1</sup> N. Kondo,<sup>1</sup> T. Shoji,<sup>1</sup> H. Sakai,<sup>1</sup> H. Wada,<sup>1</sup> T. Bando,<sup>1</sup> <sup>1</sup>Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan; <sup>2</sup>Organ Preservation Technology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

**9:15 AM (559)** *Endothelin-1 Exacerbates Hypoxic Injury through eNOS Derived Free Radical Production: Implication for Primary Allograft Dysfunction*; D. Ramzy,<sup>1</sup> L.C. Tumiati,<sup>1</sup> N. Xu,<sup>1</sup> E. Tepperman, D.H. Delgado,<sup>1</sup> J. Jackman,<sup>1</sup> M. Badiwala,<sup>1</sup> R. Sheshgiri,<sup>1</sup> V. Rao,<sup>1</sup> <sup>1</sup>Cardiac Surgery, University of Toronto, Toronto, ON, Canada

**8:00 AM – 9:30 AM**

**CONCURRENT SESSION 44**

**Innovative Alternatives to Allotransplantation (Plaza Ballroom A)**

**Chairs:** Andre R. Simon, MD and Marc P. Pelletier, MD, MSc

**8:00 AM (560) Stem Cell Transplantation and Migration: The Lung Barrier;** S. Schrepfer,<sup>1</sup> T. Deuse,<sup>2</sup> H. Reichenspurner,<sup>2</sup> M.P. Fischbein,<sup>1</sup> R.C. Robbins,<sup>1</sup> M.P. Pelletier,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA; <sup>2</sup>Cardiovascular Surgery, University Heart Center Hamburg gGmbH, Hamburg, Germany

**8:15 AM (561) Short Time In Vitro Electrostimulation Induces Cardiomyocyte Preadifferentiation of Adult Fibroblasts;** J.A. Genovese,<sup>1</sup> C. Spadaccio,<sup>1</sup> J. Langer,<sup>1</sup> A.N. Patel,<sup>1</sup> <sup>1</sup>Cardiac Regeneration Laboratory, Heart, Lung and Esophageal Surgery Institute, UPMC & McGowan Institute for Regenerative Medicine, Pittsburgh University, Pittsburgh, PA

**8:30 AM (562) Functional Vascular Network Development in Infarcted Rat Hearts by Selective Recruitment of Vessel Forming Macrophages;** P. Paulus,<sup>1</sup> M. Gmeiner,<sup>1</sup> N. Sela,<sup>1</sup> R. Schaefer,<sup>1</sup> E. Wolner,<sup>2</sup> M. Grimm,<sup>2</sup> S. Aharinejad,<sup>2,1</sup> <sup>1</sup>Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria; <sup>2</sup>Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria

**8:45 AM (563) In Vivo Remodeling of Decellularized Xenogeneic Arteries: Impact of Heparin-Crosslinking on Graft Stability;** H. Bergmeister,<sup>1</sup> F. Bastian,<sup>2</sup> C. Plass,<sup>3</sup> E. Rieder,<sup>2</sup> U. Losert,<sup>1</sup> G. Weigel,<sup>2,1</sup> <sup>1</sup>Division Biomedical Research, Medical University of Vienna, Vienna, Austria; <sup>2</sup>Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria; <sup>3</sup>Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria

**9:00 AM (564) Appraisal of Inherent Myocardial Ability to Recuperate from Ischemia/Infarction;** T. Pätälä,<sup>1</sup> T.S. Ikonen,<sup>2</sup> E. Kankuri,<sup>3</sup> J. Lommi,<sup>4</sup> K. Virtanen,<sup>4</sup> L. Krogerus,<sup>6</sup> K. Lauerma,<sup>5</sup> A. Harjula,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic Surgery, Helsinki University Meilahti Hospital, Helsinki, Finland; <sup>2</sup>Department of Vascular Surgery, Helsinki University Meilahti Hospital, Helsinki, Finland; <sup>3</sup>Department of Clinical Pharmacology, Helsinki University, Helsinki, Finland; <sup>4</sup>Department of Cardiology, Helsinki University Meilahti Hospital, Helsinki, Finland; <sup>5</sup>Department of Radiology, Helsinki University Meilahti Hospital, Helsinki, Finland; <sup>6</sup>Department of Pathology, Helsinki University Maria Hospital, Helsinki, Finland

**9:15 AM (565) Are GT-KO Pigs Essential for Successful Cardiac Xenotransplantation?;** C.G.A. McGregor,<sup>1</sup> H.D. Tazelaar,<sup>1</sup> V.P. Rao,<sup>1</sup> D. Ricci,<sup>1</sup> N. Miyagi,<sup>1</sup> M.H. Gazi,<sup>1</sup> S.L. Edgerton,<sup>1</sup> G.W. Byrne,<sup>1</sup> <sup>1</sup>Mayo Clinic-Rochester William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN

**8:00 AM – 9:30 AM**

**CONCURRENT SESSION 45**

**The Impact of Antibodies on Pediatric Heart Transplant (Plaza Ballroom B)**

**\*Chairs:** W. Jeff Dreyer, MD and \*Jacqueline R. Szmuszkovicz, MD

**8:00 AM (566) Over Twenty Years of Pediatric Heart Transplantation;** N.W. Hasaniya,<sup>1</sup> A.J. Razzouk,<sup>1</sup> L.L. Baily,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, Loma Linda University Children Hospital, Loma Linda, CA

**\*8:15 AM (567) ABO-Incompatible Paediatric Heart Transplantation: The First 10 Years;** A.I. Dipchand,<sup>1</sup> L.J. West,<sup>2</sup> S.M. Pollock BarZiv,<sup>1</sup> C. Manlhiot,<sup>1</sup> M. VanderVliet,<sup>1</sup> B.W. McCrindle,<sup>1</sup> <sup>1</sup>Cardiology, Hospital for Sick Children, Toronto, ON, Canada; <sup>2</sup>Paediatrics, Stollery Children's Hospital, Edmonton, AB, Canada

**8:30 AM (568) Cardiac Transplant Outcomes in Pediatric Patients with Preformed Anti-HLA Antibodies and/or Positive Retrospective Crossmatch;** E.J. Wright,<sup>1</sup> W.P. Fiser,<sup>1</sup> R.E. Edens,<sup>2</sup> M. Imamura,<sup>1</sup> R.D. Jaquiss,<sup>1</sup> <sup>1</sup>Surgery, University of Arkansas for Medical Sciences, Little Rock, AR; <sup>2</sup>Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR

**8:45 AM (569) Outcomes in Pediatric Cardiac Transplantation with a Positive HLA Cross-Match;** M.E. Richmond,<sup>1</sup> D.T. Hsu,<sup>1</sup> S.R. Mital,<sup>1</sup> R.S. Mosca,<sup>2</sup> J.M. Chen,<sup>2</sup> J.M. Quaegebeur,<sup>2</sup> E.M. Burke,<sup>2</sup> L.J. Addonizio,<sup>1</sup> J.M. Lamour,<sup>1</sup> <sup>1</sup>Division of Pediatric Cardiology, Morgan Stanley Children's Hospital of New York-Columbia University, New York, NY; <sup>2</sup>Division of Cardiothoracic Surgery, Columbia University, New York, NY

**9:00 AM (570) Heart Transplantation in Pediatric HLA-Sensitized Patients;** S.M. Pollock-BarZiv,<sup>1</sup> N. den Hollander,<sup>2</sup> B.Y. Ngan,<sup>3</sup> B.W. McCrindle,<sup>1</sup> P. Kantor,<sup>1</sup> A.I. Dipchand,<sup>1</sup> <sup>1</sup>Cardiology, Hospital for Sick Children, Toronto, ON, Canada; <sup>2</sup>University Health Network; HLA Laboratory, Toronto, ON, Canada; <sup>3</sup>Pathology, Hospital for Sick Children, Toronto, ON, Canada

**9:15 AM (571) Elevated PRA Is a Risk Factor for Late Mortality among Pediatric Heart Transplant Recipients;** T.A. Nasirov, A.J. Razzouk, L.L. Bailey, N.W. Hasaniya, R.E. Chinnock, Division of Cardiothoracic Surgery, Department of Surgery, Loma Linda University Medical Center, Loma Linda, CA; Department of Pediatrics, Loma Linda University Medical Center, Loma Linda, CA

**9:30 AM – 9:45 AM**

Coffee Break (West Foyer)

**9:45 AM – NOON**

**CLOSING PLENARY SESSION (Grand Ballroom B)**

**\*Chairs:** \*Lori West, MD, D.Phil. and \*Paul Corris, MB, FRCP

**9:45 AM Awards Presentations**

**10:00 AM Strategic Planning: The Future of the Society,** Robert C. Robbins, MD, Stanford University Medical Center, Stanford, CA

**10:15 AM Every Second Counts: The Race to Perform the First Human Heart Transplant,** Donald McRae, London, UK

**10:50 AM** *Using RNA Interference to Eliminate Unwanted Gene Expression*, Mark A. Kay, MD, PhD, Stanford University, Palo Alto, CA  
**11:25 AM** *Science in Society*, Lawrence M. Krauss, PhD, Case Western Reserve University, Cleveland, OH

**12:30 PM – 4:30 PM**

**ISHLT Board of Directors Meeting (Union Square 19/20)**

**EXHIBIT HALL FLOOR PLAN**

## EXHIBITING COMPANIES

Company	Booth Number
Abiomed	107
Actelion	510
Alsius Corporation	706
Astellas Pharma Europe LTD	202
Baptist Health	105
Berlin Heart	101
CardiacAssist, Inc.	703
CSL Behring	606
Cylex, Inc.	108
Elsevier	103
Encysive Pharmaceuticals	210
F. Hoffmann-LaRoche Ltd	502
ISHLT Registry	705
Levitronix, LLC	205
Lippincott/Williams & Wilkins	704
Micromed Cardiovascular, Inc.	702
Novartis Pharma AG	302
Organ Recovery Systems	604
Scanlan International, Inc.	602
Syncardia Systems, Inc.	608
Terumo Heart, Inc.	710
Thoratec Corporation	201
TransMedics	310
USCOM, Inc.	708
Ventracor Inc	207
ViraCor Laboratories	701
Vital Engineering	709
Vitrolife	102
World Heart Corporation	104
XDx	410

## EXHIBITORS AND PRODUCT DESCRIPTIONS

### **Abiomed**

22 Cherry Hill Drive  
Danvers, MA 01923  
Website: [www.abiomed.com](http://www.abiomed.com)  
Booth Number: 107 & 109

ABIOMED develops, manufactures and markets cardiac assist and recovery devices. Products include: the BVS®5000, the AB5000™, Impella® Circulatory Support Systems and the AbioCor®, the world's first fully implantable artificial heart.

### **Actelion**

5000 Shoreline Court  
Suite 200  
South San Francisco, CA 94080  
Website: [www.actelion.com](http://www.actelion.com)  
Booth Number: 510

Actelion Pharmaceuticals is a research leader in Pulmonary Arterial Hypertension. Tracleer® (bosentan) is the first oral endothelin receptor antagonist and Ventavis® (iloprost) is the first non-invasive prostacyclin for the treatment of pulmonary arterial hypertension (WHO Class III or IV).

### **ALSIUS Corporation**

15770 Laguna Canyon Road  
Suite 150  
Irvine, CA 92618  
Website: [www.alsius.com](http://www.alsius.com)  
Booth Number: 706

ALSIUS is the worldwide leader in providing catheter-based intravascular patient temperature management. The THERMOGARD™ system and catheters deliver precise core patient warming/cooling in an easy-to-use and cost-effective system to achieve and maintain normothermia.

### **Astellas Pharma US, Inc.**

3 Parkway North  
Deerfield, Illinois 60015  
Website: [www.us.astellas.com](http://www.us.astellas.com)  
Email: Booth Number: 202

Astellas Pharma, Inc. manufactures and markets proprietary pharmaceutical products in specialty therapeutic areas where there is an unmet medical need. Astellas Pharma's global mission to explore the frontiers of human health underscores the company's commitment to the field of immunology, where aggressive research and development initiatives have helped to put Astellas at the forefront of transplantation.

### **Baptist Health**

904 Autumn Road  
Suite 300  
Little Rock, AR 72211  
Website: [www.baptist-health.org](http://www.baptist-health.org)  
Booth Number: 105

Heart Clinic Arkansas, in Little Rock, is seeking to recruit a Board Certified Cardiologist with heart transplant or heart failure training to join the largest, most comprehensive group of cardiologists in the state of Arkansas. In addition, Heart Clinic Arkansas currently has opportunities for invasive cardiologist and interventionalists with carotid stenting and peripheral training.

Heart Clinic Arkansas is a partnership of 27 doctors. There were two doctors in this group that were experts in heart failure and they started a transplant program over 15 years ago. The practice is located next to the campus of Baptist Medical Center, a 787-bed facility.

**Berlin Heart**

Wiesenweg 10  
Berlin 12247 Germany  
Website: [www.berlinheart.com](http://www.berlinheart.com)  
Booth Number: 101

As the only company worldwide we cover all areas of ventricular assist device application and CHF patients of every size and age with the partly implantable INCOR®.

Excor® is a paracorporeal pulsatile blood pump for uni- or biventricular support in newborns, children, adolescents and adults. Longest time on device: 5 years.

INCOR® is an implantable axial flow blood pump for left ventricular support in adults. INCOR® is the only 3<sup>rd</sup> generation axial flow pump with CE-mark approval. Longest time on device: 3.5 years

INCOR® and EXCOR® are not FDA approved.

**CardiacAssist, Inc.**

240 Alpha Dr.  
Pittsburgh, PA 15238  
Website: [www.tandemheart.com](http://www.tandemheart.com)  
Booth Number: 703

The TandemHeart System provides up to five liters per minute (lpm) of blood flow through a cardiac catheterization procedure in as little as 30 minutes. The System is used in 17 of the top 20 heart and heart surgery hospitals in the U.S. and 11 of the top 14 hospitals overall. It is FDA approved for extracorporeal circulatory support for up to six hours for procedures not requiring full cardiopulmonary bypass. To date, more than 800 uses of the device in 28 countries at 90 different facilities by 120 different physicians have been performed.

**CSL Behring**

1020 First Ave  
King of Prussia, PA 19406  
Website: [www.cslbehring.com](http://www.cslbehring.com)  
Booth Number: 606

CSL Behring is a leader in the plasma biotherapeutics industry. Dedicated to improving the quality of life for patients worldwide, CSL Behring provides safe and effective plasma-derived and recombinant products and offers patients a wide range of related services. CSL Behring is a subsidiary of CSL Limited.

**Cylex, Inc.**

8980-I Old Annapolis Road  
Columbia, MD 21045  
Website: [www.cylex.net](http://www.cylex.net)  
Booth Number: 108

Cylex develops and manufactures the only FDA-cleared assay measuring the vitality of patients' immune systems from a single drop of blood. ImmuKnow® enables physicians to better manage and individualize treatments for life-threatening diseases, such as HIV, HCV, cancer and autoimmune disorders, as well as solid organ and bone marrow transplantation.

**Elsevier, Inc.**

1600 JFK Blvd  
Suite 1800  
Philadelphia, PA 19103  
Website: [www.elsevierhealth.com](http://www.elsevierhealth.com)  
Booth Number: 103

Elsevier is proud to publish the **Journal of Heart and Lung Transplantation**, the official journal of the International Society for Heart and Lung Transplantation. Be sure to stop by our booth to view the latest issue of the journal and browse our other books, journals and software in the field of Heart & Lung Transplantation.

**Encysive Pharmaceuticals**

4848 Loop Central Dr.  
Suite 700  
Houston, TX 77027  
Website: [www.encyrive.com](http://www.encyrive.com)  
Booth Number: 210

Encysive Pharmaceuticals, a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs, is recognized for our expertise in small molecule drug development and vascular biology. A selective endothelin receptor antagonist is currently in development to treat pulmonary arterial hypertension.

**F. Hoffmann-LaRoche Ltd**

Grenzacher Str 177  
Bldg 074/302  
CH-4070 Basel Switzerland  
Website: [www.roche.us](http://www.roche.us)  
[www.rocheusa.com](http://www.rocheusa.com)  
Booth Number: 502

Roche is a leading, global innovator of pharmaceuticals and diagnostics dedicated to enhancing people's health and quality of life. Our people are engaged in the discovery, development, manufacturing and marketing of prescription medicine in a wide variety of therapeutic areas, including cancer, HIV/AIDS, hepatitis C, transplantation, influenza and osteoporosis. We invite you to visit our booth #502 to learn more about CellCept and Valcyte

**ISHLT Registry**

700 North 4th St  
Richmond, VA 23219  
Website: [www.help@ishlt.org](mailto:www.help@ishlt.org)  
Booth Number: 705

The International Registry for Heart and Lung Transplantation provides ongoing, current information on the worldwide thoracic organ transplantation experience. The data, utilized for scientific study, contributes to the body of knowledge regarding both heart and lung transplantation efforts throughout the world. Our goal is to identify overall best practices for improving cardiothoracic patient care.

This year the exhibit will make your center-specific information available for your review. In addition, members can view data screens from the ISHLT Registry and receive guidance on enrollment, training on submission of data and instructions for submitting data requests.

**Levitronix, LLC**

45 First Ave  
Waltham, MA 02451  
Website: [www.levitronix.com](http://www.levitronix.com)  
Booth Number: 205

The Levitronix CentriMag Ventricular Assist System (VAS) is designed to provide temporary mechanical circulatory support to one or both sides of the heart with a maximal flow capability of 9.9 l/min. In the United States, the Levitronix CentriMag VAS is undergoing clinical trials to assess its safety and effectiveness for the treatment of cardiogenic shock following acute myocardial infarction or postcardiotomy cardiogenic shock, and also as an investigational RVAS for temporary right ventricular support in patients who have had a commercial LVAS implanted. The CentriMag Blood Pumping System is FDA 510 (k) cleared for use for up to six hours to provide cardiopulmonary support during cardiopulmonary surgical procedures. The CentriMag VAS is approved and commercially available throughout Europe and countries that recognize the CE Mark as a VAD or for ECMO.

**Lippincott/Williams & Wilkins**

187 Ridgecrest Dr.  
Napa, CA 94558  
Website: [www.lww.com](http://www.lww.com)  
Booth Number: 704

Lippincott/Williams & Wilkins publishes the very latest titles covering all specialties in medical and nursing books, journals and multimedia products.

**MicroMed Cardiovascular, Inc.**

8965 Interchange Dr.  
Houston, TX 77054  
Website: [www.micromedtech.com](http://www.micromedtech.com)  
Booth Number: 702

The DeBakey VAD® is a miniaturized ventricular assist device (VAD) which was jointly developed by the famed heart surgeon Dr. Michael E. DeBakey, Dr. George Noon, and the National Aeronautics and Space Administration (NASA). The DeBakey VAD® is an implantable axial flow device designed to provide long term, improved quality of life for patients who suffer from severe heart failure. It is the only device that provides accurate, real-time flow measurement improving the clinicians' patient care. It's CE-mark approved in Europe, undergoing an IDE BTT clinical study in the U.S. and is the only FDA approved pediatric ventricular assist device.

**Novartis Pharma AG**

Lichtstrasse 35  
CH-4056 Basel Switzerland  
Website: [www.novartis.com](http://www.novartis.com)  
Booth Number: 302

Novartis is a world leader in transplantation and immunology. With the discovery and introduction of cyclosporine more than 20 years ago, Novartis revolutionized the field of transplantation and now has the broadest portfolio of immunosuppressants on the market, including Noetal, Simulect, Myfortic and Certican, and a very innovative pipeline with new mechanisms of action. This allows for effective personalized care in a field where individualized therapy is most needed.

**Organ Recovery Systems**

2570 E. Devon Ave  
Des Plaines, IL 60018  
Website: [www.organ-recovery.com](http://www.organ-recovery.com)  
Booth Number: 604

Organ Recovery Systems develops technologies to improve the quality and quantity of organs for transplantation. The company markets LifePort® Kidney Transporter, now in routine use worldwide and recognized for excellence in design by Popular Science (Best of What's News 2003), the Industrial Designers Society of America (Silver Award IDEA2004), the Medical Design Excellence Awards (Gold Winner 2004), the Museum of Modern Art (SAFE2005, Permanent Collection), BusinessWeek (Ten Devices Changing Medicine 2006), the Smithsonian Cooper-Hewitt National Design Museum (Design Life Now 2006, and the Art Institute of Chicago (Young Chicago 2007). LifePorts for heart and lung are in preclinical development.

**Scanlan International, Inc.**

One Scanlan Plaza  
Saint Paul, MN 55107  
Website: [www.scanlangroup.com](http://www.scanlangroup.com)  
Booth Number: 602

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 designs in stainless steel and titanium instrumentation featuring Needle Holders, forceps, and clamps, including Scanlan SUPER CUT™ and ULTRA SHARP® scissors, Heifetz™ temporary occlusion clips, and DIAMOND DUST™ instrumentation. Offering a wide variety of custom modifications to accommodate surgeons' specific needs. Single-use products include Surg-I-Loop® PLUS, single-use Aorta/Vein Punch, A/C LOCATOR® and RADIOMARK® graft markers, Vascul-Stat® single-use bulldog clamps, as well as SURG-I-PAW® jaw covers and SOFT-GRIP™ fabric clamp covers. Exclusive worldwide distributor for Surgical Acuity HiRes™ class II Magnifying Loupes.

**SynCardia Systems, Inc.**

3940 East Silverlake  
Tucson, AZ 85713  
Website: [www.syncardia.com](http://www.syncardia.com)

Booth Number: 608

The CardioWest™ temporary Total Artificial Heart (TAH-T) is the only FDA, Health Canada and CE approved device that provides circulatory restoration in morbidly ill patients with irreversible bi-ventricular failure, providing a life-saving bridge until a donor human heart becomes available. Recently, the EXCOR® TAH-t mobile driver was granted a CE mark, enabling European hospitals to discharge stable patients on the TAH-t to return home while they are awaiting a transplant. At ISHLT, we will be recruiting investigators for our upcoming clinical trial of the Companion driver designed for use in the operating room, hospital room and at home.

**Terumo Heart, Inc.**

6180 Jackson Road  
Ann Arbor, MI 48103  
Website: [www.terumoheart.com](http://www.terumoheart.com)  
Booth Number: 710

Terumo Heart, Inc is dedicated to the innovation, introduction and advancement of products to improve the quality of healthcare of heart failure patients. Our principal focus is the development of the DuraHeart™ Left Ventricular Assist System (LVAS). The system is designed to provide long-term circulatory support and address the shortage of donor hearts for cardiac transplantation. Combining patented magnetic-levitation and centrifugal pump technologies, the DuraHeart LVAS is expected to decrease complications and improve the lives of patients with severe heart failure. The DuraHeart LVAS is not currently for sale in the United States pending clinical investigation.

**Thoratec Corporation**

6035 Stoneride Dr.  
Pleasanton, CA 94588  
Website: [www.thoratec.com](http://www.thoratec.com)  
Booth Number: 201

Thoratec® Corporation innovates and delivers technologies that enable a full range of therapies to save, support and restore failing hearts, allowing patients to reclaim their lives.

Brand Names:  
Thoratec® PVAD™  
Thoratec® IVAD™ (Implantable Ventricular Assist Device)  
Thoratec® CentriMag®  
Thoratec®HeartMate® XVE

**TransMedics**

200 Minuteman, Suite 302  
Andover, MA 01810  
Website: [www.transmedics.com](http://www.transmedics.com)  
Booth Number: 310

The TransMedics Organ Care System is a novel medical device that maintains organs in their functioning state outside the body to minimize ischemic injury and to allow ex-vivo visual, functional and metabolic assessment. The Organ Care System perfuses organs with warm, oxygenated nutrient-rich blood from time of removal until implantation. The system is designed with the goals of providing patients with the healthiest possible organs: increasing the number of organs available and improving post transplant outcomes. TransMedics completed PROTECT I: Heart and is expanding clinical activity to the US as well as to the lungs and other solid organs.

**USCOM, Inc.**

1060 Grant St, Suite 1-D  
Benicia, CA 94510  
Website: [www.uscom.com](http://www.uscom.com)  
Booth Number: 708

USCOM is a CW Doppler-based hemodynamic monitor that provides real-time information from either the right or left heart. The USCOM technique is entirely noninvasive, with no patient risk and no proprietary disposables. USCOM has been validated against bench flow models, flow-probes, echo, PAC and artificial hearts in animals, pediatrics and adults.

The USCOM system provides information regarding preload, contractility and afterload and has numerous applications in the PICU, ED, MICU, burn and trauma units. Reliable hemodynamic information will be obtained where other monitoring methods fail. On-site training is provided.

#### **Ventricor Inc**

101 Lincoln Centre  
Suite 420  
Foster City, CA 94404  
Website: [www.ventracor.com](http://www.ventracor.com)  
Booth Number: 207

Ventricor is a global medical device company which has developed a blood pump, the VentrAssist left ventricular assist device (LVAD) for patients in heart failure. Ventracor plans to bring the VentrAssist to the global market.

#### **ViraCor Laboratories**

1210 NE Windsor Dr.  
Lee's Summit, MO 64086  
Website: [www.viracor.com](http://www.viracor.com)  
Booth Number: 701

ViraCor Laboratories specializes in bringing innovative Molecular Diagnostic services for immunocompromised patients. ViraCor provides quantitative Real-Time PCR results within 24 hours for CMV, EBV, Adenovirus, HHV-6, and other relevant viral and fungal pathogens.

#### **Vital Engineering**

330 Scaife Hall  
200 Lothrop St  
Pittsburgh, PA 15213  
Website: [www.vitalengineering.com](http://www.vitalengineering.com)  
Booth Number: 709

Vital Engineering provides training and educational programs for physicians and other health care providers as well as on-site training and technical support prior to, during and following device implantation. Vital Engineering has the knowledge and resources to improve patient care from surgery through discharge planning and outpatient care. Our clinical experience equips the artificial organ industry with the ultimate product quality improvement from emerging to experienced companies. Vital Engineering offers many partnership benefits to patients, clinicians, hospital, and industry.

#### **Vitrolife**

113 Buttercup Road  
Lake Ozark, MO 65049  
Website: [www.vitrolife.com](http://www.vitrolife.com)  
Booth Number: 102

**Vitrolife**, develops and markets solutions and equipment to preserve organs and tissue prior to transplantation. Two of the products are **Perfadex**, an organ flush solution, and **Steen Solution** which along with machine perfusion methodology permits a more refined functional ex-vivo evaluation of the organ prior to transplantation.

#### **World Heart Corporation**

4750 Wiley Post Way  
Suite 120  
Salt Lake City, UT 84116  
Website: [www.worldheart.com](http://www.worldheart.com)  
Booth Number: 104

World Heart Corporation is a developer of mechanical circulatory support systems. Its Novacor® LVAS is approved for bridge-for transplantation in the US and has an unrestricted indication for use in the EU. It Levacor™ rotary VAD is the only bearingless, fully magnetically levitated implantable centrifugal heart pump in clinical trials. A next-generation pulsatile pump (Novacor II) is being developed, as is a miniature rotary VAD based on proprietary MagLev™ technology for use in neonates.

#### **XDx**

3260 Bayshore Blvd  
Brisbane, CA 94005  
Website: [www.xdx.com](http://www.xdx.com)  
Booth Number: 410

Founded in 2000, XDx is a molecular diagnostics company with a focus on gene expression testing in immune-mediated conditions such as organ transplant rejection and inflammatory diseases. Its first offering, AlloMap® molecular expression testing, is a breakthrough in heart transplant patient management. Available for patients as early as two months post transplant, AlloMap testing uses a blood sample to determine if a heart transplant patient's immune system is quiet or if the patient is at an increased risk of acute cellular rejection. AlloMap testing is a service provided by XDx through its CLIA-certified laboratory in Brisbane, California.

## **FUTURE ISHLT MEETINGS**

28<sup>th</sup> ISHLT ANNUAL MEETING AND SCIENTIFIC SESSIONS, APRIL 9 – 12, 2008  
Boston, MA  
Boston Marriott and Hynes Convention Center

29<sup>th</sup> ISHLT ANNUAL MEETING AND SCIENTIFIC SESSIONS, APRIL 22 – 25, 2009  
Paris, France  
Meridien Etoile, Concorde LaFayette, and Palais des Congress

30<sup>th</sup> ISHLT ANNUAL MEETING AND SCIENTIFIC SESSIONS, APRIL 21 – 24, 2010  
Chicago, IL  
Hilton Chicago